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Elevated serum uric acid (SUA) concentration, known as hyperuricaemia, is a common 
abnormity in individuals with metabolic disorders. There is increasing evidence supporting 
the link between high SUA level and the increased risk of a wide range of clinical disorders, 
including hypertension, cardiovascular diseases (CVD), chronic renal diseases and metabolic 
syndrome. Although there are considerable research efforts in understanding the pathogenic 
pathways of high SUA level and the related clinical consequences, their causal relationships 
have not been established except for gout. Like other complex traits, genetic determinants 
play a substantial role (an estimated heritability of 40-70%) in the regulation of SUA level. 
Investigating the role of genetic variants related to SUA in various diseases might provide 
evidence for the above hypothesis which links uric acid to clinical disorders.  
Method  
Umbrella review was carried out first to provide a comprehensive overview on the range of 
health outcomes in relation to SUA level by incorporating evidence from systematic reviews 
and meta-analyses of observational studies, meta-analyses of randomised controlled trials 
(RCTs), and Mendelian randomisation (MR) studies. The umbrella review summarised the 
range of related health outcomes, the magnitude, direction and significance of identified 
associations and effects, and classified the evidence into four categories (class I [convincing], 
II [highly suggestive], III [suggestive], and IV [weak]) with assessment of multiple sources 
of biases.  
Then, a MR-PheWAS (Phenome-wide association study incorporated with Mendelian 
randomisation [MR]) was performed to investigate the associations between the 31 SUA 
genetic risk variants and a very wide range of disease outcomes by using the interim release 
data of UK Biobank (n=120,091). The SUA genetic risk loci were employed as instruments 
individually. The framework of phenome was defined by the PheCODE schema using the 
International Classification of Diseases (ICD) diagnosis codes documented in the health 
records of UK Biobank. Phenome-wide association test was performed first to identify any 
association across the SUA genetic risk loci and the phenome; MR design and HEIDI 
(heterogeneity in dependent instruments) tests were then applied to distinguish the PheWAS 





To validate the MR-PheWAS findings, an enlarged Phenome-wide Mendelian randomisation 
(PWMR) analysis were performed by using data from the full UK Biobank cohort 
(n=339,256). A weighted polygenic risk score (GRS), incorporating effect estimates of 
multiple genetic risk loci, was employed as a proxy of the SUA level. The framework of 
phenome was defined by both the PheCODE schema and an alternative Tree-structured 
phenotypic model (TreeWAS) for analysis. Significant associations from these analyses were 
taken forward for replication in different populations by analysing data from various GWAS 
consortia documented in the MR-base database. Sensitivity analyses examining the 
pleiotropic effects of urate genetic risk loci on a set of metabolic traits were performed to 
explore any causal effects and pleiotropic associations. 
Results 
The umbrella review included 101 articles and comprised 144 meta-analyses of 
observational studies, 31 meta-analyses of randomised controlled trials and 107 Mendelian 
randomisation studies. This remarkable assembly of evidence explored 136 unique health 
outcomes and reported convincing (class I) evidence for the causal role of SUA in gout and 
nephrolithiasis. Furthermore, highly suggestive (class II) evidence was reported for five 
health outcomes, in which high SUA level was associated with increased risk of heart failure, 
hypertension, impaired fasting glucose or diabetes, chronic kidney disease, and coronary 
heart disease mortality in the general population. The remaining 129 associations were 
classified as either suggestive or weak.  
The MR-PheWAS (using the interim release cohort) identified 25 disease groups/ outcomes 
to be associated with SUA genetic risk loci after multiple testing correction (p<8.6 ×10-5). 
The MR IVW (inverse variance weighted) analysis implicated a causal role of SUA level in 
three disease groups: inflammatory polyarthropathies (OR=1.22, 95% CI: 1.11 to 1.34), 
hypertensive disease (OR=1.08, 95% CI: 1.03 to 1.14) and disorders of metabolism 
(OR=1.07, 95% CI: 1.01 to 1.14); and four disease outcomes: gout (OR=4.88, 95% CI: 3.91 
to 6.09), essential hypertension (OR=1.08, 95% CI: 1.03 to 1.14), myocardial infarction 
(OR=1.16, 95% CI: 1.03 to 1.30) and coeliac disease (OR=1.41, 95% CI: 1.05 to 1.89). After 
balancing pleiotropic effects in MR Egger analysis, only gout and its encompassing disease 
group of inflammatory polyarthropathies were considered to be causally associated with 
SUA level. The analysis also highlighted a locus (ATXN2/S2HB3) that may influence SUA 





The PWMR analysis, using data from the full UK Biobank cohort (n=339,256), examining 
the association with 1,431 disease outcomes, identified 13 phecodes that were associated 
with the weighted GRS of SUA level with the p value passing the significance threshold of 
PheWAS (p<3.4×10-4). These phecodes represent 4 disease groups: inflammatory 
polyarthropathies (OR=1.28; 95% CI: 1.21 to 1.35; p=4.97×10-19), hypertensive disease 
(OR=1.08; 95% CI: 1.05 to 1.11; p=6.02×10-7), circulatory disease (OR=1.05; 95% CI: 1.02 
to 1.07; p=3.29×10-4) and metabolic disorders (OR=1.07; 95% CI: 1.03 to 1.11; p= 3.33×10-
4), and 9 disease outcomes: gout (OR=5.37; 95% CI: 4.67 to 6.18; p= 4.27×10-123), gouty 
arthropathy (OR=5.11; 95% CI: 2.45 to 10.66; p=1.39×10-5), pyogenic arthritis (OR=2.10; 
95% CI: 1.41 to 3.14; p=2.87×10-4), essential hypertension (OR=1.08; 95% CI: 1.05 to 1.11; 
p=6.62×10-7), coronary atherosclerosis (OR=1.10; 95% CI: 1.05 to 1.15; p=1.17×10-5), 
ischaemic heart disease (OR=1.10, 95% CI: 1.05 to 1.15; p=1.73×10-5), chronic ischaemic 
heart disease (OR=1.10, 95% CI: 1.05 to 1.15; p=1.52×10-5), myocardial infarction 
(OR=1.15, 95% CI=1.07 to 1.23, p=5.23×10-5), and hypercholesterolaemia (OR=1.08, 95% 
CI: 1.04 to 1.13, p=3.34×10-4). Findings from the TreeWAS analysis were generally 
consistent with that of PheWAS, with a number of more sub-phenotypes being identified. 
Results from IVW MR suggested that genetically determined high serum urate level was 
associated with increased risk of gout (OR=4.53, 95%CI: 3.64-5.64, p=9.66×10-42), CHD 
(OR=1.10, 95%CI: 1.02 to 1.19, p=0.009), myocardial infarction (OR=1.11, 95%CI:1.02 to 
1.20, p=0.011) and decreased level of HDL-c (OR=0.93, 95%CI:0.88 to 0.98, p=0.004), but 
had no effect on RA (OR=0.92, 95%CI: 0.84 to 1.01, p=0.085) and ischaemic stroke 
(OR=1.03, 95%CI: 0.93 to 1.14, P= 0.582). Egger MR indicated pleiotropic effects on the 
causal estimates of DBP (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.014), SBP (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.003), CHD (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.008), 
myocardial infarction (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.008) and HDL-c (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.016). When balancing out 
the potential pleiotropic effects in Egger MR, a causal effect can only be verified for gout 
(OR=4.17, 95%CI: 3.03 to 5.74, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡 = 1.27 × 10
−9; 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.485). Sensitivity analyses 
on the GRSs of different groups of pleiotropic loci support an inference that pleiotropic 
effects of genetic variants on urate and metabolic traits contribute to the observed 
associations with cardiovascular/metabolic diseases.     
Conclusions 
This thesis presents a comprehensive investigation on the health outcomes in relation to SUA 
level. The causal relationship between high SUA level and gout is robustly verified in this 
thesis with consistent evidence from the umbrella review, the MR-PheWAS and the PWMR. 





the evidence from umbrella review and analyses conducted in this thesis, however, given the 
caveat of pleiotropy in the causal inference, a conclusion of causality on hypertension and 
heart diseases is not robust enough based on the current findings. Furthermore, the 
epidemiological evidence from the umbrella review indicated that high SUA level was 
associated with several components of metabolic disorders, and the analyses of the UK 
Biobank data identified a significant association with metabolic disorders and a sub-
phenotype (hypercholesterolaemia). The causal inference in this study is limited by the 
common difficulty of pleiotropy caused by the use of multiple genetic instruments. Although 
we have performed sensitivity analysis by excluding the key pleiotropic locus, unmeasured 
pleiotropy and biases are still possible. In particular, unbalanced pleiotropy is recognised as 
an issue for the causal connections on the association between SUA level and hypertension. 
Other potential causal relevance of SUA level with respiratory diseases and ocular diseases 
is also worthy of further investigation. Overall, when taken together the findings from 
umbrella review, MR-PheWAS, PheWAS/TreeWAS analysis, MR replication and sensitivity 
analysis conducted in this thesis, I conclude that there are robust associations between urate 
and several disease  groups, including gout, hypertensive diseases, heart diseases and 
metabolic disorders, but the causal role of urate only exists in gout. This study indicates that 
the observed associations between urate and cardiovascular/metabolic diseases are probably 
derived from the pleiotropic effects of genetic variants on urate and metabolic traits. Further 
investigation of therapies targeting the shared biological pathways between urate and 
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1.1 Uric acid  
1.1.1 Physiochemical properties 
Uric acid ( , 7, 9-dihydro-1H-purine-2, 6, 8(3H)-trione) is a heterocyclic organic 
compound of carbon, hydrogen, nitrogen and oxygen (C5H4N4O3) with a molecular weight of 
168 g/mol (1). Uric acid behaves as a weak hydrogenated acid with a dual dissociation constant 
(pKα=5.75, pKβ=10.30) (1). The hydrolysis reaction (uric acid <=> urate- + H+) is prone to shift 
to the right in weakly alkaline environment. The water solubility of uric acid is relatively low 
(0.6 mg/100 mL, at 20 °C) varying according to environmental temperature and the pH 
(potential of hydrogen) (1). 
In most mammals, uric acid as a break-down product of purine metabolism could be further 
metabolised into a more soluble allantoin that can be completely excreted via urine, therefore, 
the vast majority of mammalian species have a very low concentration of uric acid (range: 30-
89 µmol/L) in the blood (2, 3). However, in humans and other hominoids, due to the 
evolutionary functional loss of uricase (an enzyme, catalysing the conversion of uric acid into 
allantoin), uric acid is unable to be further degraded and thereby exists as the final product of 
purine catabolism (3). Under normal physiological condition (i.e., pH 7.4 and 37°C), uric acid 
predominantly circulates as the urate anion combined with a variety of cations (e.g., sodium, 
potassium, calcium, ammonium, and magnesium) in the plasma, extracellular and synovial fluid, 
and only a very small proportion (less than 5%) is bound to serum albumin (4). Due to the high 
concentration of sodium in human body fluids, monosodium urate (MSU) monohydrate 
(NaC5H3N4O3·H2O) exists as one of the most common forms of ionised urate, in which a urate 
molecule is bonded to one sodium and one water molecule (5). The solubility limit of urate in 
human blood is approximately 405 µmol/L (6.8 mg/dL) (5). The normal reference interval of 
serum urate level is 89-357 µmol/L (1.5-6.0 mg/dL) in women and 149-416 µmol/L (2.5-7.0 
mg/dL) in men (6). When the serum urate level exceeds the  solubility limit (at a status of near 
saturation or supersaturation), urate crystals will deposit as MSU preferentially in and around 
peripheral joints (5).  
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1.1.2 Metabolic homeostasis 
The metabolic homeostasis of uric acid is determined by the balance between its production and 
elimination. This involves a variety of complicated biological processes, including hepatic 
purine catabolism, renal excretion and intestinal uricolysis. Under normal physiological 
circumstances, healthy adults would maintain a total uric acid body pool of approximately 
1000mg (1200mg in males and 600-700mg in females), and achieve a daily turnover rate at 60% 
from the balance of uric acid metabolism (7).  
1.1.2.1 Uric acid production 
Uric acid is typically not ingested from the diet but produced from the degradation of exogenous 
and endogenous purines (human diet contains little urate but many purine precursors). The 
major site of uric acid production is the liver, with small amounts being produced in other 
tissues like intestine, muscle, kidney and vascular endothelium (8). Its production depends on 
the process of purine biosynthesis and degradation. Normally, the enzymes involved in the 
purine metabolism maintain a balanced ratio between purine synthesis and degradation in the 
cell. 
 Purine de novo synthesis and salvage  
Purines, as the monomeric precursors of nucleic acids, perform many important biological 
functions in the cell. They function as essential components of DNA and RNA nucleic acids to 
store, transcribe and translate genetic information (9). Purines are also the structural components 
of some co-enzymes (e.g., nicotinamide adenine dinucleotide [NAD]) and provide the source of 
cellular energy through adenosine triphosphate (ATP). These functions have been shown to play 
critical roles in modulating cellular energy metabolism and signal transduction (10). A balanced 
quantity of purines is required by cells for their growth, proliferation and survival. In order to 
replace the obligatory loss of purines during tissue nucleic acid turnover, purine nucleotides are 
mainly supplied through two biosynthesis pathways: de novo synthesis and salvage (Figure 1-1).  
Purine nucleotides can be synthesised de novo with simple starting materials (i.e., glycine, 
glutamine, aspartate, formate, and CO2) which involves a multistep biosynthesis (11). Purine 
biosynthesis is initiated on a backbone of ribose-5-phosphate to form a phosphorylated ring 
structure (5-phosphoribosyl-1 Pyrophosphate, PRPP), and this reaction is catalysed by the PRPP 
aminotransferase. Following a series of reactions utilising ATP, glutamine, glycine and 
aspartate, this pathway yields inosine monophosphate (IMP). IMP is then converted into either 
adenosine nucleotide (AMP) or guanosine nucleotides (GMP). Of note, the process of purine de 
Chapter 1  Background 
18 
 
novo synthesis is highly energy consuming, which consumes 8 ATP equivalents for the 
synthesis of AMP and 9 ATP equivalents for the synthesis of GMP. The two rate-limiting 
enzymes of these reactions, PRPP synthase and glutamine-PRPP amidotransferase, are both 
subject to the feed-back control of various purine nucleotides. The second pathway for purine 
biosynthesis is known as purine salvage, which contributes to recover the purine bases (i.e., 
adenine, hypoxanthine, and guanine), either from the nucleic acid turnover or from the dietary 
nucleic acids, into the forms of adenine and guanine nucleotides. Salvage process involves re-
synthesis of nucleotides from bases through two phosphoribosyltransferases: (i) adenine 
phosphoribosyltransferase (APRT) mediating the conversion from adenine to AMP; and (ii) 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) acting on either hypoxanthine to 
produce IMP or on guanine to produce GMP. These enzymes involved in salvage pathway are 
widely distributed among human tissues. The de novo synthesis and salvage pathways 
contribute interactively to maintain a constant and desired purine nucleotide pool for human 
body.  
Exogenous purines from diet, which are absorbed mainly as nucleosides and free bases, can also 
partly enter the body pool of purines. An abundant supply of exogenous purine precursors could 
affect the pathways of purine metabolism (12). Its effects on the de novo purine synthesis 
include: (i) depressing the activity of PRPP aminotransferase that catalyses the initial reaction of 
purine de novo synthesis, given this enzyme can be inhibited by the feed-back of the high level 
of purine nucleotides (e.g., ATP, ADP); and (ii) reducing the supply of PRPP (S-
phosphoribosyl-1-pyrophosphate), a substrate for de novo synthesis. These actions subsequently 
divert the PRPP away from the de novo synthesis process resulting in the de novo synthesis 
being minimised or switched off. Moreover, the purine salvage process is also subjected to 
feedback inhibition by purine levels. Once the cellular level of purine nucleotides reaches the 
required level, an increasing load of purines will inhibit the activities of enzymes (i.e., APRT 
and HGPRT) and consequently direct the purines towards the degradation process to produce 
uric acid.  




Figure 1 - 1: Precursors and pathway of purine de novo synthesis and salvage. 
Dark grey boxes denote enzymes contributing to purine de novo synthesis pathway; light grey boxes 
denote enzymes contributing to purine salvage pathway. Red lines represent feedback inhibition of 
the rate limiting steps of the purine biosynthetic pathway, regulating the activity of the PRPP 
amidotransferase. Abbreviations: PRPP, 5-phosphoribosyl 1-pyrophosphate; IMP, inosine 5-
monophosphate; AMP, adenosine 5-monophosphate; XMP xanthosine 5-monophosphate; GMP, 
guanosine 5-monophosphate; purA, adenylosuccinate synthetase; purB, adenylosuccinate lyase; 
guaB2, IMP dehydrogenase; guaA, GMP synthase; apt, adenine phosphoribosyltransferase; hpt, 
hypoxanthine-guanine phosphoribosyltransferase; (Source: adapted from reference (12) with 
permission covered by Creative Commons Attribution License [CC BY]).  
 Purine degradation and uric acid formation 
The main pathways of purine degradation are outlined in Figure 1-2. Briefly, purine nucleotides 
are converted into nucleosides by intracellular nucleosidases first; nucleosides are then 
converted to inosines by adenosine deaminase; inosines are further degraded by the enzyme 
purine nucleoside phosphorylase (PNP) to release the purine base and ribose-l-P. The PNP 
products are merged into xanthine by guanine deaminase and xanthine oxidase, and xanthine is 
then oxidised to uric acid by this latter enzyme. The major steps of uric acid formation could be 
summarised as: 
(i) Dephosphorylation – The purine molecules (AMP, IMP, and GMP) are dephosphorylated 
into the corresponding nucleotides (adenosine, inosine, and guanosine) by the enzyme 5-prime 
nucleotidase (5'-NT).  
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(ii) Deamination – The AMP (nucleotide) and adenosine (nucleoside) are deaminated into IMP 
and inosine correspondingly. These reactions are catalysed by AMP deaminase (AMPD) and 
adenosine deaminase (ADA), respectively.  
(iii) Glycosidic bond cleavage – The nucleoside inosine is then converted into hypoxanthine and 
the nucleoside guanosine is converted into guanine, which are both catalysed by purine 
nucleotide phosphorylase (PNP).  
(iv) Uric acid formation – Hypoxanthine and guanine are oxidised into xanthine by xanthine 
oxidase (XO) and guanine deaminase (GDA) respectively. Xanthine is finally catalysed into 
uric acid by xanthine oxidase. 
 
 
Figure 1 - 2: Purine degradation and UA production. 
Both endogenously and exogenously purines share the same pathway for degradation to uric acid. 
Abbreviations: GTP, guanosine triphosphate; ATP, adenosine triphosphate; PRPP, 5-phosphoribosyl 
1-pyrophosphate; IMP, inosine 5-monophosphate; AMP, adenosine 5-monophosphate; GMP, 
guanosine 5-monophosphate; (Source: adapted from Reference (13) with permission covered by CC 
BY). 
 Inborn disorders in purine metabolism  
As explained above, each step of purine metabolism highly depends on the activities of enzymes 
catalysing the corresponding reactions. Genetic deficiency in any enzyme involved in purine 
synthesis, recycling or degradation processes, will cause purine nucleotides to not be 
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metabolised properly and result in different hereditary disorders (14). Inborn disorders resulting 
in abnormalities in purine de novo synthesis include: (i) phosphoribosylpyrophosphate 
synthetase superactivity, (ii) adenylosuccinase deficiency, and (iii) 5-amino-4-
imidazolecarboxamide (AICA) riboside deficiency (AICA-ribosiduria). Inborn disorders 
causing abnormalities in purine salvage pathway include: (i) hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) deficiency, and (ii) adenine phosphoribosyltransferase 
(APRT) deficiency. Inborn disorders leading to abnormalities in purine catabolism include: (i) 
muscle adenosine monophosphate (AMP) deaminase deficiency, (ii) adenosine deaminase 
deficiency, (iii) purine nucleoside phosphorylase deficiency, and (iv) xanthine oxidoreductase 
deficiency. These inborn disorders in purine metabolism would over-ride the control of uric acid 
metabolism homeostasis and result in either hypouricaemia or hyperuricaemia (see Chapter 1, 
Section 1.2 “Hyperuricaemia” for more information).  
1.1.2.2 Uric acid excretion 
The daily production of uric acid from purine catabolism is relatively constant at 300 to 400mg 
(8). Unlike other mammals having the enzyme uricase to convert uric acid into a more soluble 
allantoin for excretion, metabolism of uric acid in human tissues is negligible. To maintain 
homeostasis, uric acid is eliminated intact from the human body via two routes: the 
gastrointestinal tract and the kidney (15). 
 Intestinal secretion 
A small portion of uric acid is secreted into the gastrointestinal tract for disposal. The secretion 
of uric acid (via biliary and/or intestine) in the gastrointestinal tract is thought to be by both 
passive permeation (depending on the urate concentration) and active transportation (mediated 
by high-capacity urate efflux transporters) (16). The intestinal urate transporters have not been 
well investigated so far, but recent studies report a high expression level of ABCG2 gene 
(encoding a high-capacity urate efflux transporter) in the intestinal epithelium and suggest that 
the ABCG2 transporter plays an important role in the intestinal secretion of uric acid (17). The 
secreted uric acid is further degraded by intestine bacteria (18). Especially in the lower intestine 
tract, uric acid is exposed to a large number of bacteria, e.g., Escherichia coli, Aerobacter 
aerogenes and Paracolobactrum species. Uricase from these bacteria can catabolise uric acid 
into carbon dioxide (CO2) and ammonia (NH3), which are then reabsorbed or eliminated as 
intestinal air (19). This breakdown process of uric acid in the gut lumen is known as intestinal 
uricolysis and is responsible for 30% of the total uric acid disposal (20). Nearly all uric acid 
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secreted in the gut is completely degraded by the intestinal flora, with a only small amount 
being found in human faeces (15).  
 Renal excretion 
It is estimated that renal excretion is responsible for the remaining 70% of the daily uric acid 
disposal (21). The excretion of urate via the kidney largely depends on renal function. 
Glomerular filtration rate (GFR) describes the flow rate of filtered fluid through the kidney, 
which is an indication of the kidney condition. Fractional extraction of urate (FEUR) is used to 
represent the percentage of filtered urate that is finally excreted via urine. It is calculated as the 
ratio of urate clearance (CUA) to creatinine clearance (CCr, an approximation to GFR), with the 
formula: FEUA= [(UUA × Urine sample volume)/PUA] / [CCr = (UCr × Urine sample volume)/PCr] 
×100% = (UUA × PCr)/ (UCr × PUA) ×100% (UUA: urinary urate concentration; PUA: plasma urate 
concentration; UCr: urinary creatinine concentration; PCr: plasma creatinine concentration). 
It is reported that nearly all circulating urate (>95%) is readily available to be filtered at the 
glomerulus, however, the FEUA in healthy adults is only 10% (range: 7-12%), indicating that 
the net tubular reabsorption of the filtered urate is about 90% (22). The renal handling process 
on urate is predominately explained by a classical model including four distinct components: (i) 
glomerular filtration, (ii) reabsorption in the proximal tubule, (iii) secretion near the terminus of 
the proximal tubule, and (iv) post-secretory reabsorption near these secretory sites. Specifically, 
almost all urate is filtered at the glomeruli; subsequently, pre-secretory reabsorption returns the 
majority of the filtered urate into the early proximal tubule; in the proximal tubule, 50% of the 
filtered urate is secreted back into the tubular lumen, and then the secreted urate undergoes post-
secretory reabsorption resulting in 7-12% of filtered urate load being excreted by the kidney 
(22).   
 Molecular mechanisms of urate transport 
The molecular mechanisms underlying the renal and intestinal handling processes of urate are 
not completely understood, but urate transporters are believed to play pivotal roles. The urate-
organic exchanger and voltage-sensitive pathways are suggested as the major two modes of 
urate transport. Among these identified transporters, URAT1 (organic anion transporter 1) and 
GLUT9 (glucose transporter 9) are believed to play important roles in renal reabsorption of 
urate, while ABCG2 (ATP-binding cassette sub-family G member 2) and ABCC4 (ATP-
binding cassette sub-family C member 4) are responsible for urate secretion (21).   
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URAT1, encoded by the SCL22A12 gene, is the major organic anion transporter (OAT) for 
urate (23).  SCL22A12 is uniquely expressed in the luminal membrane of the proximal renal 
tubular epithelium. Urate transport mediated by URAT1 is independent of the sodium-urate co-
transport but could be interfered with by organic anions, such as lactate, nicotinate, 
hydroxybutyrate, acetoacetate, and succinate. Intracellular accumulation of organic anions, 
which have an affinity with URAT1, facilitates the reabsorption of urate to exchange these 
anions out of the cell to maintain electronic balance. After being absorbed into the cell, urate 
then moves across the basolateral membrane into the blood by means of other organic anion 
exchangers, of which the most important one is GLUT9. GLUT9 is encoded by SLC2A9 gene 
and highly expressed in the kidney and weakly expressed in the liver and intestine (24). Apart 
from its strong ability in urate transport, it has also been previously identified as a fructose 
transporter (25).   
Uric acid secretion seems to be primarily mediated by the voltage-sensitive urate transporter, 
ABCG2, which substantially localises on the apical side of proximal tubular cells (26). ABCG2 
is also expressed in the intestinal epithelium to a lesser extent, which is believed to contribute to 
the movement of urate into the gut (17). Another candidate, ABCC4, also known as the 
multidrug resistance-associated protein 4 (MRP4) or multi-specific organic anion transporter B 
(MOAT-B), is a member of the adenosine triphosphate-binding cassette transporter family (27). 
ABCC4 is a novel renal apical organic anion efflux transporter, which mediates the secretion of 
urate and other organic anions, for instance, cGMP and cAMP (28).   
Other molecular mechanisms contributing to urate transport in renal tubular cells and intestinal 
epithelial cells have also been proposed, but their specific roles in the physiology of urate 
transport are still under investigation. The identified urate transporters with their localisations 
and physiological functions are summarised in Table 1-1 and Figure 1-3. 





Function Localisations Contribution 
URAT1  SLC22A12 Urate-anion exchanger Apical Reabsorption 
GLUT9  SLC2A9 Urate uniporter  Basolateral Reabsorption 
ABCG2  ABCG2 Urate uniporter Apical Secretion 
NPT1 SLC17A1 Na-phosphate cotransporter;   
Organic ion uniporter 
Apical Secretion 
NPT4  SLC17A3 Organic ion uniporter Apical Secretion 
OAT4 SLC22A11 Organic anion-dicarboxylate 
exchanger  
Uncertain Reabsorption 
OAT1  SLC22A6 Organic anion-urate exchanger Basolateral Secretion 
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OAT3  SLC22A8 Organic anion-urate exchanger Basolateral Secretion 
MCT9 SLC16A9 Monocarboxylic anion 
transporter  
Uncertain Uncertain 
ABCC4 ABCC4 ATP-dependent anion pump; 
Urate ion pump 
Uncertain Secretion 
Source: adapted from reference (21) with permission from the Springer Nature Publisher [reference 
number:4353060751528].   
 
 
Figure 1 - 3: Models for urate transport.  
Blue circles represent function confirmed by genome-wide association studies (GWAS), mutations 
in humans, and in vitro studies. Pink circles represent function confirmed by GWAS and in vitro 
studies. White circles represent strong in vitro data. Question marks refer to proposed but uncertain 
function. OAT, organic anion transporter; (Source: adapted from reference (21) with permission 
from the Springer Nature Publisher [reference number:4353060751528]).  
1.1.3 Biological function 
Uric acid has long been regarded as a metabolically inert waste product produced from catalytic 
activity of xanthine oxidoreductase. However, as increasing evidence shows uric acid has 
multiple biological roles (behaving as both anti-oxidant and pro-oxidant) in affecting the 
oxidative status in cultured cells, there are great controversies regarding its role in 
pathophysiology, with some researchers suggesting that it is simply a marker of xanthine 
oxidoreductase activity (29), others stating that it may exert beneficial effects as an anti-oxidant 
(30, 31), and others suggesting that it may induce the risk of oxidative stress due to its pro-
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oxidative properties (32, 33). This section is a brief review on the role of uric acid as an anti-
oxidant, pro-oxidant or surrogate marker under different conditions.  
1.1.3.1 Uric acid as an anti-oxidant 
According to an evolutionary hypothesis, the silencing of the uricase genes, resulting in an 
increased SUA level, provides a survival advantage for ancestors of Homo sapiens (34). Uric 
acid was believed to be one of the most important antioxidants circulating in the blood to 
protect cells from oxidative damage, thereby contributing to a prolonged lifespan and reduced 
risk of cancer (35). This hypothesis was based on in vitro experiments which demonstrated that 
uric acid can scavenge oxygen radicals and thus protect cells from oxidation.  
This property of uric acid, as a powerful scavenger of single oxygen peroxyl and hydroxyl 
radicals (-OH), was firstly demonstrated by Kellogg et al (36) and was further characterised by 
Ames et al (35). It has been indicated that uric acid acts as an antioxidant by reacting with a 
variety of oxidants, such as hydroxyl radical, peroxynitrite, and nitric oxide (37). The most 
classical scavenging process is the reaction of uric acid with the hydroxyl radical (OH), 
resulting in the formation of allantoin. In addition, uric acid could also react with peroxynitrite, 
a vital biological oxidant generated from the reaction of nitric oxide (NO) with a superoxide 
anion, to convert it into triuret (38, 39). Moreover, uric acid has also been reported to react with 
NO to produce a nitrosated compound with the capability of donating NO (40). Uric acid can 
also block ferrous (Fe2+) catalysed oxidation reactions in human (41). However, the ability of 
uric acid as an antioxidant is limited by several conditions. Specifically, uric acid is unable to 
scavenge superoxide (O2−), and the scavenging process of peroxynitrite requires the presence of 
ascorbic acid and thiols (32, 38). The antioxidant property of uric acid could also be disabled by 
some compounds present in the body fluids. For example, the presence of bicarbonate can 
significantly inhibit the ability of uric acid to prevent the process of tyrosine nitrosylation, 
which is a critical step of oxidative damage of cellular proteins (42). Additionally, uric acid 
cannot scavenge lipophilic radicals and has no ability to break the radical chain propagation 
within lipid membranes (43). These physicochemical findings indicate that the antioxidant 
effect of uric acid is limited and probably manifested only in the hydrophilic environment of 
biological fluids, such as plasma.  
1.1.3.2 Uric acid as a pro-oxidant  
The ability of uric acid acting as a pro-oxidant has always been related to the induction of 
oxidative stress. Oxidative stress is a condition of excessive production of free radicals and/or 
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reactive oxygen species (ROS), as well as reduced anti-oxidative ability, which is usually due to 
the decreased intake or excessive consumption of antioxidants (44). It has been shown that the 
antioxidant reactions of uric acid with oxidants are accompanied by the formation of a variety of 
free radicals (45, 46). Radicals derived from these antioxidant reactions represent different 
degradation degrees of the uric acid molecule, varying from the urate anion (the radical site is 
located on the five-membered ring structure of uric acid) to carbon-based radicals, such as 
aminocarbonyl (which is generated after the breakdown of the five-membered ring structure due 
to the ONOO− attack) (45, 46). Uric acid itself and/or its downstream radicals seem to induce 
lipid oxidation, which can stimulate oxidant production in adipocytes (33). The increased level 
of oxidised lipids could in turn propagate a radical chain reaction and cause oxidative stress. 
The pro-oxidative effects of uric acid are likely mechanised through activating a nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase-dependent pathway, which results in 
increased production of reactive oxygen species (ROSs) (33). In contrast to its anti-oxidative 
effect, the pro-oxidative property of uric acid inducing oxidative stress mainly occurs in the 
intracellular environment, particularly in adipocytes (32). 
1.1.3.3 Uric acid as a surrogate marker of XOR activity  
Uric acid has also been recognised as a surrogate marker of xanthine oxidoreductase (XOR) 
activity. XOR is an enzyme that catalyses the production of uric acid with two forms, xanthine 
dehydrogenase and xanthine oxidase (47). Xanthine dehydrogenase has an affinity for oxidised 
NAD to convert it into uric acid and NADH (48). Xanthine oxidase first catalyses the oxidation 
of hypoxanthine to xanthine and further catalyses the oxidation of xanthine to uric acid, with the 
production of two oxidant molecules (one superoxide is produced in each step) (47). The ROSs 
generated by XOR activity from the formation of uric acid are thought to play a vital role in 
increasing oxidative stress. Hence, in this situation it becomes unclear if uric acid itself induces 
the damaging oxidative stress or it simply represents a surrogate marker of high-level oxidative 
stress due to the increased XOR activity. Although many experimental studies in animals 
support the pathophysiologic role of uric acid as discussed above (37), evidence from human 
studies is unclear. Clinical trials have been performed to examine the role of uric acid in disease 
states by utilising XOR inhibitors (49, 50). Xanthine oxidase inhibitors can reduce uric acid 
formation, but they can also decrease XOR induced superoxide generation, thus it is uncertain if 
any benefits observed with xanthine oxidase inhibitors are due to the decreased SUA level or 
due to the reduction of xanthine oxidase-associated oxidants. Given these, more efforts are 
required to clarify the pathophysiologic role of uric acid in humans. 
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1.2 Hyperuricaemia  
Abnormally elevated SUA level is the most common dysregulation of urate metabolism. 
Hyperuricaemia is a clinical term traditionally applied to the settings in which SUA levels are 
elevated with or without any clinical manifestation. Two-thirds or more of individuals with 
hyperuricaemia may have no clinical symptoms (asymptomatic hyperuricaemia), while one-
third have the signs of monosodium urate (MSU) crystal deposition in joints (e.g., gout) or 
kidneys (e.g., nephrolithiasis) (51).  Increased uric acid production, decreased uric acid 
excretion, or a combination of both problematic processes are the commonest causes of 
hyperuricaemia. The decreased efficiency of urate excretion is responsible for about 85%-90% 
of hyperuricaemia, while the remaining 10%-15% is caused by uric acid overproduction, which 
is often induced by genetic defects, disease conditions or intake of drugs or purine-rich diet (52). 
The definition/classification, aetiology, epidemiology and management of hyperuricaemia are 
presented in this section.  
1.2.1 Definition of hyperuricaemia 
There is no universally applicable definition for hyperuricaemia. It could be defined in several 
ways (Table 1-2), including population values, physiochemical cut-point, or the levels 
associated with disease risk.  
A statistically based definition for hyperuricaemia refers to the SUA level more than two 
standard deviations (SDs) above the mean of the healthy population. However, given the non-
normal distribution of SUA level in most populations and variations based on ethnicity, age and 
sex, the statistical definition of hyperuricaemia varies among populations (53). 
A physiochemical definition of hyperuricaemia based on the solubility limit of uric acid in 
plasma is preferred when compared to the statistical definition (53). This physiochemical 
definition corresponds to a SUA level of more than 416 µmol/L (7.0 mg/dL) as measured by an 
automated enzymatic method or corresponds to a SUA level of more than 476 µmol/L (8.0 
mg/dL) as measured by a colorimetric method.  
Epidemiological studies have shown that associations of high SUA level with non-crystal 
deposition disorders are always observed without reaching the saturating concentration. In this 
case, it is indicated that the physiochemical definition may not be appropriate for clinical 
practice (54). For practical and/or clinical purposes, an alternative definition of hyperuricaemia 
is suggested by some experts, in which a concentration of SUA exceeding 357 µmol/L in blood 
is used as the threshold of clinically relevant hyperuricaemia (53, 54). This reference value 
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integrates the estimated threshold for the lifelong risk for clinical consequences of 
hyperuricaemia and fits the recommended goal (<357 µmol/L) of clinical urate-lowering 
treatment in gout patients (55). Additionally, another significant threshold of SUA level is >476 
µmol/L and this reference value is applied as the threshold of initiating evaluation and 
lifestyle/pharmacologic intervention on patients with asymptomatic hyperuricaemia (55).  
Table 1 - 2: Definitions for hyperuricaemia.  
Definition  Criteria  Weakness 
Statistical definition SUA level >2 standard deviations above 
the mean value of healthy population  
Variations due to ethnicity, 
age, and sex, etc.  
Physiochemical definition Based on the saturation point of uric acid 
when monosodium urate crystals occur.  
Changes according to 
temperature and the PH.  
Definition based on the 
treatment target of gout 
and the potential of other 
diseases 
For all gout patients, the treatment target 
of SUA level is <357 µmol/L; for 
patients with severe gout, the treatment 
target of SUA level is <297 µmol/L.  
Differs between conditions.  
Source: adapted from reference (53, 56) with permission from the Elsevier publisher [reference 
number: 4353120627211].  
Among these definitions, SUA level above 416 µmol/L is the most widely used threshold to 
define hyperuricaemia, as there appears to be little disagreement regarding to the 
physiochemical characteristics of uric acid. Hyperuricaemia could be further classified into two 
categories based on the causes: (i) primary hyperuricaemia refers to a rise of SUA level due to 
genetic deficiencies; (ii) secondary hyperuricaemia refers to excessive uric acid production or 
decreased renal clearance caused by acquired clinical disorders, drugs, purine-rich diet, or 
toxins. Primary hyperuricaemia usually occurs in childhood and last indefinitely, while 
secondary hyperuricaemia can occur at any age.  
1.2.2 Aetiology  
The underlying aetiological mechanisms of hyperuricaemia could be classified into three 
categories: increased uric acid production (e.g., inherited enzyme defects, increased cell 
turnover and tissue hypoxia, purine-rich diet), decreased uric acid excretion (e.g., kidney disease, 
certain drugs, metabolic or endocrine diseases), and mixed type (e.g., high levels of alcohol 
and/or fructose, moderate/severe exercise, starvation). The main causes of hyperuricaemia are 
described below.  
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1.2.2.1 Inherited enzyme defects  
Genetic mechanisms inducing hyperuricaemia include overproduction of uric acid due to 
hypoxanthine–guanine phosphoribosyltransferase (HGPRT) deficiency or, 
phosphoribosylpyrophosphate (PRPP) synthetase overactivity or glucose-6-phosphatase (G6PT) 
deficiency (57). These inherited defects often lead to early development of severe 
hyperuricaemia. 
 Hypoxanthine-guanine phosphoribosyltransferase (HGRPT) deficiency 
HGRPT is a transferase that catalyses the conversion of hypoxanthine to inosine 
monophosphate and guanine to guanosine monophosphate. HGRPT deficiency is a rare 
inherited disorder caused by mutations in the HGPRT gene localised on the long arm of the X 
chromosome (57). Absence of HGRPT prevents the normal metabolism of hypoxanthine 
resulting in excessive uric acid production. A complete loss of HGPRT activity results in a 
severe disorder, called Lesch-Nyhan syndrome(58), and a partial deficiency in HGPRT activity 
causes a moderate disorder, called Kelley–Seegmiller syndroms (59). Both of them are 
characterised by overproduction of uric acid.  
 Phosphoribosylpyrophosphate (PRPP) synthetase over-activity 
Phosphoribosylpyrophosphate (PRPP) synthetase over-activity is an X-linked disorder of purine 
metabolism (57). Mutations in the PRPP synthetase (PRPS) gene lead to over-activity of PRPP 
synthetase and therefore increase the production of PRPP (60). Increased level of PRPP 
enhances de novo synthesis of purine nucleotides. When excessive production of purine 
nucleotides exceeds the need of the human body, the excess purine nucleotides are catabolised 
leading to overproduction and accumulation of uric acid. Clinical consequences of PRPP 
synthetase over-activity include an early-onset severe form, characterised by gout, urolithiasis, 
and neurodevelopmental anomalies (severe PRPP synthetase over-activity), and a mild late-
onset form with no neurologic damage (mild PRPP synthetase over-activity). Both of them are 
characterised by overproduction of uric acid.  
 Glucose-6-phosphatase (G6PT) deficiency  
Deficiency in G6PT is inherited as an autosomal recessive trait, leading to type I glycogen 
storage disease (61). Clinical consequences associated with this defect are increased uric acid 
production and symptoms of gout (61). The inability to dephosphorylate G6PT leads to an 
increased diversion of glucose into the pentose phosphate pathway (PPP). One of the main 
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products of PPP is ribose 5-phosphate. Increased production of ribose 5-phosphate leads to 
substrate-level activation of PRPP synthetase. Over-activity of PRPP synthetase has the same 
consequence as the inherited defect in the PRPS gene resulting in overproduction of uric acid as 
explained above. 
1.2.2.2 Accelerated cell turnover and tissue hypoxia 
Uric acid overproduction also occurs in the setting of increased cell turnover or tissue hypoxia. 
Certain types of tumours, such as metastatic cancer, multiple myeloma, leukaemia and 
lymphomas, can induce hyperuricaemia. Overproduction of uric acid in these cancers results 
both from the increased turnover rate of cell death and from the use of chemotherapy agents. 
With rapidly growing tumours, there are high rates of cell turnover and tumour proliferation, 
generating a large amount of purine nucleotides. Chemotherapy treatments can also cause 
overproduction of  uric acid due to tumour lysis syndrome (TLS), characterised  by a rapid 
amount of cellular destruction (62). Massive cell death and nuclear breakdown generates large 
quantities of nucleic acids. Of these, the purine nucleotides are catabolised into uric acid via the 
purine degradation pathway. At a high level of uric acid production, hyperuricaemia and MSU 
crystals occur. Additionally, overproduction of uric acid could also be induced by tissue 
hypoxia, under which ATP is consumed with the generation of its isoform xanthine oxidase (a 
necessary enzyme catalysing the formation of uric acid) (63). This may probably explain the 
high SUA level in individuals with congestive heart failure, congenital cyanotic heart disease, 
high altitude hypoxia, or obstructive sleep apnoea due to hypoxia (63, 64).  
1.2.2.3 Renal insufficiency  
Decreased efficiency of renal excretion of uric acid is responsible for about 85%-90% of 
hyperuricaemia, due to the complexity of the renal handling of uric acid, the sensitivity of 
kidney to metabolites and drugs, and mutations in urate transporter coding genes. Under-
excretion of urate appears to be a combination of decreased glomerular filtration, decreased 
tubular secretion, and increased tubular reabsorption. With acute and/or chronic kidney diseases, 
the kidney loses its ability to filter uric acid properly, leading to accumulation of uric acid in the 
blood. Decreased tubular secretion of urate often occurs in patients with metabolic or endocrine 
diseases (e.g., diabetic/starvation ketoacidosis, lactic acidosis, and ethanol or salicylate 
intoxication), as organic acids (e.g., lactate, acetoacetate, and beta-hydroxybutyrate) accumulate 
in these conditions and compete with uric acid for tubular secretion. Additionally, diuretic 
therapy can induce hyperuricaemia by enhancing reabsorption of uric acid in the distal tubule. 
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Some medications, such as pyrazinamide, salicylates, nicotinic acid, ethambutol, cyclosporine 
and cytotoxic agents, can interfere with the renal urate excretion, causing a rise in SUA level.  
1.2.2.4 Diet, starvation, and exercise 
Hyperuricaemia may also result from diet rich in purines, alcohol or fructose. Diet containing a 
high concentration of purines includes organ meat such as kidney and liver, red meat, poultry, 
fish, sardines, anchovies, mushrooms, yeast and beer (65). Exogenous intake of purines from 
diet can enrich the purine pool and enhance the degradation of purine nucleotides with the 
formation of excessive uric acid. Alcohol consumption can increase uric acid synthesis due to 
enhanced turnover of ATP from the conversion of acetate to acetyl-CoA during the metabolism 
of ethanol (66). In addition, acute large amounts of alcohol consumption can increase the 
production of lactate that can reduce renal urate excretion and exacerbate hyperuricaemia (67). 
Fructose, a simple sugar widely present in sucrose, honey, and fruits, can also rapidly increase 
SUA level. This is in part due to its rapid phosphorylation in hepatocytes with ATP 
consumption, intracellular phosphate depletion, and the stimulation of AMP deaminase with the 
generation of uric acid (68). Fructose intake also stimulates the synthesis of uric acid from 
amino acid precursors (68). The remarkable increase in fructose intake in populations may play 
a role in the rising level of SUA worldwide (69). 
Starvation can also increase SUA level by both increasing uric acid production and decreasing 
uric acid excretion. In starvation, the body breaks down its own (purine-rich) tissues for energy, 
thus rapid weight loss exacerbates hyperuricaemia (70, 71). Starvation can also impair the 
ability of the kidney to excrete uric acid, because of the competition between uric acid and 
ketones for transport (72).  
In addition, SUA level may be affected by exercise, with moderate exercise reducing SUA level 
(probably because of the increased renal blood flow) and severe exercise increasing SUA level 
(probably due to the ATP consumption and thereby the formation of adenosine and xanthine) 
(73).  
1.2.3 Epidemiology of hyperuricaemia 
Elevation of SUA level is evident in all world regions, particularly in Asia and the North 
America, where epidemiological data are abundant. However, the global burden of 
hyperuricaemia is difficult to be precisely quantified due to considerable regional variations. 
The purpose of this section is to summarise the epidemiologic characteristics of hyperuricaemia 
in terms of prevalence and incidence in different world regions. In order to capture the global or 
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national data on the epidemiology of hyperuricaemia, a systematic literature search was 
conducted in the MEDLINE and EMBASE on 12th November 2017 by using the MeSH terms: 
“gout or hyperuri*” AND “prevalen* or inciden* or epidemiolo*”. The retrieved literature was 
screened in title, abstract and full text review by myself. Population-based epidemiological 
studies on hyperuricaemia were eligible for inclusion and their findings are described below.   
1.2.3.1 Geographical prevalence  
In this literature review, 34 articles were finally included, reporting the population-based 
prevalence/incidence of hyperuricaemia for a total of 24 countries, which are grouped into 6 
WHO regions (Table 1-3). The proportion of individuals with hyperuricaemia was highly 
variable (range: 4.9%-53.8%) across various regions of the world with data lacking for many 
countries.  
 Western Pacific region 
The highest prevalence of hyperuricaemia was reported in the Western Pacific region within the 
ethnic group of Taiwanese aboriginals, for which the estimate was 53.8% (74). The prevalence 
of hyperuricaemia in mainland China was between 11.0%-32.1% from the population-based 
surveys of several areas (75-79). Data from Japan reported a high prevalence of 34.5% (80, 81). 
In contrast, a very low prevalence of 4.9% was reported in South Korea (82). In Oceania area, 
the Pacific islanders also had a high prevalence of hyperuricaemia (83-85). In the Australia 
Nation Health Survey, the crude prevalence estimate of hyperuricaemia in the general 
population was 23.0% (86), while the corresponding estimate for the white Australians was 12.0% 
(87). In New Zealand, hyperuricaemia was found in 15.3% of non-Maori adults (88), while the 
corresponding estimate for Maori individuals was in the range of 27.8%-49% (88, 89). 
 South-East Asia 
Data from South-East Asia were only available for two countries, in which Indonesia reported a 
high prevalence of 34.5% (80, 81), and the corresponding estimate for Thailand was18.4% (90).  
 Americas 
Data from the US National Health and Nutrition Examination Survey (NHANES) 2007–2008 
study reported a 21.6% prevalence of hyperuricaemia in the US adults (91). The prevalence was 
much lower in European Americans (7.5%) and Native Americans (range: 3.3%-7.2%) (92, 93).  
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A sample population in Mexico City was reported to have a hyperuricaemia prevalence of 26.5% 
in men and 19.8% in women (94). In Brazil, the prevalence of hyperuricaemia was reported in 
the range of 3.2%-5.6% for different age groups (95, 96). 
 Eastern Mediterranean  
For the Eastern Mediterranean region, only one study was identified, which reported a 
prevalence of 8% for Saudi Arabia (97). 
 Europe 
The prevalence of hyperuricaemia in Europe was reported for 6 countries with a range from 6.6% 
to 19.0%. In the UK, the prevalence of hyperuricaemia was reported to be 6.6%-8.0% (98, 99). 
A similar hyperuricaemia prevalence of 6.6% was reported in the Finnish population (100). A 
regional community-based study in Italian population reported a range of 8.5%-11.9% for 
hyperuricaemia prevalence (101). Studies in France, Turkey and Russia, reported very similar 
prevalence of 17.6%, 19.0%, and 16.8%, respectively (102-104).  
 Africa 
In Africa, the prevalence of hyperuricaemia was reported to be 20.5% in Nigerian men (105), 
25.0% in black Africans in Angola (106), 35.2% in Seychellois men and 8.7% in  Seychellois 
women (107).  
Table 1 - 3: Prevalence of hyperuricaemia in different world regions.  
WHO regions  Population  Prevalence (%) Reference 
Western Pacific region    
China, Mainland Han Chinese  11.0-32.1% (75-79) 
China, Taiwan Taiwanese Aborigines 53.8% (74) 
Japan, Okinawa Japanese 34.5% (80) 
South Korea Middle-aged men 4.9% (82) 
Australia 
White Australian 12.0% (87) 
General Population  23.0% (86) 
New Zealand 
Non-Maori 15.3% (88) 
Maori 27.8-49.0% (88, 89) 
Cook Islands 
Rarotongans 44.0% (83) 
Pukapukans 48.5% (83) 
Samoa Samoans (urban) 36.4% (84) 
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Samoans (rural) 43.3% (84) 
Fiji 
Fijians (urban) 32.4% (85) 
Fijians (rural) 16.9% (85) 
South-East Asia    
Indonesia, Java Malayo-Polynesians 24.3% (81) 
Thailand Thai 18.4% (90) 
Americas    
United States (USA) 
Americans of multiple 
ancestries 
21.2% (91) 
USA, Michigan European Americans 7.5% (92) 
USA, Montana Native Americans 3.3-7.2% (93) 
Mexico 
Mexican men 26.5% (94) 
Mexican women 19.8% (94) 
Brazil  Amerindians 3.2-5.6% (95, 96) 
Eastern Mediterranean    
Saudi Arabia Saudis 8.0% (97) 
Europe    
UK English 6.6-8.0% (98, 99) 
Finland Finnish 6.6% (100) 
France French 17.6% (102) 
Turkey Turkish 19.0% (103) 
Russia  Russian 16.8% (104) 
Italy Italian 8.5-11.9% (101) 
Africa    
Nigeria  Nigeria (men) 20.5% (105) 
Angola Black Africans 25.0% (106) 
Seychelles 
Seychellois (men) 35.2% (107) 
Seychellois (women) 8.7% (107) 
 
1.2.3.2 Incidence and time trend 
Published data on hyperuricaemia incidence are limited. However, it is evident that the trend of 
hyperuricaemia has been steadily rising in recent decades (108, 109). The rising incidence of 
gout indirectly reflects the progressive increase in SUA level (110). Over time, the incidence of 
gout in the US adults increased from 0.03% in 1978 to 0.05% in 1996 (111). Similarly, the 
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NHANES found that the self-reported lifetime prevalence of gout increased from 2.6% in the 
NHANES 1988–1994 to 3.8% in the NHANES 2007–2010 (112). Correspondingly, SUA level 
had also consistently increased over the interval between the two NHANES studies (91). The 
UK General Practice Research reported that the gout incidence increased steadily from a low of 
11.9 cases per 10,000 person-years in 1991 to a high of 18.0 cases per 10,000 person-years in 
1994 (113). Subsequently, the Royal College of General Practitioners Weekly Returns Service 
reported that the annual prevalence of gout in UK increased slightly from 0.43%  in 2001 to 
0.47% in 2007 (114). Data from successive surveys undertaken in New Zealand showed a 
remarkable increase of gout prevalence in both European descents and Maori residents (115). 
The prevalence of gout in China also increased. Successive population surveys in the city of 
Qingdao found the prevalence of gout was 0.36% in 2002 and had increased to be 0.53% in 
2004 (76, 116). Successive surveys conducted in Shantou area reported a prevalence of 0.17% 
in 1992, 0.15% in 1995 and 0.26% in 1999 (117). 
1.2.3.3 Sex-, age-, and ethnicity-related demographics 
Hyperuricaemia is far more common in men than in women. Primary hyperuricaemia frequently 
begins at puberty in men but is usually delayed until after menopause in women. The sex 
difference is in concordance with the fact that SUA levels in adult men exceed that in women at 
reproductive age, but after menopause, SUA levels in normal women increase and approximate 
that of normal men at a corresponding age. Similarly, when under 65 years old, males have a 
fourfold higher prevalence of gout than females, while this ratio reduces to 3:1 male to female 
when over 65 years (108). The substantial sex difference probably relates to the enhancement of 
renal urate clearance caused by oestrogenic compounds.  
The mean SUA level in children is lower than that in adults. The upper limit of the normal 
reference range of SUA level in children is 297 µmol/L, while the corresponding value is 416 
µmol/L in adult men and 357 µmol/L in adult women (118, 119). Consistently, the risk of 
hyperuricaemia also increases with age. As reported in the NHANES survey, the 
hyperuricaemia prevalence rises with the increasing age groups (91, 108). In particular, the 
incidence of hyperuricaemia and gout is more evident from the age of 30 in men and after the 
age of 50 in women (120). 
The risk of hyperuricaemia and gout varies across different ethnicities (108). Hyperuricaemia 
was much more common in the Pacific Maori than Europeans (27.1% vs. 9.4% in males, 26.6% 
vs. 10.5% in females) (88). In the US, African Americans develop hyperuricaemia more 
frequently than European Americans. It was estimated that African American females had 2.3 
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times higher risk of developing hyperuricaemia comparing to European American females (121). 
The Hmong population in southern China also suffered higher SUA level (122). Filipinos in the 
US are at a higher risk of elevated SUA level than other ancestries in the US (123). 
1.2.4 Clinical evaluation 
Generally, health screening and laboratory evaluation of medical conditions unrelated to urate 
crystal deposition diseases do not routinely include measurement of SUA level (55, 124), unless 
in some cases where individuals were identified with SUA level >476 µmol/L, a follow-up test 
is suggested to confirm the presence of sustained hyperuricaemia (55, 124).  
1.2.4.1 Confirmatory test 
A repeated measurement of SUA level is needed to confirm the presence of sustained 
hyperuricaemia. For patients with a SUA level less than 416 µmol/L in the confirmatory test, 
further follow-up and evaluation are usually not performed. For patients with SUA level 
between 416-476 µmol/L in the confirmatory test, a repeat test should be performed during the 
following 6-12 months. For patients with a SUA level greater than 8 mg/dL in the confirmatory 
test, a more detailed evaluation should be initiated. The decision of no further evaluation on 
patients with SUA level ≤476 µmol/L is a practical compromise, considering the low incidence 
of gout in hyperuricaemia patients with SUA level between 416-476 µmol/L (125). 
1.2.4.2 Preliminary evaluation 
Evaluation is initiated for subjects with SUA level greater than 476 µmol/L in the confirmatory 
test. The preliminary evaluation includes a thorough history and physical examination, such as 
medical conditions, diet or lifestyle habits, pharmaceutical therapies, toxin exposure, or any 
known familial genetic disorders that may cause hyperuricaemia. Initial laboratory tests include 
a complete blood count and differential leukocyte counts, urinalysis, measurement of renal 
function and examinations on chemical profile, including electrolytes, calcium, and liver 
chemistries. In general, the initial evaluation would identify approximately 80%-90% causes of 
hyperuricaemia. Otherwise, additional laboratory examinations are considered to detect some 
specific causative factors. For instance, high level of SUA (>595 µmol/L in children or >714 
µmol/L in adolescents) may indicate a sign of underlying disorders, such as lymphoproliferative 
or myeloproliferative state, or inherited enzyme defects, which are indications for appropriate 
imaging, pathologic, biochemical, and/or genetic measurements. 
In summary, the main aim of preliminary evaluation of hyperuricaemia is to identify: 
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 Patients at high risk of gout or urolithiasis who need anti-hyperuricaemia treatment. 
 Drug or toxin induced hyperuricaemia that can be removed or substituted to relieve the 
hyperuricaemia status. This is especially important to patients for which lifestyle 
modifications and/or alternative pharmacologic medications are available. 
 Individuals whose hyperuricaemia is a sign of underlying disorders (e.g., inherited enzyme 
defects, lymphoproliferative or myeloproliferative state). 
1.2.4.3 Further evaluation  
A measurement of FEUR (fractional extraction of urate), representing the percent of urinary 
urate excretion per unit of GFR, should be performed for high level of SUA without identifying 
any cause during their initial evaluation. The FEUR can be determined by measuring the urate 
and creatinine concentrations in both blood and urine collections (see the Chapter 1, Section 
1.1.2.2 “Renal excretion” for more explanations on FEUR). The blood and urine collections for 
these studies should be carried out under the condition in which the individual has a standard 
diet, without consuming alcohol and drugs known to affect uric acid metabolism. The 
determination of FEUR will help to distinguish between causes resulting from increased uric 
acid production with hyperuricosuria (FEUR>10%) and causes resulting from decreased renal 
clearance (FEUR<6%) (126).  
Urinary uric acid excretion greater than 800 mg/day (4.8 mmol/day) or FEUR >10% is defined 
as hyperuricosuria, indicting excessive uric acid production from either exogenous (dietary) or 
endogenous purine catabolism (127). The exogenously and endogenously determined uric acid 
overproduction can be distinguished by the following clinical evaluations. Patients under 
clinical evaluation should have an isocaloric, purine-reduced diet (consuming 1 gram/kg dairy 
protein per day without intake of meat, seafood, alcohol and medications affecting uric acid 
metabolism) for 3-5 days. For patients with UA excretion >670 mg/day (4 mmol/day), 
endogenous causes of uric acid overproduction (e.g., inherited enzyme defects, or disorders 
resulting in increased rate of cell turnover) should be considered. Otherwise, excessive dietary 
purine consumption is confirmed as the cause of hyperuricosuria for patients whose uric acid 
excretion (less than 670 mg/day [4 mmol/day]) decreases to normal values on a purine-reduced 
diet. Under-excretion of urate but with normal renal function is indicative of genetic defects in 
urate transporter coding genes (functioning either as reduced secretion or as enhanced 
reabsorption), or secondary to reduced renal perfusion (e.g., diuretics). The distinction can 
provide further guidance on the choice of anti-hyperuricaemia drugs for individuals needing 
pharmacologic treatment. 




Despite the high prevalence of hyperuricaemia, pharmacologic therapies on this biochemical 
aberration are not widely recommended (55, 124). The implementation of either non-
pharmacologic (lifestyle-based) intervention or pharmacologic therapies should be determined 
based on the estimates of the clinical consequences of hyperuricaemia. Additionally, for 
pharmacologic urate-lowering therapy, the estimated risk of clinical consequences related to 
hyperuricaemia should be weighed against the potential benefits and risks, given urate-lowering 
medications (e.g., allopurinol or colchicine) can induce rare but very severe and even life-
threatening adverse reactions. 
1.2.5.1 General principles 
 Asymptomatic hyperuricaemia  
Patients with hyperuricaemia (SUA level >476 µmol/L) but without evidence of urate crystal 
deposition should be offered a plan for non-pharmacologic (lifestyle) management to reduce 
SUA level. The lifestyle interventions include adjustment of dietary composition, reduction of 
alcohol intake, control of body weight, and regular moderate exercise (124, 128). Consumption 
of dairy products, particularly low-fat dairy products or some dietary supplementations such as 
with vitamin C, was found to be associated with a substantially reduction in SUA level (129).  
Attentions should also be taken in the management of some accompanying diseases. 
Specifically, the use of medications that may increase SUA level should be avoided for 
hyperuricaemia patients; on the contrary, the use of medications that can reduce SUA level 
and/or decrease the risk of gout is much preferred. For example, the use of fenofibrate for 
hyperlipidaemia, and losartan or calcium channel blockers for hypertension should be promoted 
among hyperuricaemia patients (130, 131). In contrast, antihypertensive drugs, such as 
angiotensin-converting enzyme (ACE) inhibitors, thiazide or loop diuretics, non-losartan 
angiotensin II receptor blockers, and beta blockers, that may raise SUA level, should be avoided 
when possible (130). 
 Hyperuricaemia with gout and urate nephrolithiasis 
For subjects whose asymptomatic hyperuricaemia is accompanied by MSU crystal deposition 
demonstrated only on imaging but with no occurrence of gout, the same approach as for other 
asymptomatic individuals with hyperuricaemia should be taken. However, for hyperuricaemia 
patients with gouty arthritis, appropriate urate-lowering pharmacotherapy should be started with 
Chapter 1  Background 
39 
 
a recommended goal range of SUA level <357 µmol/L (55). Similarly, urate-lowering 
pharmacotherapy for the prevention of urate stone is not warranted in most individuals, unless a 
urate stone is discovered. The preferred treatment for hyperuricaemic individuals in the 
presence of urinary urate stone is hydration (fluid intake >2 L/day) and urinary alkalinisation 
with administration of potassium bicarbonate or potassium citrate, instead of allopurinol (132). 
 Sustained high levels of hyperuricaemia with hyperuricosuria 
Pharmacological urate-lowering therapy is considered for individuals with sustained marked 
hyperuricaemia or a less marked degree of hyperuricaemia but with sustained hyperuricosuria 
who are at high risk of acute uric acid nephropathy or recurrent bouts of acute renal failure. 
Sustained high levels of hyperuricaemia and hyperuricosuria always occur among individuals 
with purine and/or uric acid overproduction due to inherited enzyme defects in purine and/or 
ATP metabolism or genetic polymorphisms of urate transporter genes resulting in reduction of 
renal uric acid clearance, or due to clinical disorders associated with accelerated cell turnover. 
Under these circumstances, even when hyperuricaemia is not presented with any urate-induced 
disorders (i.e., gout, urate nephrolithiasis), a urate-lowering goal of SUA level <476 µmol/L is 
recommended to prevent acute renal failure (133).  
1.2.5.2 Urate-lowering medications   
There are several types of urate-lowering drugs available (134, 135), including (i) xanthine 
oxidase inhibitors (XOIs): allopurinol and febuxostat; (ii) uricosuric agents: probenecid, 
benzbromarone, and lesinurad; (iii) uricase:  pegloticase and rasburicase   
 Xanthine oxidase inhibitors (XOIs) 
XOIs are likely to be effective in all circumstances for urate-lowering therapies. The XOI 
allopurinol is used as first-line anti-hyperuricaemia therapy (134). However, some individuals 
showed adverse reactions, limiting the use of XOIs (136). Allopurinol and febuxostat are the 
available forms of XOIs. Oxypurinol is an active metabolite of allopurinol that was previously 
available as a substitute for patients intolerant to allopurinol.  
Allopurinol — The urate-lowering effect of allopurinol is due to its inhibition of xanthine 
oxidase (xanthine dehydrogenase) activity (137). On one hand, allopurinol, along with 
oxypurinol, produces inactivation of xanthine dehydrogenase, resulting in decreased UA 
formation. On the other hand, it can reduce the total urinary excretion of purines due to its 
inhibition on purine synthesis via drug-derived enhancement of purine base reutilisation and 
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reduction of purine catabolism. Although allopurinol is very effective in urate-lowering therapy, 
side effects and adverse reactions occur occasionally. It is estimated that 3%-5% of treated 
patients would experience rash, diarrhoea, drug fever, leukopenia or thrombocytopenia (136, 
138). Sometimes, a potentially fatal adverse event, allopurinol hypersensitivity syndrome (AHS), 
consisting of erythematous rash, drug fever, hepatitis, eosinophilia, and acute renal failure, may 
occur in <0.1% of treated patients (136, 138).  
Febuxostat — Febuxostat is another type of XOI. Unlike allopurinol, which is a purine base 
analogue, febuxostat is a thiazolecarboxylic acid derivative that inhibits xanthine oxidase by 
occupying a channel in the xanthine oxidase dimer (139). Febuxostat produces a dose-
dependent effect in the reduction of SUA level (140). Compared to allopurinol, febuxostat is 
superior in urate-lowering efficacy, but has greater incidence of nausea, arthralgia, rash and 
abnormalities in liver function test. Thus, hepatic transaminase enzyme levels should be 
monitored regularly among febuxostat-treated patients (141, 142).  
 Uricosuric drugs 
Uricosuric drugs are weak organic acids that enhance the renal clearance of urate by inhibiting 
the urate reabsorption mediated by urate-anion exchangers in the kidney (23). Uricosuric agents 
include probenecid, sulfinpyrazone, benzbromarone, and lesinurad. Other drugs with modest 
uricosuric effect include the anti-hypertension drug, angiotensin II receptor antagonist losartan, 
and anti-hyperlipidaemia drug, fenofibrate (143). Hyperuricaemic patients with renal under-
excretion of uric acid are candidates for uricosuric drugs (144). Probenecid and sulfinpyrazone 
are effective for most patients but ineffective for those with impaired renal function (134). 
Benzbromarone is likely more effective for patients with mild/moderate renal insufficiency 
(creatinine clearance 30-59 mL/min), and patients who are not tolerant for 
allopurinol/febuxostat therapy (134). Lesinurad is an inhibitor of urate transporters (URAT1 and 
OAT4), involving in uric acid reabsorption in the kidney. Lesinurad should only be used in 
combination with XOI in patients who have not achieved target SUA level with an XOI alone 
(145). The major side effects of uricosuric drugs include rash, acute gouty arthritis, 
gastrointestinal intolerance, and uric acid stone formation (146).  
 Uricase 
Uricase (urate oxidase) is an enzyme that catalyses oxidation of uric acid into the more water-
soluble compound, allantoin. The important criterion in support of uricase treatment is the 
requirement for reduction or reversal of gout symptoms, particularly for patients with severe 
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gout on whom treatment with other urate-lowering agents is not effective (134). Pegloticase and 
rasburicase are two forms of widely used uricase. Pegloticase is a porcine uricase modified by 
covalent linkage to polyethylene glycol. Pegloticase is effective in the relief of acute gout 
attacks, but it can lose the urate-lowering effectiveness due to the effects of pegloticase 
antibodies (147). Rasburicase is developed from Aspergillus flavus to minimise the risk of 
contaminant-related allergic reactions and is widely used to prevent acute urate nephropathy due 
to TLS in patients with lymphoma and leukaemia (148).  
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1.3 Genetic polymorphisms  
The heritability of SUA levels is estimated to be 40-70%, indicating the importance of its 
genetic determinants (149). In 2009, a GWAS on serum urate, including 28,141 individuals of 
European descent, was performed by the European Network for Genetic and Genomic 
Epidemiology (ENGAGE) consortium and identified nine independent genetic loci (150). 
Subsequently, in a meta-analysis of 48 genome-wide scans including 110,347 individuals of 
European descent, the Global Urate Genetics Consortium (GUGC) identified 28 genetic loci 
(151). When incorporating the GWAS findings of the ENGAGE and GUGC consortia, a total of 
31 genetic risk loci were identified in relation to serum urate level, including SLC2A9, ABCG2, 
SLC17A1, GCKR, SLC22A11, SLC22A12, PDZK1, SLC16A9, LRRC16A, INHBC, RREB1, 
HNF4G, SFMBT1, TRIM46, OVOL1, IGF1R, VEGFA, A1CF, BAZ1B, UBE2Q2, ATXN2, 
TMEM171, HLF, BCAS3, ORC4L, INHBB, NFAT5, STC1, PRKAG2, MAF, and PRPSAP1. 
Despite the success of the GWAS approach in describing the genetic background of serum urate, 
a detailed understanding of gene functions in the regulation of SUA level is still lacking, with 
the exception of urate transporter coding genes. To further describe the nature of these genetic 
risk loci, the functions of genes mapped by the consortia were annotated by using the 
GeneCards (http://www.genecards.org/) database. GeneCards is an integrative web-based 
human gene database that integrates gene-centric data from ~125 web sources and provides 
comprehensive information on all annotated and predicted human genes.  
1.3.1 Urate transporter loci  
Many of the identified loci from GWAS harbour genes encoding urate transporters or involving 
molecular pathways contributing to urate transport. Gene functions for the urate transporter loci 
are displayed in Table 1-4.  
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Table 1 - 4: Gene functions for the urate transporter loci identified in SUA GWAS. 
SNP CHR GENE  Gene function (from http://www.genecards.org/ ) 






 The SLC22A12 gene encodes the member 12 of organic 
anion transporter (OAT1) family which was the first 
characterised urate transporter regulating serum urate level 
(23). This protein is an integral membrane protein primarily 
localised in epithelial cells of the proximal tubule of the 
kidney and mutations in this gene cause renal 
hypouricaemia (152).  
 Its related biological pathways involve the transport of 
glucose and other sugars, urate, bile salts and organic acids, 
metal ions and amine compounds (153).  
 GO annotations related to this gene include the PDZ 
domain binding and urate transmembrane transporter 
activity. Its biological function is a pharmacologic target for 
urate-lowering therapy of uricosuric agents. (153) 
 Diseases associated with SLC22A12 include renal 








 The SLC2A9 gene encodes the member 9 of SLC2A 
facilitative glucose transporter family (GLUT9), 
characterised as a urate transporter and involved in renal 
urate re-absorption (25, 154).Members of this family play 
an important role in maintaining glucose homeostasis (155).  
 Its related pathways involve the transport of glucose and 
other sugars, bile salts and organic acids, metal ions and 
amine compounds (156).  
 GO annotation related to this gene includes glucose 
transmembrane transporter activity (156).  
 Disease associated with the SLC2A9 gene include renal 
hyperuricaemia and hypouricaemia (156).   
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SNP CHR GENE  Gene function (from http://www.genecards.org/ ) 







 The ABCG2 gene encodes the member 2 of ATP Binding 
Cassette Subfamily (ABCG2) (157). The superfamily of 
ATP-binding cassette (ABC) transporters transports various 
molecules across extra- and intra-cellular membranes (157).  
 Transporter ABCG2 has been shown to act as a urate 
transporter contributing to the excretion of urate in the 
kidney. This protein also functions as a xenobiotic 
transporter which may contribute to multi-drug resistance 
(158).  
 GO annotations related to this gene include ATPase activity 
and the activity of protein homo-dimerisation (159). Its 
biological function is the transport of urate, glucose and 
other sugars, bile salts and organic acids, metal ions and 
amine compounds (159). 
 Diseases associated with the ABCG2 include 
hyperuricaemia and erythroplakia (159). 






 The SLC22A11 gene encodes the member 11 of organic 
anion transporter (OAT4) family (160). The encoded 
protein is an integral membrane protein involved in the 
sodium-independent transport and excretion of organic 
anions (161).  
 This transporter is primarily found in epithelial cells of the 
proximal tubule in the kidney and in the placenta, where it 
may act to excrete harmful organic anions (160).  
 GO annotations related to this gene include inorganic anion 
exchanger activity and sodium-independent organic anion 
transmembrane transporter activity (162).  
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SNP CHR GENE  Gene function (from http://www.genecards.org/ ) 





 The SLC17A1 gene encodes the sodium-dependent 
phosphate transport protein 1 (NPT1) (163). NPT1 is 
important for the reabsorption of phosphate and the urate 
excretion in the kidney, which actively reabsorbs phosphate 
into cells via Na+ cotransport and excretes urate into the 
distal renal tubule (164).  
 Its related biological pathways involve the transport of 
glucose and other sugars, bile salts and organic acids, metal 
ions and amine compounds, and uricosuric pathway 
(pharmacodynamics) (165).  
 GO annotation related to this gene includes symporter 
activity and phosphate ion transmembrane transporter 
activity.  
 Diseases associated with the SLC17A1 gene include gout 
and hyperuricaemia (165). 





 The protein encoded by the PDZK1 is the Na+/H+ 
exchange regulatory cofactor NHE-RF3, mediating the 
localisation of cell surface proteins (166). This protein is 
likely to influence urate transport indirectly by binding with 
the urate transporters URAT1, NPT1, and OAT4 (167). It 
also contributes to cholesterol metabolism by regulating the 
HDL receptor, namely scavenger receptor class B type 1 
(168).  
 Its related biological pathways include the regulation of 
cystic fibrosis transmembrane conductance regulator 
(CFTR) activity and the uricosurics pathway 
(pharmacodynamics) (169).  
 GO annotation related to this gene includes PDZ domain 
binding and the transporter activity (169). 
 Diseases associated with the PDZK1 gene include multiple 
myeloma (169).  
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SNP CHR GENE  Gene function (from http://www.genecards.org/ ) 





 The protein encoded by SLC16A9 gene is a proton-linked 
monocarboxylate transporter (MCT9) (170). The predicted 
function of SLC16A9 (MTC9) is a carnitine efflux 
transporter, which catalyses the transport of 
monocarboxylates across the plasma membrane (171).  
 Whether SLC16A9 (MTC9) directly contributes to the 
transport of urate is not very clear, but associations between 
this gene and another two metabolites were observed, 
namely DL-carnitine and propionyl-L-carnitine, which in 
turn were associated with serum urate, forming a triangle 
between SLC16A9, serum urate and related metabolites 
(151).  
 GO annotation related to this gene includes the symporter 
activity and the transmembrane transporter activity of 
monocarboxylic acid (172).  
 Diseases associated with this gene include gout (172). 
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1.3.2 Other genetic risk loci 
For the remaining genetic risk loci identified from GWAS, their underlying biological functions 
in the regulation of serum urate have not been completely understood, but the functional 
annotation of the mapping genes highlights two broad pathways of glycolysis and 
inhibins/activins, which contribute to the biological processes of energy balance, cell 
proliferation, apoptosis, and immune response, as described below. Gene functions for other 
genetic risk loci of SUA levels are displayed in Table 1-5 and Figure 1-4.  
Table 1 - 5: Gene functions for other genetic risk loci identified in SUA GWAS. 
SNP Chr Gene Gene function (from http://www.genecards.org/ ) 




 The GCKR gene encodes a regulatory protein that inhibits 
glucokinase in liver and pancreatic islet cells by binding to 
the enzyme to form an inactive compound (173, 174).  
 Three biological pathways are related to this gene: the 
transport of glucose and other sugars, bile salts and organic 
acids, metal ions and amine compounds, cyclin-dependent 
kinase (CDK) mediated phosphorylation and the removal of 
cell division cycle 6 (Cdc6) from the cellular nucleus (175).  
 GO annotation related to this gene includes enzyme binding 
and protein domain specific binding (175).  
 Diseases associated with the GCKR include fasting plasma 
glucose level and maturity-onset diabetes (175). 




 The INHBC gene encodes a member of the transforming 
growth factor-beta (TGF-β) superfamily, that could be 
processed by proteolysis to produce a subunit of 
homodimeric and heterodimeric activin compound (176). 
The heterodimeric complex may inhibit the signalling of 
activin A (177).  
 The biological pathways related to this gene include the 
TGF-beta signalling pathway (KEGG) and signalling 
pathway regulating pluripotency of stem cells (178).  
 GO annotation of this gene includes cytokine activity and 
hormone activity (178). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 






 The product of RREB1 gene is a zinc finger transcription 
factor binding to the RAS-responsive elements (RREs) of 
gene promoters (179).  
 This protein is involved in Ras/Raf-mediated cell 
differentiation by binding to the RRE of calcitonin gene 
promoter (180).  
 GO annotation related to this gene includes the binding of 
nucleic acid and RNA polymerase II core promoter 
sequence-specific DNA (181). 






 The HNF4G gene encodes the member 2 of nuclear 
receptor subfamily 2, also known as NR2A2.  
 The related biological pathways of this gene are the 
regulation of beta-cell development and gene expression 
(182, 183).  
 GO annotations related to this gene include the transcription 
factor activity, steroid hormone receptor activity and 
sequence-specific DNA binding (184). Diseases associated 
with this gene include maturity-onset diabetes (184). 





 The protein encoded by the SFMBT1 gene contains four 
malignant brain tumour repeat (mbt) domains (185).  
 It is likely involved in antigen recognition (186).  
 GO annotations related to this gene include transcription 
corepressor activity and histone binding (187). 






 The OVOL1 gene encodes a putative zinc finger 
transcription factor which is very similar to homologous 
protein in mouse and drosophila (188).  
 Based on its known functions in these species, this protein 
is likely involved in hair formation and spermatogenesis 
(189).  
 GO annotation indicates this gene is likely involved in 
RNA polymerase II core promoter proximal region 
sequence-specific binding and transcriptional repressor 
activity (189). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 






 The product of this gene is an insulin-like growth factor I 
receptor (IGF1R), containing alpha and beta subunits (190). 
This receptor is overexpressed in most malignant tissues 
where it may act as an anti-apoptotic agent by enhancing 
cell survival (190).  
 The biological pathways related to this gene include the 
development IGF-1 receptor signalling and the mammalian 
target of rapamycin (mTOR) (191).  
 GO annotation for this gene includes protein kinase activity 
and protein binding (191).  





 The protein encoded by the VEGFA gene is the member A 
of the PDGF/VEGF growth factor family (192).  
 This growth factor is essential for both physiological and 
pathological angiogenesis and it induces the proliferation 
and migration of the vascular endothelial cell (192). This 
expression of this gene is upregulated in some known 
tumours and is also correlated with tumour stage and 
progression. Mutations of this gene have been associated 
with atherosclerosis and microvascular complications of 
diabetes 1 (MVCD1) and atherosclerosis (192).  
 GO annotation highlight the role of this gene in the protein 
homo-dimerisation activity (193). 





 The product of this gene contains three different RNA 
recognition motifs, belonging to the hnRNP R family of 
RNA-binding proteins (194). This complementation factor 
may be involved in the RNA editing or RNA processing 
events (194).  
 Its related pathways are the mRNA editing of C to U 
conversion and the gene expression (195).  
 GO annotations related to this gene include 
nucleotide/nucleic acid binding (195). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 






 This gene encodes an enzyme, tyrosine-protein kinase 
belonging to the bromodomain protein family (196).  
 The bromodomain is a structural characteristic of proteins 
involving in chromatin-dependent regulation of 
transcription (196).  
 GO annotation related to this gene includes protein tyrosine 
kinase activity and binding (197).  
 This gene is deleted in a developmental disorder, Williams-
Beuren syndrome (197). 





 The protein encoded by this gene is one of the ubiquitin 
conjugating enzymes (also known as E2 enzymes) (198).  
 Its related pathways are class I major histocompatibility 
complex (MHC) mediated antigen processing and innate 
immune response (199).  
 GO annotations of this gene include ligase activity (199). 
rs653178 12 ATXN2 
(Ataxin 2) 
 The ATXN2 gene encodes the protein that is involved in the 
trafficking of epidermal growth factor receptor (EGFR) 
(200). It functions as a negative regulator of endocytic 
EGFR internalisation at the plasma membrane (200).  
 The involving biological pathways are the regulation of 
checkpoint kinases.  
 GO annotation related to this gene includes the poly (A) 
RNA binding and protein C-terminus binding (201).  
 Diseases associated with ATXN2 include Spinocerebellar 
Ataxia 2 and late-onset Parkinson’s disease (201). 




 This gene encodes a member of the proline and acidic-rich 
(PAR) protein family, a subset of the bZIP transcription 
factors (202).  
 The encoded protein forms homodimers or heterodimers 
with other PAR family members and binds to the sequence-
specific promoter elements to activate transcription (202).  
 GO annotations related to this gene include transcription 
factor activity, double-stranded DNA binding and 
sequence-specific DNA binding (203).  
 Leukaemia is associated with this gene (203). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 





 The product of the BCAS3 gene is a microtubule associated 
cell migration factor (204).  
 This protein is involved in multiple biological processes, 
including angiogenesis, the regulation of cell polarity and 
directional endothelial cell migration, and the recruitment 
and activation of cell division control protein (Cdc42) 
(205).  
 GO annotation related to this gene includes chromatin 
binding and histone binding (205).  
 Disease associated with this gene is breast cancer (205). 






 This gene encodes the subunit 4 of the origin recognition 
complex (ORC) that is an essential complex for the 
initiation of DNA replication in the cell (206).  
 The biological pathways related to ORC4 are the regulation 
of DNA replication, the cyclin-dependent kinase (CDK) 
mediated phosphorylation and the removal of Cdc6 (207).  
 GO annotation related to this gene includes the nucleotide 
binding and the DNA replication origin binding (207).  
 Meier-Gorlin Syndromes are associated with this gene 
(207). 




 The INHBB gene encodes a subunit of the transforming 
growth factor-beta (TGF-β) superfamily that could be 
processed by proteolysis to generate a subunit of the 
dimeric activin and inhibin protein complexes (208).  
 These complexes respectively activate and inhibit the 
follicle stimulating hormone secretion activity of the 
pituitary gland (208). This gene is involved in the TGF-β 
signalling pathway (KEGG) and signalling pathways 
regulating pluripotency of stem cells (209).  
 GO annotation related to this gene includes the growth 
factor activity and protein homodimerisation activity (209).  
 Diseases associated with this genes are eclampsia and pre-
eclampsia (209). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 





 The NFAT5 gene encodes a transcription factor involved in 
the transcription of inflammatory gene and the regulation of 
activated T cells family (210).  
 GO annotation of this gene includes sequence-specific 
DNA binding, transcriptional activator activity, and RNA 
polymerase II core promoter proximal region sequence-
specific binding (211).  
 Diseases associated with this gene are kidney papillary 
necrosis and spinocerebellar ataxia (211). 









 The PRKAG2 gene encodes the non-catalytic regulatory 
gamma subunit of the AMP-activated protein kinase 
(AMPK) (212).  
 AMPK is an important energy-sensing enzyme that 
monitors cellular energy status by inactivating key enzymes 
involved in regulating de novo biosynthesis of fatty acid 
and cholesterol (212).  
 GO annotation of this gene includes protein kinase activator 
activity and protein kinase binding (213).  
 Mutations in this gene have been associated with Wolff-
Parkinson-White syndrome, familial hypertrophic 
cardiomyopathy, and glycogen storage disease of the heart 
(213). 




 The protein encoded by this gene is a DNA-binding, leucine 
zipper-containing transcription factor, acting as a 
homodimer or as a heterodimer (214).  
 This transcriptional factor involves in the regulation of 
several cellular processes, including embryonic lens fibre 
cell development, chondrocyte terminal differentiation, and 
increased T-cell susceptibility to apoptosis (214).  
 GO annotation related to this gene includes sequence-
specific DNA binding, transcriptional activator activity, and 
RNA polymerase II transcription regulatory region 
sequence-specific binding (215).  
 Diseases associated with MAF are Ayme-Gripp Syndrome 
and multiple-type cataract (215). 
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SNP Chr Gene Gene function (from http://www.genecards.org/ ) 
rs17786744 8 STC1 
(Stannioca-
lcin 1) 
 The STC1 gene encodes a secreted, homodimeric 
glycoprotein that may have autocrine or paracrine functions 
(216).  
 The protein is likely involved in the regulation of renal and 
intestinal calcium and phosphate transport, cell metabolism, 
or cellular calcium/phosphate homeostasis (216).  
 GO annotation for this gene includes the activity of 
hormone (217).  
 Diverticulitis of colon is associated with the mutations of 
this gene (217). 








 The protein coded by PRPSAP1 gene seems to play a 
negative regulatory role in 5-phosphoribose 1-diphosphate 
synthesis (218). GO annotations related to this gene include 
magnesium ion binding and enzyme inhibitor activity (219). 





 The product of this gene is a tripartite motif-containing 
protein, which is involved in the biological processes of 
interferon gamma signalling and innate immune system 
(220, 221) 





 TMEM171 is a transmembrane protein coding gene but its 
function is not clear (222, 223). 
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2 AIMS AND OBJECTIVES 
2.1 Introduction 
The role of uric acid has been explored in a large number of observational studies in relation 
to a multitude of health outcomes. Apart from gout and urolithiasis (224, 225), compelling 
evidence supports the associations between high SUA level and the increased risk of non-
crystal deposition disorders, including metabolic syndrome, hypertension, chronic renal 
diseases, and cardiovascular diseases (CVDs) (225-227). Although there are considerable 
research efforts into understanding the pathogenic role of uric acid in these non-crystal 
deposition disorders, their causal relationships have not been established. It was argued that 
either these associations are confounded by other risk factors, such as obesity and 
hypertension, or they represent reverse causality. Genetic determinants play a substantial role 
in the regulation of SUA levels and genetic studies among twins and families reported a 
substantial heritable component of SUA level with an estimated heritability of 40-70% (228, 
229). The genetic component of SUA level has been explored in several GWAS (151, 230, 
231) and the wealth of GWAS findings allows the incorporation of genetic variant(s) as an 
instrument (s) which can be used to separate causal associations from non-causal ones, given 
that the genotype is generally independent of environmental exposures and the transmission 
of genetic information is usually unidirectional. Therefore, investigating the associations 
between SUA genetic risk loci and disease outcomes might provide evidence for the 
hypotheses which link uric acid to clinical disorders.  
2.2 Aim and objectives 
The overarching aim of this project is to employ the Phenome-wide association study 
(PheWAS) approach along with other complementary methodologies to investigate the role 
of uric acid in a wide range of disease outcomes by using data from the UK Biobank.  
The specific objectives are: 
(i) To conduct an umbrella review of meta-analyses of observational studies, meta-
analyses of randomised controlled trials (RCTs) and Mendelian randomisation (MR) 
studies on the associations between SUA level and multiple health outcomes. This 
umbrella review was performed to summarise the range of related health outcomes, 
present the magnitude, direction and significance of the identified associations and 
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effects, assess the potential biases and identify which of the observed associations 
are robust. The findings of umbrella review are presented in Chapter 3.  
 
(ii) To perform a MR-PheWAS analysis by using the interim release data of UK 
Biobank to provide an overview of the disease outcomes associated with the SUA 
genetic risk loci. The SUA genetic risk loci were employed as individual instruments. 
The phenome framework was defined by the PheCODE schema. PheWAS was 
performed first to identify any association across the SUA genetic risk loci and the 
phenome; the Mendelian randomisation (MR) design and the HEIDI (heterogeneity 
in dependent instruments) test were then applied to distinguish the PheWAS 
associations that were due to causality, pleiotropy or genetic linkage. The findings of 
MR-PheWAS are presented in Chapter 5.  
 
(iii) To validate the MR-PheWAS findings, an advanced Phenome-wide Mendelian 
randomisation (PWMR) analysis is performed by using data from the full UK 
Biobank cohort. A weighted polygenic risk score (GRS), incorporating effect 
estimates of multiple genetic risk loci, was employed as a proxy of the SUA level. 
The phenome framework was also defined by an alternative tree-structured 
phenotypic model. Any novel findings and/or replication of the MR-PheWAS 
findings were further described and explored in the PWMR analysis. The findings of 
PWMR are presented in Chapter 6.
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3 UMBRELLA REVIEW ON SUA LEVEL 
3.1 Summary  
The aim of this chapter is to assess if the available evidence is robust enough to indicate any 
causal effect of SUA level on the related health outcomes. I performed an umbrella review to 
collect and evaluate the evidence from systematic reviews and meta-analyses of 
observational studies, meta-analyses of RCTs and Mendelian randomisation studies 
systematically. I identified 136 health outcomes that were examined in relation to SUA 
levels across three study types, including anthropometric outcomes, cardiovascular diseases, 
metabolic diseases, kidney disorders, various cancers, and neurocognitive diseases. I adopted 
a set of criteria to assess the credibility of the observed associations. After assessment, no 
association from observational studies was classified as convincing, and associations with 
five health outcomes (heart failure, hypertension, impaired fasting glucose or diabetes, 
chronic kidney disease, coronary heart disease mortality) were classified as highly 
suggestive; only one outcome (nephrolithiasis) from meta-analyses of RCTs and one 
outcome (gout) from Mendelian randomisation studies presented convincing evidence, 
indicating a causal effect of high SUA level on increased disease risk. 
Despite a few hundred systematic reviews, meta-analyses, and Mendelian randomisation 
studies exploring 136 unique health outcomes, convincing evidence of a clear role of SUA 
level only exists for gout and nephrolithiasis. Umbrella reviews focus on the evidence from 
existing meta-analyses and therefore outcomes that have not been assessed in a meta-
analysis are not included in this review, which represents a weakness of this study. The 
available evidence does not support any change in existing clinical recommendations in 
relation to the clinical management of SUA levels.  
This chapter has been published in the British Medical Journal (BMJ) cited as “Li, X., Meng, 
X., Timofeeva, M., Tzoulaki, I., Tsilidis, K.K., Ioannidis, P.A., Campbell, H. and 
Theodoratou, E., 2017. Serum uric acid levels and multiple health outcomes: umbrella 
review of evidence from observational studies, randomised controlled trials, and Mendelian 
randomisation studies. BMJ, 2357-2376.” (232). 
For this published work, I conducted the systematic literature review and data extraction as 
the main investigator. The extracted data was checked by the second investigator (Meng, X.). 
I performed the statistical analysis, wrote the manuscript and revised the paper according to 
the comments given by the peer reviewers and the BMJ editorial committee. Theodoratou, E. 
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and Campbell, H. conceived the study and Ioannidis, P.A. contributed to the design. 
Campbell, H., Ioannidis, P.A., Tsilidis, K.K., Timofeeva, M., and Tzoulaki, I. critically 
reviewed the manuscript and contributed important intellectual content. 
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Objective To map the diverse health outcomes associated with serum uric acid (SUA) and 
assess the credibility of evidence in favour of causal association.  
Design Umbrella review of the evidence from systematic reviews and meta-analyses of 
observational studies, meta-analyses of randomised controlled trials (RCTs) and Mendelian 
randomisation (MR) studies. 
Data sources Medline, EMBASE, Cochrane database of systematic reviews and screening 
of citations and references.  
Eligibility criteria Systematic reviews and meta-analyses of observational studies that 
examined associations between SUA and health outcomes; meta-analyses of RCTs that 
investigated health outcomes related to SUA-lowering therapy; MR studies that explored the 
causal associations of SUA with health outcomes.  
Results 47 articles reporting 144 meta-analyses of observational studies (76 unique 
outcomes), 8 articles reporting 31 meta-analyses of RCTs (20 unique outcomes) and 36 
articles reporting 107 MR studies (56 unique outcomes) met the eligibility criteria. Across all 
three study types, 136 unique health outcomes (including anthropometric outcomes, 
cardiovascular diseases, metabolic diseases, kidney disorders, various cancers, and 
neurocognitive diseases) were reported. 16 of 76 unique outcomes in meta-analyses of 
observational studies had p<10-6, 8 of 20 unique outcomes in meta-analyses of RCTs had 
p<10-3 and 4 of 56 unique MR outcomes had p<0.01. Large between-study heterogeneity 
was very common (80.3% and 45.0% in meta-analyses of observational studies and of RCTs 
respectively). 42 of 76 (55.3%) meta-analyses of observational studies and 7 of 20 (35.0%) 
meta-analyses of RCTs showed evidence of small study effects or excess significance bias. 
No SUA-health outcome associations from meta-analyses of observational studies were 
classified as convincing; five associations were classified as highly suggestive (increased 
risk of heart failure, hypertension, impaired fasting glucose or diabetes, chronic kidney 
disease (CKD), coronary heart disease mortality with high SUA levels). Only one outcome 
from RCTs (decreased risk of nephrolithiasis recurrence with SUA-lowering treatment) had 
p<10-3, 95% prediction interval excluding the null and no large heterogeneity or bias. Only 
one outcome from MR studies (increased risk of gout with high SUA levels) presented 
convincing evidence. Hypertension and CKD showed concordant evidence in meta-analyses 
of observational studies and in some (but not all) meta-analyses of RCTs with respective 
intermediate or surrogate outcomes, but they were not statistically significant in MR studies.  
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Conclusions Despite a few hundred systematic reviews, meta-analyses and MR studies 
exploring 136 unique health outcomes, convincing evidence of a clear role of SUA exists for 
only gout and nephrolithiasis. 
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What is known or unknown on this topic  
 Observational studies have suggested that high SUA levels are associated with a wide range of 
outcomes including cardiovascular and metabolic diseases (increased risk) or neurological 
diseases (decreased risk). 
 However, it remains to be determined whether these observed associations are causal.  
 Clinical trials of SUA lowering have shown that xanthine oxidase inhibition decreases blood 
pressure and improves renal function. 
 There is still much debate as to whether SUA is simply a marker of xanthine oxidase activity or 
a causal factor involved in systemic inflammation. 
Added value by this study 
 We present here a comprehensive overview and assessment of the existing evidence from 
multiple sources (including meta-analyses of observational studies, meta-analyses of RCTs and 
MR studies) for a wide range of health outcomes related to SUA.  
 We identified 136 health outcomes that were examined in relation to SUA but based on our 
evidence assessment convincing evidence of a clear role of SUA exists only for gout and 
nephrolithiasis.  
 Associations between SUA and five additional health outcomes (heart failure, hypertension, 
impaired fasting glucose or diabetes, chronic kidney disease, coronary heart disease mortality) 
were classified as highly suggestive.  
 There is a notable gap between observational studies and RCTs and MR studies. 
Implications of all available evidence 
 This study raises large uncertainty about the potential therapeutic benefits of SUA-lowering 
therapy beyond gout.  
 There is no adequate evidence against lowering SUA in gout patients in relation to an increased 
risk of neurological diseases.  
 The causal effect of SUA on the health outcomes with highly suggestive evidence might be 
worthy of further investigation.  
 
  




Uric acid was thought to be a biologically inert waste product from purine metabolism, until 
Garrod et al discovered in the early 1800s that elevated SUA level was the cause of gout 
(233). Subsequently, associations of uric acid with cardiovascular and renal disorders were 
also observed (234). These associations were explored in a number of prospective studies, 
but yielded conflicting results and, therefore, the causal role of uric acid in these diseases 
was widely questioned (235-238). It was argued that either these associations are confounded 
by other risk factors, such as obesity and hypertension, or they represent reverse causality 
(236, 239). These inconclusive findings led to a shift of interest away from uric acid and 
asymptomatic hyperuricaemia was not considered as indication for SUA-lowering therapy in 
patients with cardiovascular and renal diseases (56, 124). 
New findings have fuelled enthusiasm to address this long-standing controversy (240). 
Recent epidemiological studies have explored associations of uric acid with a wide range of 
disease conditions, including cardiovascular diseases (CVD), metabolic syndrome, diabetes, 
cancer and some intermediate phenotypes or biomarkers (227). In an attempt to understand 
the possible underlying mechanisms, laboratory studies have found that uric acid is 
potentially involved in multiple biological processes including oxidation stress, systemic 
inflammation and intra-hepatic fructose metabolism, which are mechanisms that could be 
linked to the development of CVD and metabolic syndrome (241-243). Alternatively, uric 
acid may only present a marker of high oxidative stress associated with increased xanthine 
oxidase activity, instead of an active agent in the pathogenic processes (244). Finally, taking 
into account the antioxidant properties of uric acid (acting as a free radical scavenger), its 
potential mechanistic roles on these disorders may be complex (245). 
In view of the potential importance of uric acid, assessing the credibility of the observed 
evidence may have implications both for clinical practice and public health. It is recognised 
that different types of studies have specific strengths and weaknesses that can be seen as 
complementary (see Box 1). An umbrella review, which collects and evaluates evidence 
from multiple resources systematically, might therefore help clarify the composite literature. 
Here, we have performed an umbrella review of meta-analyses of observational studies, 
meta-analyses of randomised controlled trials (RCTs) and Mendelian randomisation (MR) 
studies on associations between SUA and multiple health outcomes. As shown in Box 1, 
these three lines of evidence can be complementary. The overarching aim of this study is to 
provide an overview of the spectrum of diseases related to SUA and to assess the evidence 
from multiple sources systematically. In particular, we summarised the range of related 
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health outcomes, presented the magnitude, direction and significance of the reported 
associations and effects, assessed the potential biases and identified which associations and 
effects have the most convincing evidence.   
Box 1: observational studies, randomised clinical trials, and Mendelian randomisation 
studies  
 An observational study aims to examine the association between an exposure and an 
outcome, and tests whether the association is caused by chance, bias or confounding. 
However, conventional observational studies typically may suffer from problems of residual 
confounding, undetected bias or reverse causality which may generate associations that are 
not reliable indicators of causality. 
 
 A randomised clinical trial (RCT) is an approach to obtain evidence of a causal effect of a 
treatment or intervention on a disease process, and it eliminates many of the biases and 
confounding factors that are present in observational studies. However, this study design is 
also subject to limitations, including non-adherence to the assigned intervention, limited 
external validity, short-term intervention effects, and non-retention, which can all render the 
results invalid or questionable. In addition, high costs and ethical concerns can also limit 
the application of RCTs in scientific research.  
 
 A Mendelian randomisation (MR) study provides a cost-effective analogy to an RCT by 
using genetic variants as proxies to test the causality of an association between the exposure 
and outcome. MR is not influenced by the confounding inherent in observational studies 
and not seriously affected by reverse causality, but it does rely on several assumptions (the 
genetic instruments should be associated with the exposure of interest, they should not be 
associated with known confounders, and they should affect the outcome solely through the 
exposure) that can be hard to identify and control. This approach may also lack power 
especially when the proportion of trait variance explained by the genetic instruments is 
small.  
 
 In summary, although none of these study types are infallible, all of them are able to 
provide useful information in relation to causal inference and they can complement each 
other in order to achieve increasing certainty about causality.  
 




3.3.1 Literature search and selection criteria 
We systematically searched Medline, EMBASE and the Cochrane database from inception 
to July 17, 2016 using a comprehensive search strategy (Supplementary Table 3-1) to 
identify systematic reviews and meta-analyses of observational studies, meta-analyses of 
RCTs, and MR studies. All identified publications went through a three-step parallel review 
of title, abstract and full text (performed by XL and XM) based on pre-defined inclusion and 
exclusion criteria.  
We included: (i) systematic reviews and meta-analyses of observational studies that 
examined associations between SUA levels (or hyperuricaemia) and health outcomes; (ii) 
meta-analyses of RCTs that investigated health outcomes related to SUA-lowering therapy 
(intervention with one or a combination of two or more SUA-lowering drugs versus placebo 
or no treatment) including xanthine oxidase inhibitors (allopurinol, febuxostat, or 
oxypurinol), uricosuric agents (probenecid, benzbromarone, thiazides, or citrates), and 
uricase analogues (pegloticase or rasburicase); and (iii) individual MR studies that explored 
SUA (or hyperuricaemia) associations in relation to health outcomes by using genetic 
instruments influencing SUA levels. The identified health outcomes included a wide range of 
diseases, intermediate phenotypes and biomarkers. Studies investigating associations 
between gout and health outcomes were not included. Meta-analyses of RCTs that used non-
drug interventions, such as dietary or lifestyle interventions were excluded. We further 
excluded animal and laboratory studies, meta-analyses on the prevalence of gout and 
hyperuricaemia and meta-analyses of RCTs that focused on pharmacological parameters, 
safety and effects of reducing SUA levels without investigating other health effects.  
3.3.2 Data extraction  
Data were extracted by one investigator (XL) and then checked by a second investigator 
(XM). For each eligible study, we abstracted the PubMed ID, first author name, journal, year 
of publication, study population, number of studies included, and outcomes investigated. For 
meta-analyses investigating more than one health outcome, each outcome was recorded 
separately. For meta-analyses of observational studies and of RCTs, we extracted the 
reported summary risk estimates (risk ratio, odds ratio, hazard ratio or mean difference) with 
the 95% confidence intervals (CIs) and the corresponding number of case and control 
participants. Furthermore, for each unique outcome, data from the individual component 
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studies that were included in the meta-analyses were also extracted for further analysis. This 
second level abstraction included data on study design, number of cases, total number of 
study participants, the relative risk estimates and 95% CIs for each component study. When 
more than one meta-analysis existed for the same outcome in the same population, individual 
component data were extracted from the most recent and largest meta-analysis. In a few 
exceptions where the most recent was not also the largest meta-analysis, we explored the 
reason for this discrepancy: if the most recent included prospective studies and the largest 
one had fewer prospective studies plus some retrospective data, we kept the one with the 
largest amount of prospective data; otherwise we kept the largest meta-analysis. For MR 
studies, we abstracted data on study population, sample size, genetic instruments, the 
variance of SUA explained by the genetic instruments (R2) and MR effect estimates (odds 
ratio, hazard ratio, mean difference or regression coefficient β), standard deviation (SD) of 
SUA levels and SD of continuous outcomes.  
3.3.3 Data analysis  
For systematic reviews, we performed descriptive analyses and presented the authors’ 
conclusions. For each unique meta-analysis of observational studies and of RCTs, we 
estimated a number of metrics including (i) the summary effect and 95% CI using a random-
effect model (DerSimonian & Laird method) (246); (ii)  the heterogeneity among studies (Q 
statistic and I2 metric with 95% CI);  (iii) the 95% prediction interval (PI) to predict the range 
of effect size that would be expected in a new original study, after accounting for both the 
heterogeneity among individual studies and the uncertainty of the summary effect estimated 
in the random-effect model; the calculation of 95% PI is based on the predicted distribution 
derived from a function of the degree of heterogeneity, the number of studies included and 
the within-study standard errors (247, 248); (iv) the presence of small study effects by using 
the Egger’s regression asymmetry test to investigate if small studies tend to give larger 
estimates of effect size than large studies (significance threshold p<0.10) (249); (v) the 
excess significance test to assess if the observed number (O) of studies with significant 
results was greater than the expected number (E) using the chi-square test: A = [(O-E)2/E + 
(O-E)2/(n-E)] ~ 2 (significance threshold p<0.10) (250, 251). For the excess significance 
test the expected number (E) of studies with significant findings was calculated by using the 
sum of statistical power estimated for each component study. The statistical power of each 
component study was calculated with an algorithm that uses a non-central t distribution, by 
assuming the true effect size to be the same as that of the largest component study (with 
smallest variance) in the meta-analysis (252). If the type of metric in a meta-analysis was 
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mean difference, we firstly calculated Cohen's d by weighing the pooled SD based on the 
sample size of individual studies. We then transformed Cohen's d, Hedges g and other 
standardised mean difference metrics to odds ratios (253). We compared the results reported 
in overlapping meta-analyses to evaluate their concordance in terms of the direction and 
statistical significance of the observed associations. All statistical analyses were conducted 
in Stata version 14.0. 
For MR studies, we didn’t conduct quantitative syntheses due to the extensive differences of 
genetic instruments used in the identified studies. Instead, we performed and present here a 
descriptive analysis of the individual studies. When more than one MR study was conducted 
for the same outcome, we compared the concordance of the findings in relation to the 
direction and statistical significance of the reported association and retained the MR study 
with largest number of cases and participants for further analysis and comparison. We 
performed a power calculation for the largest MR studies by using the non-centrality parameter 
(NCP) based approach, if all necessary information required for calculation was provided (i.e., 
sample size, number of cases, R2, estimates of association, SD of continuous outcomes and SD of 
SUA levels) (254). For MR study with missing R2, we used the R2 from other MR studies that 
used the same genetic variants as instruments to perform a crude power estimation.  
3.3.4 Credibility assessment 
Evidence from meta-analyses of observational studies with nominally statistically significant 
summary results (p<0.05) was classified into four categories (class I, II, III, IV) as 
previously proposed (255): (i) convincing (class I) evidence was assigned to associations, 
which had a statistical significance of p<10-6, included more than 1,000 cases (or more than 
20,000 participants for continuous outcomes), had the largest component study reporting a 
statistically significant result (p<0.05), had a 95% PI that excluded the null, did not have 
large heterogeneity (I2<50%), and  showed no evidence of small study effects (p>0.10) and 
of excess significance bias (p>0.10); (ii) highly suggestive (class II) evidence was assigned 
to associations, which reported a statistical significance of p<10-6, included more than 1,000 
cases (or more than 20,000 participants for continuous outcomes), and had the largest 
component study reporting a statistically significant result (p<0.05); (iii) suggestive (class III) 
evidence was assigned to associations, which reported a statistical significance of p<10-3 
with more than 1,000 cases (or more than 20,000 participants for continuous outcomes); (iv) 
weak (class IV) evidence was assigned to the remaining statistically significant associations 
with p<0.05. For each association in the convincing or highly suggestive categories we re-
assessed the evidence after excluding the retrospective and case-control studies (in an 
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attempt to address reverse causality). Finally, for each association in the convincing category 
we re-assessed the evidence after we examined each meta-analysis in depth ourselves by 
assessing the eligibility of the included studies as well as verifying the data used in the meta-
analysis.  
Evidence from meta-analyses of RCTs was assessed in terms of the statistical significance of 
the summary effect (p<10-3, 10-3≤p<0.05, p≥0.05), 95% PI (excluding the null or not), and 
presence of large heterogeneity (I2>50%), small study effects (p>0.10) and excess 
significance (p>0.10). We also noted the conclusions from any evidence classification 
(GRADE (256) or equivalent system) applied by  the original meta-analyses. Finally, 
evidence from individual MR studies was assessed in terms of statistical significance of the 
MR effect estimate (p<0.01) and of the statistical power (>80%) (257). 
For overlapping outcomes that were investigated in meta-analyses of observational studies 
and/or meta-analyses of RCTs and/or individual MR studies, we examined if the direction 
and statistical significance of the associations were reported concordantly across the different 
study types. We noted the overlapping outcomes that were graded as class I-II in meta-
analyses of observational studies and had 95% PI excluding the null in meta-analyses of 
RCTs. For these outcomes we also presented the evidence from MR studies if available.    
3.3.5 Patient involvement 
No patients were involved in setting the research question or the outcome measures, nor 
were they involved in the design and implementation of the study. No patients were asked to 
advice on interpretation or writing up of results. There are no plans to disseminate the results 
of the research to study participants or the relevant patient community.   




3.4.1 Literature review 
Overall, the parallel reviews identified 4,608 publications across three databases. After 
application of the inclusion/exclusion criteria, 101 publications were selected for inclusion 
(Figure 3-1). Specifically, 15 systematic reviews of observational studies were reported in 
10 articles (Supplementary Table 3-2) (258-267); 144 meta-analyses of observational 
studies were reported in 47 articles (Supplementary Table 3-3) (16, 268-313); 31 meta-
analyses of RCTs were reported in 8 articles (Supplementary Table 3-4) (50, 314-320); and 
107 MR studies were reported in 36 articles (Supplementary Table 3-5) (321-356). Across 
all three study types, 136 unique outcomes were reported. 
 
Figure 3 - 1: Study flowchart. 
3.4.2 Meta-analyses of observational studies   
One hundred and forty-four meta-analyses of observational studies were identified in total 
(Supplementary Table 3-3). The median number of studies included in meta-analyses was 5 
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(range: 2-31) and the median number of participants and median number of cases were 7,932 
(range: 129-1,017,810) and 1,176 (range: 49-34,370) respectively. More than one meta-
analysis was conducted for 16 outcomes (Supplementary Table 3-3). The direction and 
statistical significance of the reported associations in overlapping meta-analyses were 
concordant for 14 (87.5%) outcomes: atrial fibrillation incidence (n=3) (268, 280, 310), 
coronary heart disease (CHD) (n=4) (16, 300, 304, 311), hypertension incidence (n=3) (272, 
302, 313), stroke incidence (n=2) (276, 303), diabetes (n=3) (277, 278, 307), chronic kidney 
disease (CKD) (n=3) (282, 283, 305), mild cognitive impairment (MCI) (n=2) (286, 308), 
Parkinson’s disease (PD) (n=3) (286, 287, 309), multiple sclerosis (n=2) (288, 306), CHD 
mortality (n=3) (16, 300, 304), CVD mortality (n=2) (293, 312), stroke mortality (n=2) (276, 
303), all-cause mortality in heart failure patients (n=2) (271, 295), and all-cause mortality in 
the general population (n=2) (293, 312). Discordance in the statistical significance was 
present for 2 outcomes: diabetic neuropathy (n=2) (279, 281) and Alzheimer’s disease (AD) 
(n=4) (285, 286, 301, 308). 
After removing the overlapping meta-analyses (which were conducted in the same 
population for the same outcome), 76 unique meta-analyses were retained reporting a wide 
range of outcomes (Table 3-1): cardiovascular outcomes (n=13), diabetes related outcomes 
(n=9), kidney disorders (n=7), neurocognitive disorders (n=11), cancer outcomes (n=6), all-
cause or cause-specific mortality (n=22), and other outcomes (n=8). Overall, 58 (76.3%) of 
the 76 non-overlapping meta-analyses reported nominally statistically significant summary 
results (p<0.05). In Supplementary Figure 3-1 and 3-2, we plot the summary effects of the 
unique meta-analyses of observational studies. Of these, 12 (92.3%) meta-analyses in 
cardiovascular outcomes, 8 (88.9%) meta-analyses in diabetes related outcomes, all 7 
(100.0%) meta-analyses in kidney disorders, one (9.1%) meta-analyses in neurocognitive 
disorders, one (16.7%) meta-analyses in cancer outcomes, 15 (68.2%) meta-analyses in all-
cause and cause-specific mortality, and 6 (75.0%) meta-analyses in other outcomes reported 
summary estimates with p<0.05 and suggested that high levels of SUA were associated with 
an increased risk of disease. In addition, 7 (63.6%) meta-analyses in neurocognitive 
disorders, and 1 (12.5%) meta-analysis in other outcomes (composite of adverse outcomes 
(death or major cardiovascular event [MACE]) in acute ischaemic stroke patients) reported 
summary estimates with p<0.05 and suggested inverse associations with SUA.  
We then applied our evidence classification criteria. Sixteen (21.1%) meta-analyses had 
p<10-6; 10 (13.2%) meta-analyses had a 95% PI that excluded the null; 27 (35.5%) meta-
analyses had more than 1,000 cases (or more than 20,000 participants for continuous 
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outcomes); 15 (19.7%) meta-analyses had no large heterogeneity (I2<50%); 34 (44.7%) 
meta-analyses had neither small study effects nor excess significant bias. Based on these 
metrics, only one of 76 (1.3%) outcomes presented convincing evidence (class I: stroke 
mortality in general population); 7 (9.2%) outcomes presented highly suggestive evidence 
(class II: heart failure incidence, hypertension incidence, impaired fasting glucose or diabetes, 
CKD incidence, CHD mortality, all-cause mortality in heart failure patients, and non-
alcoholic fatty liver disease); 9 (11.8%) outcomes presented suggestive evidence (class III: 
atrial fibrillation, CHD incidence, CVD, prehypertension, medium term MACE, T2DM, 
CVD mortality, CKD mortality, death or cardiac events). The remaining 41 (53.9%) 
nominally significant outcomes presented weak evidence (class IV).  
We performed in-depth examination and re-assessed the meta-analyses of stroke mortality 
(276) (class I) and found that data from the largest study was incorrect (the events 
represented stroke incidence cases rather than stroke deaths and the included study had not 
published data on stroke mortality) (357). Furthermore, the data from two individual studies 
reported comparisons of SUA categories that differed from other studies (the highest sextile 
versus the second or third sextile rather than the lowest) (358, 359), and a fourth study had 
been included using only data on ischaemic stroke deaths but missing the data on 
haemorrhagic stroke deaths (360). When we excluded the stroke incidence study, used the 
proper comparison for the other two studies, and added the missing data in the fourth study, 
the association with stroke mortality was found to be non-significant (Table 3-2). For the 
highly suggestive outcomes (class II), when we limited the data to prospective cohort studies, 
all associations retained their ranking, except for all-cause mortality in heart failure patients 
and non-alcoholic fatty liver disease that were downgraded to class III (Table 3-2). 
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Table 3 - 1: Health outcomes and evidence class reported in meta-analyses of observational studies.     
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1.75E-10 55 (0, 81) 0.66 NP 1.09-6.67 IV 
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0.02 NP 0.99-3.74 II  
Abbreviations: MA, meta-analysis; AF, atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; MACE, major adverse cardiovascular events; 
AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; T2DM, Type 2 diabetes; CKD, chronic kidney disease; AD, Alzheimer’s disease; PD, 
Parkinson’s disease; VaD, Vascular dementia; MCI, mild cognitive impairment; MS, multiple sclerosis; NMO, neruomyelistsopticis; ALS, amyotrophic lateral 
sclerosis; NAFLD, non-alcoholic fatty liver disease; MD, mean difference; SMD, standard mean difference; NA, not available; NS, not significant; NP, not 
pertinent (because the number of expected significant studies was larger than the number of observed significant studies).  
† The heterogeneity (I2), Egger’s test or 95% PI could not be calculated, either because data about the individual component studies were insufficient or because the 
number of studies included in meta-analyses was less than 3.  
§ Evidence class criteria: (i) Class I (convincing): statistical significance with p<10-6, more than 1,000 cases (or more than 20,000 participants for continuous 
outcomes), the largest component study reported statistically significant effect (p<0.05); 95% prediction interval excluded the null; no large heterogeneity (I2<50%), 
no evidence of small study effects (p>0.10) and excess significance bias (p>0.10); (ii) Class II (highly suggestive): statistical significance with p<10-6, more than 
1,000 cases (or more than 20,000 participants for continuous outcomes), the largest component study reported statistically significant effect (p<0.05); (iii) Class III 
(suggestive): statistical significance with p<10-3, more than 1,000 cases (or more than 20,000 participants for continuous outcomes); (iv) Class IV (weak): the 
remaining statistically significant associations with p<0.05.  
*Evidence was re-assessed by examining the meta-analyses in depth to verify the eligibility/appropriateness of the data included in analysis and errors were found; 
when errors and analyses were corrected, the association became non-statistically significant.   
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1.62 (1.47, 
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2 12,631 2,530 OR 
1.43 (1.20, 
1.71) 




Abbreviations: MA, meta-analysis; AF, atrial fibrillation; CHD, coronary heart disease; T2DM, Type 2 diabetes; NA, not available; NS, not significant; NP, not 
pertinent (because the number of expected significant studies was larger than the number of observed significant studies).  
† The heterogeneity (I2), Egger’s test and 95% PI could not be calculated, because the number of studies included in meta-analyses was less than 3. 
§ Evidence class criteria: (i) Class I (convincing): statistical significance with p<10-6, more than 1,000 cases (or more than 20,000 participants for continuous 
outcomes), the largest component study reported statistically significant effect (p<0.05); 95% prediction interval excluded the null value; no large heterogeneity 
(I2<50%), no evidence of small study effects (p>0.10) and excess significance bias (p>0.10); (ii) Class II (highly suggestive): statistical significance with p<10-6, 
more than 1,000 cases (or more than 20,000 participants for continuous outcomes), the largest component study reported statistically significant effect (p<0.05); (iii) 
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Class III (suggestive): statistical significance with p<10-3, more than 1,000 cases (or more than 20,000 participants for continuous outcomes); (iv) Class IV (weak): 
the remaining statistically significant associations with p<0.05.  
*Evidence was re-assessed by examining the meta-analyses in depth to verify the eligibility/appropriateness of the data included in analysis or excluding the data 
from retrospective/case-control studies to address reverse causality.  
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3.4.3 Meta-analyses of randomised controlled trials   
We identified 31 meta-analyses of RCTs on SUA-lowering therapy from 8 publications 
(Supplementary Table 3-4). The median number of studies included in the meta-analyses 
was 5 (range: 2-10) and the median number of participants was 216 (range: 41-738). More 
than one meta-analysis was found for 5 outcomes (Supplementary Table 3-4). The 
direction and statistical significance of the effects in overlapping meta-analyses were in 
concordance only for one (20.0%) outcome: serum creatinine (SCr) (n=2) (316, 317). 
Discordance in either the direction and/or the statistical significance was found for the 
remaining 4 outcomes: glomerular filtration rate (eGFR) (n=2) (316, 317), end-stage kidney 
disease (n=2) (316, 317), systolic blood pressure (SBP) (n=2) (317, 320), and diastolic blood 
pressure (DBP) (n=2) (317, 320). 
Twenty unique meta-analyses (Table 3-3) were identified for the outcomes in relation to 
kidney disorders (n=10), endothelial function (n=2), all-cause and cause-specific mortality 
(n=4), and other outcomes (n=4). In Supplementary Figure 3-3 we plot the summary 
effects of the unique meta-analyses of RCTs. Overall, 12 (60.0%) of unique meta-analyses of 
RCTs reported a nominally statistically significant summary result at p<0.05 (8 had p<0.001). 
Only 3 (15.0%) meta-analyses had a 95% PI that excluded the null (two nephrolithiasis 
outcomes [with thiazide and citrate treatment] and one renal function outcome); 11 (55.0%) 
meta-analyses showed no large heterogeneity (I2<50%); and 13 (65.0%) meta-analyses 
showed neither small study effects nor excess significant bias.  
Taken all these together, only one outcome (recurrence of nephrolithiasis [with citrates 
treatment]) reported a p<10-3, had a 95% PI excluding the null and had no evidence of large 
heterogeneity or bias. In the original meta-analyses, the strength of evidence was graded 
collectively for three nephrolithiasis outcomes (with thiazide, citrate and allopurinol 
treatment) by using an approach conceptually similar to the GRADE ranking system (361) 
and evidence for these three nephrolithiasis outcomes was graded as moderate. 
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Table 3 - 3: Health outcomes reported in meta-analysis of RCTs. 






























Allopurinol 2 152 RR 
0.59 (0.42, 
0.84) 





Thiazides 5 300 RR 
0.52 (0.39, 
0.69) 





Citrates 4 197 RR 
0.26 (0.15, 
0.45) 
2.84E-06 0 (0, 68) 0.19 NP 0.08-0.88 








4.64E-04 93 (90, 95) 0.39 NP 0.01-13.21 
SCr (316) CKD Patients Allopurinol 6 354 MD to OR 
0.16 (0.08, 
0.34) 
1.00E-06 70 (0, 85) 0.01 0.59 0.02-1.76 








9.79E-03 29 (0, 80) 0.24 NP 0.01-497.40 
eGFR (317) 
Patients with CKD 
or decreased kidney 
function 
Allopurinol 5 346 MD to OR 
1.18 (0.97, 
1.42) 
0.09 0 (0, 64) 0.29 NP 0.86-1.60 
Proteinuria (317) 
Patients with CKD 
or decreased kidney 
function 
Allopurinol 5 250 MD to OR 
0.91 (0.73, 
1.12) 
0.40 0 (0, 64) 0.42 NP 0.64-1.28 
Blood urea nitrogen 
(BUN) (316) 
CKD patients Allopurinol 3 169 MD to OR 
0.18 (0.10, 
0.32) 
1.47E-08 0 (0, 73) 0.88 0.67 0.01-7.16 
End-stage renal disease 
(316) 
CKD patients Allopurinol 5 267 RR 
0.33 (0.21, 
0.51) 









5 144 MD to OR 
4.38 (1.85, 
10.38) 
8.76E-04 60 (0, 83) 0.23 0.24 0.27-70.69 







5 148 MD to OR 
2.69 (1.22, 
5.93) 
0.014 53 (0, 81) 0.09 0.61 0.24-30.73 
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Death during neonatal 
or infancy (319) 
All infants  Allopurinol 3 114 RR 
0.87 (0.43, 
1.75) 
0.71 34 (0, 81) 0.49 NP 0.01-952.4 
Death during neonatal 
or infancy† (319) 
Infants with severe 
hypoxic-ischaemic 
encephalopathy 
Allopurinol 2 41 RR 
0.92 (0.39, 
2.15) 
0.86 NA NA NP NA 
Death or serve 
neurodevelopmental 
disability (319)  
All infants Allopurinol 3 110 RR 
0.85 (0.63, 
1.15) 
0.29 0 (0, 73) 0.12 NP 0.12-5.98 
Death or serve 
neurodevelopmental 
disability† (319)  
Infants with severe 
hypoxic-ischaemic 
encephalopathy 
Allopurinol 2 41 RR 
0.93 (0.67, 
1.30) 








Allopurinol 3 73 RR 
0.58 (0.27, 
1.26) 
0.17 0 (0, 73) 0.69 NP 0.01-86.99 






Allopurinol 3 114 RR 
0.98 (0.84, 
1.15) 
0.81 0 (0, 73) 0.15 NP 0.35-2.79 
SBP* (320) 
Patients with 
elevated SUA or 
kidney dysfunction 





0.001 87 (79, 91) 0.60 NP -13.61-6.94 
DBP* (320) 
Patients with 
elevated SUA or 
kidney dysfunction 





0.03 82 (68, 88) 0.38 NP -8.22-5.65 
Abbreviations: RR, relative risk; CKD, chronic kidney disease; SCr, serum creatinine; eGFR, glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
MD, mean difference; SMD, standard mean difference; NA, not applicable (did not calculate with only 2 studies); NS, not significant; NP, not pertinent (because the number of 
expected significant studies was larger than the number of observed significant studies).   
§ The strength of evidence was graded based on the evidence-based practice centre approach (conceptually similar to the GRADE ranking system); recurrence of nephrolithiasis (with 
allopurinol, thiazides or citrates treatment) was all considered with moderate evidence in original meta-analyses.  
† The heterogeneity (I2), Egger’s test or 95% PI could not be calculated, because the number of studies included in meta-analyses was less than 3.  
* Meta-analyses included one prospective study.  
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3.4.4 Mendelian randomisation studies 
A total of 107 MR analyses were identified from 36 publications (Supplementary Table 3-
5). The median number of participants and median number of cases were 7,158 (range: 343-
206,822) and 2,225 (range: 19-65,877), respectively. The proportion of SUA variance 
(adjusted R2) explained by genetic instruments was 1.8%-6.0%. More than one MR study 
was identified for 14 outcomes (Supplementary Table 3-5). Discordance in either the 
direction and/or the statistical significance of association among overlapping MR existed for 
all the identified outcomes: BMI (n=7) (322, 323, 328, 329, 337, 342, 348), BMD in femoral 
neck (n=2)  (324, 325), CHD (n=5) (323, 327, 333, 345, 353), DBP (n=7) (323, 328, 333, 
337, 346, 348, 351), SBP (n=7) (323, 328, 333, 337, 346, 348, 351), metabolic syndrome 
(n=2) (334, 347), glucose (n=3) (323, 333, 348), TG (n=3) (323, 348, 350), diabetes (n=6) 
(323, 326, 332), (327, 349, 354), SCr (n=2) (337, 356), eGFR (n=5) (333, 337, 348, 355, 
356), Parkinson’s disease (n=5) (338, 339, 343, 344, 352), memory performance (n=2) (341), 
and gout (n=3) (326, 327, 333).   
The 56 unique outcomes (Table 3-4) investigated in individual MR studies belonged to the 
following categories: anthropometric variables (n=9), cardiovascular outcomes (n=15), 
kidney disorders (n=6), metabolic disorders (n=5), neurocognitive disorders (n=5), 
metabolites (n=11), all-cause and cause-specific mortality (n=3) and other outcomes (n=2). 
Only 9 (16.1%) outcomes (diabetic macrovascular disease, arterial stiffness [internal 
diameter of carotid artery], adverse renal events, Parkinson’s disease, lifetime anxiety 
disorders, memory performance, CVD mortality, sudden cardiac death, and gout) presented 
statistically significant associations of p<0.05. Three MR studies (on memory performance, 
Parkinson’s disease and gout) reported discordant results in the direction and/or statistical 
significance in other MR studies. Of note, only 4 outcomes (diabetic macrovascular disease, 
arterial stiffness [internal diameter of carotid artery], renal events, and gout) reported a 
p<0.01, and only that for gout was based on convincing evidence (p=3.55×10-40, N sample 
size=71,501, power>99%).  
3.4.5 Comparing findings from meta-analyses  
Outcomes reported in meta-analyses of observational studies with highly suggestive 
evidence or meta-analyses of RCTs with 95% PI excluding the null are summarised in Table 
3-5. Among these outcomes, hypertension and CKD showed concordant evidence between 
meta-analyses of observational studies and the selected (largest) meta-analyses of RCTs on 
their corresponding intermediate traits or surrogate outcomes (e.g. SBP, DBP, SCr, eGFR 
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and end-stage renal disease), but had discordant evidence from MR studies. Moreover, as we 
mention above, even for these outcomes, there were additional meta-analyses of RCTs that 
had found discordant effects in terms of direction and/or statistical significance for all these 
intermediate traits or surrogate outcomes with the exception of SCr. Heart failure, impaired 
fasting glucose or diabetes and CHD mortality showed no evidence from meta-analyses of 
RCTs, and MR studies reported discordant evidence on either the corresponding outcomes, 
intermediate traits or surrogate outcomes. Recurrence of nephrolithiasis was only reported in 
meta-analysis of RCTs, and no evidence was found from meta-analyses of observational 
studies or MR studies.
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Table 3 - 4: Health outcomes reported in Mendelian randomisation studies.  
Outcomes Population 
N/n Events  
(N studies)* 
Genetic instruments (GI) 
SUA variance 










Appendicular lean mass 
(kg) (321) 
British 3,953 rs737267 in SCL2A9 NA β  0.013 (NA, NA) 0.51 NA 
Fat mass (kg) (322) Swiss 6,184 rs6855911 in SCL2A9 3.2% β  0.05 (-0.10, 0.19) 0.52 0.07 
BMI (kg/m2) (323)  European 127,600 (64)* 
Genetic risk score of 31 SUA-related 
SNPs 




Waist circumference (cm) 
(322) 
Swiss 6,184 rs6855911 in SCL2A9 3.2% β  0.08 (-0.05, 0.21) 0.24 0.06 
BMD in femoral 
neck(g/cm2) (324) 
American 2,501 Genetic risk score of 5 SUA-related SNPs 3.3% β  -0.27 (-0.58, 0.03) 0.08 0.07 
BMD in L1–L4 (g/cm2) 
(325) 
Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β 0.39 (-0.26, 0.98) 0.26 0.19 
BMD in spine (g/cm2) (324) American 2,501 Genetic risk score of 5 SUA-related SNPs 3.3% β 0.08 (-0.32, 0.48) 0.68 0.18 
BMD in total femur (g/cm2) 
(324) 
American 2,501 Genetic risk score of 5 SUA-related SNPs 3.3% β  -0.29 (-0.60, 0.01) 0.06 0.11 
BMD in total hip (g/cm2) 
(325) 
Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β  0.19 (-0.36, 0.74) 0.50 0.19 
Cardiovascular outcomes  
Arrhythmia (326) German 3,060/444 Genetic risk score of 8 SUA-related SNPs NA OR 0.98 (0.88, 1.08) 0.64 0.05‡ 
Atrial fibrillation (326) German 3,060/368 Genetic risk score of 8 SUA-related SNPs NA OR 1.03 (0.93, 1.15) 0.57 0.05‡ 
Cardiomyopathy (326) German 3,060/316 Genetic risk score of 8 SUA-related SNPs NA OR 1.00 (0.89, 1.12) 0.93 0.05‡ 
CHD (323) European 206,822/65,877 (58)* 
Genetic risk score of 31 SUA-related 
SNPs 
4.2% OR 1.05 (0.92, 1.18) 0.49 0.57 
Heart failure (327) Pakistani 22,926/4,526 (2)* 
Genetic risk score of 14 SUA-related 
SNPs 
3.1% OR 1.07 (0.88, 1.30) 0.51 0.11 
Ischaemic heart disease 
(328) 
Danish 68,674/3,742 (2)* rs7442295 in SCL2A9 2.2% HR 0.93 (0.79, 1.09) 0.38 0.10 
Hypertension (326) German 3,060/2,225 Genetic risk score of 8 SUA-related SNPs NA OR 0.98 (0.90, 1.06) 0.56 0.05‡ 
Ischaemic stroke (327) Pakistani 82,091/14,779 (2)*  
Genetic risk score of 14 SUA-related 
SNPs 
3.1% OR 0.99 (0.88, 1.12) 0.93 0.05 
Peripheral vascular disease 
(326) 
German 3,060/295 Genetic risk score of 8 SUA-related SNPs NA OR 0.92 (0.82, 1.04) 0.18 0.06‡ 




N/n Events  
(N studies)* 
Genetic instruments (GI) 
SUA variance 














3,207 Genetic risk score of 3 SUA-related SNPs NA OR 1.18 (1.06, 1.33) 0.004 NA 




Arterial stiffness (internal 
diameter of carotid artery) 
(mm) (331) 
Italian 449 rs734553 in SLC2A9 NA β 0.48 (NA, NA) 0.003 NA 
DBP (mm Hg) (323) European 89,667 (37)* 






SBP (mm Hg) (323) European 89,667 (37)* 






Metabolic disorders  
T2DM (327) Pakistani 110,452/26,488 (2)* 
Genetic risk score of 14 SUA-related 
SNPs 
3.1% OR 0.95 (0.86, 1.05) 0.28 0.24 
Diabetes (332) European 
165,482/41,508 
(2)* 
Genetic risk score of 24 SUA-related 
SNPs 
4.0% OR 0.99 (0.92, 1.06) 0.79 0.06 
Fasting glucose (mmol/L) 
(323)  
European 57,397 (28)* 






Fasting insulin† (333) American 19,899 (5)* Genetic risk score of 8 SUA-related SNPs 6.0% 
Z 
statistic 
-0.015 (NA, NA) 0.99 NA 
Metabolic syndrome (334) Chinese 7,827 
Genetic risk score of 2 SNPs (rs11722228 
in SLC2A9 and rs2231142 in ABCG2) 
2.1% OR 1.03 (0.98, 1.09) 0.23 NA 
Kidney disorders  
CKD (333) American 23,387/3,092 (5)* Genetic risk score of 8 SUA-related SNPs 6.0% OR 1.20 (0.96, 1.50) 0.12 0.70 
Acute kidney injury (335) American 7,553/823 Genetic risk score of 8 SUA-related SNPs 6.0% HR 1.01 (0.77, 1.34) 0.92 0.05 
Adverse renal events (336) Italian 755/244 rs734553 in GLUT9 NA HR 2.35 (1.25, 4.42) 0.01 NA 
Log eGFR (mL/min/1.73 
m2) (333)  
American 23,844 (5)* Genetic risk score of 8 SUA-related SNPs 6.0% β 0.001 (-0.01, 0.02) 0.91 0.05 








3,604 (3)* Genetic risk score of 5 SUA-related SNPs  5.3% 
Residual 
variance¶   
Overall p>0.05 NA 
 




N/n Events  
(N studies)* 
Genetic instruments (GI) 
SUA variance (R2) 
explained by GI 
Type of 
metric 






Parkinson’s disease (PD) 
(343) 
Birtish 1,815/1,061 Genetic risk score of 8 SUA-related SNPs  NA OR 1.55 (1.10, 2.18) 0.01 0.59‡ 
Age at onset of PD (339) European 664 (3)* 
4 SNPs in SCL2A9 NA 
β 
Null after multiple testing 
correction 
 
rs737267 NA 3.10 (0.17, 6.03) 0.04 
NA 
rs6449213 NA -1.18 (-4.96, 2.59) 0.54 
rs1014290 NA -4.56 (-8.13, -1.00) 0.01 
rs733175 NA 3.59 (0.67, 6.51) 0.02 
Lifetime anxiety disorders 
(340) 
Swiss 3,716 rs6855911 in SLC2A9 3.2% 
OR 
(male) 
1.40 (1.07, 1.84) 0.02 0.11 
OR 
(female) 
0.97 (0.80, 1.17) 0.73 0.05 
Current anxiety disorders 
(340) 
Swiss 3,716 rs6855911 in SLC2A9 3.2% 
OR 
(male) 
1.42 (0.99, 2.03) 0.06 0.12 
OR 
(female) 
0.84 (0.66, 1.06) 0.14 0.07 
Memory performance (341) 
European: 
Population 1 
1,091 4 SNPs in SCL2A9 NA β Overall p<0.05 NA 
European: 
Population 2 
1,066 4 SNPs in SCL2A9 NA β Overall p>0.05  NA 
Metabolites 








TC (mmol/L) (323) European 196,621 (68)* Genetic risk score of 31 SUA-related SNPs 4.2% MD§ 0.000 (-0.002, 0.002) NA NA 
TG (mmol/L) (323) European 196,621 (68)* Genetic risk score of 31 SUA-related SNPs 4.2% MD§ 0.01 (0.01, 0.02) NA NA 
Parathyroid hormone 
(pg/mL) (325) 
Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β -0.63 (-2.12, 0.85) 0.40 0.05 
Phosphorus (mmol/L) (325) Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β -0.16 (-0.74, 0.42) 0.59 0.05 
CRP (mg/L) (342) European 7,158 Genetic risk score of 29 SUA-related SNPs NA β -0.05 (-0.15, 0.05) 0.37 NA 
Calcium (mmol/L) (325) Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β 0.06 (-0.10, 0.21) 0.48 0.20 
 




N/n Events  
(N studies)* 
Genetic instruments (GI) 
SUA variance (R2) 
explained by GI 
Type of 
metric 





Tropocollagen type 1 N-
terminal propeptide (ng/L) 
(325) 
Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β 0.11 (-1.53, 1.75) 0.90 0.05 
β-crosslaps of type I 
collagen containing cross-
linked C telopeptide (ng/L) 
(325) 
Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β -1.45 (-3.17, 0.27) 0.10 0.05 
25(OH)D (ng/mL) (325) Chinese 1,667 Genetic risk score of 5 SUA-related SNPs 1.8% β 0.76 (-0.63, 2.15) 0.28 0.05 
All-cause and cause-specific mortality 
Cardiovascular mortality 
(326) 
German 3,060/NA Genetic risk score of 8 SUA-related SNPs NA aHR 1.11 (1.02, 1.21) 0.02 NA 
All-cause mortality (326) German 3,060/NA Genetic risk score of 8 SUA-related SNPs NA aHR 1.02 (0.95, 1.09) 0.59 NA 
Sudden cardiac death (326) Germany 3,060/NA Genetic risk score of 8 SUA-related SNPs NA aHR 1.18 (1.03, 1.35) 0.02 NA 
Other outcomes  
Cancer (326) German 3,060/226 Genetic risk score of 8 SUA-related SNPs NA OR 0.95 (0.83, 1.08) 0.41 0.05‡ 




Abbreviations: GI: Genetic instruments; BMI, body mass index; BMD, bone mineral density; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, 
coronary heart disease; IMT, intima-media thickness; CVD, cardiovascular disease; T2DM, Type 2 diabetes; CKD, chronic kidney disease; SCr, serum creatinine; 
eGFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; 
CRP, C-reactive protein; PD, Parkinson’s disease; MD, mean difference; NA, not available.  
* If the outcomes were reported from Mendelian randomisation analysis with pooling multiple studies, the number of studies included in pooled analysis was 
displayed in brackets.  
† Because of the lack of a standard to covert insulin in different studies to the same scale, sample size-weighted pooled analysis were performed and Z statistics 
were reported instead of the β coefficient. 
§ MD (mean difference) represented the difference in mean caused by per inverse variance weighted allele estimated from pooled analysis.   
¶ Residual variance represented the proportion of residual variance explained by the SUA related SNPs.  
‡ The statistical power was a crude estimation, as the MR studies failed to report R2; we used the extrapolated R2 from other MR studies that used the same genetic 
variants as instruments for calculation.  
# When MR studies that did not provide other necessary information for calculation (e.g. SD of SUA levels, SD of outcomes, or the number of cases), the statistical 
power was not calculated (reported as NA).   
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Table 3 - 5: Summary of evidence grading and comparison of multiple evidence.  
Outcomes MA of observational studies MA of RCTs* MR studies 
Heart failure  Class II  NA 
Heart failure:  




SBP: (p=0.001; 95% PI included null) 
DBP: (p=0.034; 95% PI included null) 
Hypertension:  
(N sample size=3,060; p=0.56; power=0.05) 
Impaired fasting 
glucose or diabetes 
 
Class II NA 
Diabetes:  
(N sample size=165,482; p=0.79; power=0.06) 
Fasting glucose: 
(N sample size=57,397; p>0.05) 
Fasting insulin: 
(N sample size=19,899; p=0.99) 
CKD† Class II 
SCr: (p=4.64×10-4; 95% PI included null) 
eGFR: (p=9.79×10-3; 95% PI included null) 
End stage renal disease: 
(p=1.38×10-6; 95% PI excluded null) 
CKD:  (N sample size=23,387; p=0.12; power=0.70) 
Adverse renal events: (N sample size=755; p=0.01) 
SCr: (N sample size=7,979; p=0.07) 
eGFR: (N sample size=23,844; p=0.91;power=0.05) 





(p=2.84×10-6; 95% PI excluded null) 
Thiazides treatment: 
(p=9.00×10-6; 95% PI excluded null) 
NA 
Abbreviations: MA, meta-analyses; MR, Mendelian randomisation; CKD, chronic kidney disease; CHD, coronary heart disease; HF, heart failure; NA, not 
applicable; NS, not significant. † If there was no identical outcomes investigated in meta-analyses of RCTs and/or MR studies to match with the class I-II 
observational associations, we juxtaposed the corresponding intermediate traits as surrogates for comparison. 
*Data presented on the largest meta-analysis of RCTs for each outcome; for SBP, DBP, eGFR, and end-stage renal disease other meta–analyses of RCTs on the 
same outcomes showed discordant results in direction of effect and/or statistical significance.
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3.5 Discussion  
In this study, we provide a comprehensive overview of reported associations between SUA 
levels and a wide range of health outcomes by incorporating evidence from meta-analyses of 
observational studies, meta-analyses of RCTs and MR studies. We also further evaluated the 
reported evidence by following criteria that we have previously applied to appraise the 
epidemiological credibility in several research fields (255, 362, 363). In summary, our study 
comprised 76 unique meta-analyses of observational studies, 20 unique meta-analyses of 
RCTs and 56 unique individual MR studies, which overall covered 136 unique health 
outcomes.  
3.5.1 Main findings and possible explanations  
Most health outcomes which were reported to be associated with SUA were identified from 
meta-analyses of observational studies, but after the application of our criteria none of them 
was classified as convincing (class I). Highly suggestive evidence (class II) existed for 5 
health outcomes, including heart failure, hypertension, impaired fasting glucose or diabetes, 
CKD and CHD mortality in general population. It is notable that a large proportion (80.3%) 
of the examined meta-analyses displayed substantial heterogeneity (I2>50%), indicating that 
these associations should be interpreted with caution. Possible sources of the observed 
heterogeneity include the mixture of prospective, retrospective or case-control studies and 
the mixture of different comparison groups, since some meta-analyses synthesised individual 
studies with diverse contrasted categories of SUA levels (e.g. various choices of tertiles, 
quartiles, quintiles or sextiles of SUA levels). Likewise, although the outcomes with class I-
II evidence fulfilled the criteria of credibility assessment for meta-analyses of observational 
studies, it would be inadvisable to conclude causation on this basis alone, due to the inherent 
limitations of unmeasured confounding, undetected bias or reverse causality in observational 
studies. In relation to reverse causality for example, some of the associations which were 
initially classified as class II (e.g. all-cause mortality in heart failure patients and non-
alcoholic fatty liver disease), were no longer highly suggestive (and were downgraded to 
class III) when focusing on prospective observational data and excluding the retrospective 
studies. 
Current evidence from meta-analyses of RCTs was limited to the beneficial effects of SUA-
lowering therapy on some intermediate traits or biomarkers related to cardiovascular and 
renal disorders (e.g. blood pressure, endothelial functions and renal function). However, 
when multiple meta-analyses of RCTs existed for their traits or markers, often their results 
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were not concordant in direction of effect and/or statistical significance. Although 12 health 
outcomes had p<0.05, only recurrence of nephrolithiasis with citrates treatment achieved 
p<10-3 with 95% PI excluding the null. Two additional health outcomes (recurrence of 
nephrolithiasis with thiazides treatment and end-stage renal disease in CKD patients with 
allopurinol treatment) also had a 95% PI excluding the null. Large heterogeneity and 
evidence of bias were common even in meta-analyses of RCTs (in 45.0% and 35.0% of 
meta-analyses of RCTs respectively). When incorporating evidence from meta-analyses of 
RCTs with that from meta-analyses of observational studies, there was a notable gap, as 
health outcomes that were investigated in meta-analyses of observational studies and 
classified as class I-II, have generally not been evaluated in meta-analyses of RCTs. In a few 
cases, data from RCTs on surrogate outcomes (e.g. SBP, DBP, renal function tests) that 
correspond to disease outcomes in observational studies (hypertension, CKD) were available, 
but conclusions from extrapolation of surrogate outcomes, which were evaluated in short-
term trials, to long-term clinical outcomes should be treated with caution.   
As an alternative to RCTs, MR design has been developed for exploring the causal effect of 
biomarkers on health outcomes. Fifty-six MR studies were identified that explored the causal 
role of SUA in cardiovascular, metabolic, neurocognitive and renal disorders or related traits 
and biomarkers. In contrast to the meta-analyses of observational studies where most of the 
results (76.3%) were statistically significant at p<0.05, the majority (83.9%) of health 
outcomes investigated in MR studies were not statistically significant. The generally 
negative results across so many health outcomes suggest that the large effects have probably 
not been missed, but most of the included MR studies could have been underpowered to 
detect modest effects. When retaining the largest MR study for each health outcome, 
significant results with p<0.05 were only reported for 9 health outcomes, and only 4 of these 
health outcomes (diabetic macrovascular disease, arterial stiffness [internal diameter of 
carotid artery], renal events, and gout) had p<0.01, while only the gout outcome was based 
on evidence from MR study with adequate power. Of the other 5 health outcomes with 
p<0.05, Parkinson’s disease and memory performance had at least one other MR study that 
was not significant or had an association in the opposite direction.  
There are a number of instrumental variable assumptions that need to be fulfilled for the 
results of an MR analysis to be valid. The first assumption states that the genetic instrument 
should be strongly associated with the intermediate phenotype. SUA has a significant 
heritable component with an overall heritability of 40%-60% (364), but the strength of 
genetic instruments used in MR studies was small or moderate, accounting for only 1.8%-6.0% 
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of SUA variance. Currently, the proportion of SUA variance explained by all common 
genetic variants identified by GWAS remains relatively small (7.0%) (151). This limits the 
power of genetic instruments to detect causal associations with SUA. The second and third 
assumptions (the instrument is associated with the outcome through the studied exposure 
only and the genotype is independent of other factors which affect the outcome) are more 
difficult to evaluate given the largely unknown complexity and interconnectedness of 
biologic pathways underlying the genetic variants related to SUA. The included MR studies 
tried to validate these assumptions either by excluding SNPs related to other known 
confounding factors, by excluding SNPs that had potential pleiotropic effects or by applying 
novel MR methods to account for pleiotropic effects (e.g. Egger or network MR).  
3.5.2 Clinical implications and future research  
Current recommendations on the pharmacological treatment of hyperuricaemia are related to 
gout or nephrolithiasis (124). Since a wide range of health outcomes have been identified to 
be associated with SUA, a renewed interest in whether individuals with asymptomatic 
hyperuricaemia should be treated with SUA-lowering drugs for the prevention or treatment 
of these non-crystal deposition diseases developed. In this study, we raised large uncertainty 
about the potential therapeutic benefits of an expansion of SUA-lowering therapy. Although 
we identified some highly suggestive associations from observational studies, there was a 
lack of concordance with clinically relevant endpoints from RCTs or surrogate endpoints 
from MR studies and therefore there is insufficient evidence to support any SUA-lowering 
drug intervention for these outcomes. Furthermore, the adverse effects of SUA-lowering 
drugs should be taken into consideration (for example an estimated 0.1% of patients treated 
with allopurinol, the first line SUA-lowering drug, develop allopurinol hypersensitivity 
syndrome, which can be life-threatening) (56).  
On the other hand, our study does not support one of the recommendations in the recently 
updated EULAR gout treatment guidelines which suggests that SUA level <178 µmol/L is 
not recommended for gout management in the long term (55). This recommendation is based 
on a number of observational studies in which low SUA levels were associated with 
increased risk of multiple neurological diseases, including Alzheimer’s and Parkinson’s 
disease (365-367). However, in our umbrella review a number of meta-analyses reported 
nominally statistically significant associations of low SUA levels with increased risk of 
multiple neurological diseases, but several other (9 out of 28) meta-analyses did not support 
these findings. Moreover, our credibility assessment showed that the nominally significant 
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associations were consistent with Class IV evidence, and a causal effect has not consistently 
been established for any neurological disease in MR studies. Therefore, there is no adequate 
evidence against lowering SUA in gout patients in relation to an increased risk of 
neurological diseases. 
In relation to future research, efforts to address the limitations and caveats in current 
evidence will be beneficial. In particular, as the current clinical trials of SUA-lowering 
treatment largely focus on the effect of allopurinol on some intermediate traits or biomarkers, 
the effect of SUA reduction on clinically relevant endpoints of the convincing and highly 
suggestive associations might be worth of further investigation. In addition, efforts to 
evaluate whether other SUA-lowering agents have the same effect as xanthine oxidase 
inhibitors, will help to determine if these effects are truly due to the SUA reduction per se 
rather than the mechanisms of xanthine oxidase inhibition. Finally, noting the largely 
discordant evidence in MR studies, better designed MR studies with collaboration of large 
international consortia may assist in deciding whether the lack of replication of highly 
suggestive findings of observational studies is due to low power to detect moderate/small 
effects or due to truly negative effects.  
3.5.3 Strengths and weaknesses of this review  
The strengths of the umbrella reviews have been previously described in detail (255, 362, 
363). Here, we summarised and presented the evidence of the associations between SUA and 
a wide spectrum of health related outcomes systematically and thoroughly by incorporating 
information from meta-analyses of observational studies, meta-analyses of RCTs and MR 
studies. We then calculated a number of additional metrics and applied well-defined criteria 
to assess the credibility of the observed associations. 
In relation to study weaknesses, umbrella reviews focus on existing meta-analyses and 
therefore outcomes that were not assessed in a meta-analysis are not included in the review. 
For example, we found no formal meta-analysis of observational studies on SUA and 
urolithiasis or gout, even though these associations are very well established. Although there 
are some differences in SUA levels between men and women, there is not sufficient evidence 
at a meta-analysis level and therefore we did not attempt to perform subgroup analyses by 
gender. To avoid subjectivity, we did not include reviews without explicit systematic 
literature searches, but this could limit the breadth of the results to some extent, if some non-
systematic reviews cover questions that have not been addressed by systematic reviews (368, 
369). Furthermore, we did not appraise the quality of the individual studies, since this should 
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be the responsibility of the authors of the original meta-analysis and it was beyond the scope 
of the current umbrella review. 
We adopted credibility assessment criteria, which were based on established tools for 
observational evidence and their individual limitations have been summarised previously 
(255, 362, 363). None of the components of these criteria provide firm proof of lack of 
reliability, but they cumulatively map the possibility that the results are susceptible to bias 
and uncertainty. Given the wide variety of study designs and populations considered in 
several of the meta-analyses, one may claim that large heterogeneity in particular may not 
necessarily be worrisome. However, considering it is difficult to differentiate the real 
heterogeneity from the heterogeneity that reflects some forms of bias or uncertainty, we 
applied I2<50% as one of the criteria for Class I evidence (convincing) for meta-analyses of 
observational studies, so as to assign the top evidence grade only to associations that are 
most robust and without hints of bias. In most cases I2>50% indicates the presence of 
component studies with opposite effects or of component studies with and without 
statistically significant associations. However, nine meta-analyses of observational studies 
classified as class II, III or IV had an I2>50% with all component studies reporting a 
statistically significant association of the same direction. Only one of these nine meta-
analyses (heart failure incidence) would be upgraded from Class II to Class I, if we did not 
consider the heterogeneity criterion, since the other 8 also failed additional class I criteria. 
No meta-analyses of RCTs had an I2>50% with all component studies reporting a statistically 
significant association with the same direction.    
Finally, another limitation of the umbrella review approach is the use of existing meta-
analyses taking their results at face value. Meta-analyses are known to have common flaws 
(370) and their results may also depend on choices made about what estimates to select from 
each primary study and how to represent them in the meta-analysis, e.g. in what contrast of 
exposure levels. This may be a common problem when the factor of interest is continuous, as 
in the case of SUA and where very different comparisons of levels of the risk factor may be 
selected to express risk (371). We therefore decided to investigate any meta-analyses with 
seemingly convincing evidence in more detail. In this process, the only meta-analysis that 
seemed to achieve convincing evidence (class I: stroke mortality) was found to actually have 
major flaws. Re-calculation of the results showed that the evidence was actually downgraded 
to be non-significant. It is possible that similar in-depth evaluations might have downgraded 
the credibility of some additional meta-analyses. In addition, we noted that many primary 
studies are represented in the calculations of meta-analyses by using only a small subset of 
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the data of extreme groups, e.g. as the risk ratio for an event in extreme quintiles of SUA. In 
these cases, the number of events pertinent to these extreme groups may be much fewer than 
the total number of events used in calculating the amount of evidence criterion. Therefore, 
some meta-analyses that seemingly include studies with a total of over 1000 cases may 
actually capture fewer than 1000 cases in the main calculations and thus their grading 
appraisal should have been weaker. These flaws and deficiencies are very difficult to 
decipher without an in-depth re-construction from scratch of all observational meta-analyses 
and they may explain why observational evidence for SUA associations generally did not 
show good concordance with randomised trial and MR evidence in our umbrella evaluation.  
Meta-analyses of observational data for SUA and other risk factors need to be strengthened. 
For continuous putative risk factors such as SUA, a wide consensus on the categorisation of 
levels of interest would be useful to achieve and careful meta-analyses of individual level 
data in inclusive consortia may help achieve this. This approach would allow a more 
accurate and reliable exploration of both linear and non-linear associations, e.g. the 
possibility of U-shaped associations with increased risk at both very high and very low levels. 
Currently available data from meta-analyses do not allow for consistent handling and 
assessment of such non-linear relationships. Conversely, data dredging using different 
categorisations of levels and exposure contrasts is likely to be fuelling a literature with 
spurious associations (372).  
3.6 Conclusion    
This comprehensive umbrella review will help investigators to judge the relative priority of 
health outcomes related to SUA in relation to future research and to clinical management of 
disease. In summary, despite a few hundred systematic reviews, meta-analyses and MR 
studies exploring 136 unique health outcomes, convincing evidence of a clear role of SUA 
exists for only gout and nephrolithiasis. Concordant evidence between observational studies 
and RCTs existed for hypertension and CKD, but a potential causal role of SUA for these 
outcomes has not been verified by current MR studies and even for these two outcomes not 
all meta-analyses of RCTs are concordant among themselves and with observational 
evidence. Therefore, the available evidence does not support any change in the existing 
clinical recommendations in relation to hyperuricaemia.  
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3.7 Supplementary information 
Supplementary Table 3 - 1: Keywords and search strategy used in the umbrella review. 
MEDLINE (OvidSP)  
1. Uric acid.mp. or Uric Acid/ 
2. Uric Acid/ or urate*.mp. 
3. Acid uric.mp. or Uric Acid/ 
4. Hyperuricaemia.mp. or Uric Acid/ or Hyperuricaemia/ 
5. Uric Acid/ or hypouricaemia.mp. 
6. Uric Acid/ or hyperuricosuria.mp. 
7. Uric Acid/ or hypouricosuria.mp. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. "Review Literature as Topic"/ or "Review"/ or review*.mp. 
10. Meta-Analysis as Topic/ or meta-analys*.mp. 
11. Mendelian Randomisation Analysis/ or Mendelian randomi*.mp. 
12. 9 or 10 or 11 
13. 8 and 12 
EMBASE (OvidSP)  
1. Uric acid.mp. or uric acid/ 
2. Urate*.mp. or urate/ 
3. Uric acid/ or acid uric.mp. 
4. Hyperuricaemia.mp. or hyperuricaemia/ 
5. Hypouricaemia.mp. or hypouricaemia/ 
6. Hyperuricosuria.mp. or hyperuricosuria/ 
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7. Uric acid/ or hypouricosuria.mp. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. Systematic review.mp. or "systematic review"/  
10. "Systematic review"/ or meta-analys*.mp. 
11. Mendelian randomisation analysis/ or Mendelian randomi*.mp. or Mendelian randomisation/ 
12. 9 or 10 or 11 
13. 8 and 12 
Cochrane library  
(uric acid OR acid uric OR urate* OR hyperuricaemia OR hypouricaemia OR hyperuricosuria OR 
hypouricosuria) AND (systematic review* OR meta-analys*) 
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Supplementary Table 3 - 2: General characteristics and main findings of the systematic reviews of observational studies. 
Author Year Population Study design Comparison Outcome N studies Authors' interpretation 
Cardiovascular Outcomes 
Baker(373) 2005 Healthy subjects Cohort SUA level CVD 10 The excess risk associated with SUA in healthy patients is likely to be 
small. High SUA is likely an independent risk factor in patients at high 
CVD risk. 
Baker(373) 2005 
Patients at high 
CVD risk 
Cohort SUA level CVD 11 
Strazzullo(374) 2007 General Cohort SUA level CVD 16 
SUA is a very weak predictor of CVD in healthy population, but a 
significant independent predictor among subjects at high or very high 
risk. 
Strazzullo(374) 2007 
Patients with arterial 
hypertension 
Cohort SUA level CVD 8 
Strazzullo(374) 2007 
Patients at high 
CVD risk 
Cohort SUA level CVD 5 
Barron(260) 2015 General Cohort SUA level CVD 3 
Greater risk of CVD/all-cause mortality in those with the highest than 
with the lowest quartiles of SUA. 
Dimitroula(261) 2008 General Cohort SUA level Stroke 13 
It remains controversial whether elevated serum uric acid is 
neuroprotective or injurious at the onset of acute stroke. 
Hwu(262) 2010 General 
Cross-
sectional 
SUA level Hypertension 6 
All except one study have documented a direct association with either 
incident hypertension or increase in blood pressure. 











Nearly all published prospective studies support the role of 
hyperuricaemia as an independent risk factor for renal dysfunction.  




The preponderance of epidemiological evidence suggests a direct link 
between uric acid and CKD. 
Cognitive diseases 







PD patients have lower SUA levels than controls; SUA is strongly and 
linearly associated with reduced risk of PD. 













AD patients vs 
control 




Three studies elaborate that plasma or serum uric acid level is 
significantly lower in AD, while three other studies do not observe this 
difference. 
Other Outcomes 
Cnossen(378) 2006 Women Cohort SUA level Pre-eclampsia 5 
There is currently insufficient evidence to draw firm conclusions about 
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Supplementary Table 3 - 3: General characteristics and main findings of the 144 meta-analyses of observational studies. 























Highest vs lowest 
SUA category 


















Atrial fibrillation  
incidence 
General  Hyper vs normal 6 426,159 7,595 RR Random 
1.49 (1.24, 
1.79) 
Tamariz(310) 2014 Atrial fibrillation 
Atrial fibrillation 
vs controls 














General Hyper vs normal 2 61,955 NA aRR Random 
2.07 (1.61, 
2.67)  
Wheeler(380) 2005 CHD incidence  General 
Highest vs lowest 
SUA category 





Kim(381) 2010 CHD General Hyper vs normal 9 53,750 5,113 aRR Random 
1.09 (1.03, 
1.16) 
Braga(382) 2015 CHD incidence  General Hyper vs normal 9 457,915 19,119 RR Random 
1.21 (1.07, 
1.36) 
Li(16) 2016 CHD incidence General Hyper vs normal 13 70,382 6,666 aRR Random 
1.13 (1.05, 
1.21) 
Qin(270) 2016 CVD 
Hypertensive 
patients 
Hyper vs normal 6 19,546 1,054 aHR Random 
1.17 (1.07, 
1.27)  
Qin(270) 2016 CVD 
Hypertensive 
patients 






General Hyper vs normal 5 427,917 101,71 HR Random 
1.65 (1.41, 
1.94)  




Highest vs lowest 
SUA category 
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General 1 mg/dL SUA increase 3 420,756 9,812 HR Fixed 
1.19 (1.17, 
1.21)  
Zhang(384) 2009 Hypertension General  
Highest vs lowest 
SUA category 












































General 1 mg/dL SUA increase 5 15,951 4,941 aRR Random 
1.15 (1.06, 
1.26) 
Jiang(273) 2016 Prehypertension General  
Highest vs lowest 
SUA category 




Left atrial thrombus 
or spontaneous echo 
contrast 
(LATH/LASEC) 
Patients with mitral 
stenosis,  
sinus rhythm or 
atrial fibrillation 
Highest vs lowest 
SUA category 









patients vs controls 
Hyper vs normal 6 2,406 651 RR Fixed 
3.44 (2.33, 
5.08)  






Patients with acute 
myocardial 
infarction 
Highest vs lowest 
SUA category 
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Trkulja(388) 2012 Short term MACE 
Patients with acute 
myocardial 
infarction 
Highest vs lowest 
SUA category 
7 6,470 787 OR Random 
2.21 (1.64, 
2.97)  
Qin(270) 2016 Stroke 
Hypertensive 
patients 
Hyper vs normal 5 NA NA HR Random 
0.94 (0.67, 
1.33)  
Qin(270) 2016 Stroke 
Hypertensive 
patients 
Continuous SUA level 3 9,978 217 aHR Random 
1.11 (0.98, 
1.16)  




Li(276) 2014 Stroke incidence General Hyper vs normal 5 24,548 1,290 aRR Random 
1.22 (1.02, 
1.46) 
Diabetes related outcomes 
Jia(390)  2013 
Impaired fasting 
glucose or T2DM 
General 
Highest vs lowest 
SUA category 




Type 2 diabetes 
(T2DM) 





Jia(390) 2013 T2DM General 
Highest vs lowest 
SUA category 
9 48,808 5,115 RR Fixed 
1.67 (1.51, 
1.86) 
Lv(307) 2013 T2DM incidence  
General without 
diabetes 
Hyper vs normal 8 32,016 2,930 RR Fixed 
1.56 (1.39, 
1.76) 
Lv(307) 2013 T2DM incidence  
General without 
diabetes 
1 mg/dL SUA increase 6 21,592 2,203 RR Fixed 
1.06 (1.04, 
1.07) 
Qin(270) 2016 Diabetes incidence 
Hypertensive 
patients 
Hyper vs normal 2 8,247 564 aHR Random 
1.84 (1.02, 
3.30)  
Qin(270) 2016 Diabetes incidence 
Hypertensive 
patients 









3 3,166 196 OR Random 
1.91 (1.07, 
3.42)  
Xu(279) 2013 Diabetic retinopathy T2DM patients 
Continuous/categorical 
SUA level 
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3 2,538 187 OR Fixed 
1.03 (1.00, 
1.06)  
Xu(279) 2013 Diabetic neuropathy T2DM patients 
Continuous/categorical 
SUA level 
2 2,034 231 OR Random 
1.19 (0.61, 
2.32) 









vs diabetic controls 








vs diabetic controls 
Hyper vs normal  5 4,097 894 RR Random 
2.83 (2.13, 
3.76) 




General Hyper vs normal 3 3,004 NA RR Random 
1.35 (1.12, 
1.63)  





Zhu(282) 2014 CKD incidence 
Middle-aged 
Populations 
















1 mg/dL SUA increase 7 153,620 7,014 HR Random 
1.06 (1.04, 
1.08) 
Li(283)  2014 
CKD new-onset 
incidence 
Healthy population Hyper vs normal 4 NA NA HR Random 
2.86 (2.30, 
3.56) 
Li(283)  2014 
CKD new-onset 
incidence 
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Huang(284) 2012 SCr (μmol/L) 
Renal transplant 
recipients 
Hyper vs normal 5 873 NA MD Fixed 
0.24 (0.17, 
0.31)  
Huang(284) 2012 Graft loss 
Renal transplant 
recipients 
Hyper vs normal 3 910 154 OR Fixed 
2.29 (1.55, 
3.39)  
Huang(284) 2012 Graft loss 
Renal transplant 
recipients 















AD patients vs 
controls 











AD patients vs 
controls 









AD patients vs 
controls 






AD patients vs 
controls 







patients vs controls 
Highest vs lowest 
SUA category 
3 7,372 NA RR Fixed 
0.66 (0.52, 
0.85) 
Bartoli(394) 2016 Bipolar disorder  
Bipolar disorder vs 
controls 
SUA level (mg/dL) 9 1,127 619 SMD Random 
0.65 (0.33, 
0.97)  
Bartoli(394) 2016 Bipolar disorder  
Bipolar disorder vs 
major depression 

































patients vs controls 
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patients vs controls 
Highest vs lowest 
SUA category 







patients vs controls 






MCI patients vs 
controls 










MCI patients vs 
controls 

















PD patients vs 
controls 








PD patients vs 
controls 
























MS  patients vs 
controls 







MS patients vs 
control 






NMO patients vs 
control 
SUA level (μmol/L) 3 1,137 229 SMD Random 
-0.85 (-1.24, -
0.46)  
Wang(397) 2016 MS and NMO 
MS+NMO patients 
vs control 






ALS patients vs 
controls 
SUA level ( mg/dL) 3 826 311 
Hedge's 
G 
NA 0.84 (NA, NA) 
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patients  vs 
controls 


















Yan(400) 2015 Cancer incidence General 
Highest vs lowest 
SUA category 




Cancer in Digestive 
organs incidence 
General 
Highest vs lowest 
SUA category 








Highest vs lowest 
SUA category 








Highest vs lowest 
SUA category 









Highest vs lowest 
SUA category 




Cancer in Urinary 
organs incidence 
General 
Highest vs lowest 
SUA category 
2 86,739 536 RR Random 
1.17 (0.44, 
3.15)  
All-cause and cause-specific mortality  





Kim(381) 2010 CHD mortality General 1 mg/dL SUA increase 4 102,342 770 aRR Random 
1.12 (1.05, 
1.19) 
Braga(382) 2015 CHD mortality General Hyper vs normal 6 237,421 5,572 RR Random 
1.21 (1.00, 
1.46) 
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effect (95% CI)  
Li(16) 2016 CHD Mortality General 1 mg/dL SUA increase 6 NA NA RR Random 
1.15 (1.09, 
1.21) 
Qin(270) 2016 CVD mortality 
Hypertensive 
patients 
Hyper vs normal 3 NA NA aHR Random 
1.31 (0.96, 
1.78)  
Huang(383) 2014 CVD mortality 
Heart failure 
patients 
Hyper vs normal 2 2,250 NA HR Random 
1.45 (1.18, 
1.78)  
Zhao(293) 2014 CVD mortality General 
Highest vs lowest 
SUA category 




Yang(401) 2015 CVD mortality General  
Highest vs lowest 
SUA category 
3 105,329 1,829 RR Random 
1.25 (1.00, 
1.56) 




Li(276)* 2014 Stroke mortality General Hyper vs normal 9 1,017,810 21,281 aRR Random 
1.33 (1.24, 
1.43) 
Qin(270) 2016 Stroke mortality 
Hypertensive 
patients 
Continuous SUA level 2 NA NA aHR Random 
1.20 (0.95, 
1.51)  
Xia(294) 2016 CKD mortality General 
Highest vs lowest 
SUA category 
14 15,930 3,245 aHR Random 
1.52 (1.33, 
1.73)  
Xia(294) 2016 CKD mortality General 1 mg/dL SUA increase 21 23,443 3,904 aHR Random 
1.08 (1.04, 
1.11)  
Yan(400) 2015 Cancer mortality General 
Highest vs lowest 
SUA category 




Cancer mortality in 
bone, connective 
tissue, soft tissue, 
and skin 
General 
Highest vs lowest 
SUA category 




Cancer mortality in 
digestive organs 
General 
Highest vs lowest 
SUA category 









Highest vs lowest 
SUA category 




Cancer mortality in 
male genital organs 
General 
Highest vs lowest 
SUA category 
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Highest vs lowest 
SUA category 




Cancer mortality in 
urinary organs 
General 
Highest vs lowest 
SUA category 
2 112,296 NA RR Fixed 
1.35 (0.88, 
2.07)  
Tamariz(402) 2009 All-cause mortality 
Heart failure 
patients  




Tamariz(402) 2009 All-cause mortality 
Acute heart failure 
patients  
Hyper vs normal 4 772 NA RR Fixed 
2.40 (1.50, 
3.70) 
Tamariz(402) 2009 All-cause mortality 
Chronic heart 
failure patients  
Hyper vs normal 2 772 NA RR Fixed 
2.10 (1.50, 
2.90) 
Huang(383) 2014 All-cause mortality 
Heart failure 
patients 
Hyper vs normal 11 12,444 1,888 HR Random 
2.15 (1.64, 
2.83) 
Huang(383) 2014 All-cause mortality 
Heart failure 
patients 
1 mg/dL SUA increase 10 21,119 5,755 HR Random 
1.04 (1.02, 
1.06) 
Li(305) 2011 All-cause mortality CKD population Hyper vs normal 5 1,789 609 RR Random 
1.67 (1.29, 
2.16)  
Trkulja(388) 2012 Short-term mortality AMI patients 
Highest vs lowest 
SUA category 






AMI patients  
Highest vs lowest 
SUA category 
5 5,194 565 OR Random 
2.28 (1.82, 
2.86)  
Yan(386) 2014 In-hospital mortality  
AMI patients vs 
controls 
Hyper vs normal 6 5,686 218 RR Random 
2.10 (1.03, 
4.26)  
Xu(279) 2013 Mortality T2DM patients Hyper vs normal 3 5,534 NA HR Random 
1.09 (1.03, 
1.16)  
Zhao(293) 2014 All-cause mortality General 
Highest vs lowest 
SUA category 




Yang(401) 2015 All-cause mortality General  
Highest vs lowest 
SUA category 
6 126,702 12,863 RR Random 
1.17 (1.03, 
1.32) 
Song(387) 2015 Mortality Patients after PCI Hyper vs normal 9 17,268 NA RR Fixed 
1.31 (1.21, 
1.42)  
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Qin(270) 2016 All-cause mortality 
Hypertensive 
patients 
Hyper vs normal 4 46,103 5,820 aHR Random 
1.12 (1.02, 
1.23)  
Qin(270) 2016 All-cause mortality 
Hypertensive 
patients 










Highest vs lowest 
SUA category 





occurrence of poor 
outcomes 
(death/MACE) 









Highest vs lowest 
SUA category 































Highest vs lowest 
SUA category 








SUA level (μmol/L) 4 1,879 631 MD Fixed 
30.61 (20.13, 
41.08)  
Li(298) 2016 Psoriasis  
Psoriasis patients 
vs controls 
SUA level (mg/dL) 13 29,037 1,644 MD Random 
0.89 (0.05, 
1.73)  
Li(298) 2016 Psoriasis severity 
Sever psoriasis 
patients vs controls 








Highest vs lowest 
SUA category 
9 55,573 10,581 OR Random 
1.92 (1.59, 
2.31)  
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Abbreviations: MA, meta-analysis; CHD, coronary heart disease; CVD, cardiovascular disease; MACE, major adverse cardiovascular events; AMI, acute 
myocardial infarction; PCI, percutaneous coronary intervention; T2DM, Type 2 diabetes; CKD, chronic kidney disease; AD, Alzheimer’s disease; PD, Parkinson’s 
disease; VaD, Vascular dementia; MCI, mild cognitive impairment; MS, multiple sclerosis; NMO, neruomyelistsopticis; ALS, amyotrophic lateral sclerosis; 
NAFLD, non-alcoholic fatty liver disease; MD, mean difference; SMD, standard mean difference; NA, not available.  
* We corrected the errors and inappropriateness of the original meta-analysis, when conducted the quantitative analysis. 
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Supplementary Table 3 - 4: General characteristics and main findings of the 31 meta-analyses of RCTs. 



















































2 152 78 RR Random 
0.59 (0.42, 
0.84)  





SCr (mg/dL) 9 580 NA SMD Random 
-1.25 (-1.98, -
0.52)  







3 218 NA SMD Fixed 
0.41 (0.14, 
0.68)  
Zhang(405) 2014 CKD Patients Allopurinol 
Placebo/no 
treatment 












SCr (mg/dL) 3 130 NA MD Random 
-0.40 (-0.80, 
0.00) 





2 184 96 MD Fixed 
5.65 (1.88, 
9.41) NO(405, 406)  
(discordance in 
statistical 










5 346 NA MD Random 
3.10 (-0.90, 
7.10) 





5 267 132 RR Fixed 
0.30 (0.19, 















2 164 NA RR Random 
1.01 (0.15, 
6.98) 
Zhang(405) 2014 CKD Patients Allopurinol 
Placebo/no 
treatment 
Blood urea nitrogen 
(mmol/L) 
3 169 83 MD Fixed 
-6.15 (-8.17, -
4.13)  
Zhang(405) 2014 CKD Patients Allopurinol 
Placebo/no 
treatment 
24-h urinary  
protein (g/day) 
3 184 94 MD Fixed 
0.13 (0.28, 
0.02)  
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Forearm blood flow 5 148 74 MD Random 
68.80 (18.70, 
118.90)  





6 285 142 MD Fixed 
2.75 (2.49, 
3.01)  
Kanbay(408)* 2014 General Allopurinol 
Placebo/no 
treatment 
Forearm blood flow 
(%) 
5 130 71 MD Fixed 
2.62 (2.32, 
2.91)  






11 415 213 MD Fixed 
2.69 (2.49, 
2.89)  



















neonatal or infancy 












neonatal or infancy 
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in surviving infants 











Seizures in neonatal 
period 











SBP (mmHg) 10 738 NA MD Random 
-3.33 (-5.25, -























DBP (mmHg) 10 738 NA MD Random 
-1.29 (-2.48, -












DBP (mmHg) 5 309 NA MD Random 
-1.90 (-4.90, 
1.20) 
Abbreviations: MA, meta-analysis; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; MD, mean difference; SMD, standard mean difference; 
NA, not available. * Quantitative analyses were not performed, because we suspected some of the reported data misused standard error as standard deviation.  
Chapter 3  Umbrella review 
116 
 
Supplementary Table 3 - 5: General characteristics and main findings of the 107 Mendelian randomisation studies.* 
Author  Year  Population 


















Korostishevsky(321) 2016 British 3,953 
Appendicular lean 
mass (kg) 
rs737267 in SCL2A9 NA β  
0.01 (NA, NA) 0.51 
 
Lyngdoh(322) 2012 Swiss 6,184 Fat mass (kg) rs6855911 in SCL2A9 3.2% β  
0.05 (-0.10, 0.19) 0.52 
 
Burgess(342) 2015 European 7,158 BMI (kg/m2) 
Genetic risk score of 29 
SUA-related SNPs  
NA β 
-0.12(-0.53, 0.29) 0.57 
NO(322, 323, 




Palmer(328) 2013 Danish  68,674 (2)* BMI (kg/m2) rs7442295 in SCL2A9 2.2% MD  
-0.04 (-0.25, 0.16) NA 
Hughes(337) 2013 European  7,979 (2)* BMI (kg/m2) 
Genetic risk score of 5 
SUA-related SNPs  
2.3% 
β  -0.05 (-0.12, 0.01) 0.11 
Lyngdoh(322) 2012 Swiss 6,184 BMI (kg/m2) rs6855911 in SCL2A9 3.2% β  -0.01 (-0.16, 0.14) 0.94 
Oikonen(329) 2012 Finnish (male) 1,985 BMI (kg/m2) rs13129697 in SCL2A9 NA 
β  0.04 (NA, NA) 0.82 
Parsa(348) 2012 American  868 BMI (kg/m2) rs16890979 in SCL2A9 NA 
MD  0.24 (-0.33, 0.81) 0.39 
White(323) 2016 European 127,600 (64)* BMI (kg/m2) Genetic risk score of 31 
SUA-related SNPs  




Lyngdoh(322) 2012 Swiss 6,184 
Waist circumference 
(cm) 
rs6855911 in SCL2A9 3.2% β  0.08 (-0.05, 0.21) 0.24 
 
Xiong(325) 2016 Chinese 1,667 
BMD in femoral 
neck (g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
0.19 (-0.42, 0.81) 0.53 
NO(324, 325) 
(discordance in 
direction) Dalbeth(324) 2015 Americans 2,501 
BMD in femoral 
neck (g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
3.3% β 
-0.27 (-0.58, 0.03) 0.08 
Xiong(325) 2016 Chinese 1,667 
BMD in L1–L4 
(g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
0.39 (-0.26, 0.98) 0.26 
 
Dalbeth(324) 2015 American 2,501 
BMD in spine 
(g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
3.3% β 
0.08 (-0.32, 0.48) 0.68 
 
Dalbeth(324) 2015 American 2,501 
BMD in total femur 
(g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
3.3% β 
-0.29 (-0.60, 0.01) 0.06 
 
Xiong(325) 2016 Chinese 1,667 
BMD in total hip 
(g/cm2) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
0.19 (-0.36, 0.74) 0.50 
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Author  Year  Population 

















Cardiovascular outcomes  
Kleber(326) 2015 German 3,060/444 Arrhythmia 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.98 (0.88, 1.08) 0.64 
 
Kleber(326) 2015 German 3,060/368 Atrial fibrillation 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
1.03 (0.93, 1.15) 0.57 
 
Kleber(326) 2015 German 3,060/316 Cardiomyopathy 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
1.00 (0.89, 1.12) 0.93 
 




Genetic risk score of 31 
SUA-related SNPs  
4.2% OR 
1.05 (0.92, 1.20) 0.49 
NO(323, 327, 
333, 345, 353)  
(discordance in 
direction) 





Genetic risk score of 14 
SUA-related SNPs  
3.1% OR 
1.02 (0.92, 1.12) 0.73 
Kleber(326) 2015 German 3,060/2,418 
Coronary artery 
disease (CAD) 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.99 (0.91, 1.09) 0.90 
Han(345) 2015 Chinese  2,292/1,123 CHD 
rs11722228 in SLC2A9 NA OR 
1.09 (0.88, 1.35) 0.43 
rs4148152 in ABCG2 NA OR 
0.84 (0.70, 1.11) 0.31 




Genetic risk score of 8 
SUA-related SNPs  
6.0% OR 
1.03 (0.85, 1.25) 0.76 
Stark(353) 2009 German 2,714/1,473 CAD 




1.04 (0.93, 1.15) 0.54 
rs780094 
0.95 (0.85, 1.06) 0.39 
rs734553 
1.14 (1.00, 1.29) 0.06 
rs734553 
1.14 (0.96, 1.36) 0.13 
rs742132 
0.98 (0.87, 1.10) 0.74 
rs1183201 
0.96 (0.86, 1.07) 0.48 
rs12356193 
0.94 (0.81, 1.09) 0.42 
rs17300741 
1.08 (0.97, 1.21) 0.15 
rs505802 
1.04 (0.93, 1.17) 0.5 
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Author  Year  Population 





















Genetic risk score of 14 
SUA-related SNPs  
3.1% OR 
1.07 (0.88, 1.30) 0.51 
 





rs7442295 in SCL2A9 2.2% HR 
0.93 (0.79, 1.09) 0.38 
 
Kleber(326) 2015 German 3,060/2,225 Hypertension 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.98 (0.90, 1.06) 0.56 
 




Genetic risk score of 14 
SUA-related SNPs  
3.1% OR 
0.99 (0.88, 1.12) 0.93 
 
Kleber(326) 2015 German 3,060/295 
Peripheral vascular 
disease 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.92 (0.82, 1.04) 0.18 
 
Kleber(326) 2015 German 3,060/538 Valve disease 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 









Genetic risk score of 3 
SUA-related SNPs  
NA OR 
1.18 (1.06, 1.33) 0.004 
 





rs13129697 in SCL2A9 NA β 
<0.0001  0.99 
 
Mallamaci(331) 2015 Italian 449 cIMT (mm) rs734553 in SLC2A9 NA β 
0.40 (NA, NA) <0.001 
 




rs734553 in SLC2A9 NA β 
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Author  Year  Population 

















White(323) 2016 European 89,667 (37)* DBP (mm Hg) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% MD§ 
0.005 (0.003, 0.007) 
NA 
NO(323, 328, 






Sedaghat(351) 2014 Dutch 5,974 DBP (mm Hg) 
Genetic risk score of 30 
SUA-related SNPs  
4.2% β 
-0.42 (-0.72, -0.13) 0.01 
Mallamaci(346) 2014 Italian 449 DBP (mm Hg) rs734553 in SCL2A9 NA MD NA 
0.02 
Palmer(328) 2013 Danish 68,674 (2)* DBP (mm Hg) rs7442295 in SCL2A9 2.2% MD 
0.63 (-0.04, 1.29) NA 
Hughes(337) 2013 European  7,979 (2)* DBP (mm Hg) 
Genetic risk score of 5 
SUA-related SNPs  
2.3% β 
-0.002 (-0.13, 0.13) 0.97 
Yang(333) 2010 American 20,699 (5)* DBP (mm Hg) 
Genetic risk score of 8 
SUA-related SNPs  
6.0% β 
-0.34 (-1.04, 0.35) 0.33 
Parsa(348) 2012  American  868 
DBP-Clinic visit 1 (mm 
Hg)  
rs16890979 in SCL2A9 NA MD 
0.52 (-0.62, 1.66) 0.36 
Parsa(348) 2012 American  868 
DBP-High-salt 24-h (mm 
Hg) 
rs16890979 in SCL2A9 NA MD 
0.42 (-0.56, 1.40) 0.41 
Parsa(348) 2012 American  868 
DBP-Low-salt 24-h (mm 
Hg) 
rs16890979 in SCL2A9 NA MD 
0.19 (-0.75, 1.13) 0.69 
Parsa(348) 2012 American  868 
DBP-Salt sensitivity 24-h 
(mm Hg) 
rs16890979 in SCL2A9 NA MD 
-0.01 (-0.62, 0.60) 0.99 
White(323) 2016 European 89,667 (37)* SBP (mm Hg) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% MD§ 
0.005 (0.003, 0.006) NA 
NO(323, 328, 






Sedaghat(351) 2014 Dutch 5,974 SBP (mm Hg) 
Genetic risk score of 30 
SUA-related SNPs  
4.2% β 
-0.75 (-1.31, -0.19) 0.01 
Mallamaci(346) 2014 Italian 449 SBP (mm Hg) rs734553 in SLC2A9 NA β 
NA 0.02 
Palmer(328) 2013 Danish 68,674 (2)* SBP (mm Hg) rs7442295 in SCL2A9 2.2% MD 
0.65 (-0.54, 1.85) NA 
Hughes(337) 2013 European  7,979 (2)* SBP (mm Hg) 
Genetic risk score of 5 
SUA-related SNPs  
2.3% β 
0.07 (-0.12, 0.26) 0.47 
Yang(333) 2010 American 20,673 (5)* SBP (mm Hg) 
Genetic risk score of 8 
SUA-related SNPs  
6.0% β 
-0.83 (-1.96, 0.30) 0.15 
Parsa(348) 2012 American  868 
SBP-Clinic visit 1  (mm 
Hg) 
rs16890979 in SCL2A9 NA MD 
0.08 (-1.70, 1.86) 0.38 
Parsa(348) 2012 American  868 
SBP-High-salt 24-h  (mm 
Hg) 
rs16890979 in SCL2A9 NA MD 
2.20 (0.65, 3.75) 0.01 
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Author  Year  Population 

















Parsa(348) 2012 American  868 
SBP-Low-salt 24-h  (mm 
Hg) 
rs16890979 in SCL2A9 NA MD 
1.48 (0.09, 2.87) 0.04 
 
Parsa(348) 2012  American 868 
SBP-Salt sensitivity 24-h  
(mm Hg) 
rs16890979 in SCL2A9 NA MD 
0.62 (-0.34, 1.58) 0.21 
 
Metabolic disorders  
  




Genetic risk score of 31 
SUA-related SNPs  
4.2% OR 
0.99 (0.99, 1.01) 0.82 
NO(323, 326, 






Kleber(326) 2015 German 3,060/1,236 Diabetes 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.94 (0.88, 1.01) 0.10 




Genetic risk score of 24 
SUA-related SNPs  
4.0% OR 
0.99 (0.92, 1.06) 0.79 




Genetic risk score of 14 
SUA-related SNPs  
3.1% OR 
0.95 (0.86, 1.05) 0.28 




Genetic risk score of 8 
SUA-related SNPs  
NA OR 
0.99 (0.94, 1.04) 0.68 
Sun(354) 2015 Chinese 5,198/2,999 T2DM 
15 SUA-related SNPs  
NA OR 
No overall result 
rs12129861 1.03 (0.92, 1.16) 0.59 
rs780094 1.22 (1.11, 1.35) 
3.9E-
05 
rs2544390 0.97 (0.88, 1.06) 0.50 
rs11722228 1.01 (0.91, 1.12) 0.83 
rs16890979 0.98 (0.66, 1.45) 0.91 
rs3775948 1.03 (0.93, 1.13) 0.59 
rs10489070 0.96 (0.84, 1.10) 0.54 
rs2231142 0.94 (0.85, 1.04) 0.21 
rs742132 1.01 (0.91, 1.13) 0.80 
rs1183201 0.98 (0.86, 1.11) 0.75 
rs1165205 0.98 (0.87, 1.11) 0.75 
rs1333049 1.024 (0.93, 1.12) 0.61 
rs17300741 0.97 (0.80, 1.19) 0.78 
rs506338 0.99 (0.89, 1.10) 0.87 
rs606458 1.11 (1.01, 1.22) 0.04 
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Author  Year  Population 
N/n Events  
(N studies)* 













Yang(333) 2010 American 25,877 (5)* 
Fasting glucose 
(mmol/L) 
Genetic risk score of 8 SUA-related 
SNPs  
6.0% β 






White(323) 2016 European 57,397 (28)* 
Fasting glucose 
(mmol/L) 
Genetic risk score of 31 SUA-
related SNPs  
4.2% MD§ 
-0.001 (-0.003, 0.001) NA 
Parsa(348) 2012 American  868 Glucose (mmol/L) rs16890979 in SCL2A9 NA β 0.78 (-0.87, 2.43) 0.36 
Yang(333) 2010 American 19,899 (5)* Fasting insulin† 





-0.015 (NA, NA) 0.99 
 
Dai(334) 2013 Chinese 7,827 
Metabolic 
syndrome 
Genetic risk score of 2 SNPs 
(SLC2A9 and ABCG2) 
2.1% OR 




McKeigue(347) 2010 Scottish 1,017/203 
Metabolic 
syndrome 
Genetic risk score of 6 SNPs in 
SCL2A9 
NA NA NA 
>0.05 
Kidney disorders  




Genetic risk score of 8 SUA-related 
SNPs  
6.0% OR 
1.20 (0.96, 1.50) 0.12 
 
Greenberg(335) 2015 American 7,553/823 
Acute kidney 
injury 
Genetic risk score of 8 SUA-related 
SNPs  
6.0% HR 
1.01 (0.77, 1.34) 0.92 
 
Testa(336) 2014 Italian 755/244 Renal events rs734553 in GLUT9 NA HR 2.35 (1.25, 4.42) 
0.01 
 
Hughes(337) 2013 European  7,979 (2)* 
eGFR (mL/min/1.73 
m2) 
Genetic risk score of 5 SUA-related 
SNPs  
2.3% β 12.20 (-11.50, 35.90) 0.31 
NO(333, 337, 





Parsa(348) 2012 American  868 
eGFR (mL/min/1.73 
m2) 
rs16890979 in SCL2A9 NA MD 0.42 (-1.78, 2.62) 0.71 
Yang(333) 2010 American 23,844 (5)* 
Log eGFR 
(mL/min/1.73 m2) 
Genetic risk score of 8 SUA-related 
SNPs  
6.0% β 0.001 (-0.01, 0.02) 
0.91 
Tabara(355) 2010 Japanese 5,165 (2)* 
eGFR (mL/min/1.73 
m2) 
Genetic risk score of 3 SUA-related 
SNPs  












No overall result 
rs16890979 0.52 (NA, NA) 0.002 
rs6832439 0.52 (NA, NA) 0.002 
rs6449213 0.22 (NA, NA) 0.08 
rs13131257 0.58 (NA, NA) 0.001 
rs737267 0.44 (NA, NA) 0.004 
rs10805346 0.69 (NA, NA) <0.001 
rs12498956 0.24 (NA, NA) 0.05 
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Author  Year  Population 
N/n Events  
(N studies)* 
















3,604 (3)* SCr (mmol/L) 




No overall result 





0.53 (NA, NA) 0.001 
rs6832439 
0.54 (NA, NA) 0.002 
rs6449213 
0.27 (NA, NA) 0.003 
rs13131257 
0.60 (NA, NA) 0.000 
rs737267 
0.46 (NA, NA) 0.004 
rs10805346 
0.68 (NA, NA) 0.000 
rs12498956 
0.23 (NA, NA) 0.06 
Hughes(337) 2013 European  7,979 (2)* SCr (mmol/L) 
Genetic risk score of 5 SUA-related 
SNPs  
2.3% β 











Overall P>0.05  
 
rs16890979 
0.13 (NA, NA) 0.07 
 
rs6832439 
0.16 (NA, NA) 0.05 
 
rs6449213 
0.01 (NA, NA) 0.64 
 
rs13131257 
0.14 (NA, NA) 0.05 
 
rs737267 
0.14 (NA, NA) 0.06 
 
rs10805346 
0.14 (NA, NA) 0.10 
 
rs12498956 
0.07 (NA, NA) 0.15 
 
All-cause and cause-specific mortality 
Kleber(326) 2015 German 3,060/na 
Cardiovascular 
mortality 
Genetic risk score of 8 SUA-related 
SNPs  
NA aHR 
1.11 (1.02, 1.21) 0.02 
 
Kleber(326) 2015 German 3,060/na All-cause mortality 
Genetic risk score of 8 SUA-related 
SNPs  
NA aHR 
1.02 (0.95, 1.09) 0.59 
 




Author  Year  Population 

















Kleber(326) 2015 German 3,060/na Sudden cardiac death 
Genetic risk score of 8 
SUA-related SNPs  
NA aHR 
1.18 (1.03, 1.35) 0.02 
 
Metabolites 
White(323) 2016 European 
196,621 (68)* 
HDL-C (mmol/L) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% 
MD§ -0.008 (-0.010, -0.006) 
NA 
 
White(323) 2016 European 
196,621 (68)* 
LDL-C (mmol/L) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% 
MD§ -0.001 (-0.003, 0.001) NA 
 
White(323) 2016 European 
196,621 (68)* 
TC (mmol/L) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% 
MD§ 0.000 (-0.002, 0.002) NA 
 
White(323) 2016 European 
196,621 (68)* 
TG (mmol/L) 
Genetic risk score of 31 
SUA-related SNPs  
4.2% 
MD§ 0.014 (0.013, 0.016) 




Rasheed(350) 2014 European 8,208 (2)* TG (mmol/L) 
Genetic risk score of 5 
SUA-related SNPs  
1.7% β 
−1.01 (-2.57, 0.56) 0.21 
Parsa(348) 2012 American  868 TG (mmol/L) rs16890979 in SCL2A9 NA MD 2.38 (-2.87, 7.63) 0.35 
Xiong(325) 2016 Chinese 1,667 
Parathyroid hormone 
(pg/mL) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
-0.63 (-2.12, 0.85) 0.40 
 
Xiong(325) 2016 Chinese 1,667 Phosphorus (mmol/L) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
-0.16 (-0.74, 0.42) 0.59 
 
Burgess(342) 2015 European 7,158 
C-reactive protein (CRP) 
(mg/L) 
Genetic risk score of 29 
SUA-related SNPs  
NA β 
-0.05 (-0.15, 0.05) 0.37 
 
Xiong(325) 2016 Chinese 1,667 Calcium (mmol/L) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
0.06 (-0.10, 0.21) 0.48 
 
Xiong(325) 2016 Chinese 1,667 
Tropocollagen type 1 N-
terminal propeptide 
(ng/L) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
0.11 (-1.53, 1.75) 0.90 
 
Xiong(325) 2016 Chinese 1,667 
β-crosslaps of type I 
collagen (ng/L) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
-1.45 (-3.17, 0.27) 0.10 
 
Xiong(325) 2016 Chinese 1,667 25(OH)D (ng/mL) 
Genetic risk score of 5 
SUA-related SNPs  
1.8% β 
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Author  Year  Population 




















2014 Spanish 343 Dementia in PD 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 
1.05 (0.70, 3.00) 0.31 
NO(338, 339, 





Simon(352) 2014  American 808 (2)* PD progression 
Genetic risk score of 3 
SNPs in SCL2A9 
NA HR 
1.16 (1.00, 1.35) 0.06 
Gao(338) 2013 American 1,699 Parkinson’s disease 
12 SNPs in SCL2A9 
NA OR 
Overall P>0.05 
rs16890979 1.06 (0.90, 1.24) 0.51 
rs13129697 0.99 (0.85, 1.16) 0.91 
rs737267 1.01 (0.86, 1.18) 0.91 
rs6855911 1.00 (0.85, 1.18) 0.98 
rs4697700 1.03 (0.88, 1.22) 0.69 
rs4481233 1.01 (0.85, 1.21) 0.90 
rs7442295 1.06 (0.90, 1.26) 0.50 
rs6449213 1.01 (0.85, 1.21) 0.88 
rs1014290 1.04 (0.88, 1.22) 0.67 
rs12509955 0.99 (0.84, 1.18) 0.93 
rs17251963 1.05 (0.88, 1.25) 0.59 
rs12510549 0.96 (0.81, 1.14) 0.65 
Gonzalez-
Aramburu(343) 
2013 British 1,061 Parkinson’s disease 
Genetic risk score of 9 
SUA-related SNPs  
NA OR 1.55 (1.10, 2.18) 0.01 
Facheris(339) 2011 European 664 (3)* Age at onset of PD 
4 SNPs in SCL2A9 NA 
β 
Null after multiple testing 
correction 
rs737267 NA 3.10 (0.17, 6.03) 0.04 
rs6449213 NA -1.18 (-4.96, 2.59) 0.54 
rs1014290 NA -4.56 (-8.13, -1.00) 0.01 
rs733175 NA 3.59 (0.67, 6.51) 0.02 
Lyngdoh (340) 2013 Swiss 3,716/660 
Lifetime anxiety 
disorders 
rs6855911 in SLC2A9 3.2% 
OR 
(male) 
1.40 (1.07, 1.84) 0.02  
OR 
(female) 
0.97 (0.80, 1.17) 0.73  
 
Chapter 3  Umbrella review 
125 
 
Author  Year  Population 

















Lyngdoh(340) 2013 Swiss 3,716/370 
Current anxiety 
disorders 
rs6855911 in SLC2A9 3.2% 
OR 
(male) 













4 SNPs in SCL2A9 
NA β 





rs733175 -0.10 (NA, NA) 0.0002 
rs1014290 -0.07 (NA, NA) 0.01 
rs6449213 -0.07 (NA, NA) 0.01 








4 SNPs in SCL2A9 
NA β 
Overall P>0.05  
rs733175 -0.03 (NA, NA) 0.27 
rs1014290 -0.04 (NA, NA) 0.22 
rs6449213 -0.03 (NA, NA) 0.41 
rs6449213 -0.04 (NA, NA) 0.19 
Other outcomes  
Kleber(326) 2015 German 3,060/226 Cancer 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 0.95 (0.83, 1.08) 0.41 
 




Genetic risk score of 14 
SUA-related SNPs  
3.1% OR 5.84 (4.56,0 7.49) 
3.55E-





Kleber(326) 2015 German 3,060/19 Gout 
Genetic risk score of 8 
SUA-related SNPs  
NA OR 1.15 (0.72, 1.82) 0.56 




Genetic risk score of 8 
SUA-related SNPs  
6.0% OR 12.40 (8.50, 18.00) 
3.00E-
39 
Abbreviations: MR, Mendelian randomisation study; BMI, body mass index; BMD, bone mineral density; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, 
coronary heart disease; IMT, intima-media thickness; CVD, cardiovascular disease; T2DM, Type 2 diabetes; CKD, chronic kidney disease; SCr, serum creatinine; eGFR, glomerular 
filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; PD, Parkinson’s disease; LBC1936, 
the Lothian birth cohort; ET2DS, the Edinburgh type 2 diabetes study; MD, mean difference; NA, not available.  
* If the outcomes were reported from Mendelian randomisation analysis with pooling multiple studies, the number of studies included in pooled analysis was displayed in brackets.   
† Because of the lack of a standard to covert insulin in different studies to the same scale, sample size-weighted pooled meta-analyses were performed and Z statistics were reported 
instead of the β coefficient. 
§ MD (mean difference) represented the difference in mean caused by per inverse variance weighted allele estimated from meta-analyses.   
¶ Residual variance represented the proportion of residual variance explained by the SUA related SNPs.  
  




Supplementary Figure 3 - 1: Summary random-effect estimates of cardiovascular, diabetes, 
kidney disorders and cancer outcomes reported in meta-analyses of observational studies.  
Abbreviations: AF, atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; 
LATH/LASEC, left atrial thrombus or spontaneous echo contrast; PCI, percutaneous coronary 
intervention; MACE, major adverse cardiovascular events; AMI, acute myocardial infarction; 
T2DM, type 2 diabetes; CKD, chronic kidney disease; SCr, serum creatinine; eGFR, glomerular 
filtration rate. 




Supplementary Figure 3 - 2: Summary random-effect estimates of neurocognitive disorders, 
all-cause and cause-specific mortality, and other outcomes reported in meta-analyses of 
observational studies.   
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; T2DM, type 2 
diabetes; MACE, major adverse cardiovascular events; AMI, acute myocardial infarction; PCI, 
percutaneous coronary intervention; CKD, chronic kidney disease; NAFLD, non-alcoholic fatty 
liver disease.




Supplementary Figure 3 - 3: Summary random-effect estimates of health outcomes 
reported in meta-analyses of RCTs. 
Abbreviations: CKD, chronic kidney disease; SCr, serum creatinine; eGFR, glomerular filtration 
rate; HIE, hypoxic-ischaemic encephalopathy.
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4 DESCRIPTION AND MANIPULATION OF UK 
BIOBANK DATABASE 
This chapter describes the UK Biobank resource used in this thesis. The first section of this 
chapter presents the study design, ethical approval, participant recruitment, data collection 
and data release of UK Biobank cohort. The second part provides a summary description of 
the UK Biobank dataset. The third part presents the processes of data cleaning and data 
preparation and summarises the characteristics of the datasets used in the following analysis.  
4.1 The UK Biobank cohort  
4.1.1 Study design  
The UK biobank is a large-scale, population-based prospective cohort study designed to 
improve the prevention, diagnosis and treatment of a wide range of diseases. It was funded 
by a body of organisations including the Wellcome Trust, Medical Research Council, 
Department of Health, Scottish Government, Northwest Regional Development Agency, 
Welsh Government, British Heart Foundation and Diabetes UK. This cohort was designed to 
include ~500,000 participants and to combine extensive measurements of baseline data and 
genetic data with longitudinal follow-up of participants’ national medical records (e.g. in-
patient hospital episode records and data from the cancer registry and death registry). The 
participant recruitment and baseline data collection took place from 2006 to 2010. The 
longitudinal follow-up will last for 20 years to allow detailed investigation of the genetic and 
non-genetic determinants of a wide range of complex diseases and phenotypes. The 
establishment of the cohort, the baseline assessment, the measurement and quality control of 
the genotype data, and the collection of the medical records for longitudinal follow-up were 
all carried out centrally by the UK Biobank team. Further manipulation of the UK Biobank 
data, for example, selecting study population, constructing genetic instruments and defining 
the phenome framework were performed by myself with help from collaborators.    
4.1.1.1 Ethics approval and research ethics requirements 
The detailed research protocol and ethics and governance aspects of the UK Biobank project 
have gone through an extensive review. An independent Ethics and Governance Council 
(EGC) was established by the MRC and the Wellcome Trust to ensure that the UK Biobank 
project met the required standards for conducting research on human participants. The key 
ethics and governance principles of UK Biobank were presented in the Ethics and 
Chapter 4  UK Biobank  
130 
 
Governance Framework (EGF) (411). Based on the standards set by the EGF, research 
activities of UK Biobank were approved by the North West Multi-Centre Research Ethics 
Committee (MREC) in relation to the process of participant invitation and assessment and 
follow-up procedures. Additionally, ethics approvals from the National Information 
Governance Board for Health & Social Care (NIGB) in England and Wales and approval 
from the Community Health Index Advisory Group (CHIAG) in Scotland were also obtained 
to gain access to the information that would allow invitation of participants. UK Biobank had 
also sought a generic Research Tissue Bank (RTB) approval, which covered the vast 
majority of research using this resource, instead of requiring each application to apply for 
separate ethics approval. Informed consent was given by participants during their visit to the 
assessment centres. This consent related to their understanding and awareness of the 
following aspects: the purpose of UK Biobank, the information and samples that will be 
collected at enrolment, the linkage to their full medical records, the role of UK Biobank as 
the legal owner of the datasets, the safeguards in place relating to data and samples, the 
possibility of being re-contacted and the right to withdraw at any time without giving any 
reason and without penalty.   
The research protocol of this study was reviewed by the UK Biobank committee to ensure 
this study was consistent with the access procedures, the EGF and the consent provided by 
the participants. The application (application ID: 10775) was officially approved by the UK 
Biobank committee in 2015. The study did not require to re-contact the participants and did 
not involve any use of samples that were not covered by the RTB approval; therefore, 
following the instruction from the National Research Ethics Service (NRES) and UK 
Biobank’s governing Research Ethics Committee (REC), a separate ethics approval was not 
required for this study. When performing the data analysis, I complied with the UK Biobank 
Access Policy and the EGF regulation (411, 412) and acted in accordance with the Data 
Protection Act (DPA) (413). Findings deriving from the UK Biobank resource have been and 
will be published with the approval from UK Biobank. Knowledge developed from this 
study will be disseminated to benefit public health.  
4.1.1.2 Participant recruitment and enrolment  
Potentially eligible participants of UK Biobank were identified from the National Health 
Service (NHS) patient registry (414). People who were registered with the UK NHS, 
between the ages of 40 and 69 years old and living within 25 miles from any of the local 
study assessment centres, were eligible to participate in the study. The assessment centres 
were located across the UK and included Edinburgh, Glasgow, Newcastle, Middlesbrough, 
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Leeds, Sheffield, Bury, Manchester, Liverpool, Wrexham, Stoke, Nottingham, Birmingham, 
Oxford, Reading, Bristol, Swansea, Hounslow, Central London, and Croydon (Figure 4-1). 
The NHS number and date of birth from NHS register data were used to verify the age (40-
69 years old) of potential participants and remove duplicates or death records. A list of 
contact details of eligible participants was generated from the NHS register data by 
stratifying key demographic characteristics (e.g., age, gender and postcode as an index of 
social deprivation) to recruit a widely generalisable population. Over-sampling was 
performed for several particular diseases of interest (e.g. chronic obstructive pulmonary 
disease [COPD], schizophrenia) in order to recruit an adequate number of cases.  
 
Figure 4 - 1: The geographic locations of assessment centres across UK. 
(Source: adapted from (414)).  
Potential participants were sent an invitation letter for participation. They were asked to 
confirm the pre-booked provisional appointment at the local assessment centre. People who 
didn’t want to participate in the study were encouraged to indicate their unwillingness and to 
cancel the appointment. People who confirmed the appointment were sent a written 
confirmation of their appointment details along with instructions on preparing for the 
baseline assessment. A pre-visit reminder message or mail was sent to the confirmed 
participants before the scheduled appointment for baseline assessment. Between 2006 and 
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2010, about 9,000,000 people were invited by mail and 502,656 individuals were finally 
enrolled. The median number of participants recruited across the 23 assessment centres was 
21,290 (range: 649 to 44,220) (Table 4-1).  
Table 4 - 1: The number of participants recruited across the 23 assessment centres. 
Clinic ID Assessment centre Dates of operation No. of recruitment 
  11021    Birmingham    29/10/2009 - 21/07/2010    25,503  
  11011    Bristol    09/07/2008 - 28/11/2009    43,015  
  11008    Bury    14/01/2008 - 20/12/2008    28,336  
  11003    Cardiff    08/10/2007 - 31/05/2008    17,882  
  11024    Cheadle (revisit)    01/08/2012 - 06/06/2013    20,346  
  11020    Croydon    24/09/2009 - 09/07/2010    27,385  
  11005    Edinburgh    07/11/2007 - 07/06/2008    17,201  
  11004    Glasgow    16/07/2007 - 19/04/2008    18,651  
  11018    Hounslow    17/06/2009 - 26/06/2010    28,879  
  11010    Leeds    27/02/2008 - 11/07/2009    44,209  
  11016    Liverpool    28/01/2009 - 01/04/2010    32,818  
  11012    London Barts    27/08/2008 - 29/08/2009    12,583  
  11001    Manchester    16/04/2007 - 22/12/2007    13,940  
  11017    Middlesbrough    29/04/2009 - 06/02/2010    21,289  
  11009    Newcastle    23/01/2008 - 28/03/2009    37,008  
  11013    Nottingham    30/07/2008 - 12/09/2009    33,877  
  11002    Oxford    30/04/2007 - 27/10/2007    14,062  
  11007    Reading    14/05/2008 - 02/05/2009    29,417  
  11014    Sheffield    05/08/2009 - 13/07/2010    30,397  
  10003    Stockport (pilot)    13/03/2006 - 13/06/2006    3,798  
  11006    Stoke    05/12/2007 - 26/07/2008    19,440  
  11022    Swansea    11/03/2010 - 03/07/2010    2,281  
  11023    Wrexham    16/08/2010 - 01/10/2010    649 
(Source: adapted from (414)). 
 
4.1.2 Baseline assessment and data collection  
4.1.2.1 Overview of the baseline assessment process 
When individuals attended the assessment visit, UK Biobank staff provided an explanation 
and clarification about the research process. They were asked for their consent to participate 
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and went through a series of assessment stations. People who were unable to give consent or 
unable to take part in data collection or who were uncomfortable with any aspect of the 
participation were not enrolled. In general, information on participants’ sociodemographic 
status, family history, early life exposure, lifestyle and environmental exposures, health 
status, and psychosocial factors were collected by a self-completed questionnaire and 
computer-assisted personal interview. A series of physical and functional measurements 
were also taken for further analysis (e.g., anthropometrics, blood pressure and heart rate, 
spirometry, and eye examinations). Biological samples of blood and urine were collected for 
biochemical tests. The process of baseline assessment is summarised in Figure 4-2.  
 
 
Figure 4 - 2: Baseline assessment process.  
(Source: adapted from (414)). 
4.1.2.2 Baseline data collected from the questionnaire and interview 
The UK Biobank questionnaire collected a variety of baseline data, which could be 
summarised into the following broad data fields (Table 4-2): sociodemographic factors, 
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lifestyle and environmental exposures, family history and early life exposures, general health 
and disability, psychiatric or psychosocial state, and cognitive function (415).  
 Sociodemographic factors: Sociodemographic information on education and 
qualifications, employment status and current occupation, marital status, car ownership, 
household income, household structure, ethnicity and country of birth, was collected 
during the baseline assessment. 
 Environmental factors: A large number of environmental exposures were collected for 
the UK Biobank participants, including living address, residence at birth, occupation and 
other workplace factors, sleep, domestic heating, indoor air pollution and mobile phone 
use, etc.  
 Smoking and alcohol: Comprehensive questions on smoking were asked for those who 
smoked; alcohol consumption was assessed in terms of quantity, frequency and beverage 
specificity.  
 Physical activity: Physical activity was assessed by a self-ranking of activity level 
(vigorous, moderate and walking) and a 24-hour recall of daily activities.  
 Dietary habits: Dietary habits were recorded by a self-administered questionnaire 
developed based on the European standardised program for computer-assisted 24-hour 
dietary recall instruments (EPIC-SOFT).  
 Family history and early life exposures: Family history of common serious illnesses 
and early life exposures on birth weight, maternal smoking, breastfeeding, and childhood 
body size were collected during the baseline assessment. 
 General health and disability: Data on medical conditions, general health questions, 
self-reported disability, wheeze, chronic pain and chest pain, reproductive history of 
women were all collected.   
 Psychosocial and psychiatric state: Psychological and psychiatric traits were assessed 
by a series of standardised questionnaires (neuroticism/mood). 
 Cognitive function: Paired-associated learning questions to assess global cognition and 
reaction time tests for touch-screen administration were adopted to assess the cognitive 
function of the study participants.  
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Table 4 - 2: A summary of data collected from questionnaire and interview. 
Data fields  Variables available 
Sociodemographic 
factors 
Social class, education and qualifications, employment status and current 
occupation, marital status, car ownership, household income, household 
structure, ethnicity and country of birth, etc.  
Family history and 
early life exposures  
Family history of illness, birth weight, breast feeding, maternal smoking, 
childhood body size/height, place of birth, being a twin or other multiple 
order birth, etc. 
Lifestyle and 
environmental factors 
Physical activity, smoking, diet, alcohol consumption, sleep, occupations, 
domestic heating, etc. 
General health and 
disability 
Medical conditions, medications, disability, hearing, sight, reproductive 
history, chronic pain and chest pain, wheeze, skin and hair colour, etc. 
Psychiatric or 
psychosocial factors  
Neurosis, mood, depression status, satisfaction (job, family, health), social 
support, mental categories, and history of psychiatric care, etc. 
Cognitive function 
Fluid intelligence, numeric/prospective memory, pairs matching, reaction 
time, trail making, etc. 
 
4.1.2.3 Physical measurements taken at baseline assessment 
Baseline data from physical measurements were taken by well-trained stuff during the 
participants’ visit to the assessment centre (Table 4-3). These included: 
 Blood pressure (and pulse rate): Blood pressure and pulse rate were measured twice by 
the Omron HEM-7015IT digital blood pressure monitor.  
 Weight: Weight was measured by the Tanita BC-418 MA body composition analyser 
with removing shoes and heavy outer clothing.  
 Height: Standing and sitting heights (shoeless) were measured using a Seca 202 height 
measure. 
 Waist and hip circumference: Waist and hip circumferences were measured using a 
Wessex non-stretchable sprung tape measure.  
 Bio-impedance: Bio-impedance was measured by the Tanita BC-418MA body 
composition analyser.  
 Hand grip strength: Right- and left-hand grip strengths were measured once each using 
a Jamar J00105 hydraulic hand dynamometer.  
 Spirometry: The forced expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVC) were measured three times using the Vitalograph Pneumotrac 6800 spirometer.  
 Bone densitometry: Bone mineral density (left heel) was measured by the Norland 
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McCue Contact Ultrasound Bone Analyser (CUBA).  
 Other measurements: Measurements (e.g., electrocardiogram [ECG], ankle-brachial 
index, pulse wave velocity, carotid intimal-medial thickness) were available in the pilot 
study but excluded from the main assessment. 
Table 4 - 3：A summary of data collected from physical measurements. 
Data fields  List of variables  
Anthropometrics  Height, weight, bio-impendence, hip and waist circumference, etc. 
Blood pressure and 
heart rate  
Systolic blood pressure, diastolic blood pressure, peripheral pulse pressure, 
average heart rate, etc. 
Arterial stiffness 
Pulse wave reflection index, pulse wave pressure versus time response 
curve, pulse wave arterial stiffness index, etc. 
Spirometry  
Forced vital capacity (FVC), forced expiratory volume in 1-second (FEV1), 
peak expiratory flow (PEF), etc. 
Eye examination 
Visual acuity, refractive index, intra-ocular pressure, optical-coherence 
tomography, etc. 
Others  Grip strength, bone mineral density, electrocardiograph, etc. 
 
4.1.3 Genotypic data and quality control (QC) 
4.1.3.1 DNA extraction 
The blood samples collected from participants at the baseline assessment were stored in the 
UK biobank facilities (at either -80°C or -196°C) in Stockport, UK. Full details of the 
procedures of sample retrieval and DNA extraction are provided in the following references 
(416, 417). Briefly, buffy coat samples for genotyping were located by robot to a 96-position 
plate; then DNA was extracted and purified by an automated process system using the 
Maxwell 16 Instrument. The Maxwell 16 Blood DNA Purification Kit was applied to test if 
the extracted DNA samples were free from contamination and had suitable concentration and 
purity. The DNA quantification was assessed with a set of pre-defined criteria: (i) average 
plate concentration was at least 20 ng/μl; (ii) average absorbance ratio (measured at 260 nm / 
280nm) was between 1.8-2.2; (iii) at least 80% of sample DNA concentrations was greater 
than 10 ng/μl; (iv) at least 80% of sample absorbance ratio (measured at 260 nm / 280nm) 
was between 1.8-2.2; (v) the extraction concentration of negative control was less than 1 
ng/μl. Samples failing to meet the pre-defined criteria (if possible these samples were re-
processed) were excluded. A brief overview of the process for DNA extraction is shown in 
Figure 4-3.  





Figure 4 - 3: Overview of the automated process for DNA extraction.  
(Source: adapted from (417)). 
4.1.3.2 Genotyping and initial quality control (QC) 
The Affymetrix research service laboratory (Santa Clara, California, USA) was responsible 
for genotyping the samples, generating the genotypic data and performing the initial quality 
control checks (417, 418). Extracted DNA samples were genotyped on two arrays, the UK 
BiLEVE array and UK Biobank Axiom Array. The UK BiLEVE array was applied on an 
initial ~50,000 (11 batches) individuals. UK Biobank Axiom Array was used to genotype the 
remaining ~450,000 (95 batches) samples. The two genotyping arrays were very similar to 
each other (common marker content >95%) and included a comprehensive coverage of 
genome-wide common and low frequency variants, rare coding variants, and genetic markers 
of specific interest (e.g., pharmacogenomic markers, human leukocyte antigen [HLA], 
inflammation, and expression quantitative trait loci [eQTL] variants). A summary of the 
marker content on the UK Biobank Axiom Array is shown in Figure 4-4. The positions of 
markers were reported based on the Genome Reference Consortium Human Reference 37 
(GRCh37). Further details about the genotyping process and the design of UK Biobank 
Axiom Array are available at (419).  
Step 
1
• Load plates onto deck of DNA extraction system
Step 
2




• Robot performs checks on all plates prior to processing
Step 
4
• DNA extracted in batches of 32 samples
Step 
5
• DNA transferred from Maxwell to destination plates
Step 
6
• DNA in one plate quantified on Trinean DropSense
Step 
7




• Plate for genotyping sealed 
Step 
9
• DNA concentration checks completed 




Figure 4 - 4: Summary of UK Biobank genotyping array content. 
This is a schematic representation of the different categories of content on the UK Biobank 
Axiom array (Source: adapted from (419)).  
An initial round of quality control (QC) of genotyping was conducted by the Affymetrix 
laboratory to exclude markers with poor cluster properties (418). In summary, variants which 
failed the basic Affymetrix genotyping quality metrics indicating poor genotype clustering 
(cluster QC) were excluded. This included the exclusion of variants for which (i) more than 
three genotype clusters were observed (indicating an off-target measurement), (ii) the call 
rate was less than 95%, or (iii) there was failure in one of the cluster quality metrics of 
Fisher’s linear discriminant (FLD), Heterozygous cluster strength offset (HetSO), 
Homozygote Ratio Offset (HomRO) (thresholds were defined in the Affymetrix Axiom 
Genotyping Solution Data Analysis Guide). SNPs failing to meet the cluster QC Metrics 
were set to missing for all samples in that batch. More details about the Affymetrix calling 
algorithms and filtering protocols were documented in (418). The cluster QC conducted by 
Affymetrix resulted in a data set of 489,212 individuals typed at 812,428 unique markers 
proceeded to post-genotyping QC. 
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4.1.3.3 Additional post-genotyping QC  
The Wellcome Trust Centre for Human Genetics (WTCHG) performed an additional round 
of marker-based QC to account for the population structure and check the consistency of 
genotype frequency between batches/plates. Details of the process of QC performed by the 
WTCHG is available at (420, 421). Briefly, to account for the population structure, they 
computed the SNP QC metrics by using a homogenous subset of European participants in 
UK Biobank. To identify homogenous individuals they projected UK Biobank samples on 
major principal components (PCs) computed by using the HapMap3 reference panel. 
Samples projected to the North-West European ancestry cluster were selected for computing 
the marker-based QC metrics. To detect any batch effects they tested whether the given 
batch had the same genotype frequencies as all other batches combined. Similarly, to look 
for any plate effects, they tested whether the given plate had the same genotype frequencies 
as all other plates, within the same batch. They also performed an exact Hardy-Weinberg 
Equilibrium (HWE) test for each batch within a homogenous sample. Genotypes at the SNPs 
that failed any of these tests with a p-value of <10-12 were set to missing in that batch. Two 
tests (array effect and discordance across control replicates) were performed for each marker 
across all batches. Any marker that did not pass one of these two tests was excluded from the 
dataset for all batches. After the marker-based QC the final release of genotype data 
contained 805,426 SNPs (>99% of the array content). Examples of markers failing these QC 
tests are displayed in Figure 4-5. 
Sample-based QC was then performed by the WTCHG based on a set of 605,876 high 
quality markers (genotyped on both arrays, passed QC in all batches) to identify samples 
with poor quality genotype calls, control for population structure (genetic ancestry/ethnicity) 
and to find related individuals. The PCs were further computed to indicate the genetic 
ancestry and account for population structure in other sample-based QC metrics (such as 
heterozygosity). The results of the PC analysis were then applied to adjust the heterozygosity 
and refine the relatedness inference. The sex of each individual was inferred based on the 
relative intensity of markers on the Y and X chromosomes. Samples with high 
missingness/heterozygosity rates or sex mismatch were not removed from the data release, 
but instead referred by a list of variables to indicate the insufficient data quality. The 
relatedness of samples was also indicated by a number of variables for further assessment. A 
small number of samples (835 in total) that were identified as sample duplicates (as opposed 
to identical twins), were likely mishandled in the laboratory or were withdrawn from the 
project, were excluded prior to the data release.  




Figure 4 - 5: Examples of markers failing quality control tests.  
Each sub-figure presents an example of markers failing the corresponding QC tests (Source: 
adapted from (421)).  
4.1.3.4 Genotype imputation 
The WTCHG was responsible for the genotype imputation. This process aimed to predict 
genotypes that were not directly assayed by the genotype arrays by using reference panels 
with a large number of haplotypes (422). The details of imputation for the UK Biobank 
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genotype data are presented in the reference (421). Briefly, the imputation process started 
with pre-phasing the genotyped markers and followed by a haploid imputation step.  
 Pre-phasing  
A series of QC filters were applied first to select markers and samples for the phasing step. 
Genotyped markers were removed from the phasing step if they (i) were only present in 
either the UK BiLEVE or the UK Biobank Axiom arrays, (ii) failed the SNP QC in at least 
one of the batches, (iii) had a minor allele frequency < 0.0001, (iv) had >5% missingness. 
Samples were also removed if they were identified as outliers for heterozygosity and 
missingness. These filters resulted in a dataset of 670,739 autosomal SNPs in 487,442 
samples. Phasing and imputation were carried out on the filtered dataset. 
Phasing on the autosomes, in which a statistical method is applied to infer the underlying 
haplotypes of each individual, was carried out using the SHAPEIT3 (423). The accuracy of 
the pre-phasing method was assessed by taking advantage of the 696 mother-father-child 
trios that were identified in the UK Biobank and the median switch error rate was estimated 
to be 0.229% (421).  
 Imputation 
For the interim data release (~150,000), genotypes were imputed with a merged reference 
panel of the UK10K (424) and the 1000 Genomes Phase 3 (425), which consisted of ~ 87 
million variants in 12,570 haplotypes. For the final release of the full UK Biobank data, 
genotypes were imputed by using the IMPUTE4 (https://jmarchini.org/software/) with a 
combined reference panel of the Haplotype Reference Consortium (HRC) (426), UK10K 
haplotype resources (424), and the 1000 Genomes Phase 3 (425). This reference panel 
increased the number of testable markers to ~96 million variants and was expected to 
produce better imputation performance. In addition, they also imputed classical allelic 
variation at 11 human leukocyte antigen (HLA) genes localised in the histocompatibility 
complex (MHC) on chromosome 6, by using the HLA*IMP:02 algorithm with a multi-
population reference panel (427). The imputation quality of the HLA genes were checked 
across the two imputation methods among samples of European ancestry and the reported 
call rates were >95.1% for all HLA loci (421).  
The imputation process finally generated a dataset consisting of 92,693,895 autosomal SNPs 
for 487,442 individuals. 
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4.1.4 Medical records for longitude follow-up 
A variety of sources and systems were used to follow up the disease occurrence, death and 
other health outcomes among enrolled participants (428). Currently, there were three 
different types of health records (i.e., hospital inpatient episodes, cancer registry data and 
death registry data) that have been incorporated into the central database. The process of 
incorporating routine electronic health records into the UK Biobank resource involved 
several steps (Figure 4-6). 
 
Figure 4 - 6: Steps involved in incorporating externally linked data into UK Biobank.  
(Source: adapted from (428)). 
4.1.4.1 Hospital inpatient data 
UK Biobank collected information on health events experienced by participants via in-
patient hospital records. Hospital admission data of England and Wales were collected at 
national level from the Department of Health’s Hospital Episode Statistics (HES) and were 
managed by the NHS Health and Social Care Information Centre (HSCIC) (429). For 
Scotland, Scottish Morbidity Records (SMR) have been routinely collecting admission data 
of all Scottish NHS hospitals since 1980; these data are managed by the Information 
Services Division (ISD) of the NHS Common Service Agency. Historical hospital data back 
to 1996 in England & Wales and back to 1981 in Scotland have been provided to the UK 
Biobank as supplementary information prior to enrolment. Hospital inpatient data 
documented in the UK Biobank currently comprise five main domains:  
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 Admissions and discharge  
 Diagnostic and operation codes (ICD-9/10)  
 Maternity records  
 Psychiatric census  
 Critical care data 
The availability of data types with corresponding dates is shown in Table 4-4. The diagnosis 
information of patients was recorded following the World Health Organisation’s ICD and the 
operative procedures information were recorded following the OPCS (Office of Population, 
Censuses and Surveys: Classification of Interventions and Procedures). 





































































(Source: adapted from (429)).  
4.1.4.2 Cancer registry data  
The cancer registration incorporated information on cancer diagnosis from a variety of 
sources including hospitals, cancer and treatment centres, hospices and nursing homes, 
private hospitals, cancer screening programmes, other cancer registries, general practices, 
death certificates, HES and Cancer Waiting Time (CWT) data (430). Cancer records were 
provided to UK Biobank by the Medical Research Information Service of the National 
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Health Service Information Centre (HSCIC) for participants from England and Wales and by 
the Information Services Division (ISD) of NHS Scotland for participants from Scotland. 
UK Biobank received details of cancer registration both prior to the inception of study 
(cancer registry data were available back to the early 1970s when the cancer registry was 
first established) and following the establishment of UK Biobank. The cancer registry data 
present in UK Biobank comprise (Table 4-5): 
 Date of cancer diagnosis 
 Age at cancer diagnosis  
 Type of cancer (ICD-9/10) 
 Reported occurrences of cancer  
 Histology and behaviour code (ICD10-O-3) 
The type of cancer was coded by either the ICD-9 or ICD-10 according to the time of 
registration. The histology and behaviour codes of neoplasms are presented as five-digit 
codes in ICD10-O-3, with the first four digits coding the histology and the fifth digit coding 
the behaviour. 
Table 4 - 5: Source of cancer registry data.  
Cancer 
registry 
Data provider  
International classification 
of diseases (ICD) 





Heath & Social Care 
Information Centre (HSCIC) 
1979-1994 1995-present 1996-present 
Scotland 
National Records of Scotland, 
NHS Central Register 
1980-1996 1997-present 1981-present 
Source: adapted from reference (430). 
4.1.4.3 Death registry data  
The follow-up of deaths was initiated at the recruitment phase of UK Biobank. UK Biobank 
participants were flagged at the NHS Central Registry from the date of their recruitment and 
UK Biobank received death notifications of participants (431). Data from the death 
certificates (all deaths and their certified causes) are sent to UK Biobank on a quarterly basis. 
The data presented in UK Biobank comprise (Table 4-6):  
 Date of death  
 Age at death  
 Underlying (primary) cause of death: ICD-10  
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 Contributory (secondary) causes of death: ICD-10  
 Description of cause of death  
 
Table 4 - 6: Source of death registry data. 
Death 
registry 
Data provider  
International classification 
of diseases (ICD) 





Heath & Social Care 
Information Centre (HSCIC) 
-- 2006-present April 2006-present 
Scotland 
Information and Statistics 
Division (ISD), Scotland 
-- 2006-present April 2006-present 
Source: adapted from reference (431). 
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4.2 Characteristics of the UK Biobank database 
4.2.1 Summary of baseline data in UK Biobank 
The UK Biobank includes 502,656 participants, of which 89% are from England, 7% from 
Scotland and 4% from Wales. The cohort consists of 94.1% (self-reported) white population 
(88.1% British, 2.6% Irish and 3.4% other white background) and 5.5% other ethnicities 
(2.28% Asian, 1.16% Black, 0.59% mixed and 1.46% other/unknown). There are 229,221 
(45.6%) men and 273,445 (54.4%) women. The mean age of participants at recruitment was 
56.53 years old (range: 40-69, SD: 8.10), with 23.8% aged at 40-49 years old, 33.6% aged at 
50-59 years old and 42.6% aged at 60-69 years old. The mean BMI (body mass index) of 
participants at recruitment was 27.39 (range: 12.12-74.68, SD: 4.79) kg/m2. According to the 
indices of multiple deprivation measured based on income, employment, health, education, 
access to services, community safety and physical environment, 48.2% of participants were 
characterised as low level of deprivation, 33.2% were characterised as moderate level of 
deprivation and 18.4% were characterised as high level of deprivation. The 
sociodemographic characteristics of UK Biobank participants are summarised in the Table 
4-7.   
Table 4 - 7: A summary of baseline characteristics of UK Biobank participants. 





Age (years) 56.53 ± 8.10  502,620 99.9 
Standing height (cm) 168.48 ± 9.27  500,130 99.5 
Weight (kg) 77.97 ± 15.92 499,904 99.5 
BMI (kg/m2) 27.39 ± 4.79  499,579 99.4 
DBP (mmHg)* 82.02 ± 10.50 473,465 94.2 






Sex Male 229,211 45.6 
Female 273,445 54.4 
Age group 40-49 years 119,632 23.8 
50-59 years 168,892 33.6 
60-69 years 214,131 42.6 
Self-reported ethnic 
background 
White (British, Irish, and other 
white background)  
472,798 94.06 
Asian (Indian, Pakistani, Chinese, 11,461 2.28 
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Bangladeshi and other Asian 
background) 
Black (Africa, Caribbean and 
other black background) 
8,093 1.61 
Mixed (White & Asian, White & 
Black, other mixed background) 
2,966 0.59 
Other/Unknown 7,339 1.46 
Resident location England  447,364 89.0 
Wales 35,186 7.0 
Scotland  20,106 4.0 
Deprivation Low 243,286 48.4 
Moderate  166,882 33.2 
High 92,489 18.4 
*Blood pressures (Data-field 4079 [DBP] and Data-field 4080 [SBP]) were measured at the baseline 
assessment by using standard automated device (automated reading, two measures of blood pressure 
were taken a few moments apart).  
4.2.2 Summary of health-outcome data in UK Biobank  
As described above, UK Biobank incorporated three types of health records into the central 
database, including hospital inpatient records, cancer registry data and death registry data.  
4.2.2.1 Hospital inpatient data 
 Hospital inpatient episodes: A total of 361,234 hospital episodes were available in the 
UK Biobank database in 2016, covering 395,978 participants. In particular, there were 
346,379 general episodes, 14,599 delivery episodes, 95 birth episodes, 94 psychiatric 
episodes and 50 other delivery/birth events (Figure 4-7).  
 
       Figure 4 - 7: A summary of hospital episodes available in the UK Biobank database. 




 ICD-9/10 codes for disease diagnosis: In the hospital inpatient data, each episode had a 
primary ICD-10 or ICD-9 diagnosis code to describe the event of hospitalisation, when 
applicable, one or more secondary ICD-10 or ICD-9 diagnosis codes follows to annotate 
the corresponding hospitalisation event. Thus, 361,234 hospital episodes recorded 
1,491,042 items of primary ICD-10 code (8,160 distinct ICD-10 values) for 392,294 
participants, 2,066,751 items of secondary ICD-10 code (10,528 distinct ICD-10 values) 
for 320,450 participants, 42,837 items of primary ICD-9 code (2,448 distinct ICD-9 
values) for 20,309 participants and 17,293 items of secondary ICD-9 code (2,276 distinct 
ICD-9 values) for 8,716 participants. In summary, the hospital inpatient data included 
10,528 unique ICD-10 codes covering 392,338 participants, and 2,449 unique ICD-9 
codes covering 20,311 participants (Table 4-8). 
Table 4 - 8: A summary of hospital inpatient data. 
Diagnosis code Data items Distinct values No. of participants 
Main ICD-10 code  1,491,042 8,160 392,294 
Secondary ICD-10 code  2,066,751 10,528 320,450 
Sub-total  3,557,793 10,528 392,338 
Main ICD-9 code  42,837 2,448 20,309 
Secondary ICD-9 code  17,293 2,276 8,716 
Sub-total  60,130 2,449 20,311 
Total -- -- 395, 978 
 
 Common prevalent diseases in hospital inpatient data: The individual ICD-10 codes 
were classified into 22 disease categories according to the ICD system: the number of 
cases included in each disease category is summarised in Table 4-9 (range: 27-503,234; 
median: 50,218). Within the hospital episode data, the top 20 common prevalent ICD-10 
codes (with the first 3 digits) and the corresponding diseases were identified and 
summarised in Table 4-10. 
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Table 4 - 9: A summary of the disease categories included in hospital inpatient data.  
Disease category Description  No. of cases 
Chapter I Certain infectious and parasitic diseases 35,981 
Chapter II Neoplasms 66,299 
Chapter III Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism 
28,450 
Chapter IV Endocrine, nutritional and metabolic diseases 137,440 
Chapter V Mental and behavioural disorders 51,770 
Chapter VI Diseases of the nervous system 34,496 
Chapter VII Diseases of the eye and adnexa 27,258 
Chapter VIII Diseases of the ear and mastoid process 7,699 
Chapter IX Diseases of the circulatory system 257,515 
Chapter X Diseases of the respiratory system 86,615 
Chapter XI Diseases of the digestive system 202,376 
Chapter XII Diseases of the skin and subcutaneous tissue 20,844 
Chapter XIII Diseases of the musculoskeletal system and connective tissue 149,703 
Chapter XIV Diseases of the genitourinary system 111,762 
Chapter XV Pregnancy, childbirth and the puerperium 20,489 
Chapter XVI Certain conditions originating in the perinatal period 27 
Chapter XVII Congenital malformations, deformations and chromosomal 
abnormalities 
5,162 
Chapter XVIII Symptoms, signs and abnormal clinical and laboratory findings, 
not elsewhere classified 
165,904 
Chapter XIX Injury, poisoning and certain other consequences of external 
causes 
48,666 
Chapter XX External causes of morbidity and mortality 103,511 
Chapter XXI Factors influencing health status and contact with health 
services 
503,234 
Other Codes for special purposes 1,550 
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Table 4 - 10: The top 20 prevalent ICD-10 codes/diseases in hospital inpatient data. 
ICD-10 Disease description  No. of cases 
I10 Essential (primary) hypertension 95,606 
E78 Disorders of lipoprotein metabolism and other lipidaemias 44,949 
R07 Pain in throat and chest 39,856 
R10 Abdominal and pelvic pain 38,914 
K29 Gastritis and duodenitis 35,786 
K44 Diaphragmatic hernia 32,580 
J45 Asthma 32,371 
K57 Diverticular disease of intestine 32,304 
I25 Chronic ischaemic heart disease 31,136 
I84 Haemorrhoids 29,176 
K62 Other diseases of anus and rectum 28,525 
K21 Gastro-oesophageal reflux disease 28,100 
M17 Gonarthrosis [arthrosis of knee] 24,283 
E11 Type 2 diabetes mellitus 24,147 
N39 Other disorders of urinary system 23,571 
I20 Angina pectoris 22,422 
Y83 Surgical operation and other surgical procedures as the cause of 
abnormal reaction 
22,055 
M19 Other arthrosis 19,966 
K52 Other non-infective gastroenteritis and colitis 19,815 
R69 Unknown and unspecified causes of morbidity 19,655 
 
4.2.2.2 Cancer registry data 
 Data items: A total of 233,875 data items, covering 79,111 participants, were available 
for cancer diagnosis, of which 76,321 data items were derived from the NHS information 
centre for Cancer Registry (2012 onwards), 8,468 data items were derived from the 
Scottish Cancer Registry (2012 onwards), and 63,002 data items were derived from the 
National Cancer Intelligence Network Cancer Registry (Figure 4-8).  




       Figure 4 - 8: A summary of cancer registry data available in the UK Biobank database. 
 ICD-9/10 for cancer diagnosis: Within the cancer registry data, 207,935 items were 
coded by ICD-10 system covering 73,841 participants, and 25,818 items were coded by 
ICD-9 system covering 11,227 participants. Overall, the database included 556 unique 
ICD-10 codes and 302 unique ICD-9 codes, covering 79,066 unique participants 
diagnosed with cancer (Table 4-11). 
     Table 4 - 11: A summary of cancer registry data.  
Disease classification  Data items Distinct values No. of participants 
Type of cancer: ICD-10 207,935 556 73,841 
Type of cancer: ICD-9 25,818 302 11,227 
Total 233,753 858 79,066 
 
 Common prevalent cancers in cancer registry data: The types of cancer coded by ICD-
10 codes were classified according to the sites of neoplasms. The number of cases 
included in each sites of neoplasms were summarised in Table 4-12 (range: 1-19,620; 
median: 2,032). Within the cancer registry data, the top 20 common prevalent cancers 
(with the first 3 digits of ICD-10 code) were identified and summarised in Table 4-13. 
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Table 4 - 12: A summary of the types of cancer according to the sites of neoplasms. 
Sites of neoplasms No. of cases* 
Malignant neoplasms of lip, oral cavity and pharynx 913 
Malignant neoplasms of digestive organs 6,563 
Malignant neoplasms of respiratory and intrathoracic organs 1,978 
Malignant neoplasms of bone and articular cartilage 83 
Melanoma and other malignant neoplasms of skin 19,620 
Malignant neoplasms of mesothelial and soft tissue 603 
Malignant neoplasm of breast 13,025 
Malignant neoplasms of female genital organs 3,748 
Malignant neoplasms of male genital organs 7,942 
Malignant neoplasms of urinary tract 2,087 
Malignant neoplasms of eye, brain and other parts of central nervous system 615 
Malignant neoplasms of thyroid and other endocrine glands 630 
Malignant neoplasms of ill-defined, secondary and unspecified sites 468 
Malignant neoplasms, stated or presumed to be primary, of lymphoid, hematopoietic 
and related tissue 3,738 
Malignant neoplasms of independent (primary) multiple sites 1 
In situ neoplasms 11,218 
Benign neoplasms 1,009 
Neoplasms of uncertain or unknown behavior 2,453 
*Including both incident and prevalent cases. 
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Table 4 - 13: The top 20 common prevalent cancers in cancer registry data. 
ICD-10 Type of cancer   No. of cases* 
C44 Other malignant neoplasms of skin 18,628 
C50 Malignant neoplasm of breast 13,663 
C61 Malignant neoplasm of prostate 8,379 
D06 Carcinoma in situ of cervix uteri 3,972 
C18 Malignant neoplasm of colon 3,358 
C43 Malignant melanoma of skin 3,290 
D05 Carcinoma in situ of breast 2,455 
C34 Malignant neoplasm of bronchus and lung 2,301 
C54 Malignant neoplasm of corpus uteri 1,697 
C20 Malignant neoplasm of rectum 1,562 
D04 Carcinoma in situ of skin 1,446 
D03 Melanoma in situ 1,276 
C67 Hereditary factor IX deficiency 1,196 
C64 Malignant neoplasm of bladder 1,187 
C56 Malignant neoplasm of ovary 1,177 
C83 Non-follicular lymphoma 961 
D41 Neoplasm of uncertain or unknown behaviour of urinary organs 912 
D09 Carcinoma in situ of other and unspecified sites 717 
C91 Lymphoid leukaemia 683 
C15 Malignant neoplasm of oesophagus 645 
*Including both incident and prevalent cases. 
4.2.2.3 Death registry data 
 Data items: A total of 16,505 data items, covering 14,423 participants, were available 
from the death registry data (Figure 4-9), of which 13,217 data items were derived from 
the NHS information centre (10,252 items from post-2012 and 2,965 items from pre-
2012), and 3,288 data items were derived from the Scottish Morbidity Record (726 items 
from post-2015 and 2,562 items from pre-2015).  




Figure 4 - 9: A summary of death registry data available in the UK Biobank database. 
 ICD-10 codes for cause of death: Within the death registry data, a total of 37,293 data 
items were available to record the causes of death of 14,418 participants. Primary 
(underlying) causes of death (16,500 data items) were reported for all 14,418 participants, 
consisting of 888 unique ICD-10 codes. Contributory/secondary causes of death (20,793 
data items) were reported for 8,782 participants, consisting of 1,144 unique ICD-10 
codes. Overall, the database included 1,525 unique ICD-10 codes to annotate the causes 
of death for 14,418 participants (Table 4-14). 
Table 4 - 14: A summary of death registry data. 
Cause of death Data items Distinct values No. of participants 
Primary (underlying) cause of death: 
ICD10 
16,500 888 14,418 
Secondary (contributory) cause of 
death: ICD10 
20,793 1,144 8,782 
Total 37,293 1,525 14,418 
 
 Common causes of death in death registry data: The primary and secondary causes of 
death coded by ICD-10 codes were classified into 22 disease categories according to the 
ICD system: the number of deaths caused by each disease category were summarized in 
Table 4-15 (range: 27-503,234; median: 50,218). Within the death registry data the top 
20 common prevalent ICD-10 codes (with the first 3 digits) and the corresponding 
causes of death were identified and summarised in Table 4-16. 
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Chapter I Certain infectious and parasitic diseases 146 791 
Chapter II Neoplasms 9,577 2,905 
Chapter III Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
33 193 
Chapter IV Endocrine, nutritional and metabolic diseases 153 1,174 
Chapter V Mental and behavioural disorders 129 338 
Chapter VI Diseases of the nervous system 517 503 
Chapter VII Diseases of the eye and adnexa 0 2 
Chapter VIII Diseases of the ear and mastoid process 0 2 
Chapter IX Diseases of the circulatory system 3,438 6,248 
Chapter X Diseases of the respiratory system 943 3,238 
Chapter XI Diseases of the digestive system 669 1,268 
Chapter XII Diseases of the skin and subcutaneous tissue 14 56 
Chapter XIII Diseases of the musculoskeletal system and connective 
tissue 
90 227 
Chapter XIV Diseases of the genitourinary system 84 801 
Chapter XV Pregnancy, childbirth and the puerperium 34 0 
Chapter XVI Certain conditions originating in the perinatal period 0 0 





Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 
576 738 
Chapter XIX Injury, poisoning and certain other consequences of 
external causes 
0 1,142 
Chapter XX External causes of morbidity and mortality 576 1,121 
Chapter XXI Factors influencing health status and contact with health 
services 
0 10 
Other Codes for special purposes 14 0 
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Table 4 - 16: The top 20 common prevalent death causes in death registry data. 
ICD-10 Disease description  No. of cases* 
C34 Lung cancer 1,786 
I25 Chronic ischaemic heart disease 1,089 
C50 Malignant neoplasm of breast 841 
I21 Acute myocardial infarction 819 
C25 Malignant neoplasm of pancreas 617 
C18 Malignant neoplasm of colon 526 
C61 Malignant neoplasm of prostate 485 
C71 Malignant neoplasm of brain 468 
C15 Malignant neoplasm of oesophagus 434 
C80 Malignant neoplasm, without specification of site 414 
J44 Other chronic obstructive pulmonary disease 341 
C56 Malignant neoplasm of ovary 340 
C22 Malignant neoplasm of liver and intrahepatic bile ducts 297 
C64 Malignant neoplasm of kidney, except renal pelvis 265 
C16 Malignant neoplasm of stomach 242 
C45 Mesothelioma 235 
J84 Other interstitial pulmonary diseases 234 
J18 Influenza and pneumonia 198 
C19 Malignant neoplasm of rectosigmoid junction 195 
C20 Malignant neoplasm of rectum 192 
*Including both incident and prevalent cases. 
4.2.3 Summary of genotype data in UK Biobank 
4.2.3.1 Genotype data quality 
The application of marker-based and sample-based QC processes resulted in a released 
genotypic dataset of 805,426 markers for 488,377 samples. The number and proportion of 
SNPs which failed marker-based quality tests are summarised in Table 4-17. Specifically, 
197 SNPs (proportion: 0.25‰) failed the batch effect test, 284 SNPs (proportion: 0.36‰) 
failed the plate effect test, 572 SNPs (proportion: 0.72‰) violated the HWE test, 45 SNPs 
(proportion: 0.06‰) failed the sex effect test, 5,417 SNPs (proportion: 6.83‰) failed the 
array effect test and 45 SNPs (proportion: 0.06‰) were in discordance in genotyping calls 
against the controls. Overall, the proportion of SNPs removed because of poor genotyping 
call was 9.7‰. 
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Table 4 - 17: Failure rates in marker-based quality control. 
QC steps Average number of SNPs 
failed per batch (SD) 
Proportion of all genotype 
calls affected (‰) 
Marker-based QC   
Batch effect 197 (86) 0.25 
Plate effect 284 (266) 0.36 
Violation of HWE 572 (77) 0.72 
Sex effect 45 (5) 0.06 
Array effect 5,417 6.83 
Discordance across control replicates 622  0.80 
Total 7,704 (721) 9.71 
 
A total of 3,163 genotyped samples (6.5‰) were identified as poor quality based on the 
sample-based QC (Table 4-18). After adjusting heterozygosity with the first six PCs of 
population structure, 968 samples (2.0‰) were identified as having an unusually high 
heterozygosity and/or >5% missing rate. When comparing the self-reported sex and the 
genetic inferred sex, 378 samples (0.8‰) were identified as a sex mismatch. Additionally, 
652 samples (proportion: 1.3‰) were indicated as instances of sex chromosome aneuploidy. 
Another 188 samples (proportion: 0.4‰) that appeared to be related (3rd degree) to a very 
large number (>10) of individuals were suggested to be excluded, as the excess related pairs 
were likely to be false positives. Another set of 977 samples (proportion: 2.0‰) were 
indicated to be excluded by the kinship estimation, as they had properties (e.g., high missing 
rates) that would lead to unreliable kinship estimates. 
Table 4 - 18: Failure rates in sample-based quality control. 
Sample-based QC 
Number of samples 
failed QC 
Proportion of samples affected 
(‰) 
High heterozygosity and/or 
 >5% missing rate 
968 2.0 
Sex mismatch 378 0.8 
Putative sex-chromosome aneuploidy 652 1.3 
Excess related pairs 188 0.4 
Unreliable kinship estimates 977 2.0 
Total  3,163 6.5 
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4.2.3.2 Genetic population structure  
The population structure of UK Biobank is diverse as indicated by the self-reported ethnic 
background (Table 4-19). Genetic PCs were calculated to quantify the population structure 
from genetic ancestry/ethnicity. The top 40 PCs were calculated using the fastPCA (432). 
Then the SNP-loads for each PC were computed by carrying out the appropriate matrix 
multiplications based on mean-centred and variance-scaled genotypes and the PC scores 
were computed by the fastPCA. All samples were then projected onto the PCs using their 
SNP-loads. As expected, individuals with similar PC scores have similar self-reported ethnic 
backgrounds. The overall population structure of UK Biobank as revealed by the first six 
pairs of PCs is shown in Figure 4-10. Of the 488,377 samples, 409,694 individuals 
(proportion: 83.9%) were identified as White with their PC scores falling in the 
neighbourhood of the North-West European ancestry cluster. This was in concordance with 
the self-reported ethnicity, where a majority of the UK Biobank participants reported their 
ethnic background as “British” (within the broader-level group “White”). When analysing 
the PCs within the self-reported British, a homogeneous population of White British ancestry 
subset (defined with a combination of self-reported ethnic background as “British” and 
genetic indicated ethnic background as “White” based on the PCs) was identified, which 
included 409,703 individuals.  
Table 4 - 19: Self-reported ethnic background. 





White (British, Irish, and other white background)  472,798 94.06 
Asian (Indian, Pakistani, Chinese, Bangladeshi and other 
Asian background) 
11,461 2.28 
Black (Africa, Caribbean and other black background) 8,093 1.61 
Mixed (White & Asian, White & Black, other mixed 
background) 
2,966 0.59 
Other/Unknown 7,339 1.46 
 




Figure 4 - 10: Ancestral diversity in the UK Biobank cohort.  
Plots were made of consecutive pairs of the first six PCs in a PC analysis of genotype data for 
UK Biobank participants. Each point represents an individual and is placed according to their 
principal component scores (using genetic data only), with shapes and colours indicating their 
self-reported ethnic background as shown in the legend (Source: adapted from (417)). 
4.2.3.3 Genetic relatedness  
The genetic relatedness among UK Biobank participants was estimated by the kinship 
coefficients for all pairs of samples. According to the kinship inference, a total of 147,731 
UK Biobank participants (30.3%) were inferred to be related (3rd degree or closer) to at least 
one other participant in the cohort. The related individuals formed a total of 107,162 related 
pairs (Table 4-20), including 179 pairs of monozygotic twins, 6,276 pairs of parent-offspring, 
22,666 pairs of full siblings, 11,113 pairs of 2nd degree relatives (e.g., uncle-niece) and 
66,928 pairs of 3rd degree relatives (e.g., first cousins). In order to find the subset with the 
maximum number of unrelated individuals, further examination of the relationships among 
the samples within family groups was required (the procedure of identifying the largest 
possible subset of unrelated individuals is described below in the Chapter 4, Section 4.3.1 
“Study population selection”).  
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179 6,276 22,666 11,113 66,928 107,162 
*Counts are derived from the kinship coefficients. 
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4.3  Cleaning and preparation of UK Biobank data 
4.3.1 Study population selection 
The SUA PheWAS analysis was constrained to a subset of unrelated White British 
individuals with high quality genotype data in order to minimize the influence of diverse 
population structure within UK Biobank. The metrics used to select the target study 
population were based on the data fields created for the genotype QC in UK Biobank. The 
detailed process for selecting target population is described below.  
4.3.1.1 Sex mismatch  
There are two data fields available to describe the sex of samples. Field one is the self-
reported sex submitted by participants (coded by data field 31 as “male” and “female”) and 
the other is the genetic sex (coded by data field 22001 as “male” and “female”) inferred 
from the calling genotypes on the male-specific region of the Y chromosome and the non- 
pseudoautosomal region of the X chromosome. When self-reported sex was not consistent 
with the inferred sex from genotype data samples were referred to as a sex mismatch. When 
comparing the data field 31 with the data field 22001, 99.9% samples showed concordance, 
but for a small number of samples (n=378) the data fields did not match and were thus 
excluded from the target population.  
4.3.1.2 Outliers in heterozygosity and missing rates  
The property of outliers in heterozygosity and high missing rates was coded as 0 (no) or 1 
(yes) and was described in the variable: “het.missing.outliers”. A total of 968 samples (coded 
as 1 [“yes”]) were identified as outliers and were excluded from the study population.  
4.3.1.3 Putative aneuploidy in sex chromosome  
The property of putative aneuploidy in sex chromosome (putatively carrying sex 
chromosome configurations that are not either XX or XY) was coded as 0 (“no”) or 1 (“yes”) 
and was described in the variable: “putative.sex.chromosome.aneuploidy”. A total of 652 
samples (coded as 1 [“yes”]) were identified as aneuploidy in sex chromosome and thus 
were excluded from the study population. 
4.3.1.4 Excess relatives 
The property of excess relatives (with more than 10 putative 3rd degree relatives in the 
kinship table) was coded as 0 (“no”) or 1 (“yes”) and was described in the variable: 
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“excess.relatives”. A total of 188 samples (coded as 1 [“yes”]) were identified to have excess 
relatives in UK Biobank and thus excluded from the study population.  
4.3.1.5 White British ancestry   
The property of White British ancestry (self-reported ethnic background as “British” and 
genetic ethnic background as “White”) was coded as 0 (“no”) or 1 (“yes”) and was described 
in the variable: “in.white.British.ancestry.subset”.  A total of 78,674 samples (coded as 0 
[“no”]) did not belong to the White British subset and thus were excluded from the study 
population. 
4.3.1.6 Subset of unrelated individuals 
To find the subset with the maximum number of unrelated individuals, Bycroft et al 
developed a procedure by using the R package “i-graph (v1.0.1)”. I first pruned the full 
pairwise kinship table so that it only included White British individuals that passed the 
sample quality control;  I then converted the pruned kinship table into a graph object where 
each vertex is an individual and edges exist between pairs of related individuals (421). Then, 
for each “family” (i.e. a network of nodes joined by edges as shown in Figure 4-11), the 
largest subset of individuals (vertices) without relatedness were identified and chosen by an 
algorithm implemented in the “largest_ivs” function in “i-graph” R package. For instance, 
in a simple case of trios, the child would be excluded, leaving the maximum number of two 
unrelated parents. When there were multiple possible solutions for the choice of the largest 
subset of unrelated individuals, one of these solutions were chosen at random. By following 
this procedure, the largest possible subset was identified, it included 339,256 unrelated 
individuals when restricted to the quality-filtered subset of White British. 
 




Figure 4 - 11: Familial relatedness in the UK Biobank cohort.  
This figure illustrates examples of family groups within the UK Biobank cohort. Points indicate 
participants and lines between points indicate familial relatedness (3rd degree and closer), as 
inferred from the genetic data. The colour and thickness of the lines indicate different relative 
classes, as shown in the key. No integer means there is only the one shown; for example, there is 
only one network that comprises 6 full siblings (plus one 3rd degree relative who is related to all 
siblings). An integer next to a network indicates the total number of family networks in the 
cohort with the same configuration, ignoring 3rd degree pairs. For example, there are 10 networks 
that comprise exactly 5 full siblings (two examples, which differ with respect to a 3rd degree 
relative, are shown on this plot); when selecting the subset of unrelated individuals, one of the 5 
full sibling were retained at random; (Source: adapted from (421)).  
4.3.2 Covariate selection 
Covariates for the SUA PheWAS analysis were selected based on consideration of the 
baseline characteristics of UK Biobank cohort, the properties of genotyping data and the 
potential confounding factors related to SUA level. The following list of potential covariates 
were included: age, sex, BMI, assessment centre, the first 6 PCs, deprivation index, smoking 
status and alcohol intake frequency. Some other potential confounding variables such as data 
on creatinine concentration, HDL cholesterol and triglycerides were not available in UK 
Biobank and thus were not included as covariates. 
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4.3.2.1 Sex, age and BMI  
Among the selected study population (with 339,256 unrelated White British individuals), 
there were 182,110 females and 157,146 males (data field 32). To describe the age of study 
populatio, two data fields are available: age at recruitment (data field 21022) and age when 
attended assessment centre (data field 21003). The mean age of the study population at 2016 
was 64.82 (SD: 8.00) years. The distribution of male and female participants in each age 
group is shown in Figure 4-12.  The BMI (defined as: weight (kg) / [height (m)]2) was coded 
by the data field 21001 as a continuous variable expressed in kg/m2. The mean value of BMI 
was 27.02 (SD: 4.76) kg/m2 for female and 27.83 (SD: 4.23) kg/m2 for male (Figure 4-13).  
 
Figure 4 - 12: The age distribution of male and female participants. 




Figure 4 - 13: The boxplot for BMI (kg/m2) in each sex.  
 
4.3.2.2 Assessment centre 
Assessment centre, where the participants were recruited, is coded by the data field f.54.0.0. 
The 339,256 unrelated White British individuals included in this study were distributed 
across 22 assessment centres. The number of participants recruited from each assessment 
centre is displayed in Figure 4-14. The assessment centre with the largest number of 
participants in this study was Leeds (n=31,348). The characteristics of the other covariates 
(sex, age, BMI) are summarised for each assessment centre and are shown in Table 4-21.  




Figure 4 - 14: The number of participants recruited from each assessment centre.  
Table 4 - 21 A summary of the baseline characteristics of participants recruited from each 
assessment centre. 






Barts       5,908 3,103/2,805 63.47±8.13 26.24±4.79 
Birmingham 16,056 8,385/7,671 63.92±8.11 27.70±4.85 
Bristol   30,830 16,982/13,848 63.98±8.27 27.02±4.66 
Bury 20,383 10,629/9,691 65.87±7.76 27.70±4.70 
Cardiff 12,781 6,885/5,896 65.01±7.84 27.97±4.86 
Croydon 15,076 8,217/6,859 64.28±7.79 26.98±4.70 
Edinburgh 12,355 6,826/5,529 65.39±7.92 27.02±4.67 
Glasgow 12,693 6,983/5,710 65.45±8.16 27.65±4.85 
Hounslow     14,763 7,922/6,841 64.22±7.98 26.71±4.70 
Leeds   31,348 16,984/14,364 64.97±7.92 27.44±4.72 
Liverpool 22,685 12,105/10,580 64.64±7.9 27.83±4.90 
Manchester 9,078 4,804/4,274 65.15±8.34 27.46±4.94 
Middlesborough     15,295 8,103/7,192 64.32±8.06 27.81±4.77 
Newcastle 26,285 14,184/12,101 65.2±7.94 27.73±4.74 
Nottingham   24,411 13,129/11,282 65.14±7.92 27.38±4.70 
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Oxford 9,922 5,654/4,268 66.04±7.96 26.67±4.62 
Reading   21,249 11,489/9,760 64.97±7.91 26.87±4.50 
Sheffield  21,885 11,651/10,234 64.36±7.82 27.53±4.81 
Stockport (pilot) 319 169/150 65.84±7.52 26.46±4.90 
Stoke 13,824 6,703/7,121 65.45±8.00 27.75±4.69 
Swansea 1,620 882/738 64.37±7.98 28.19±5.18 
Wrexham 490 258/232 63.53±8.22 28.62±5.81 
Overall   339,256 182,110/157,146 64.82±8.00 27.40±4.76 
 
4.3.2.3 Genetic principal components  
As explained in Section 2.3.2, the top 40 genetic PCs were computed and represented by a 
set of PC scores for all samples in the UK Biobank cohort. The top 40 PC scores were coded 
by the data field 22009 with an array index (multiple data items for each instance) running 
from 1 to 40. The first six PC scores were chosen as covariates to adjust for the 
heterozygosity of the population structure in SUA PheWAS, as they explained the most 
variation. The plots for the first six PC scores (pairs of PCs: 1&2; 3&4; 5&6) for the UK 
Biobank samples are shown in Figure 4-15 and the blue crosses represent the subset of 
White British ancestry (the target population of SUA PheWAS analysis) with their first six 
PC scores falling in the neighbourhood of the North-West Europe ancestry  cluster.  
 




Figure 4 - 15: Plots for the first six PC scores.  
Each plot shows the principal component scores for all UK Biobank samples used to select the 
white British ancestry subset. Non-grey points indicate participants who have self-reported ethnic 
background “British” and participants with other ethnic backgrounds are coloured grey (Source: 
adapted from reference (421)). 
4.3.2.4 Other covariates 
To adjust for any effect of environmental exposures, smoking status and alcohol intake 
frequency were also included as covariates. Smoking status (coded by data field 20116) was 
categorised as “current smoking”, “previous smoking”, “never smoking” and “prefer not to 
answer”. The number of participants assigned to each smoking status is shown in Table 4-22. 
Alcohol intake frequency (coded by data field 1558) was grouped as “daily or almost daily”, 
“three or four times a week”, “once or twice a week”, “one to three times a month”, “special 
occasion only”, “never”, and “prefer not to answer”. The number of participants grouped in 
each category is summarised in Table 4 - 22. 
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Table 4 - 22: The smoking status and alcohol intake frequency among participants. 
Categorical Levels No. of participants Proportion (%) 
Smoking status 
Current smoking 35,798 29.0 
Previous smoking 31,090 25.2 
Never smoking 55,376 44.9 
Prefer not to answer 1,029 0.8 
Missing 88 <0.1 
Alcohol intake 
frequency 
Daily or almost daily 25,653 21.4 
3 or 4 times a week 28,224 23.5 
1 or 2 times a week 31,434 26.2 
1 to 3 times a month 13,373 11.1 
Special occasions only 13,161 11.0 
Never 8,168 6.8 
Prefer not to answer 78 <0.1 
Missing 0 0 
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4.3.3 Construction of genetic instruments  
4.3.3.1 Genetic risk loci and effect sizes 
To generate genetic instruments for SUA levels I searched for genetic variants associated 
with SUA levels from the GWAS catalogue (accessed in 07 Feb, 2017). Thirty genetic risk 
loci in relation to SUA levels (p<5×10-8) were identified from previous GWAS (150, 151). 
Based on the MR analysis performed by White et al (323), one more SNP rs164009 located 
in the PRPSAP1 gene (p=7.06×10-7) was included given its functional role in urate 
metabolism (i.e., it encodes a protein involved in the regulation of purine synthesis). In total, 
31 independent SNPs were selected as genetic proxies of SUA level (Table 4-23). These 
SNPs are distributed across 14 chromosomes (Chromosome 1 [n=2], Chromosome 2 [n=3], 
Chromosome 3 [n=1], Chromosome 4 [n=2], Chromosome 5 [n=1], Chromosome 6 [n=4], 
Chromosome 7 [n=2], Chromosome 8 [n=2], Chromosome 10 [n=2], Chromosome 11 [n=3], 
Chromosome 12 [n=2], Chromosome 15 [n=2], Chromosome 16 [n=2], Chromosome 17 
[n=3]).  
Each SNP effect on SUA level (effect size and standard error [SE]) was taken from the 
largest meta-analysis of GWAS in European populations performed by the GUGC 
consortium (151). This meta-analysis included 48 individual GWAS with 110,347 
individuals. The overall proportion of variance (adjusted R2) of SUA level explained by the 
31 selected SNPs was estimated to be 7%, of which 3.4% was explained by two SNPs 
(rs12498742 located at SLC2A9 and rs2231142 located at ABCG2) alone. Genome-wide sex-
interaction on the serum urate effect sizes were also examined in this study (151). They 
performed meta-analyses of GWAS separately for 49,825 men and 60,522 women. Except 
for SLC2A9 and ABCG2, no additional regions contained SNPs that differed significantly 
(p<5×10-8) in their effect sizes between men and women. The effect estimates of the 31 
selected SNPs on SUA level for the overall and sex-specific subjects are summarised in 
Table 4-23.  
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Table 4 - 23: The GWAS summary estimates for the effect of 31 SNPs on SUA level. 
Genetic instruments Overall effect  Male-specific effect Female-specific effect 
SNP Chr A1 A2 Closest/GRAIL gene beta se p_gc beta1 se1 p1 beta2 se2 p2 
rs10480300 7 T C PRKAG2/PRKAG2 0.032 0.006 9.37E-07 0.043 0.010 1.70E-05 0.024 0.008 3.20E-03 
rs10821905 10 A G A1CF/ASAH2 0.053 0.007 3.45E-12 0.042 0.011 3.80E-04 0.060 0.009 2.50E-10 
rs11264341 1 T C TRIM46/PKLR -0.048 0.006 1.04E-14 -0.055 0.009 1.10E-08 -0.044 0.007 9.10E-09 
rs1165151 6 T G SLC17A1/SLC17A3 -0.092 0.005 4.52E-60 -0.096 0.008 1.30E-28 -0.089 0.007 4.20E-37 
rs1171614 10 T C SLC16A9/SLC16A9 -0.074 0.007 6.48E-23 -0.086 0.011 1.90E-13 -0.067 0.009 3.00E-13 
rs1178977 7 A G BAZ1B/MLXIPL 0.050 0.007 6.68E-12 0.055 0.011 8.20E-07 0.046 0.009 2.60E-07 
rs12498742 4 A G SLC2A9/SLC2A9 0.380 0.006 0.00E+00 0.269 0.010 6.40E-153 0.460 0.008 0.00E+00 
rs1260326 2 T C GCKR/GCKR 0.077 0.006 1.31E-40 0.091 0.009 3.00E-25 0.063 0.007 1.90E-04 
rs1394125 15 A G UBE2Q2/NRG4 0.043 0.006 9.78E-11 0.060 0.010 5.50E-06 0.032 0.008 1.00E-04 
rs1471633 1 A C PDZK1/PDZK1 0.061 0.005 1.40E-26 0.069 0.008 3.50E-15 0.054 0.007 1.60E-14 
rs164009 17 A G QRICH2/PRPSAP1 0.029 0.006 7.06E-07 0.024 0.009 6.20E-03 0.032 0.007 8.20E-06 
rs17050272 2 A G INHBB/INHBB 0.037 0.006 9.36E-09 0.049 0.010 6.50E-07 0.030 0.008 1.90E-04 
rs17632159 5 C G TMEM171/TMEM171 -0.038 0.006 2.00E-09 -0.043 0.010 1.30E-05 -0.039 0.008 1.10E-06 
rs17786744 8 A G STC1/STC1 -0.031 0.005 8.82E-08 -0.033 0.009 2.10E-04 -0.029 0.007 2.10E-04 
rs2078267 11 T C SLC22A11/SLC22A11 -0.078 0.006 8.73E-36 -0.085 0.009 2.90E-19 -0.071 0.007 5.70E-20 
rs2079742 17 T C BCAS3/C17orf82 0.051 0.008 6.24E-09 0.054 0.013 5.60E-05 0.048 0.010 1.00E-05 
rs2231142 4 T G ABCG2/ABCG2 0.220 0.009 4.43E-116 0.270 0.014 3.80E-75 0.181 0.011 1.30E-52 
rs2307394 2 T C ORC4L/ACVR2A -0.035 0.006 7.26E-09 -0.036 0.009 1.20E-04 -0.034 0.007 4.70E-06 
rs2941484 8 T C HNF4G/HNF4G 0.049 0.006 3.91E-17 0.048 0.009 6.20E-08 0.046 0.007 1.30E-10 
rs3741414 12 T C INHBC/INHBE -0.071 0.007 9.79E-22 -0.091 0.011 7.00E-16 -0.057 0.009 4.30E-10 
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Genetic instruments Overall effect Male-specific effect Female-specific effect 
SNP Chr A1 A2 Closest/GRAIL gene beta se p_gc beta1 se1 p1 beta2 se2 p2 
rs478607 11 A G NRXN2/SLC22A12 -0.048 0.007 5.31E-10 -0.058 0.012 9.60E-07 -0.043 0.009 8.80E-06 
rs642803 11 T C OVOL1/LTBP3 -0.043 0.005 4.51E-14 -0.047 0.008 8.00E-08 -0.042 0.007 2.10E-09 
rs653178 12 T C ATXN2/PTPN11 -0.036 0.005 2.45E-10 -0.044 0.009 7.50E-07 -0.032 0.007 5.50E-06 
rs6598541 15 A G IGF1R/IGF1R 0.044 0.006 5.20E-13 0.039 0.009 2.70E-05 0.050 0.007 1.60E-11 
rs675209 6 T C RREB1/RREB1 0.063 0.006 1.38E-21 0.060 0.010 3.30E-09 0.064 0.008 2.00E-15 
rs6770152 3 T G SFMBT1/MUSTN1 -0.048 0.006 2.66E-16 -0.052 0.009 6.70E-09 -0.047 0.007 6.00E-11 
rs7188445 16 A G MAF/MAF -0.032 0.006 1.15E-07 -0.025 0.009 7.90E-03 -0.040 0.007 6.40E-08 
rs7193778 16 T C NFAT5/NFAT5 -0.047 0.008 2.36E-08 -0.048 0.012 2.10E-04 -0.045 0.010 1.00E-05 
rs7224610 17 A C HLF/HLF -0.038 0.006 4.74E-11 -0.043 0.009 9.00E-07 -0.034 0.007 3.00E-06 
rs729761 6 T G VEGFA/VEGFA -0.046 0.006 3.05E-12 -0.047 0.010 3.20E-06 -0.047 0.008 3.20E-06 
rs742132 6 A G LRRC16A/LRRC16A 0.035 0.006 1.90E-08 0.035 0.006 1.90E-08 0.035 0.006 1.90E-08 
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4.3.3.2 Use of individual SNPs as genetic instruments  
To achieve the primary goal of the PheWAS, which is to identify the cross-phenotype 
associations (genetic risk locus shared by multiple phenotypes), the simplest and most 
appropriate approach is to use each single genetic variant of interest as a predictor to observe 
its associations with the phenome. For this purpose, all 31 SNPs related to SUA level were 
applied as genetic predictors individually to explore their associations with the phenome. 
Genotypes of the 31 selected SNPs were extracted from the UK Biobank genetic datasets for 
the selected study population. Of these, 10 SNPs (rs11264341, rs1260326, rs1394125, 
rs17050272, rs2078267, rs2231142, rs2307394, rs675209, rs742132, rs653178) were 
genotyped for all included individuals (n=339,256). Genotypes of the remaining 21 SNPs 
were extracted from the imputed data. The number of participants with missing genotypes 
for the 21 SNPs ranges from 51-12,004 (median: 3,206) and the missing rates of genotypic 
data were less than 5% (range: 0.2%-4.2%; median: 0.09%). The allele frequency and 
genotype count of the study population (n=339,256) from UK Biobank is presented in Table 
4-24.  
To describe the nature and potential effect of each single variant, the function of putative 
genes where these variants map to was annotated by using NCBI gene database and 
GeneCards (www.genecards.org) database (Chapter 1, Section 1.3 “Genetic 
polymorphisms” for more information). In summary, of these 31 SNPs, 7 were mapped to 
genes (SLC22A11/OAT4, SLC22A12/URAT1, SLC17A1/NPT, PDKZ1, SLC2A9/GLUT9, 
ABCG2, and SLC16A9) encoding proteins related to urate transport across renal and gut 
membranes; one SNP (rs164009) is located within a candidate gene (PRPSAP1) that encodes 
a protein involved in the regulation of purine synthesis and thus affects urate generation; the 
remaining SNPs were largely mapped to genes encoding proteins for transcription or 
inhibins-activins growth factors with broad downstream responses and highlighting 
pathways in relation to carbohydrate metabolism, such as regulation of glycolysis, glucose, 
insulin and pyruvate.  
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Table 4 - 24: The allele frequency and genotype count of the 31 selected SNPs in the study population (n=339,265) from UK Biobank.  
SNP A1 A2 A1_freq A2_freq Genotype 1 (A1A1) Genotype 2 (A1A2) Genotype 3 (A2A2) Missing number Missing 
rate 
rs10480300 T C 0.727 0.273 25,212 132,730 178,115 3,206  0.009 
rs10821905 A G 0.824 0.176 10,415 97,284 227,374 4,190 0.012 
rs11264341 T C 0.571 0.429 62,651 166,037 110,575 0 0 
rs1165151 T G 0.549 0.451 68,897 167,982 101,915 469 0.001 
rs1171614 T C 0.769 0.231 17,960 120,040 199,948 1,315 0.004 
rs1178977 G A 0.802 0.198 13,322 107,362 218,528 51 0.000 
rs12498742 G A 0.768 0.232 18,453 120,558 199,922 330 0.001 
rs1260326 T C 0.607 0.393 52,424 161,510 125,329 0 0 
rs1394125 A G 0.638 0.362 44,414 156,803 138,046 0 0 
rs1471633 A C 0.538 0.462 72,514 168,505 97,945 299 0.001 
rs164009 G A 0.613 0.387 50,142 159,289 126,229 3,603 0.011 
rs17050272 A G 0.589 0.411 57,230 164,105 117,928 0 0 
rs17632159 C G 0.697 0.303 31,048 141,910 163,384 2,921 0.009 
rs17786744 G A 0.590 0.410 56,472 162,194 116,523 4,074 0.012 
rs2078267 C T 0.548 0.452 69,205 168,460 101,598 0 0 
rs2079742 C T 0.864 0.136 6,053 78,293 247,447 7,470 0.022 
rs2231142 T G 0.887 0.113 4,470 67,948 266,845 0 0 
rs2307394 C T 0.697 0.303 30,747 144,185 164,331 0 0 
rs2941484 T C 0.553 0.447 65,907 161,615 100,841 10,900 0.032 
rs3741414 T C 0.755 0.245 20,467 124,940 193,647 209 0.001 
rs478607 G A 0.847 0.153 8,044 87,168 243,012 1,039 0.003 
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SNP A1 A2 A1_freq A2_freq Genotype 1 (A1A1) Genotype 2 (A1A2) Genotype 3 (A2A2) Missing number Missing 
rate 
rs642803 T C 0.536 0.464 72,507 166,237 96,539 3,980 0.012 
rs653178 C T 0.517 0.483 79,137 169,471 90,655 0 0 
rs6598541 A G 0.645 0.355 42,133 153,913 139,819 3,398 0.010 
rs675209 T C 0.731 0.269 24,595 133,343 181,325 0 0 
rs6770152 G T 0.576 0.424 60,131 163,329 111,108 4,695 0.014 
rs7188445 A G 0.672 0.328 36,423 148,347 152,201 2,292 0.007 
rs7193778 C T 0.850 0.150 7,559 86,228 243,737 1,739 0.005 
rs7224610 C A 0.604 0.396 51,092 154,994 118,920 14,257 0.042 
rs729761 T G 0.715 0.285 26,764 132,929 167,566 12,004 0.035 
rs742132 G A 0.706 0.294 29,186 140,891 169,186 0 0 
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4.3.3.3 Calculation of a weighted polygenic risk score as a proxy of SUA level  
To explore the potential causal effect of SUA level across phenome-wide health outcomes, a 
weighted polygenic genetic risk score (GRS) was constructed by incorporating information 
from the 31 genetic risk loci associated with SUA level. Specifically, the polygenic risk score 
was created by adding up the number of SUA level increasing alleles carried by all 31 SNPs 
and then weight it based on their effect estimates on SUA level (regression coefficient beta) 
derived from the SUA GWAS performed by the GUGC consortium. For instance, if 
individual 𝑖 carries 𝑔𝑖𝑘 copies of the SUA-increasing allele for each variant 𝑘 = 1, … ,31, the 
weight for variant 𝑘 is 𝑤𝑘  then their weighted polygenic score is 𝑍𝑖 = ∑ 𝑤𝑘𝑔𝑖𝑘
31
𝑘=1 .  
The weighted polygenic risk score was calculated by using plink 2.0 for all individuals 
(n=339,256) included in the SUA PheWAS analysis. The weighted GRS was normally 
distributed among the study population with a mean value of 0.436 (SD: 0.309) (Table 4-25, 
Figure 4-16).  
 
Figure 4 - 16: The distribution of weighted polygenic risk score among study population. 
 
Table 4 - 25: A summary of weighted polygenic risk score among study population.  
Weighted GRS 
n Min. 1st Qu. Median 
3rd 
Qu. 
Max. Mean SD 
339,256 -0.880 0.231   0.461 0.656 1.545 0.436 0.309 
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4.3.4 Definition of the phenome framework  
The focus on a wider spectrum of phenotypes, termed the phenome, is an important aspect of 
the PheWAS approach. The phenome has been defined as a systematic and comprehensive 
set of phenotypes, including both clinical, biochemical and imaging traits, which could be 
measured as outcome phenotypes (e.g., disease status), or intermediate phenotypes (e.g., 
clinical variables). Unlike the genome, in which the genetic structure could be measured by 
reliable biological techniques, generating a framework of phenome highly relies on the 
clinical measurements and disease diagnoses. The phenome framework defined in currently 
published PheWASs varies according to studies (the characteristics of these PheWAS are 
summarised in Table 4-26), but the most effective and straightforward way for phenotyping 
is to use the electronic medical records (EMRs). In this PheWAS analysis for SUA level, I 
focused on phenotypes in relation to disease outcomes.  
4.3.4.1 ICD codes in UK Biobank 
We analysed three phenotypic datasets (in-patient hospital records, cancer registry data and 
death registry data) in the UK Biobank database. The coding for clinical diagnoses in these 
datasets follows the World Health Organisation’s ICD coding systems but uses different ICD 
versions (ICD-10 or ICD-9) based on the date of record. Within the in-patient hospital data, 
each episode has a primary ICD-10/9 diagnosis code to describe the event of hospitalisation, 
and when applicable, one or more secondary diagnosis codes followed to annotate the 
corresponding hospitalisation event. We included both the primary and secondary codes to 
define the case and control groups. Since cancer registry and death registry data overlapped 
with the disease diagnosis in hospital episode records, we pooled them into the hospital 
episode data to complement the disease diagnoses of participants. In these phenotypic 
datasets, we identified 2,779,598 unique records of hospital inpatient data corresponding to 
395,978 unique individuals (2,714,364 records had an ICD10 diagnosis code, 52,123 had an 
ICD9 diagnosis code and 13,111 records had no diagnosis code), 233,753 records 
corresponding to 79,066 unique participants (207,935 records had an ICD10 diagnosis code, 
and 25,818 had an ICD9 diagnosis code) from the cancer registry data, and 14,417 records 
from the death registry data. The breadth of the ICD-10/9 coding system ensures that it can 
describe well the range of human diseases but the individual ICD codes cannot be directly 
used to define an independent phenotype, as they are not designed to represent distinct 
phenotype groups. To aggregate the ICD codes, the PheCODE schema has been developed 
and successfully adopted in a number of PheWAS to combine one or more individual ICD 
codes into distinct phenotype groups (see the Chapter 4, Section 4.3.4.2 “PheCODE 
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schema”  for more information) (433-435).  
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Table 4 - 26: The characteristics of currently published PheWAS studies.  
Study Population Sample 
size  




Significant phenotypic associations  
Genetic variants  
Denny, 2010 
(436) 
BioVU 6005 5 SNPs (with known 
associations) 
EMR (ICD-9-CM) 733  23 phenotypes (4 replicated, 19 novel) 
Denny, 2011 
(437) 





6307 4 SNPs (associated with T2DM 
and related traits) 
EMR(ICD-9-CM) 285 Diabetes, disorders of lipid metabolism 
Denny, 2013 
(439) 
eMERGE 21,241 3144 SNPs (all SNPs in GWAS 
catalog) 
EMR(ICD-9-CM) 1385 263 phenotypes (210 replicated with 





4235 1 SNP (tagging HLA-
DRB1*1501) 
EMR(ICD-9-CM) 4841 MS, alcohol–induced cirrhosis, 
erythematous conditions, benign 
neoplasms of respiratory organs 
Pendergrass, 
2013 (441) 
PAGE network 70,061 83 SNPs (SNPs overlapped 
across PAGE study sites) 
Cohort studies 4706 111 phenotypes (26 replicated, 33 novel) 
Ritchie, 2013 
(434) 
eMERGE 13,859 23 SNPs (associated with ECG 
QRS duration) 
EMR(ICD-9-CM) 778 Cardiac arrhythmias; atrial fibrillation 
Cronin, 2014 
(442) 
Emerge & BioVU 24,198 54 SNPs (all in FTO gene) EMR(ICD-9-CM) 1645 Obesity, T2DM, fibrocystic breast disease  
Hall,         2014 
(443) 
Genetic NHANES  14,042 80 SNPs (GWAS-identified SNPs 
in NHANES datasets) 
Cohort studies 1008 69 phenotypes (21 novel) 
Mitchell, 2014 
(444) 
BioVU 11,519 130 SNPs (cardiovascular-related 
mtSNPs) 
EMR derived 8 T2DM, total cholesterol level  
Namjou, 2014 
(445) 
Paediatric patients   4268 2476 SNPs (overlapped SNPs 
between the dataset and GWAS 
catalog) 
EMR(ICD-9-CM) 539 JRA, thyroiditis, T1DM 
Shameer, 2014 
(446) 
eMERGE 13,582 81 SNPs (associated with platelet 
parameters) 
EMR(ICD-9-CM) 1368 Myocardial infarction, autoimmune, 
hematologic disorders  
Carroll, 2014 
(447) 
BioVU 6005 1 SNP (near HLA-DRB, 
associated with multiple 
sclerosis) 
EMR(ICD-9-CM) 1127 Multiple sclerosis 




14,875 105 SNPs (presumed functional 
stop-gain and stop-loss variants) 
EMR(ICD-9-CM) 4841 Age-related macular degeneration  
Diogo, 2015 
(449) 
BioVU & other 29,377 3 SNPs (in TYK2 gene) EMR(ICD-9) 502 Rheumatoid Arthritis (RA) 
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Study Population Sample 
size  




Significant phenotypic associations  
Moore, 2015 
(450) 
AIDS Clinical Trial 
Group 
2547 10,584 SNPs (SNPs passed the 




27 Higher total bilirubin 






4235 5 SNPs (reported in GWAS) EMR (ICD code & 
text-mining) 
23,384 & 4841 Nonexudative senile macular 
degeneration, spondylitis, MS, atrial 
fibrillation, triglyceride level 
Non-genetic predictors  
Warner, 2012 
(452) 




New Yorkers  2475 Presence of periodontitis EMR(ICD-9-CM) 993 9 phenotypes (e.g. T1DM, T2DM) 
Liao,         2013  
(454) 
RA cases vs. controls 2526 Autoantibody  EMR(ICD-9-CM) 512 Hypothyroidism, sicca, chronic non-
alcoholic liver disease  
Neuraz, 2013 
(455) 
Patients treated by 
thiopurine drugs 
442 TPMT activity  EMR(ICD-10) 445 Diabetes, nutritional anaemia 
Warner, 2013a 
(456) 
MIMIC II 24,580 Length of hospitalisation EMR(ICD-9-CM) 5657 191 (e.g. hospital-acquired complications) 
Warner,  2013b 
(457) 






128 FGF19 and FGF21 EMR  205 Higher glucose 
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4.3.4.2 PheCODE schema 
The PheCODE schema was developed to combine one or more related ICD codes into 
distinct diseases or traits (459). In principle, ICD codes representing diseases with common 
aetiology were combined into one phenotype group defined by the phecode. On the other 
hand, for some diseases with distinctly different aetiologies, like type 1 and type 2 diabetes, 
their individual codes are retained and allocated into different phenotype groups. The 
PheCODE system has been continuously refined by clinical experts helping with revisions of 
different domains, such as cardiology and oncology. The latest version of the PheCODE 
system includes 1,866 hierarchical phenotype codes. The PheCODE system also provides a 
scheme to automatically exclude patients that have similar or potentially overlapping 
diseases (e.g. excluding type 1 diabetes and secondary diabetes mellitus for an analysis of 
type 2 diabetes) from the corresponding control group. Although the PheCODE system is 
effective at replicating genotype-phenotype associations, the current version of the 
PheCODE system was designed for the International Classification of Diseases, version 9, 
Clinical Modification (ICD-9-CM), and the phecode algorithm was not directly applicable to 
the ICD-10 coding system in the UK Biobank. 
To develop an aggregation method for the PheWAS analysis applicable to the ICD-10 coding 
system in UK Biobank, we collaborated with the Electronic Medical Records and Genomics 
(eMERGE) group of Vanderbilt University Medical Center and mapped ICD-10 codes to 
phecodes in both direct and indirect ways (Figure 4-17). An ICD-10 code could be mapped 
to a phecode directly if their descriptions matched each other regardless of capitalisation. An 
ICD-10 code can also be mapped to a phecode indirectly through an ICD-9-CM code.  The 
unified medical language system (UMLS) was used to map the ICD-10 code to ICD-9-CM 
(or map the ICD-10 code to systematised nomenclature of medicine clinical terms 
[SNOMED CT] code first and then to ICD-9-CM) and then the previous mapping of ICD-9-
CM to phecode was used to finally link the ICD-10 to the phecode. When an ICD-10 code 
could be mapped to both a child phecode and its parent phecode, only the mapping to the 
child phecode was retained and the child phecode was then mapped to its parent phecode; or 
when an ICD-10 code can be mapped to multiple distinct phecodes, all the mappings are 
kept. The mapping process was developed by the Vanderbilt group and I matched the ICD 
codes in the UK Biobank to the PheCODE schema for analysis. 




Figure 4 - 17: Mapping ICD-10 codes to phecodes.  
Abbreviations: SNOMED CT = Systematised Nomenclature of Medicine, Clinical Terms; UMLS = 
Unified Medical Language System; GEM = General Equivalence Mappings; OHDSI = Observational 
Health Data Sciences and Informatics. 
Among the 7,990 ICD-10 codes used in UKBB, 6,654 (83.2%) codes were successfully 
mapped to phecodes. An additional 3,500 ICD codes within UKBB did not exist in the 
current ICD-10 versions, therefore, were not mapped to phecodes. When examining the 
mapping procedure, the majority of the unmapped ICD-10 codes were composed of 
encounter or procedural codes (i.e. codes beginning with Z) or supplementary codes (i.e. 
codes beginning with Y), which were not a description of a specific phenotype or disease. In 
addition, some ICD-10 code areas used in the UKBB representing the personal and family 
history were also unable to be mapped due to the missing corresponding elements in the 
PheCODE system. The top 10 unmapped ICD-10 codes are listed in Table 4-27. In total, 
8,947 ICD-10 codes were mapped to at least one phecode, with 256 (2.9%) codes mapped to 
more than one phecode. After mapping diagnostic ICD-10/9 codes to phecodes, the 
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Table 4 - 27: The top ten unmapped ICD-10 codes in the UKBB. 

























Z53.8 Procedure not carried out for other reasons 
Z92.2 Personal history of long-term (current) use of other medicaments 
Z30.2 Sterilisation 
Z82.4 Family history of ischaemic heart disease and other diseases of the 
circulatory system 
Z37.0 Single live birth 
Z03.8 Observation for other suspected diseases and conditions 
Z12.1 Special screening examination for neoplasm of intestinal tract 
Z92.1 Personal history of long-term (current) use of anticoagulants 
Z96.6 Presence of orthopaedic joint implants 
Z09.0 Follow-up examination after surgery for other conditions 
 
4.3.4.3 Tree-structured phenotypic model  
A novel Bayesian analysis framework, termed a tree-structured phenotypic model 
(TreeWAS), was developed to interrogate increasingly specific sub-phenotypes encoded by 
ICD-10 codes while retaining the statistical power to detect genetic associations (460). This 
application models the genetic coefficients across all phenotypes as a set of random 
variables. Given that ICD-10 codes are organised in a hierarchical tree-like structure, to 
model the correlation of this structure, a Markov process is applied to allow the genetic 
coefficients to evolve down the tree trunk and branches. The tree structure is determined 
from a known classification hierarchy based on the ICD coding system where each node of 
the tree is a clinical term in the classification and observations can be made at both terminal 
and internal nodes. The prior probability determines the expected degree of correlation 
between genetic coefficients across phenotypes. The coefficient at a parent node can either 
be inherited by a child node (the probability is denoted as e-θ) or can transition to a new 
uncorrelated value (the probability is denoted as 1- e-θ). This new value will be zero with a 
probability of 1 – π1, or non-zero with a probability π1. Thus, the e-θ and π1 parameters define 
the transition probabilities that control the Markov process. Given the structure of the model 
and the Markov process assumption, the likelihood over the genetic coefficients could be 
calculated across all clinical phenotypes using a dynamic programming model and the 
forward and backward algorithms (see reference (460) for more details). An overall Bayes 
Factor (BF) is estimated if the genetic coefficients are non-zero for at least one of the nodes 
in the tree. The marginal posterior probability (PP) at each node in the tree where the genetic 
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coefficient is non-zero, and the magnitude of the corresponding effect were determined by 
using the maximum a posteriori (MAP) estimator (see reference (460) for more details). 
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5 MR-PheWAS: INTERIM RELEASE OF UK BIOBANK DATA 
5.1 Summary 
This chapter presents a MR-PheWAS (phenome-wide association study incorporated with 
Mendelian randomisation [MR]) analysis that was performed to investigate the associations 
between the 31 SUA genetic risk variants and a very wide range of disease outcomes (n=568) 
by using the interim release data of UK Biobank (n=120,091). The SUA genetic risk loci 
were employed as instruments individually. The framework of phenome was defined by the 
PheCODE schema using the ICD diagnosis codes documented in the health records of UK 
Biobank. Phenome-wide association tests were performed first to identify associations across 
the SUA genetic risk loci and the Phenome; MR and HEIDI (heterogeneity in dependent 
instruments) analyses were then applied to investigate whether the observed PheWAS 
associations were due to causality, pleiotropy or genetic linkage.  
The MR-PheWAS (using the interim release cohort) identified 25 disease groups/ outcomes 
to be associated with SUA genetic risk loci after multiple testing correction (p<8.57×10-5). 
The MR IVW (inverse variance weighted) analysis implicated a causal role of SUA level in 
three disease groups: inflammatory polyarthropathies (OR=1.22, 95% CI: 1.11 to 1.34), 
hypertensive disease (OR=1.08, 95% CI: 1.03 to 1.14) and disorders of metabolism 
(OR=1.07, 95% CI: 1.01 to 1.14); and four disease outcomes: gout (OR=4.88, 95% CI: 3.91 
to 6.09), essential hypertension (OR=1.08, 95% CI: 1.03 to 1.14), myocardial infarction 
(OR=1.16, 95% CI: 1.03 to 1.30) and coeliac disease (OR=1.41, 95% CI: 1.05 to 1.89). After 
balancing pleiotropic effects in MR Egger analysis, only gout and its encompassing disease 
group of inflammatory polyarthropathies were considered to be causally associated with 
SUA level. The analysis also highlighted a locus (ATXN2/S2HB3) that may influence SUA 
level and multiple cardiovascular and autoimmune diseases via pleiotropy. 
This chapter has been published in the Annals of the Rheumatic diseases cited as “Li, X., 
Meng, X., Spiliopoulou, A., Timofeeva, M., Wei, W.Q., Gifford, A., Shen, X., He, Y., Varley, 
T., McKeigue, P., Tzoulaki, I., McKeigue, P., Joshi, P., Denny, J.C., Campbell, H. and 
Theodoratou, E. 2018. MR-PheWAS: exploring the causal effect of SUA level on multiple 
disease outcomes by using genetic instruments in UK Biobank. Annals of the rheumatic 
diseases, pp.annrheumdis-201. doi: 10.1136/annrheumdis-2017-212534” (461).  
I was fully involved in all aspects of the research work presented in this chapter and the 
publication. In the study design, I read a vast amount of literature and found different 
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methodologies to decide the most appropriate one for this study. During the implementation 
of data analysis, I sought guidance from my supervisors to ensure each step of the analysis 
was robust and reasonable. I accomplished the data analysis with detailed reports to present 
the research findings. For publishing this work, I wrote the manuscript and revised the paper 
according to the comments given by the peer reviewers and the journal editors. Specific to 
the contribution of co-authors, Theodoratou, E. and Campbell, H. conceived the study. Meng, 
X., Wei, Q., Gifford, A., Tzoulaki, I., Denny, J.C., and Varley, T., contributed to create the 
mapping of ICD-10/9 codes to phecode. All authors critically reviewed the manuscript and 
contributed important intellectual content. 
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Objectives: We aimed to investigate the role of serum uric acid (SUA) level in a broad 
spectrum of disease outcomes using data for 120,091 individuals from UK Biobank.  
Methods: We performed a phenome-wide association study (PheWAS) to identify disease 
outcomes associated with SUA genetic risk loci. We then implemented conventional 
Mendelian randomisation (MR) analysis to investigate the causal relevance between SUA 
level and disease outcomes identified from PheWAS. We next applied MR Egger analysis to 
detect and account for potential pleiotropy, which conventional MR analysis might mistake 
for causality, and used the HEIDI (heterogeneity in dependent instruments) test to remove 
cross-phenotype associations that were likely due to genetic linkage. 
Results:  Our PheWAS identified 25 disease groups/outcomes associated with SUA genetic 
risk loci after multiple testing correction (p<8.57×10-5). Our conventional MR analysis 
implicated a causal role of SUA level in 3 disease groups: inflammatory polyarthropathies 
(OR=1.22, 95%CI: 1.11 to 1.34), hypertensive disease (OR=1.08, 95%CI: 1.03 to 1.14), 
disorders of metabolism (OR=1.07, 95% CI: 1.01 to 1.14), and 4 disease outcomes: gout 
(OR=4.88, 95%CI: 3.91 to 6.09), essential hypertension (OR=1.08, 95%CI: 1.03 to 1.14), 
myocardial infarction (OR=1.16, 95%CI: 1.03 to 1.30), coeliac disease (OR=1.41, 95%CI: 
1.05 to 1.89). After balancing pleiotropic effects in MR Egger analysis, only gout and its 
encompassing disease group of inflammatory polyarthropathies were considered to be 
causally associated with SUA level. Our analysis highlighted a locus (ATXN2/S2HB3) that 
may influence SUA level and multiple cardiovascular and autoimmune diseases via 
pleiotropy.   
Conclusions: Elevated SUA level is convincing to cause gout and inflammatory 
polyarthropathies, and might act as a marker for the wider range of diseases with which it 
associates. Our findings support further investigation on the clinical relevance of SUA level 
with cardiovascular, metabolic, autoimmune, and respiratory diseases.  
  




Uric acid (UA) is the end product of the exogenous and endogenous purine metabolisms, 
catalysed by the action of xanthine oxidase (8). Due to the evolved loss of uricase enzyme, 
humans are unable to convert UA into highly soluble compounds, leaving urate circulating in 
blood and resulting in a high basal level of serum uric acid (SUA).(34) The prevalence of 
hyperuricaemia (elevated SUA level >416 µmol/L) is in the range of 5-25% across different 
countries (91, 462, 463). A progressively rising trend of hyperuricaemia prevalence has been 
observed worldwide (463). Concerningly, hyperuricaemia is thought to inflict multiple 
clinical consequences, which is believed to be causally related to gout and suggestively 
associated with a number of prevalent health conditions, such as cardiovascular and 
metabolic diseases (236, 464, 465). 
Our recently published umbrella review presented a comprehensive overview of the breadth 
of disease outcomes related to SUA level by incorporating evidence from multiple sources 
(466). A large number of disease outcomes were reported to be associated with SUA level in 
observational studies, covering a wide range of diseases, including cardiovascular disease, 
metabolic syndrome, diabetes, cancer, and neurological disorders. However, evidence as to 
whether these associations are actually causal is not yet well developed, given that 
observational associations are susceptible to a variety of biases, confounding and/or reverse 
causality. Although results from randomized controlled trials (RCTs) have provided some 
evidence about the beneficial effects of SUA-lowering therapy on some intermediate traits or 
biomarkers (e.g. blood pressure, endothelial function, serum creatine), there remains a lack 
of RCTs focusing on the more important clinical disease endpoints (50, 316, 320). A number 
of Mendelian randomisation (MR) studies, using the genetic variants influencing SUA level 
as instruments, provide alternative evidence to distinguish causal from non-causal 
associations. However, these MR studies examined a limited set of disease outcomes and 
were not able to detect moderate effect size due to limited power (323, 326-328, 332, 337, 
349). Increasing sample size and the range of outcomes in an enlarged MR study thus offers 
the prospect of deeper and wider insight into the causal role of SUA. 
MR analysis is typically hypothesis-driven based on prior knowledge to specify the outcome 
to be examined in relation to the exposure of interest. Traditionally, only one (or a limited 
number) association between the exposure and one (or a few) pre-defined outcome(s) is 
tested in a MR study. Recently, Phenome-wide Mendelian randomisation (MR-PheWAS) 
analysis is proposed by integrating the Phenome-wide association study (PheWAS) and MR 
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method to build a hypothesis-searching approach, which aims to explore potential causal 
relationships between an exposure (using genetic instruments as proxies) and a range of 
phenome-wide disease outcomes in a high-throughput manner (467). This approach is 
effective in evaluating or replicating the associations reported in observational studies, as 
well as discovering new relationships, and generating new hypotheses on the genetic 
architecture shared by the related phenotypes. With its wealth of genotypic and phenotypic 
data collected in very large numbers, the UK Biobank study provides an excellent 
opportunity to explore the causal role of SUA level across a broad spectrum of disease 
outcomes. In this study, we performed a MR-PheWAS in UK Biobank database to discover 
disease outcomes related to genetic variations of SUA level and to investigate if any 
association is causal.  
5.3 Methods 
5.3.1 UK Biobank data 
The UK Biobank is a large-scale population-based prospective cohort, which enrolled over 
500,000 participants aged at 40-69 years. The recruited participants provided a wide range of 
self-reported baseline information. Blood samples were collected for biochemical tests and 
genotyping. Their national health records has been linked with the baseline and genotypic 
data for longitudinal follow-up. Genotypic and phenotypic data used in this study were 
obtained from UK Biobank under an approved data request application (application ID: 
10775).   
5.3.2 Genotyping and quality control  
Genotyping, quality control and genetic imputation were performed by the UK Biobank team 
prior to the interim release of genotypic data for 150,000 participants. The procedure of 
genotyping and quality control is presented in detail at 
https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_qc.pdf. We used the field variables 
made available by the UK Biobank for quality control to exclude the samples that had high 
missing or heterozygosity, outlying short runs of homozygosity, and sex mismatch (see 
online Supplementary Table 5-1). We constrained our analyses to participants who were 
self-reported British and confirmed to be European heritage based on the genetic principle 
component analysis performed by the UK Biobank. The quality control process generated a 
genotypic dataset output with 120,091 individuals included in the current analysis.  
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5.3.3 Phenotyping and mapping ICD-10/9 to phecode 
We focused on phenotypes in relation to diagnostic disease outcomes. We analysed two 
phenotypic datasets (in-patient hospital episode records and cancer registry data) in the UK 
Biobank using the PheCODE schema (see online supplementary text for phenotyping and 
mapping process).(433) The coding for clinical diagnoses in these datasets followed the 
World Health Organisation’s International Classification of Diseases (ICD) coding systems, 
but used different ICD versions (ICD-10 or ICD-9) according to the date of record. We 
included both ICD-10 and ICD-9 codes to define the case and control groups. Since cancer 
registry data overlapped with the cancer diagnosis in in-patient hospital records, we pooled 
the cancer registry data into the hospital episode data as a complement to the cancer 
diagnosis. 
5.3.4 Statistical analysis  
The statistical analysis included three main steps: first, we performed a PheWAS to identify 
disease outcomes that were associated with genetic risk loci of SUA level; second, we 
performed MR analysis by using both the inverse-variance weighted (IVW) method and MR 
Egger approach to explore causal relationship for identified PheWAS associations (468, 469); 
third, we applied HEIDI (heterogeneity in dependent instruments) test to exclude the cross-
phenotype associations caused by genetic linkage (470). 
5.3.4.1 Genetic instruments 
We selected 31 SUA-associated SNPs as genetic instruments (see online Supplementary 
Table 5-2), which were previously reported to be independently associated with SUA level 
in genome-wide association studies (GWAS) (150, 151). We obtained the SNP effect on 
SUA level from the largest GWAS performed in European population (151). The overall 
proportion of variance (adjusted R2) of SUA level explained by the selected genetic 
instruments was estimated to be close to 7.0% (151). 
5.3.4.2 Phenome-wide association analysis   
In phenome-wide analysis, we used 31 SUA-associated SNPs as genetic instruments 
individually to scan across a wide range of disease outcomes defined by the PheCODE 
system (433). With the PheWAS algorithm (471), a series of PheWAS association tests were 
performed: (i) the case group was generated by including patients with the tested phecode; (ii) 
participants were assigned to the control group based on the absence of both the tested 
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phecode and related phecodes (patients who had the parent, child or sibling phecodes of the 
tested phecode were excluded from the control group) (471); (iii) to ensure statistical power, 
analysis was only performed for phecode with no less than 200 cases. This minimum number 
of cases was suggested based on a simulation of power estimates for PheWAS analysis (472). 
We used logistic regression to test the associations between 31 individual genetic 
instruments (assuming an additive genetic model) and each phecode (number of cases ≥ 200) 
after adjusting for multiple covariates, including sex, BMI, age, assessment center and the 
principle components. Considering many phecodes were not independent, we used the false 
discovery rate (FDR) method developed by Benjamini et al to account for multiple testing 
(473). 
5.3.4.3 MR IVW, MR Egger and HEIDI test 
We then explored the identified PheWAS associations in three possible scenarios (see online 
Supplementary Figure 5-1): (i) causality: the observed association was causal  (through the 
SUA pathway); (ii) pleiotropy: the observed association was due to pleiotropic effect of one 
causal variant, (i.e. linked to SUA level and the particular disease outcome through 
pleiotropy); (iii) genetic linkage: the observed association was caused by the LD between 
two distinct causal variants, with one affecting SUA level and the other affecting the disease 
outcome.  
MR IVW To explore if there was any causal effect on identified disease outcomes, we 
performed the conventional MR analysis by pooling the individual effect of each SNP using 
the IVW method to estimate the overall causal effect (see online supplementary text) (474). 
MR Egger We then performed MR Egger to attempt to correct for any potential pleiotropic 
effect in the causal estimates. This approach is applied to balance the pleiotropic effects 
derived from multiple genetic instruments (see online supplementary text) (469).   
HEIDI test We calculated HEIDI statistics for the SUA genetic loci that were associated 
with more than one disease outcome. This test was to examine if the cross-phenotype 
association was due to genetic linkage (see online supplementary text) (470).  
5.3.5 Sex stratification analysis  
To account for any sex difference, we performed PheWAS and MR analyses in men and 
women separately. The sex-specific effects of SNPs on SUA level (see online 
Supplementary Table 5-2) were taken from the summary-level GWAS data provided by 
Köttgen et al (151). 




A total of 120,091 UK Biobank participants were included in the analysis, consisting of 
56,845 men and 63,246 women with a mean age of 64.86 years in 2016 (standard deviation 
[SD] of 7.95) (see online Supplementary Table 5-3). Within phenotypic datasets, we 
identified 684,324 hospital episodes and 23,174 cancer registration records, which included 
7,990 unique ICD-10 codes and 1,998 unique ICD-9 codes. After mapping diagnostic ICD-
10/9 codes to phecodes, the phenotypic data consisted of 1807 distinct phecodes. After 
filtering out disease outcomes with low prevalence (number of cases <200), 568 phecodes 
(median number of cases = 694 [range: 200-39,142]) were included in PheWAS analysis.   
These 568 phecodes were classified into 17 broadly related disease categories (Table 5-1). 
We noted that the distribution of phenotypes examined was skewed across the different 
disease categories (see online Supplementary Figure 5-2), in which a large number of 
disease phenotypes was included in digestive, circulatory, endocrine and metabolic systems, 
but some disease categories, for example congenital anomalies, were not well represented in 
the study population.  




Number of cases 
Min. Median Mean Max. 
Circulatory system 61 221 665 2,937 39,142 
Congenital anomalies 6 206 265 302 522 
Dermatological diseases 24 201 706 2,736 32,738 
Diseases in sense organs 34 201 425 1,216 11,306 
Digestive diseases 73 201 949 2,176 23,129 
Neoplasms 59 203 763 1,916 30,101 
Infectious diseases 16 205 787 975 3,192 
Endocrine and metabolic diseases 25 229 492 2,304 13,592 
Hematopoietic diseases 10 205 1,187 1,600 3,669 
Neurological diseases 21 229 452 1,282 11,828 
Respiratory diseases 38 219 712 1,713 19,238 
Mental disorders 18 205 673 1,926 8,942 
Genitourinary diseases 77 200 666 1,606 29,859 
Pregnancy complications 11 227 360 707 2,531 
Musculoskeletal diseases 44 263 1,076 2,482 21,822 
Clinical symptoms 14 267 1,237 2,570 12,287 
Injuries and poisonings 37 211 589 911 4,842 




5.4.1 Phenome-wide association analysis  
The PheWAS analysis performed 17,608 case-control tests, leading to an adjusted 
significance threshold of p<8.57×10-5 corresponding to a FDR of q<0.05 to account for the 
multiple testing. A total of 27 pairs of genotype-phenotype associations passed the 
significance threshold of FDR correction (p<8.57×10-5) in the overall PheWAS analysis with 
adjustment for covariates (Table 5-2). Results of PheWAS without adjustment for BMI are 
shown in online Supplementary Table 5-4. The sex-stratified PheWAS analysis identified 
10 pairs of genotype-phenotype association in men and 10 pairs of genotype-phenotype 
association in women (see online Supplementary Table 5-5). When compared to the overall 
PheWAS analysis, 5 new pairs of association were identified from the sex-stratified 
PheWAS analysis (see online Supplementary Table 5-5). 
These identified genotype-phenotype associations were distributed across 15 SUA genetic 
loci, of which 5 loci were associated with more than one disease outcome: rs653178 in the 
ATXN2/SH2B3 locus (number of disease outcomes: 𝑛𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 = 10), rs1165151 in the 
SLC17A3 locus (𝑛𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 =3), rs1260326 in the GCKR locus (𝑛𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 =3), rs2231142 
in the ABCG2 locus (𝑛𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 =4) and rs2079742 in the BCAS3 locus (𝑛𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 =2). Of 
note, six disease outcomes shared genetic associations with SUA level at more than one 
locus: gout (number of loci: 𝑛𝑙𝑜𝑐𝑖 =3), inflammatory polyarthropathies (𝑛𝑙𝑜𝑐𝑖 =2), disorders 
of iron metabolism (𝑛𝑙𝑜𝑐𝑖 =2), coeliac disease (𝑛𝑙𝑜𝑐𝑖 =2), hypertensive disease (𝑛𝑙𝑜𝑐𝑖 =2) 
and essential hypertension (𝑛𝑙𝑜𝑐𝑖 =2).  
In summary, the PheWAS analyses identified 25 unique disease groups/outcomes 
(corresponding to 25 unique phecodes) that shared genetic risk loci with SUA level, which 
included 9 disease groups (inflammatory polyarthropathies, hypertensive disease, circulatory 
disease, disorders of metabolism, disorders of thyroid, other diseases of respiratory system, 
disorder of skin and subcutaneous tissue, benign neoplasm of digestive system, and 
complications of labor and delivery) and 16 specific disease outcomes (gout, essential 
hypertension, angina pectoris, myocardial infraction, coronary atherosclerosis, ischaemic 
heart disease, atrial fibrillation and flutter, varicose veins of lower extremity, 
hypercholesterolaemia, disorders of iron metabolism, coeliac disease, hypothyroidism, 
gastritis and duodenitis, poisoning by antibiotics, cataract, and nasal polyps). The mappings 
of ICD codes to these 25 phecodes and their hierarchical relationships are shown in online 
Supplementary Table 5-6. 
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5.4.2 MR IVW, MR Egger and HEIDI test  
We then performed MR analysis using the IVW method to explore if there was any causal 
link between SUA level and the 25 disease groups/outcomes identified from PheWAS 
analysis. The MR IVW analysis suggested a potential causal link for 7 out of 25 disease 
groups/outcomes. The corresponding effect estimate on each disease outcome is presented in 
Table 5-3. It was indicated that genetically determined higher SUA level was potentially 
causally linked with an increased risk of 3 disease groups, including inflammatory 
polyarthropathies (OR=1.22, 95% CI: 1.11-1.34, p=1.10×10-4), hypertensive disease 
(OR=1.08, 95% CI: 1.03-1.14, p=0.004), disorders of metabolism (OR=1.07, 95% CI:1.01-
1.14, p=0.03), and of 4 specific disease outcomes including gout (OR=4.88, 95% CI: 3.91-
6.09, p=3.55e-15), essential hypertension  (OR=1.08, 95 %CI: 1.03-1.14, p=0.005), 
myocardial infarction (OR=1.16, 95% CI: 1.03-1.30, p=0.015), coeliac disease (OR=1.41, 95% 
CI:1.05-1.89, p=0.02).  
To explore and correct for any possible pleiotropic effect of multiple instruments, we then 
conducted the MR Egger analysis (Table 5-3). After balancing out the potential pleiotropic 
effects, the putative causal link of SUA level with gout (OR=4.58, 95%CI: 2.72 to 7.72, 
𝑃𝑒𝑓𝑓𝑒𝑐𝑡 = 1.76×10
-6) and its umbrella disease group, inflammatory polyarthropathies 
(OR=1.15, 95%CI: 1.01 to 1.31, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡=0.03) remained statistically significant and there 
was no indication of unbalanced pleiotropy ( 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =0.73 and 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =0.23, 
respectively). The putative causal effect of SUA level on the other 5 disease 
groups/outcomes was not statistically significant in the MR Egger model. The causal effects 
of each individual SNPs on these 7 disease groups/outcomes are shown in online 
Supplementary Figures 5-3, 5-4, 5-5, 5-6, 5-7, 5-8, and 5-9. Unbalanced pleiotropy was 
observed for essential hypertension (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =0.001) and its umbrella disease group, 
hypertensive disease (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =0.001). For myocardial infarction, coeliac disease and 
disorders of metabolism, the putative causal effect was not statistically significant in the MR 
Egger model (𝑃𝑒𝑓𝑓𝑒𝑐𝑡=0.75, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡  =0.41 and 𝑃𝑒𝑓𝑓𝑒𝑐𝑡  =0.80, respectively), although there 
was no evidence of unbalanced pleiotropy ( 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =0.13,  𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦  =0.75 and 
𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦=0.18, respectively). The results of the sex-stratified MR IVW are presented in 
online Supplementary Table 5-7. 
Finally, to distinguish the genotype-phenotype association of pleiotropy from LD, the HEIDI 
test was performed for the 5 genetic loci (rs653178 at ATXN2/SH2B3, rs1165151 at 
SLC17A3, rs1260326 at GCKR, rs2231142 at ABCG2 and rs2079742 at BCAS3) that were 
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associated with multiple disease outcomes in the PheWAS analysis (see online 
Supplementary Figures 5-10, 5-11, 5-12, 5-13, and 5-14). Based on the HEIDI test, we 
identified 14 disease outcomes that were associated with the SUA genetic risk loci due to 
pleiotropy (with 𝑃𝐻𝐸𝐼𝐷𝐼 >0.05). The strongest pleiotropic locus was the ATXN2/SH2B3, 
where three SNPs (rs653178, rs4766578, and rs3184504) in near-complete LD (r2=0.99) 
were tagged as the lead SNPs associated with 10 disease groups/outcomes as a cluster of 
cardiovascular diseases and autoimmune disorders (see online Supplementary Figure 5-10). 
Other potential pleiotropic effects included the associations of the BCAS3 locus (rs2079742) 
with essential hypertension (𝑃𝐻𝐸𝐼𝐷𝐼  =0.10) and hypertensive disease (𝑃𝐻𝐸𝐼𝐷𝐼  =0.09) (see 
online Supplementary Figure 5-11), the associations of the ABCG2 locus (rs2231142) with 
varicose veins of lower extremity (𝑃𝐻𝐸𝐼𝐷𝐼 =0.32) (see online Supplementary Figure 5-12), 
and the association of  the SLC17A3 locus (rs1165151) with poisoning by antibiotics 
(𝑃𝐻𝐸𝐼𝐷𝐼 =0.26) (see online Supplementary Figure 5-13).  
Our analysis rejected the null hypothesis of a pleiotropic model for the shared genetic 
association between SUA level and disorders of iron metabolism at the SLC17A3 locus 
(rs1165151) (𝑃𝐻𝐸𝐼𝐷𝐼 =5.54×10
-28); we identified a different causal variant (rs17342717 in 
SLC17A1) that was in LD with the SNP rs1165151 (r2=0.24) and strongly associated with the 
disorders of iron metabolism (P=1.69×10-129) (see online Supplementary Figure 5-13). 
Similarly, for the associations between the SLC17A3 locus (rs1165151) and coeliac disease 
(𝑃𝐻𝐸𝐼𝐷𝐼 =6.51×10
-16) (see online Supplementary Figure 5-13), the GCKR locus (rs1260326) 
and hypercholesterolaemia (𝑃𝐻𝐸𝐼𝐷𝐼  =3.27×10
-11) (see online Supplementary Figure 5-14), 
the pattern of shared regional genetic association was more consistent with a genetic linkage 
model, and the SNP with the smallest p-value was tagged as an index of the distinct causal 
variant affecting the examined disease outcome.  
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Table 5 - 2: Genotype-phenotype associations identified from PheWAS after correcting multiple testing by FDR (p<8.57×10-5). 
Phecode Description SNP_risk allele† allele_freq n_total n_cases OR (95%CI) P* 
274.1 Gout rs2231142_T 0.11 119,555 1,003 1.89 (1.69, 2.12) 5.41e-28 
275.1 Disorders of iron metabolism rs1165151_G 0.45 119,063 205 3.56 (2.78, 4.56) 1.41e-23 
244.4 Hypothyroidism rs653178_C 0.48 118,821 4,146 1.21 (1.16, 1.27) 3.90e-17 
246 Disorders of thyroid rs653178_C 0.48 119,601 4,926 1.18 (1.14, 1.23) 8.82e-16 
274.1 Gout rs12498742_A 0.23 118,960 1,002 1.54 (1.37, 1.74) 7.94e-13 
275.1 Disorders of iron metabolism rs742132_A 0.29 119,271 205 2.80 (2.10, 3.74) 3.13e-12 
401 Hypertensive disease rs653178_C 0.48 119,762 23,634 1.06 (1.04, 1.09) 1.68e-08 
401.1 Essential hypertension rs653178_C 0.48 119,688 23,560 1.06 (1.04, 1.09) 2.00e-08 
411.4 Coronary atherosclerosis rs653178_C 0.48 119,460 9,526 1.09 (1.05, 1.12) 1.27e-07 
411 Ischaemic heart disease rs653178_C 0.48 119,401 9,467 1.09 (1.05, 1.12) 1.33e-07 
211 Benign neoplasm of digestive system rs11264341_C 0.43 117,030 1,504 0.83 (0.77, 0.89) 2.41e-07 
274.1 Gout rs1260326_T 0.39 119,555 1,003 1.26 (1.15, 1.38) 3.86e-07 
459.9 Circulatory disease rs653178_C 0.48 119,677 39,142 1.05 (1.03, 1.06) 2.24e-06 
411.2 Myocardial infarction rs653178_C 0.48 113,559 3,625 1.12 (1.07, 1.18) 2.80e-06 
557.1 Coeliac disease rs1165151_G 0.45 99,783 549 1.33 (1.18, 1.51) 4.30e-06 
557.1 Coeliac disease rs653178_C 0.48 99,965 550 1.31 (1.16, 1.48) 9.28e-06 
427.2 Atrial fibrillation and flutter rs6598541_A 0.35 113,261 4,333 1.11 (1.06, 1.16) 9.92e-06 
960 Poisoning by antibiotics rs1165151_G 0.45 112,343 1,027 0.82 (0.75, 0.90) 1.22e-05 
535 Gastritis and duodenitis rs478607_G 0.15 115,386 5,233 1.12 (1.07, 1.19) 1.34e-05 
411.3 Angina pectoris rs653178_C 0.48 114,967 5,033 1.09 (1.05, 1.14) 3.01e-05 
669 Complications of labour and delivery  rs729761_G 0.28 113,240 2,376 1.17 (1.09, 1.26) 3.78e-05 
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Phecode Description SNP_risk allele† allele_freq n_total n_cases OR (95%CI) P* 
272.11 Hypercholesterolaemia rs1260326_T 0.39 118,921 10,201 1.07 (1.03, 1.10) 3.82e-05 
366 Cataract rs6770152_G 0.43 116,218 4,567 1.09 (1.05, 1.14) 4.14e-05 
471 Nasal polyps rs10821905_A 0.17 112,745 983 1.26 (1.13, 1.40) 4.61e-05 
454.1 Varicose veins of lower extremity rs2231142_T 0.11 111,390 3,204 0.84 (0.78, 0.92) 5.79e-05 
401 Hypertensive disease rs2079742_T 0.13 115,659 22,832 1.07 (1.03, 1.10) 7.00e-05 
401.1 Essential hypertension rs2079742_T 0.13 115,588 22,761 1.07 (1.03, 1.10) 7.02e-05 
*Significance threshold of p<8.57×10-5corresponds to a FDR of q<0.05 after correcting the multiple testing.  
† Effect allele was harmonised to the SUA-raising allele defined by Köttgen et al.(151) 
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Table 5 - 3: PheWAS associations assessed by conventional MR IVW and MR Egger analysis. 
Disease outcomes MR IVW MR Egger 
 OR (95%CI) P effect Power* OR (95%CI) P effect P pleiotropy Power* 
Gout  4.88 (3.91, 6.09) 3.55e-15 1.00 4.58 (2.72, 7.72) 1.76e-06 0.73 1.00 
Inflammatory polyarthropathies‡ 1.22 (1.11, 1.34) 1.10e-04 0.99 1.15 (1.01, 1.31) 0.03 0.23 0.83 
Essential hypertension 1.08 (1.03, 1.14) 5.07e-03 0.82 0.93 (0.83, 1.05) 0.23 1.13e-03 0.73 
Hypertensive disease 1.08 (1.03, 1.14) 4.23e-03 0.82 0.93 (0.83, 1.05) 0.24 1.19e-03 0.73 
Myocardial infarction 1.16 (1.03, 1.30) 0.02 0.70 1.03 (0.84, 1.27) 0.75 0.13 0.08 
Coeliac disease 1.41 (1.05, 1.89) 0.02 0.72 1.31 (0.68, 2.54) 0.41 0.75 0.48 
Disorders of metabolism‡ 1.07 (1.01, 1.14) 0.03 0.52 1.01 (0.91, 1.14) 0.80 0.18 0.06 
Coronary atherosclerosis 1.07 (0.99, 1.15) 0.08 0.41 0.99 (0.85, 1.17) 0.95 0.20 0.06 
Ischaemic heart disease 1.07 (0.99, 1.15) 0.09 0.41 0.99 (0.85, 1.16) 0.91 0.20 0.06 
Angina pectoris 1.04 (0.94, 1.15) 0.41 0.11 0.95 (0.80, 1.12) 0.51 0.11 0.15 
Atrial fibrillation and flutter 1.01 (0.91, 1.12) 0.87 0.05 0.90 (0.75, 1.08) 0.23 0.07 0.41 
Circulatory disease 1.04 (1.00, 1.09) 0.08 0.40 0.97 (0.89, 1.07) 0.57 0.05 0.26 
Varicose veins of lower extremity 0.86 (0.72, 1.02) 0.09 0.55 0.86 (0.67, 1.10) 0.24 0.97 0.55 
Disorders of iron metabolism 1.19 (0.74, 1.90) 0.45 0.11 0.79 (0.15, 4.07) 0.77 0.47 0.12 
Hypercholesterolaemia 1.14 (0.96, 1.36) 0.12 0.94 1.18 (0.88, 1.58) 0.27 0.78 0.99 
Hypothyroidism 1.10 (0.99, 1.23) 0.07 0.39 0.99 (0.75, 1.32) 0.97 0.30 0.05 
Disorders of thyroid 1.08 (0.98, 1.20) 0.10 0.31 1.01 (0.79, 1.29) 0.94 0.41 0.05 
Benign neoplasm of digestive system 0.93 (0.78, 1.10) 0.36 0.11 0.90 (0.64, 1.26) 0.52 0.79 0.18 
Gastritis and duodenitis 0.97 (0.88, 1.07) 0.53 0.09 0.95 (0.80, 1.13) 0.55 0.70 0.16 
Nasal polyps 1.08 (0.88, 1.34) 0.45 0.10 1.09 (0.73, 1.60) 0.67 0.98 0.12 
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Disease outcomes MR IVW MR Egger 
 OR (95%CI) P effect Power* OR (95%CI) P effect P pleiotropy Power* 
Cataract 0.99 (0.90, 1.09) 0.85 0.05 0.91 (0.75, 1.10) 0.34 0.23 0.36 
Poisoning by antibiotics 0.85 (0.70, 1.04) 0.14 0.25 1.00 (0.68, 1.48) 1.00 0.28 0.05 
Complications of labour and delivery‡ 0.89 (0.76, 1.03) 0.12 0.30 0.78 (0.59, 1.02) 0.08 0.20 0.83 
Other diseases of respiratory system‡ 1.11 (0.94, 1.31) 0.19 0.22 1.16 (0.92, 1.46) 0.22 0.64 0.42 
Disorder of skin and subcutaneous tissue‡   0.99 (0.93, 1.06) 0.77 0.06 0.98 (0.89, 1.09) 0.75 0.85 0.09 
‡ Disease outcomes identified from sex-stratified PheWAS analysis. 
*The statistical power of MR analyses was calculated by using the non-centrality parameter (NCP) based approach (254); the overall proportion of variance 
(adjusted R2) of SUA level explained by the genetic instruments was estimated to be 7.0%.(151)  
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5.5 Discussion  
In PheWAS analysis by using SUA-associated SNPs as genetic instruments, we identified 32 
pairs of genotype-phenotype associations, which covered a wide range of phenotypic 
categories including endocrine/metabolic diseases, cardiovascular diseases, and autoimmune 
disorders. Our PheWAS analysis replicated 14 pairs of previously known genotype-
phenotype (or closely related phenotypic groups) associations reported in the GWAS Catalog 
(see online Supplementary Table 5-2 and Table 5-2). For example, rs653178 
(ATXN2/SH2B3 locus) was previously reported to be associated with diastolic blood 
pressure,(475) myocardial infarction (476), peripheral artery disease (477), coeliac disease 
(478), and serum thyroid peroxidase antibody levels (479). In our PheWAS, this SNP was 
statistically significantly associated with the same phenotypes (i.e. coeliac disease, 
myocardial infarction) or similar phenotypic groups (i.e. hypertension, circulatory and heart 
diseases, hypothyroidism and other disorders of thyroid). Our study also replicated the 
findings of the largest GWAS performed by Köttgen and the findings of the most recent 
candidate gene-based association study conducted in UK Biobank, which indicated that 2 
SUA-related SNPs (rs12498742 at the SLC2A9 locus and rs2231142 at the ABCG2 locus) are 
statistically significantly associated with gout at GWAS p-value threshold (p<5.0×10-8) (151, 
480). We also identified 18 novel genotype-phenotype associations (at the PheWAS 
threshold of p<8.57×10-5), of which the association between rs1165151 (SLC17A3) and 
disorders of iron metabolism had the smallest p-value (p=1.23×10-19).   
We performed conventional MR analysis, using the IVW method, to investigate whether 
there was a potentially causal link between SUA level and the 25 unique disease 
groups/outcomes identified from PheWAS. The results of MR IVW analysis suggested a 
potential causal effect of SUA level on 3 disease groups including inflammatory 
polyarthropathies, hypertensive disease, disorders of metabolism and 4 specific individual 
disease outcomes including gout, essential hypertension, myocardial infarction, coeliac 
disease. When adopting the advanced MR Egger analysis to account for potential pleiotropic 
effects, it is indicated that, except for gout and its umbrella disease group, inflammatory 
polyarthropathies, all the other putative causal associations suggested by MR IVW analysis 
were probably inflated by the presence of pleiotropy. However, although the MR Egger is 
more robust in dealing with pleiotropy, this method is not infallible (481). Intuitively, the 
genetic instrument with larger effect on SUA level is expected to have a larger effect on 
disease outcome and would exert stronger influence in the MR Egger regression model. With 
in-depth examination of the individual SNP effects on SUA level against the SNP effects on 
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disease outcomes (see online Supplementary Figures 5-5, 5-6, 5-7, and 5-8), we found that 
the outlying variant (rs12498742 at SLC2A9) that had the strongest association with SUA 
level showed a negative (null) effect on essential hypertension and hypertensive disease, 
which reversed the sign of the overall putative causal effect and led to a rejection of the 
intercept test. Given the influence of the outlying variant, the unbalanced pleiotropy and 
relatively small statistical power (power=0.73), we would interpret that unbalanced 
pleiotropy between SUA level and hypertension is an issue for their causal inference in MR 
Egger analysis. 
Previous observational studies have reported a sex difference in the association between 
SUA level and the development of cardiovascular diseases (235, 482-485), but few studies 
have addressed the sex difference by using a MR approach to remove the influence of 
environmental confounders. Our study identified a few more cardiovascular diseases (e.g. 
coronary atherosclerosis, ischaemic heart disease) that were potentially causally linked with 
the genetic variation of SUA level in women, but not in men. These MR findings were 
concordant with results from observational studies, which indicated that the relationship 
between SUA level and cardiovascular disease was particularly strong in women, especially 
for heart disease (235, 486, 487). Although these putative causal associations specific to 
females were not verified by MR Egger, this may be due to the decreased statistical power of 
MR Egger (and a higher risk of type 2 error). The biological mechanism that could lead the 
association of SUA level with cardiovascular disease to be more pronounced in women than 
in men remains a matter for further investigation.  
To gain a further exploratory sense of pleiotropy in PheWAS findings, we applied the HEIDI 
test to exclude the PheWAS associations that were probably caused by genetic linkage. The 
HEIDI test indicated that several PheWAS associations were likely driven by LD. For 
instance, the outstanding PheWAS association between disorders of iron metabolism and the 
SNP rs1165151 at the SLC17A3 locus was not consistent with a pleiotropic model and 
further examination found the SUA-associated SNP rs1165151 was located in linkage 
disequilibrium (LD) (r2=0.24) with the rs17342717 variant at the SLC17A1 locus, which was 
strongly associated with disorders of iron metabolism (p=1.69×10-129). This SNP 
(rs17342717) is also associated with red blood cell traits and serum iron levels in previous 
GWAS (488, 489). We suggest that the implications of these findings have wider relevance 
for PheWAS studies. Typically, associations of a single SNP with multiple phenotypes were 
claimed to be due to pleiotropy in previous PheWAS (490, 491). However, as PheWAS 
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focused on single variant without considering the correlations between SNPs, we would 
suggest that an additional examination of LD is necessary when we identify pleiotropic links.  
In contrast, the pattern of shared regional genetic associations of SUA level with multiple 
disease outcomes at ATXN2/S2HB3 locus was more consistent with a pleiotropic model, 
where we interpreted this locus influenced a cluster of cardiovascular diseases and 
autoimmune disorders. However within the ATXN2/S2HB3 locus there are three leading 
SNPs (rs653178, rs4766578, and rs3184504) in high LD (r2 =0.99). In this case, the HEIDI 
test was unable to provide an indication of whether the observed associations are due to 
pleiotropy or genetic linkage, as it was difficult to infer the causal variant. Although SNP 
rs653178 was reported as the lead variant influencing SUA level at this locus in GWAS, the 
potential biological mechanism underlying this effect is unclear (151). Furthermore, 
although, an effect of rs653178 on the regulation of blood pressure, cardiovascular diseases 
and coeliac disease has been suggested by a few GWAS (475-478), a clear biological 
explanation for this role could not be demonstrated. Evidence from the functional follow-up 
of the S2HB3 gene indicated that rs3184504 may be the causal variant, as the S2HB3 gene 
encodes one of the S2HB family proteins, which have a diverse physiological roles on 
haematopoiesis, immune response and signalling, and variation in rs3184504 may introduce 
a new phosphorylation site affecting the function of the S2HB protein (492, 493). We 
believe that further uncovering of the biological functions of this pleiotropic locus (e.g. gene 
function follow-up, expression quantitative trait loci [eQTL] analysis) might be helpful to 
understand the complex underlying relationship of SUA level with cardiovascular and 
autoimmune diseases.  
To judge the nature of PheWAS associations more comprehensively, it is important to 
consider different lines of evidence, including underlying biological plausibility. Therefore, 
we would like to highlight a few disease outcomes beyond joints and cardiovascular events. 
The sex-stratified MR IVW analysis identified that unspecified diseases in respiratory 
system were potentially causally linked with SUA level in women (with the MR Egger 
analysis showing a consistent causal effect). This finding is consistent with recently 
published experimental studies, which demonstrated that human airway epithelial cells and 
lung tissue expressed a functional UA production/secretion system and UA was crucial in 
mediating the development of allergic airway diseases and regulating the antigen-specific T-
cell proliferation (494-497). It was also speculated that fine, inhaled particulate matter (PM) 
can induce increased UA production in the human airway which may contribute to allergic 
sensitisation and asthma pathogenesis (498). Evidence from epidemiological studies in 
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relation to the association between SUA level and respiratory diseases has not been well 
explored (499, 500). Our findings support further investigation of the clinical relevance of 
SUA level in lung health and respiratory diseases.     
Key strengths of our study included its potential to make novel discoveries in genotype-
phenotype associations and to identify novel cross-phenotype associations, possibly 
reflecting common aetiology or causal mechanisms. Unlike the genome, for which genetic 
structure can be measured by reliable biological techniques, the definition of the phenome 
varies across studies. Current published PheWAS have been limited primarily to billing ICD
‑9‑CM to phecode system, and the method for aggregating ICD-9-CM codes into phecodes 
has proven to be valuable in previous PheWAS studies (433, 459). Our work broadened the 
utility of the PheCODE system and illustrated the process of adopting the system to the 
updated ICD-10 version to define the phenome framework. Our mapping process revealed 
some potential shortcomings of the current PheCODE system (e.g. the ICD-10 code 
involving the personal or family history were missing elements in the PheCODE system), 
which should be improved as a future undertaking. Recent methodological applications (e.g. 
tree-structured phenotypic model [TreeWAS]) can be applied for future PheWAS analyses 
(501). As we were preparing the manuscript for submission, a web-resource within UK 
Biobank, the GeneATLAS, was released in the bioRxiv (prior to peer review) (502). We 
checked our PheWAS findings in this database, but only 10 of the 31 SUA related SNPs 
were included in their database (and associations with some disease outcomes were 
replicated for these SNPs) (502). We focused on the causal relationships between SUA level 
and binary disease outcomes in MR analyses, and these findings were complementary to MR 
estimates of urate archived in the MR-Base database (http://eve.mrbase.org/), which mainly 
focused on quantitative traits. 
On the other hand, our analysis was limited to phenotypes with no less than 200 cases, 
therefore diseases with relatively low prevalence were not analysed. As the UK biobank 
grows we expect to perform PheWAS and MR analysis for more phenotypes, with the 
priority given for the ones of which the relationships with SUA level are much controversial 
such as dementia (503, 504). Furthermore for some analysed phenotypes, our PheWAS 
analysis may still have low power to detect small effect size. The use of the interim release 
of UK Biobank data and focusing on a very homogenous population (self-reported British 
confirmed by PCAs) limited the power of this study. Additionally, we did not analyse the 
self-reported UK Biobank data to avoid information bias, but this may impact the 
comprehensiveness of PheWAS and reduce the precision of MR estimates. To remedy this 
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limitation, we performed a sensitivity analysis for gout by comparing the MR estimates for 
hospital-diagnosed gout, self-reported gout and hospital-diagnosed/self-reported gout (see 
online Supplementary Table 5-8). The MR estimates are consistently statistically 
significant in any of the cases but with differences in their effect sizes. These differences 
might be due to the fact that gout cases ascertained from hospital discharge coding may be 
unrepresentative of gout, given hospitalised gout is more likely to be complicated by co-
morbidities, as reported by Cadzow et al (480). While making efforts to dissect the PheWAS 
associations with different models, given the complexity of human genetic structure, these 
models are not mutually exclusive and each model has its own methodological limitations, 
thus strong conclusions are not always possible. Therefore, the realistic goal for the present 
study was to assess different lines of evidence (i.e. causality, pleiotropy or genetic linkage) 
in order to characterize the identified PheWAS associations in relation to SUA level. It 
would be beneficial to assess whether measured SUA level, rather than its genetic proxy, are 
also associated with the observed disease outcomes, but data on the SUA biomarker are not 
yet available in UK Biobank.  
Overall, this PheWAS analysis demonstrated that SUA level shares genetic risk loci with 
multiple disease outcomes, particularly cardiovascular/metabolic diseases and autoimmune 
disorders. These findings provide the rationale for further investigation of whether these 
associations are causal. Our study indicated a putative causal effect of SUA level on 3 
disease groups (inflammatory polyarthropathies, hypertensive disease, and disorders of 
metabolism) and 4 specific disease outcomes (gout, essential hypertension, coeliac disease, 
and myocardial infarction); when balancing out the pleiotropy, a robust conclusion about 
causality was made for gout and its encompassing disease group, inflammatory 
polyarthropathies. Unbalanced pleiotropy was identified as an issue for the causal inference 
on the association between SUA level and hypertension. Other potential causal relevance of 
SUA level with respiratory diseases and ocular abnormalities are also worthy of further 
investigation. When interpreting the PheWAS associations from a view of pleiotropy, our 
analysis highlighted a key pleiotropic locus that influenced SUA level and multiple 
cardiovascular and autoimmune diseases. A further functional annotation of this locus might 
be helpful to understand the biological pathways that contribute to the phenotypic 
associations between SUA level and cardiovascular diseases (including hypertension).  
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5.6 Supplementary information 
Online Supplementary text   
Phenotyping and mapping ICD-10/9 to phecode 
ICD-9/10 codes were organised in a hierarchical tree-like structure. The individual ICD-9/10 
codes could not be directly used for PheWAS analysis, because they were not designed for 
representing distinct disease phenotypes. To aggregate the ICD codes, the PheCODE schema 
has been successfully adopted in a number of PheWAS to combine one or more individual 
ICD codes into distinct phenotype groups (433, 459). However, since the current version of 
the PheCODE was developed based on ICD-9-Clinical Modification (CM), the phencode 
algorithm was not directly applicable to the ICD-10 coding system in the UK Biobank. To 
develop an aggregation method for PheWAS analysis in UK Biobank, we collaborated with 
the Electronic Medical Records and Genomics (eMERGE) group of Vanderbilt University 
Medical Center and mapped ICD-10 codes to phecodes in both direct and indirect ways. We 
mapped the ICD-10 codes to phecodes directly if their descriptions matched each other 
regardless of capitalisation. Otherwise, we used the unified medical language system (UMLS) 
to map the ICD-10 code to ICD-9-CM (or map the ICD-10 code to systematised 
nomenclature of medicine clinical terms [SNOMED CT] code first and then to ICD-9-CM) 
and then used the previous mapping of ICD-9-CM to phecode to finally link the ICD-10 to 
phecode. The ICD-9 codes in UK Biobank were directly mapped to the phecodes through the 
first fourth or full (five) digital codes or through the descriptions regardless of capitalisation. 
MR IVW, MR Egger and HEIDI test  
MR IVW For each independent genetic instrument 𝑖, the causal effect of SUA level on the 
disease outcome (denoted as 𝑏𝑥𝑦(𝑖) ) was estimated by the ratio method, in which the 
coefficient from the regression of outcome on the genetic variant (using individual-level data 
from the UK Biobank and denoted as 𝑏𝑧𝑦(𝑖) ) was divided by the coefficient from the 
regression of SUA level on the genetic variant (using the summary-level GWAS data made 
available by Köttgen et al and denoted as 𝑏𝑧𝑥(𝑖)) (151). The overall causal effect of SUA 
level on the outcome mediated by all 31 genetic instruments was estimated by pooling the 
individual effect estimates of each SNP using the IVW method (474).  
MR Egger Briefly, instead of assuming that the genetic instruments are only associated with 
SUA level (no pleiotropy criterion of MR), the MR Egger uses a weighted linear regression 
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to regress the effect estimates of SNP-outcome associations against the effect estimates of 
SNP-SUA associations with the intercept unconstrained. The unconstrained intercept 
represents the average pleiotropic effects across the genetic variants (with a zero intercept 
indicating that there are no direct pleiotropic effects or the pleiotropic effects are balanced 
among the multiple genetic instruments). The slope coefficient from the MR Egger 
regression represents the overall estimate of the causal effect after accounting for the 
pleiotropic effects of multiple genetic instruments (469).  
HEIDI test The HEIDI test was firstly proposed by Zhu et al (470), but the principle of this 
test can be broadly applied to any pair of traits. The rationale and mathematical theories of 
this metric are explained elsewhere in detail (470). The HEIDI method assumes only one 
causal variant affected both the SUA level and disease outcome (via either vertical 
pleiotropy [including causality] or horizontal pleiotropy) within a genetic region. If we 
denote the 𝑏𝑧𝑥 as the effect estimate of a genetic variant on SUA level, and 𝑏𝑧𝑦 as the effect 
estimate of a genetic variant on disease outcome, the effect estimate of SUA level on disease 





If we describe the casual variant as 𝑆𝑁𝑃0, under the Hardy-Weinberg equilibrium, for any 
𝑆𝑁𝑃𝑖  in LD with the causal variant, the effect estimate 𝑏𝑥𝑦(𝑖) calculated by the ratio method 











where 𝑟0𝑖 is the LD correlation between the casual variant SNP (0) and SNP (𝑖), and ℎ0/𝑖 is 
determined by the allele frequency (ℎ = 2𝑝(1 − 𝑝)). Thus testing linkage against pleiotropy 
is equivalent to testing if there were any heterogeneity between 𝑏𝑥𝑦(0)  and 𝑏𝑥𝑦(𝑖) . If we 
defined  
𝑑𝑖 = 𝑏𝑥𝑦(𝑖) − 𝑏𝑥𝑦(0) 
then it is equivalent to testing if 𝑑𝑖 = 0.  
With the matrix of any pair of SNPs(𝑖, 𝑗) , the covariance could be calculated by 













2 𝑧𝑧𝑥(𝑗)  
2 ) 
𝑐𝑜𝑣(𝑑𝑖,𝑑𝑗) = 𝑐𝑜𝑣(𝑏𝑥𝑦(𝑖), 𝑏𝑥𝑦(𝑗)) − 𝑐𝑜𝑣(𝑏𝑥𝑦(𝑖), 𝑏𝑥𝑦(0)) − 𝑐𝑜𝑣(𝑏𝑥𝑦(𝑗), 𝑏𝑥𝑦(0))
+ 𝑣𝑎𝑟(𝑏𝑥𝑦(0)) 
Then, we calculated the Z values of 𝑑𝑖 
𝑧𝑑(𝑖) = 𝑑𝑖/√𝑣𝑎𝑟(𝑑𝑖) 
Under the null hypothesis, where 𝑑𝑖 = 0, we have a vector of 𝑧𝑑  value that follows the 
multivariate normal distribution (approximated by the Satterthwaite method) with 𝑧𝑑 ~ MVN 
(0, R), where R is the correlation matrix with the ijth element  
𝑟(𝑧𝑑(𝑖), 𝑧𝑑(𝑗)) = 𝑐𝑜𝑣(𝑑𝑖 , 𝑑𝑗)/√𝑣𝑎𝑟(𝑑𝑖)𝑣𝑎𝑟(𝑑𝑗) 
The HEIDI statistics was calculated as  





with 𝑚 being the number of SNPs associated with SUA level with p<1.57×10-3 (equivalent 
to 2 >10).  
In the analysis, we defined a region of ±250kb (upstream and downstream) around the locus 
associated with SUA level. For each locus, we calculated the HEIDI statistic only including 
SNPs that were associated with SUA level at p<1.57×10-3 (equivalent to 2 >10) in order to 
avoid very weak instruments and to increase the power. The larger the heterogeneity, the 
smaller the HEIDI’s P-value, and the higher the probability of association is caused by LD. 
The pattern of regional genetic association with SUA level and disease outcome was 
visualised by the LocusZoom (505).  
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Online Supplementary tables 
Supplementary Table 5-1: Sample quality control (QC) of genotype data in UK Biobank. 
Supplementary Table 5-2: Summary of the 31 SUA-associated SNPs identified from GWAS. 
Supplementary Table 5-3: Demographic characteristics of the sampled UK Biobank participants 
(n=120,091). 
Supplementary Table 5-4: Genotype-phenotype associations identified from PheWAS analysis 
without adjustment for BMI. 
Supplementary Table 5-5: Genotype-phenotype associations identified from sex-stratified 
PheWAS after correcting multiple testing by FDR. 
Supplementary Table 5-6: The mappings of ICD codes to phecodes for the 25 disease outcomes 
identified from PheWAS.  
Supplementary Table 5-7: Sex-stratified MR IVW analysis and MR Egger analysis. 
Supplementary Table 5-8: A sensitivity analysis of MR for gout cases defined by multiple criteria.  
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Supplementary Table 5 - 1: Sample quality control (QC) of genotype data in UK Biobank.  
Sample QC variables  Sample selection 
f.22050  Pass or not   This variable indicates the genotype quality for ~50,000 samples genotyped by UKBiLEVE array 
 Sample quality control undertaken by Affymetrix was a DNA quality filter (dish quality control < 0.82) and 
initial clustering call rate (<97%); 
 520 duplicates passed Affymetrix quality control in both samples, 33 passed Affymetrix quality control in 1 
sample, and 0 duplicates failed Affymetrix quality control in both samples.  
Pass  
f.22051 Pass or not   This variable indicates QC steps performed for ~50,000 samples genotyped by UKBiLEVE array 
 Sex mismatch (remove sample if submitted gender is different to gender inferred from sex chromosomes); 
 Final call rate (<95%), 
 Heterozygosity outliers (outlier if >3sd from mean heterozygosity); 
 Unintended duplicate (>98% of alleles shared identical by descent); 
 Ancestry principal components outlier (outlier if >10sd from mean on first 10 principal components).  
Pass  
f.22010 Pass or not   This variable indicates the genotype quality for all samples; 
 Samples showed signs of insufficient data quality; 
 Individuals with high missing or for which heterozygosity rates were not explained by the long runs of 
homozygosity (ROH) nor mixed ethnicity. 
Pass 
Population structure  
f.22006  Genetic ethnic 
group 
 Ethnic groups determined by principle genetic components.  Select self-
reported British 
and confirmed to 
be Europeans by 
PCAs  
f.21000  Ethnic background  Self-reported ethnic background 
f.22009  Genetic principal 
components 
(PCAs) 
 The first fifteen PCAs were available for the samples 
Sex mismatch  
f.22001 Genetic sex  Sex inferred from X chromosome genotypes Remove samples 
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Supplementary Table 5 - 2: Summary of the 31 SUA-associated SNPs identified from GWAS. 
Genetic predictors Overall effect  Male-specific effect Female-specific effect Other  associated 
phenotypes reported  in the 
human GWAS catalog 
SNPs Chr Effect 
allele 
Closest/GRAIL gene Beta SE p_val Beta SE p_val Beta SE p_val 
rs10480300 7 T PRKAG2/PRKAG2 0.032 0.006 9.37E-07 0.043 0.010 1.70E-05 0.024 0.008 3.20E-03 Red blood cell traits(506) 
rs10821905 10 A A1CF/ASAH2 0.053 0.007 3.45E-12 0.042 0.011 3.80E-04 0.060 0.009 2.50E-10 None 
rs11264341 1 C TRIM46/PKLR 0.048 0.006 1.04E-14 0.055 0.009 1.10E-08 0.044 0.007 9.10E-09 None 
rs1165151 6 G SLC17A1/SLC17A3 0.092 0.005 4.52E-60 0.096 0.008 1.30E-28 0.089 0.007 4.20E-37 None 
rs1171614 10 C SLC16A9/SLC16A9 0.074 0.007 6.48E-23 0.086 0.011 1.90E-13 0.067 0.009 3.00E-13 Acylcarnitine levels,(507) 
Glycerophospholipid 
levels,(507) Blood metabolite 
levels(508)  
rs1178977 7 A BAZ1B/MLXIPL 0.050 0.007 6.68E-12 0.055 0.011 8.20E-07 0.046 0.009 2.60E-07 None 
rs12498742 4 A SLC2A9/SLC2A9 0.380 0.006 0.00E+00 0.269 0.010 6.40E-
153 
0.460 0.008 0.00E+00 Gout(151) 





Chronic kidney disease,(513) 
Hypertriglyceridaemia(514)  
rs1394125 15 A UBE2Q2/NRG4 0.043 0.006 9.78E-11 0.060 0.010 5.50E-06 0.032 0.008 1.00E-04 Chronic kidney disease(513), 
Kidney function(515) 
rs1471633 1 A PDZK1/PDZK1 0.061 0.005 1.40E-26 0.069 0.008 3.50E-15 0.054 0.007 1.60E-14 None 
rs164009 17 A QRICH2/PRPSAP1 0.029 0.006 7.06E-07 0.024 0.009 6.20E-03 0.032 0.007 8.20E-06 None  
rs17050272 2 A INHBB/INHBB 0.037 0.006 9.36E-09 0.049 0.010 6.50E-07 0.030 0.008 1.90E-04 Glomerular filtration 
rate(creatinine)(515) 
rs17632159 5 G TMEM171/TMEM171 0.038 0.006 2.00E-09 0.043 0.010 1.30E-05 0.039 0.008 1.10E-06 None  
rs17786744 8 G STC1/STC1 0.031 0.005 8.82E-08 0.033 0.009 2.10E-04 0.029 0.007 2.10E-04 None  
rs2078267 11 C SLC22A11/SLC22A11 0.078 0.006 8.73E-36 0.085 0.009 2.90E-19 0.071 0.007 5.70E-20 Gout,(333)  
Cardiovascular disease risk 
factors(333) 
rs2079742 17 T BCAS3/C17orf82 0.051 0.008 6.24E-09 0.054 0.013 5.60E-05 0.048 0.010 1.00E-05 Metabolite levels (small 
molecules and protein 
measures)(516) 
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Genetic predictors Overall effect  Male-specific effect Female-specific effect Other  associated 
phenotypes reported  in the 
human GWAS catalog 
SNPs Chr Effect 
allele 
Closest/GRAIL gene Beta SE p_val Beta SE p_val Beta SE p_val 
rs2231142 4 T ABCG2/ABCG2 0.220 0.009 4.43E-116 0.270 0.014 3.80E-75 0.181 0.011 1.30E-52 Gout(151) 
rs2307394 2 C ORC4L/ACVR2A 0.035 0.006 7.26E-09 0.036 0.009 1.20E-04 0.034 0.007 4.70E-06 None  
rs2941484 8 T HNF4G/HNF4G 0.049 0.006 3.91E-17 0.048 0.009 6.20E-08 0.046 0.007 1.30E-10 None  
rs3741414 12 C INHBC/INHBE 0.071 0.007 9.79E-22 0.091 0.011 7.00E-16 0.057 0.009 4.30E-10 None  
rs478607 11 G NRXN2/SLC22A12 0.048 0.007 5.31E-10 0.058 0.012 9.60E-07 0.043 0.009 8.80E-06 None  
rs642803 11 C OVOL1/LTBP3 0.043 0.005 4.51E-14 0.047 0.008 8.00E-08 0.042 0.007 2.10E-09 None  
rs653178 12 C ATXN2/SH2B3 0.036 0.005 2.45E-10 0.044 0.009 7.50E-07 0.032 0.007 5.50E-06 Coeliac disease,(517) 
Diastolic Blood 
Pressure,(475) Chronic 
kidney disease,(513) Serum 






disease(520)   
rs6598541 15 A IGF1R/IGF1R 0.044 0.006 5.20E-13 0.039 0.009 2.70E-05 0.050 0.007 1.60E-11 None  
rs675209 6 T RREB1/RREB1 0.063 0.006 1.38E-21 0.060 0.010 3.30E-09 0.064 0.008 2.00E-15 Gout,(333)  
Cardiovascular disease risk 
factors(333) 
rs6770152 3 G SFMBT1/MUSTN1 0.048 0.006 2.66E-16 0.052 0.009 6.70E-09 0.047 0.007 6.00E-11 None  
rs7188445 16 G MAF/MAF 0.032 0.006 1.15E-07 0.025 0.009 7.90E-03 0.040 0.007 6.40E-08 None  
rs7193778 16 C NFAT5/NFAT5 0.047 0.008 2.36E-08 0.048 0.012 2.10E-04 0.045 0.010 1.00E-05 None  
rs7224610 17 C HLF/HLF 0.038 0.006 4.74E-11 0.043 0.009 9.00E-07 0.034 0.007 3.00E-06 None  
rs729761 6 G VEGFA/VEGFA 0.046 0.006 3.05E-12 0.047 0.010 3.20E-06 0.047 0.008 3.20E-06 None  
rs742132 6 A LRRC16A/LRRC16A 0.035 0.006 1.90E-08 0.035 0.006 1.90E-08 0.035 0.006 1.90E-08 Cardiovascular disease risk 
factors,(333) Haematological 
and biochemical traits,(512) 
Metabolite levels(521)  
Abbreviations: SNP=Single Nucleotide Polymorphism; GWAS= Genome Wide Association Study; GRAIL=Gene Recognition and Analysis Internet Link.  
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Supplementary Table 5 - 3: Demographic characteristics of the sampled UK Biobank 
participants (n=120,091). 
Continuous variable Mean (S.D.) Number of missing 
Age# 64.86 (7.95) years 0 
Standing height 168.79 (9.20) cm 200 
Weight 78.68 (16.08) kg 288 
BMI† 27.54 (4.83) kg/m2 329 



























# Variable represents the mean age of participants at the year when we assessed their medical records.  
†BMI (body mass index) was calculated as the weight divided by the square of the height
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Supplementary Table 5 - 4: Genotype-phenotype associations identified from PheWAS analysis without adjustment for BMI. 
Phecode Description SNP_risk allele n_total n_cases allele_freq HWE_p beta SE OR (95%CI) P 
274.1 Gout rs2231142_T 119884 1008 0.113 0.642 0.619 0.057 1.86 (1.66, 2.08) 4.17E-27 
275.1 Disorders of iron metabolism rs1165151_G 119389 205 0.451 0.920 1.270 0.127 3.56 (2.78, 4.57) 1.34E-23 
244.4 Hypothyroidism NOS rs653178_C 119145 4169 0.482 0.690 0.184 0.023 1.20 (1.15, 1.26) 3.19E-16 
246 Other disorders of thyroid rs653178_C 119929 4953 0.483 0.708 0.163 0.021 1.18 (1.13, 1.23) 4.56E-15 
274.1 Gout rs12498742_A 119284 1007 0.233 0.773 0.429 0.060 1.54 (1.37, 1.73) 1.00E-12 
275.1 Disorders of iron metabolism rs742132_A 119598 205 0.293 0.790 1.029 0.148 2.80 (2.10, 3.74) 3.15E-12 
211 
Benign neoplasm of other parts of 
digestive system 
rs11264341_C 117350 1507 0.429 0.949 -0.189 0.037 0.83 (0.77, 0.89) 2.68E-07 
411.8 Other chronic ischaemic heart disease rs653178_C 119699 9495 0.483 0.720 0.075 0.016 1.08 (1.05, 1.11) 1.24E-06 
411.4 Coronary atherosclerosis rs653178_C 119787 9583 0.483 0.716 0.075 0.015 1.08 (1.05, 1.11) 1.41E-06 
411 Ischaemic Heart Disease rs653178_C 119728 9524 0.483 0.723 0.075 0.015 1.08 (1.05, 1.11) 1.47E-06 
274.1 Gout rs1260326_T 119884 1008 0.393 0.813 0.218 0.045 1.24 (1.14, 1.36) 1.48E-06 
401 Hypertension rs653178_C 120091 23755 0.483 0.720 0.049 0.011 1.05 (1.03, 1.07) 3.59E-06 
427.2 Atrial fibrillation and flutter rs6598541_A 113564 4368 0.353 0.549 0.106 0.023 1.11 (1.06, 1.16) 3.69E-06 
401.1 Essential hypertension rs653178_C 120017 23681 0.483 0.707 0.049 0.011 1.05 (1.03, 1.07) 4.20E-06 
557.1 Coeliac disease rs1165151_G 100035 550 0.450 0.904 0.285 0.062 1.33 (1.18, 1.50) 5.11E-06 
960 Poisoning by antibiotics rs1165151_G 112628 1031 0.451 0.864 -0.199 0.045 0.82 (0.75, 0.89) 8.01E-06 
557.1 Coeliac disease rs653178_C 100218 551 0.482 0.306 0.271 0.061 1.31 (1.16, 1.48) 8.27E-06 
411.2 Myocardial infarction rs653178_C 113854 3650 0.482 0.603 0.105 0.024 1.11 (1.06, 1.16) 1.31E-05 
535 Gastritis and duodenitis rs478607_G 115704 5252 0.152 0.914 0.114 0.027 1.12 (1.06, 1.18) 2.50E-05 
459.9 Circulatory disease NEC rs653178_C 120005 39322 0.483 0.702 0.037 0.009 1.04 (1.02, 1.06) 4.54E-05 
471 Nasal polyps rs10821905_A 113054 986 0.172 0.725 0.227 0.056 1.26 (1.12, 1.40) 5.06E-05 
366 Cataract rs6770152_G 116535 4592 0.427 0.063 0.087 0.022 1.09 (1.05, 1.14) 6.44E-05 
292.1 Aphasia/speech disturbance rs164009_A 116338 425 0.385 0.969 0.291 0.074 1.34 (1.16, 1.55) 8.38E-05 
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Supplementary Table 5 - 5: Genotype-phenotype associations identified from sex-stratified PheWAS after correcting multiple testing by FDR.* 
Phecode Description SNP_effect _allele n_total n_cases allele_freq hwe_p Beta SE OR (95%CI) P 
Significant associations identified from PheWAS analysis in men 
274.1 Gout rs2231142_T 56528 885 0.113 0.939 0.681 0.061 1.98 (1.75, 2.23) 8.23E-29 
274.1 Gout rs12498742_A 56253 884 0.234 0.876 -0.430 0.064 1.54 (1.36, 1.74) 2.68E-11 
714 Inflammatory polyarthropathies rs2231142_T 56306 2685 0.113 0.956 0.209 0.042 1.23 (1.14, 1.34) 5.82E-07 
274.1 Gout rs1260326_T 56528 885 0.393 0.554 0.238 0.049 1.27 (1.15, 1.40) 1.01E-06 
401 Hypertensive disease rs653178_C 56668 13027 0.482 0.834 0.073 0.015 1.08 (1.04, 1.11) 1.34E-06 
401.1 Essential hypertension rs653178_C 56630 12989 0.482 0.824 0.073 0.015 1.08 (1.04, 1.11) 1.42E-06 
277 Disorders of metabolism‡ rs3741414_C 56503 8017 0.243 0.604 -0.096 0.021 1.10 (1.06, 1.15) 3.98E-06 
714 Inflammatory polyarthropathies‡ rs1260326_T 56306 2685 0.393 0.657 0.120 0.029 1.13 (1.07, 1.19) 3.09E-05 
512 Other diseases of respiratory system‡ rs1471633_A 55070 977 0.462 0.930 -0.193 0.046 0.82 (0.75, 0.90) 3.25E-05 
274.1 Gout rs642803_C 55592 872 0.460 0.573 -0.198 0.050 1.22 (1.11, 1.34) 6.17E-05 
Significant associations identified from PheWAS analysis in women 
244.4 Hypothyroidism NOS rs653178_C 62363 3362 0.483 0.030 0.205 0.025 1.23 (1.17, 1.29) 7.95E-16 
246 Other disorders of thyroid rs653178_C 62970 3969 0.483 0.096 0.179 0.023 1.20 (1.14, 1.25) 2.51E-14 
211 Benign neoplasm of digestive system rs11264341_C 61908 896 0.431 0.872 0.257 0.048 0.77 (0.70, 0.85) 7.47E-08 
411.4 Coronary atherosclerosis rs653178_C 62971 2997 0.483 0.185 0.113 0.027 1.12 (1.06, 1.18) 2.71E-05 
411 Ischaemic Heart Disease rs653178_C 62954 2980 0.483 0.157 0.112 0.027 1.12 (1.06, 1.18) 3.35E-05 
669 Complications of labor and delivery# rs729761_G 59622 2376 0.283 0.958 -0.159 0.039 1.17 (1.09, 1.27) 3.78E-05 
401.1 Essential hypertension rs2079742_T 60918 10237 0.136 0.339 -0.098 0.024 1.10 (1.05, 1.16) 5.35E-05 
689 Disorder of skin and subcutaneous tissue#  rs2231142_T 63094 6142 0.113 0.349 -0.126 0.031 0.88 (0.83, 0.94) 5.72E-05 
401 Hypertensive disease rs2079742_T 60952 10271 0.136 0.310 -0.098 0.024 1.10 (1.05, 1.16) 5.78E-05 
535 Gastritis and duodenitis rs478607_G 60962 2845 0.153 0.790 0.144 0.036 1.15 (1.08, 1.24) 7.46E-05 
*Significance threshold of p<8.57×10-5corresponds to a FDR of q<0.05 after correcting the multiple testing. 
‡ Genotype-phenotype associations that were not identified in PheWAS analysis of overall population.   
# Genotype-phenotype association that were not identified in PheWAS analysis of overall population.
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Supplementary Table 5 - 6: The mappings of ICD codes to phecodes for the 25 disease 
outcomes identified from PheWAS. 




274 Gouty arthropathy 
274.1 Gouty nephropathy 
274.8 Gout with other specified manifestations 
274.9 Gout, unspecified 
ICD-10 
M10 Gout 
M10.0 Idiopathic gout 
M10.1 Lead-induced gout 
M10.2 Drug-induced gout 
M10.3 Gout due to impairment of renal function 
M10.4 Other secondary gout 
M10.9 Gout, unspecified 
714 Inflammatory polyarthropathies 
ICD-9 
714 Rheumatoid arthritis and other inflammatory polyarthropathies 
714 Rheumatoid arthritis 
714.1 Felty's syndrome 
714.2 Other rheumatoid arthritis with visceral or systemic involvement 
714.3 Juvenile chronic polyarthritis 
714.4 Chronic postrheumatic arthropathy 
714.8 Other specified inflammatory polyarthropathies 
714.9 Unspecified inflammatory polyarthropathy 
ICD-10 
M05 
Seropositive rheumatoid arthritis 
M05.0-M05.9 
M06 
Other rheumatoid arthritis 
M06.0-M06.9 
M07 












Other crystal arthropathies 
M11.0-M11.9 
M12 
Other specific arthropathies 
M12.0-M12.8 







Arthropathies in other diseases classified elsewhere 
M14.0-M14.8 




ICD-10 I10 Essential (primary) hypertension 






Hypertensive heart disease 
402.0-402.9 
403 
 Hypertensive chronic kidney disease 
403.0-403.9 
404 
Hypertensive heart and chronic kidney disease 
404.0-404.9 
405 
 Secondary hypertension 
405.0-405.9 
ICD-10 
I10 Essential (primary) hypertension 
I11 
Hypertensive heart disease 
I11.0-I11.9 
I12 
Hypertensive renal disease 
I12.0-I12.9 
I13 





411.4 Coronary atherosclerosis 
ICD-9 
411.81 Acute coronary occlusion without myocardial infarction 
414 
Other forms of chronic ischaemic heart disease 
414.00-414.07 
414.1 
Aneurysm and dissection of heart 
414.10-414.19 
414.2 Chronic total occlusion of coronary artery 
414.3 Coronary atherosclerosis due to lipid rich plaque 
996.03 Due to coronary bypass graft 
V45.81 Aortocoronary bypass status 








Acute myocardial infarction 
I21.0-I21.9 
I22 
Subsequent myocardial infarction 
I22.0-I22.9 
I23 
Certain current complications following acute myocardial infarction 
I23.0-I23.9 
I24 
Other acute ischaemic heart diseases 
I24.0-I24.9 
I25 
Chronic ischaemic heart disease 
I25.0-I25.9 
Z95.1 Presence of aortocoronary bypass graft 
Z95.5 Presence of coronary angioplasty implant and graft 
411.2 Myocardial infarction 
ICD-9 
410 
Acute myocardial infarction 
410.0-410.9 
411 Postmyocardial infarction syndrome 
412 Old myocardial infarction 
429.7 




Acute myocardial infarction 
I21.0-I21.9 
I22 
Subsequent myocardial infarction 
I22.0-I22.9 
I23 
Certain current complications following acute myocardial infarction 
I23.0-I23.9 
I24.1 Dressler syndrome 
I25.2 Old myocardial infarction 
I51.0 Cardiac septal defect 
I51.3 Intracardiac thrombosis, not elsewhere classified 
427.2 Atrial fibrillation and flutter 
ICD-9 427.3 
Atrial fibrillation and flutter 
427.31-427.32 
ICD-10 I48 
Atrial fibrillation and flutter 
I48.0-I48.9 







411 Ischaemic heart disease 
ICD-9 410 Acute myocardial infarction 





Other acute and subacute forms of ischaemic heart disease 
411.0-411.8 





Other forms of chronic ischaemic heart disease 
414.0-414.9 
429 Ill-defined descriptions and complications of heart disease 






Acute myocardial infarction 
I21.0-I21.9 
I22 
Subsequent myocardial infarction 
I22.0-I22.9 
I23 
Certain current complications following acute myocardial infarction 
I23.0-I23.9 
I24 
Other acute ischaemic heart diseases 
I24.0-I24.9 
I25 
Chronic ischaemic heart disease 
I25.0-I25.9 
454.1 Varicose veins of lower extremity 
ICD-9 454 
Varicose veins of lower extremities 
454.0-454.9 
ICD-10 I83 
Varicose veins of lower extremities 
I83.0-I83.9 
459.9 Circulatory disease  
ICD-9 459 
Other disorders of circulatory system 
459.0-459.9 
ICD-10 
I00-I02  Acute rheumatic fever   
I05-I09  Chronic rheumatic heart diseases   
I10-I15  Hypertensive diseases   
I20-I25 Ischaemic heart diseases   
I26-I28    Pulmonary heart disease and diseases of pulmonary circulation 
I30-I52  Other forms of heart disease   
I60-I69  Cerebrovascular diseases   
I70-I79  Diseases of arteries, arterioles and capillaries   
I80-I89 Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified   
244.4 Hypothyroidism NOS 
ICD-9 244.9 Unspecified hypothyroidism 
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ICD-10 E03.9 Hypothyroidism, unspecified 
246 Disorders of thyroid 
ICD-9 246 




Congenital iodine-deficiency syndrome 
E00.0-E00.9 
E01 
Iodine-deficiency-related thyroid disorders and allied conditions 
E01.1-E01.8 














Other disorders of thyroid 
E07.0-E07.9 
557.1 Coeliac disease 
ICD-9 
579 Coeliac disease 
579.1 Tropical sprue 
ICD-10 
K90.0 Coeliac disease 
K90.1 Tropical sprue 
275.1 Disorders of iron metabolism 
ICD-9 275 Disorders of iron metabolism 
ICD-10 E83.1 Disorders of iron metabolism 
272.11 Hypercholesterolaemia 
ICD-9 272 Pure hypercholesterolaemia 
ICD-10 E78.0 Pure hypercholesterolaemia 
277 Disorders of metabolism 
ICD-9 
277 
Other and unspecified disorders of metabolism 
277.0-277.9 
783.9 Other symptoms concerning nutrition, metabolism, and development 
794.7 Basal metabolism 
ICD-10 
C96.0 Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis  
E43 Unspecified severe protein-energy malnutrition 
E70 
Disorders of aromatic amino-acid metabolism 
E70.1-E70.9 
E71  Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism   
E72  Other disorders of amino-acid metabolism   
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E73  Lactose intolerance   
E74 Other disorders of carbohydrate metabolism   
E75  Disorders of sphingolipid metabolism and other lipid storage disorders   
E76    Disorders of glycosaminoglycan metabolism 
E77  Disorders of glycoprotein metabolism   
E78  Disorders of lipoprotein metabolism and other lipidaemias   
E79  Disorders of purine and pyrimidine metabolism   
E80 Disorders of porphyrin and bilirubin metabolism  
E83  Disorders of mineral metabolism   
E84  Cystic fibrosis   
E85  Amyloidosis   
E86   Volume depletion  
E87 Other disorders of fluid, electrolyte and acid-base balance   
E88  Other metabolic disorders   
E89  Postprocedural endocrine and metabolic disorders, not elsewhere classified   






998.82 Cataract fragments in eye following cataract surgery 
ICD-10 
V43.1  Lens 





Cataract and other disorders of lens in diseases classified elsewhere 
H28.0-H28.8 
Z96.1 Presence of intraocular lens 
960 Poisoning by antibiotics 
ICD-9 
960 
Poisoning by antibiotics 
960.1-960.9 
961.8 Other anti-mycobacterial drugs 
V14.0 Personal history of allergy to Penicillin 
V14.1 Personal history of allergy to other antibiotic agent 
E856 Accidental poisoning by antibiotics 
E930 
Adverse effects in therapeutic use of antibiotics 
E930.0- E930.9 
E931.8 Adverse effects in therapeutic use of anti-mycobacterial drugs 
E933.4 Adverse effects in therapeutic use of Penicillinase 
ICD-10 
T36 
Poisoning by systemic antibiotics 
T36.5- T36.9 
T37.1 Poisoning by anti-mycobacterial drugs 
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T37.8 Poisoning by other specified systemic anti-infectives and antiparasitics 
Z88.1 Personal history of allergy to other antibiotic agents 







512 Other diseases of respiratory system 
ICD-9 
519 
Other diseases of respiratory system 
519.0-519.9 
786 




Postprocedural respiratory disorders, not elsewhere classified 
J95.0-J95.9 
J96 
Respiratory failure, not elsewhere classified 
J96.0-J96.9 
J98 
Other respiratory disorders 
J98.0-J98.9 
J99 
Respiratory disorders in diseases classified elsewhere 
J99.0-J99.9 
535 Gastritis and duodenitis 
ICD-9 535 
Gastritis and duodenitis 
535.0-535.7 
ICD-10 K29 
Gastritis and duodenitis 
K29.0-K29.9 
211 Benign neoplasm of digestive system 
ICD-9 
211 Benign neoplasm of other parts of digestive system 
  211.0-211.9 
ICD-10 
D13 Benign neoplasm of other and ill-defined parts of digestive system 
  D13.0-D13.9 
D19.1 Mesothelial tissue of peritoneum 
K31.7 Polyp of stomach and duodenum 
669 Complications of labour and delivery  
ICD-9 
667 Retained placenta without haemorrhage 
669 
Other complications of labour and delivery, not elsewhere classified 
669.0-669.9 
674 
Other and unspecified complications of the puerperium, not elsewhere classified 
674.0-674.9 
677 Late effect of complication of pregnancy, childbirth, and the puerperium 
ICD-10 O26.5 Maternal hypotension syndrome 




Preterm labour and delivery 
O60.0- O60.9 
O61 
Failed induction of labour 
O61.0- O61.9 
O62 






Obstructed labour due to malposition and malpresentation of foetus 
O64.0- O64.9 
O65 
Obstructed labour due to maternal pelvic abnormality 
O65.0- O65.9 
O66 
Other obstructed labour 
O66.0- O66.9 
O67 




Labour and delivery complicated by foetal stress 
O68.0- O68.9 
O69 
Labour and delivery complicated by umbilical cord complications 
O69.0- O69.9 
O70 
Perineal laceration during delivery 
O70.0- O70.9 
O71 






Retained placenta and membranes, without haemorrhage 
O73.0- O73.9 
O74 
Complications of anaesthesia during labour and delivery 
O74.0- O74.9 
O75 
Other complications of labour and delivery, not elsewhere classified 
O75.0- O75.9 
O81 
Single delivery by forceps and vacuum extractor 
O81.3-O81.5 
O82 Single delivery by caesarean section 
O83 Other assisted single delivery 
O90.4 Postpartum acute renal failure 
689 Disorder of skin and subcutaneous tissue  
ICD-9 709 Other disorders of skin and subcutaneous tissue 
ICD-10 L00-L08 Infections of the skin and subcutaneous tissue   
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L10-L14  Bullous disorders   
L20-L30 Dermatitis and eczema   
L40-L45 Papulosquamous disorders   
L50-L54  Urticarial and erythema   
L55-L59 Radiation-related disorders of the skin and subcutaneous tissue   
L60-L75 Disorders of skin appendages   
L80-L99  Other disorders of the skin and subcutaneous tissue   
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Supplementary Table 5 - 7: Sex-stratified MR IVW analysis and MR Egger analysis.  
Outcomes 
Male-specific effect Female-specific effect 
MR IVW MR Egger MR IVW MR Egger 
Beta  SE 
OR 
(95%CI) 
P effect Beta  SE OR (95%CI) P effect P pleiotropy Beta  SE 
OR 
(95%CI) 
P effect Beta  SE 
OR 
(95%CI) 
P effect P pleiotropy 





























0.49 -0.04 0.06 
0.96 (0.85, 
1.07) 




Essential hypertension 0.09 0.04 
1.10 (1.02, 
1.19) 
0.02 -0.07 0.08 
0.93 (0.78, 
1.10) 
0.37 0.02 0.07 0.03 
1.08 (1.00, 
1.15) 




Hypertensive disease 0.09 0.04 
1.10 (1.02, 
1.19) 
0.02 -0.07 0.08 
0.93 (0.78, 
1.10) 
0.37 0.02 0.07 0.03 
1.08 (1.00, 
1.16) 




Myocardial infarction 0.15 0.07 
1.17 (1.01, 
1.34) 
0.03 0.03 0.15 
1.03 (0.76, 
1.39) 
0.84 0.29 0.18 0.11 
1.20 (0.96, 
1.50) 




Coeliac disease 0.35 0.26 
1.42 (0.83, 
2.43) 
0.19 0.03 0.60 
1.03 (0.31, 
3.49) 
0.96 0.51 0.27 0.16 
1.31 (0.94, 
1.84) 




Disorders of metabolism 0.10 0.04 
1.10 (1.01, 
1.20) 
0.04 0.04 0.09 
1.04 (0.86, 
1.26) 
0.70 0.44 0.37 0.38 
1.44 (0.66, 
3.14) 




Coronary atherosclerosis 0.05 0.05 
1.05 (0.95, 
1.16) 
0.32 -0.03 0.10 
0.97 (0.79, 
1.20) 
0.79 0.36 0.14 0.06 
1.15 (1.02, 
1.30) 




Ischaemic heart disease 0.04 0.05 
1.04 (0.95, 
1.15) 
0.39 -0.03 0.10 
0.97 (0.79, 
1.19) 
0.77 0.38 0.14 0.06 
1.15 (1.02, 
1.30) 




Angina pectoris 0.03 0.06 
1.03 (0.90, 
1.17) 
0.66 -0.02 0.12 
0.98 (0.77, 
1.26) 
0.89 0.64 0.12 0.08 
1.13 (0.97, 
1.32) 




Atrial fibrillation and flutter -0.03 0.07 
0.97 (0.85, 
1.11) 
0.67 -0.20 0.11 
0.81 (0.65, 
1.03) 
0.08 0.06 0.08 0.08 
1.09 (0.92, 
1.29) 




Circulatory disease 0.05 0.03 
1.05 (0.98, 
1.12) 
0.16 0.01 0.06 
1.01 (0.89, 
1.13) 
0.92 0.39 0.03 0.03 
1.03 (0.98, 
1.09) 




Varicose veins of lower extremity -0.15 0.11 
0.86 (0.69, 
1.08) 
0.19 -0.15 0.21 
0.86 (0.55, 
1.33) 
0.48 0.97 -0.14 0.07 
0.87 (0.76, 
0.99) 




Disorders of iron metabolism 0.15 0.30 
1.16 (0.63, 
2.16) 
0.62 -0.42 1.05 
0.66 (0.08, 
5.60) 
0.69 0.50 0.37 0.38 
1.44 (0.66, 
3.14) 




Hypercholesterolaemia 0.22 0.12 
1.24 (0.98, 
1.57) 
0.07 0.20 0.19 
1.22 (0.82, 
1.81) 
0.32 0.91 0.06 0.05 
1.06 (0.95, 
1.18) 




Hypothyroidism 0.20 0.13 
1.23 (0.95, 
1.59) 
0.12 0.21 0.26 
1.23 (0.73, 
2.08) 
0.42 0.98 0.06 0.05 
1.06 (0.95, 
1.18) 




Disorders of thyroid 0.20 0.12 
1.22 (0.96, 
1.55) 
0.09 0.22 0.22 
1.25 (0.80, 
1.97) 
0.32 0.90 0.04 0.05 
1.04 (0.94, 
1.15) 









0.70 -0.01 0.26 
0.99 (0.59, 
1.68) 
0.97 0.75 -0.11 0.10 
0.89 (0.73, 
1.10) 









Male-specific effect Female-specific effect 
MR IVW MR Egger MR IVW MR Egger 
Beta  SE 
OR 
(95%CI) 
P effect Beta  SE OR (95%CI) P effect P pleiotropy Beta  SE 
OR 
(95%CI) 
P effect Beta  SE 
OR 
(95%CI) 
P effect P pleiotropy 
Gastritis and duodenitis -0.04 0.07 
0.96 (0.82, 
1.11) 
0.56 -0.03 0.15 
0.97 (0.71, 
1.33) 
0.83 0.93 -0.03 0.06 
0.97 (0.86, 
1.09) 




Nasal polyps 0.23 0.14 
1.25 (0.95, 
1.65) 
0.11 0.41 0.28 
1.51 (0.86, 
2.68) 
0.15 0.40 -0.23 0.17 
0.79 (0.56, 
1.11) 




Cataract -0.01 0.08 
0.99 (0.84, 
1.16) 
0.88 -0.13 0.16 
0.88 (0.63, 
1.23) 
0.43 0.38 -0.02 0.06 
0.98 (0.86, 
1.11) 




Poisoning by antibiotics -0.15 0.23 
0.86 (0.53, 
1.39) 
0.52 0.03 0.45 
1.03 (0.41, 
2.56) 
0.95 0.62 -0.14 0.11 
0.87 (0.70, 
1.09) 




Complications of labour and 
delivery 
NA NA NA NA NA NA NA NA NA -0.11 0.07 
0.90 (0.78, 
1.04) 









0.21 -0.35 0.24 
0.70 (0.43, 
1.14) 











Disorder of skin and 




0.60 0.003 0.09 
1.00 (0.84, 
1.20) 
0.97 0.74 0.003 0.04 
1.00 (0.92, 
1.09) 





In sex-stratified MR IVW analysis of 25 disease groups/outcomes (Supplementary Table 5-7), 3 disease groups/outcomes (gout, hypertensive disease, and 
essential hypertension) showed potential causal link with SUA level in both men and women, 3 disease groups/outcomes (inflammatory polyarthropathies, 
myocardial infarction, and disorders of metabolism) had potential causal link in men, and 4 disease groups/outcomes (coronary atherosclerosis, ischaemic heart 
disease, varicose veins of lower extremity and other diseases of respiratory system) had potential causal link only in women. The sex-stratified MR Egger analysis 
suggested causal effect of SUA level on gout in both men (OR=7.81, 95%CI: 4.39 to 13.90, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡= 4.87×10
-8, 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦=0.20) and women (OR=3.01, 95%CI: 
1.16 to 7.81, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡= 0.03, 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦=0.68), on inflammatory polyarthropathies in men (OR=1.90, 95%CI: 1.45 to 2.48, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡= 3.76×10
-5, 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦=0.49), 
and on other diseases of respiratory system in women (OR=1.66, 95%CI: 1.22 to 2.26, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡= 2.27×10
-3, 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦=0.20). 
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Supplementary Table 5 - 8: A sensitivity analysis of MR for gout cases defined by multiple 
criteria.  
Case ascertainment  
No. of 
cases* 
MR IVW MR Egger 
































*Note the number of study population is 120,091. 
Chapter 5  MR-PheWAS analysis 
229 
 




Supplementary Figure 5 - 1: Three possible explanations for the PheWAS association 
between SUA level and disease outcome through genotypes. 
(Reshaped based on the publication of Zhu et al). 
  




Supplementary Figure 5 - 2: The number of phenotypes and median number of cases in each disease category (outliers>15K are not plotted). 









Supplementary Figure 5 - 3: A scatter plot of the SNP effect on SUA level against the SNP 
effect on gout.  
  









Supplementary Figure 5 - 4: A scatter plot of the SNP effect on SUA level against the SNP 
effect on inflammatory polyarthropathies.   
  








Supplementary Figure 5 - 5: A scatter plot of the SNP effect on SUA level against the SNP 
effect on hypertensive disease. 
  








Supplementary Figure 5 - 6: A scatter plot of the SNP effect on SUA level against the SNP 
effect on essential hypertension.  
  








Supplementary Figure 5 - 7: A scatter plot of the SNP effect on SUA level against the SNP 
effect on myocardial infarction.  
  








Supplementary Figure 5 - 8: A scatter plot of the SNP effect on SUA level against the SNP 
effect on coeliac disease.  
  








Supplementary Figure 5 - 9: A scatter plot of the SNP effect on SUA level against the SNP 
effect on disorders of metabolism.




Supplementary Figure 5 - 10: Regional association plots of SH2B3_ATXN2 locus with associated phenotypes.    
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Results of regional association were plotted as –log10 P-value for all SNPs located within a±250 kb window around SH2B3_ATXN2 ordered by the chromosome 
position. The LD between the index SNP (rs653178) and other SNPs in this region were indicated by using color scheme. Location of genes were given by blue 
narrows at the bottom, pointing the direction of transcription. Both the index SNP (rs653178) and the most significant SNPs associated with the phenotypes (top 
SNP with the smallest P-value) were tagged. Results were shown for (A) the regional association of the SH2B3_ATXN2 locus with SUA level; (B) the regional 
association of the SH2B3_ATXN2 locus with essential hypertension (top SNP: rs4766578; p value of HEIDI test = 0.99); (C) the regional association of the 
SH2B3_ATXN2 locus with hypertensive disease (top SNP: rs4766578; p value of HEIDI test = 0.99); (D) the regional association of the SH2B3_ATXN2 locus with 
angina pectoris (top SNP: rs4766578; p value of HEIDI test = 0.20); (E) the regional association of the SH2B3_ATXN2 locus with coronary atherosclerosis (top 
SNP: rs4766578; p value of HEIDI test = 0.91); (F) the regional association of the SH2B3_ATXN2 locus with ischaemic heart disease (top SNP: rs4766578; p value 
of HEIDI test = 0.93); (G) the regional association of the SH2B3_ATXN2 locus with myocardial infarction (top SNP: rs4766578; p value of HEIDI test = 0.06); (H) 
the regional association of the SH2B3_ATXN2 locus with circulatory disease (top SNP: rs3184504; p value of HEIDI test = 0.99); (I) the regional association of the 
SH2B3_ATXN2 locus with coeliac disease (top SNP: rs3184504; p value of HEIDI test = 0.67); (J) the regional association of the SH2B3_ATXN2 locus with 
hypothyroidism (top SNP: rs3184504; p value of HEIDI test = 0.57); (K) the regional association of the SH2B3_ATXN2 locus with thyroid disorders (top SNP: 
rs3184504; p value of HEIDI test = 0.88).  
  




Supplementary Figure 5 - 11: Regional association plots of the BCAS3_TBX2 locus with associated phenotypes.    
Results of regional association were plotted as –log10 P-value for all SNPs located within a ±250 kb window around BCAS3_TBX2 ordered by the chromosome 
position. The LD between the index SNP (rs2079742) and other SNPs in this region were indicated with the color scheme. Location of genes were given by blue 
narrows at the bottom, pointing the direction of transcription. Both the index SNP (rs2079742) and the most significant SNP (with the smallest P-value) associated 
with the phenotypes (rs11650989). Results were shown for (A) the regional association of the BCAS3_TBX2 locus with SUA level; (B) the regional association of 
the BCAS3_TBX2 locus with essential hypertension (top SNP: rs11650989; p value of HEIDI test = 0.09); (C) the regional association of the BCAS3_TBX2 locus 
with hypertensive disease (top SNP: rs11650989; p value of HEIDI test = 0.10).  




Supplementary Figure 5 - 12: Regional association plots of the ABCG2 locus with associated phenotypes.    
Results of regional association were plotted as –log10 P-value for all SNPs located within a ±250 kb window around ABCG2 ordered by the chromosome position. 
The LD between the index SNP (rs2231142) and other SNPs in this region were indicated with the color scheme. Location of genes were given by blue narrows at 
the bottom, pointing the direction of transcription. Both the index SNP (rs2231142) and the most significant SNP (with the smallest P-value) associated with the 
phenotypes were tagged. Results were shown for (A) the regional association of ABCG2 locus with SUA level; (B) the regional association of the ABCG2 locus 
with varicose veins of lower extremity (top SNP: rs2231142; p value of HEIDI test = 0.32).  




Supplementary Figure 5 - 13: Regional association plots of the SLC17A3 locus with associated phenotypes.    
Results of regional association were plotted as –log10 P-value for all SNPs located within a ±250 kb window around SLC17A3 ordered by the chromosome position. 
The LD between the index SNP (rs1165151) and other SNPs in this region were indicated with the color scheme. Location of genes were given by blue narrows at 
the bottom, pointing the direction of transcription. Both the index SNP (rs1165151) and the most significant SNP (with the smallest P-value) associated with the 
phenotypes were tagged. Results were shown for (A) the regional association of the SLC17A3 locus with SUA level; (B) the regional association of the SLC17A3 
locus with poisoning by antibiotics (top SNP: rs1165205; p value of HEIDI test = 0.26); (C) the regional association of SLC17A3 locus with disorders of iron 
metabolism (top SNP: rs17342717; p value of HEIDI test = 5.54×10-28); (D) the regional association of the SLC17A3 locus with coeliac disease (top SNP: 
rs13202688; p value of HEIDI test = 6.51×10-16). 




Supplementary Figure 5 - 14: Regional association plots of the GCKR locus with associated phenotypes.    
Results of regional association were plotted as –log10 P-value for all SNPs located within a ±250 kb window around GCKR ordered by the chromosome position. 
The LD between the index SNP (rs1260326) and other SNPs in this region were indicated with the color scheme. Location of genes were given by blue narrows at 
the bottom, pointing the direction of transcription. Both the index SNP (rs1260326) and the most significant SNP (with the smallest P-value) associated with the 
phenotypes (rs4665383) were tagged. Results were shown for (A) the regional association of GCKR locus with SUA level; (B) the regional association of the 
GCKR locus with hypercholesterolaemia (top SNP: rs4665383; p value of HEIDI test = 3.27×10-11).  
Chapter 6  PWMR analysis 
244 
 
6 PWMR ANALYSIS: FULL UK BIOBANK DATA 
6.1 Summary  
This chapter presents a Phenome-wide Mendelian randomisation (PWMR) study by using 
data from an unrelated White British subset (n=339,256) selected from the full UK Biobank 
cohort (the selection process is presented in Chapter 4, Section 4.3.1 “Study population 
selection”). The present study aims to extend the prior findings by combining genetic risk 
loci of urate into a weighted GRS, investigating more disease outcomes, assessing their 
associations with more cases (>3-fold), examining consistency of findings across two 
different phenotyping models, and replicating the findings by performing two-sample MR in 
different populations. 
A weighted polygenic risk score (GRS), incorporating effect estimates of multiple genetic 
risk loci, was employed as a proxy of serum urate level. The framework of phenome was 
defined by using both the PheCODE schema (also used in the previous MR-PheWAS) and a 
novel Bayesian analysis framework, termed TreeWAS: tree-structured phenotypic model. To 
validate the findings, identified associations were further examined in the MR-base database 
for replication in different populations. Sensitivity analysis examining the pleiotropic effects 
of urate genetic risk loci on a set of metabolic traits was performed to explore any causal 
effect and pleiotropic association.  
The PheWAS analysis based on the PheCODE schema examined the association between a 
weighted GRS of SUA level and 1,431 disease outcomes and identified 13 phecodes that had 
p value less than the significance threshold of PheWAS (p<3.35×10-4). These phecodes 
represent 4 disease groups: inflammatory polyarthropathies (OR=1.28; 95% CI: 1.21 to 1.35; 
p=4.97×10-19), hypertensive disease (OR=1.08; 95% CI: 1.05 to 1.11; p=6.02×10-7), 
circulatory disease (OR=1.05; 95% CI: 1.02 to 1.07; p=3.29×10-4) and metabolic disorders 
(OR=1.07; 95% CI: 1.03 to 1.11; p= 3.33×10-4), and 9 disease outcomes: gout (OR=5.37; 95% 
CI: 4.67 to 6.18; p= 4.27×10-123), gouty arthropathy (OR=5.11; 95% CI: 2.45 to 10.66; 
p=1.39×10-5), pyogenic arthritis (OR=2.10; 95% CI: 1.41 to 3.14; p=2.87×10-4), essential 
hypertension (OR=1.08; 95% CI: 1.05 to 1.11; p=6.62×10-7), coronary atherosclerosis 
(OR=1.10; 95% CI: 1.05 to 1.15; p=1.17×10-5), ischaemic heart disease (OR=1.10, 95% CI: 
1.05 to 1.15; p=1.73×10-5), chronic ischaemic heart disease (OR=1.10, 95% CI: 1.05 to 1.15; 
p=1.52×10-5), myocardial infarction (OR=1.15, 95% CI=1.07 to 1.23, p=5.23×10-5), and 
hypercholesterolaemia (OR=1.08, 95% CI: 1.04 to 1.13, p=3.34×10-4).  In the Bayesian 
analysis framework, containing 10,750 diagnostic terms, a total of 27 parent/child nodes of 
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ICD-10 terms were identified with a PP (posterior probability) ≥0.95. They were clustered 
mainly in five branches of the hierarchical tree structure: (i) block M10 (gout, OR=5.16, 
95%CI: 4.55 to 5.84; PP=1.00); (ii) block I10-I15 (hypertensive disease, OR=1.07, 95%CI: 
1.06 to 1.08; PP>0.99); (iii) block I20-I25 (ischaemic heart diseases, OR=1.07, 95%CI: 1.06 
to 1.08; PP>0.99); (iv) block I30-I52 (other forms of heart disease, OR=1.07, 95%CI: 1.06 to 
1.08; PP>0.99); (v) block I60-I69 (cerebrovascular diseases, OR=1.07, 95%CI: 1.06 to 1.08; 
PP>0.99). Findings from PheWAS and TreeWAS were generally consistent in their 
associations with gout, hypertensive disease, and heart diseases, while 14 more sub-
phenotypes were identified from TreeWAS. 
MR IVW analysis successfully replicated the association between urate and the risk of gout, 
CHD, myocardial infarction and decreased level of HDL-c in different populations by 
analysing various GWAS consortia summary data that are included in the MR-base database. 
However, the MR Egger analysis indicated the existence of unbalanced genetic pleiotropy on 
the observed associations between urate and cardiovascular/metabolic diseases. When 
balancing out the potential pleiotropic effects in Egger MR, causal effect was verified for 
gout (OR=4.17, 95%CI: 3.03 to 5.74, 𝑃𝑒𝑓𝑓𝑒𝑐𝑡 = 1.27 × 10
−9; 𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.485).     
To further investigate the influence of pleiotropy, we re-calculated the PheWAS estimates by 
using a number of GRSs created based on their association with a set of metabolic traits. The 
GRS of urate-specific loci was only associated with gout and its upper disease group of 
inflammatory polyarthropathies, but not with any cardiovascular/metabolic diseases. In 
contrast, the GRSs of pleiotropic loci on BMI, BP, lipids and glucose showed association 
with both gout and the cardiovascular/metabolic diseases. When removing any group of 
pleiotropic loci from the creation of GRS, their association with hypertensive diseases, heart 
diseases, and metabolic disorders were not statistically significant.  
Overall, when taken together the findings from PheWAS/TreeWAS, MR replication and 
sensitivity analysis, I conclude that there are robust associations between urate and a group 
of diseases, including gout, hypertensive diseases, heart diseases and metabolic disorders of 
lipids, but the causal role of urate only exists in gout. Findings in this chapter indicate that 
the association between urate and cardiovascular/metabolic diseases is probably due to the 
pleiotropic effects of genetic variants on urate and metabolic traits. These findings suggest 
that urate could be a good predictor for the cardiovascular/metabolic disease risk. Further 
investigation on therapies targeting on the shared biological pathways between urate and 
metabolic traits would be beneficial for both the treatment of gout and the primary 
prevention of cardiovascular/metabolic diseases. 
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Objective: To explore the causal and pleiotropic associations between serum urate levels and 
a phenome-wide spectrum of disease outcomes using data of 339,256 individuals from the 
UK Biobank cohort.  
Methods: A weighted polygenic risk score (GRS) of 31 genetic variants was employed as 
genetic proxy of serum urate levels. The phenome framework was defined by using both the 
PheCODE schema (termed PheWAS) and a tree-structured phenotypic model (termed 
TreeWAS). Significant associations from these analyses were taken forward for replication in 
different populations by analysing data from various GWAS consortia documented in the 
MR-base database. Sensitivity analyses examining the pleiotropic effects of urate genetic 
risk loci on a set of metabolic traits were performed to explore any causal effects and 
pleiotropic associations.  
Results: The PheWAS analysis, examining the association with 1,431 disease outcomes, 
identified 13 distinct phecodes representing 4 disease groups (inflammatory 
polyarthropathies, hypertensive disease, circulatory disease, metabolic disorders) and 9 
disease outcomes (gout, gouty arthropathy, pyogenic arthritis, essential hypertension, 
coronary atherosclerosis, ischaemic heart disease, chronic ischaemic heart disease, 
myocardial infarction, and hypercholesterolaemia) that were associated with the genetically 
determined serum urate levels after multiple testing correction (p<3.35×10-4). The Bayesian 
analysis of TreeWAS, examining 10,750 ICD-10 diagnostic terms, identified 27 parent/child 
nodes of ICD-10 terms reporting a posterior probability (PP) ≥0.95, with a few more sub-
phenotypes being identified than in the PheWAS analysis. MR IVW analysis successfully 
replicated the associations with gout, CHD, myocardial infarction and decreased level of 
HDL-c, but MR Egger analysis indicated the existence of pleiotropy for most of the 
associations. After balancing out pleiotropic effects, a causal role of urate was verified for 
gout (OR=4.17, 95%CI: 3.03 to 5.74). Sensitivity analyses on the GRSs of different groups 
of pleiotropic loci support an inference that pleiotropic effects of genetic variants on urate 
and metabolic traits contribute to the observed associations with cardiovascular/metabolic 
diseases.     
Conclusion: We conclude that there are robust associations between urate and a group of 
diseases, including gout, hypertensive diseases, heart diseases and metabolic disorders, but 
the causal role of urate is only supported in gout. Our study indicates that the observed 
associations between urate and cardiovascular/metabolic diseases are probably derived from 
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the pleiotropic effects of genetic variants on urate and metabolic traits. Further investigation 
of therapies targeting the shared biological pathways between urate and metabolic traits may 
be beneficial for the treatment of gout and the primary prevention of 
cardiovascular/metabolic diseases. 
  




The role of urate has been explored in a large number of observational studies in relation to a 
multitude of health outcomes (232). Apart from gout, compelling evidence supports the 
association between high serum urate level and the increased risk of non-crystal deposition 
disorders, including hypertension, cardiovascular diseases (CVDs), and metabolic syndrome 
(225, 226, 232, 486). Although considerable research efforts have been made in trying to 
understand the pathogenic role of uric acid in these non-crystal deposition disorders, its 
causal role has not been established (232). Therefore, it has been argued that either these 
associations are confounded by other risk factors, such as obesity, or they represent reverse 
causality (227, 522).  
As in other complex traits, genetic determinants play a crucial role in the regulation of serum 
urate levels. Genetic studies among twins and families have reported a substantial heritable 
component of serum urate level with an estimated heritability of 40-70% (228, 229). The 
genetic determinants of serum urate level have been explored in several genome-wide 
association studies (GWAS) (150, 151, 230, 523) and the wealth of GWAS findings allows 
the application of genetic variants as instruments to help separate causal from non-causal 
associations, given that genotypes are generally independent of environmental exposures and 
the transmission of genetic information is usually unidirectional. Investigating the 
associations between urate genetic risk loci and disease outcomes might help provide causal 
evidence in support of the hypotheses which links urate to clinical disorders.  
Our recently published MR-PheWAS analysis (phenome-wide association study 
incorporated with Mendelian randomisation [MR] design) on the interim release data of UK 
Biobank (n=120,091) provided an overview of the disease outcomes that were associated 
with the urate genetic risk loci (461). Our study demonstrated that serum urate level shared 
the same genetic risk loci with multiple disease outcomes, particularly those related to 
cardiovascular/metabolic diseases and autoimmune disorders (461). These findings provide a 
rationale for the further investigation of whether these cross-phenotype associations are 
causal. Although we have applied multiple methodologies to distinguish the PheWAS 
associations that were causal from those due to pleiotropy or genetic linkage, the use of the 
interim release data of UK Biobank set power limitations to our investigation and did not 
allow us to investigate less prevalent phenotypes. The release of the full UK Biobank GWAS 
genotype dataset provides a unique opportunity to validate the previous MR-PheWAS 
findings and to include phenotypes that were not investigated in the previous study due to 
insufficient number of cases and controls.  
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In this study, we performed an updated phenome-wide Mendelian randomisation study 
(PWMS) by using data from the full UK Biobank cohort. A weighted polygenic risk score 
(GRS), incorporating effect estimates of multiple genetic risk loci taken from the most recent 
and largest GWAS (151), was employed as a proxy of serum urate level. The framework of 
phenome was defined by using both the PheCODE schema (also used in the previous MR-
PheWAS) (461) and a novel Bayesian analysis framework, termed TreeWAS: tree-structured 
phenotypic model (460). Any replication of previous findings and/or novel findings were 
further explored in this study. 
6.3 Methods 
6.3.1 UK Biobank data 
UK Biobank is a large-scale, population-based prospective cohort study, designed to 
investigate the genetic and non-genetic determinants of a wide range of complex diseases 
and phenotypes (415). The study recruited over 500,000 participants aged between 40-69 
years in 2006-2010 and combined extensive measurement of baseline data and genotype data 
with linked national medical records (e.g. in-patient hospital episode records, cancer registry 
and death registry) for longitudinal follow-up. UK Biobank obtained ethical approval from 
the North West Multi-Centre Research Ethics Committee (11/NW/0382). The research 
protocol of this study was reviewed by the UK Biobank committee to ensure it was in 
concordance with the Ethics and Governance Framework of UK Biobank. The genotype and 
phenotype data used in this study were obtained from UK Biobank under an approved data 
request application (application ID: 10775).  
Genotype data - Genotyping, quality control and genotype imputation were conducted by the 
UK Biobank team prior to the data release and the detailed procedures are described by 
Bycroft et al (421). The initial 50,000 participants were genotyped by the Affymetrix UK 
BiLEVE Axiom array and the remaining 450,000 participants were genotyped by the 
Affymetrix UK Biobank Axiom array. Genotype imputation was performed based on a 
merged reference panel of the Haplotype Reference Consortium (HRC) (426) and the 
UK10K haplotype resources (424), and the classical allelic variations at the MHC region 
were further imputed by using an additional multi-population reference panel (427). For 
quality control, a list of field variables was made available by the UK Biobank to indicate the 
genotype quality, population structure, and genetic relatedness.   
Phenotype data - A variety of national health systems and sources were used by the UK 
Biobank to follow up the disease diagnosis, cancer occurrence, and causes of death among 
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the enrolled participants. Currently, there are three main different types of health records (i.e. 
hospital inpatient episodes, cancer registry data and death registry data) that have been 
incorporated into the central database. The coding for clinical diagnoses in these datasets 
followed the World Health Organisation’s International Classification of Diseases (ICD) 
coding systems but used different ICD versions (ICD-10 or ICD-9) according to the date of 
record.  Primary and/or secondary ICD codes are available in the hospital inpatient data 
and/or death registry data to classify the main causes and contributory causes of the event of 
hospitalisation and/or death respectively.  
6.3.2 Study population and quality control 
In order to minimise the influence of the diverse population structure in UK Biobank, our 
study was constrained to a subset of unrelated White British subjects with high quality 
genotype data. The metrics used for genotype quality control (QC) were based on the data 
fields created by the UK Biobank. Samples that were identified as a sex mismatch, outliers 
with high heterozygosity or with high missing rate, putative sex chromosome aneuploidy, 
individuals with excess relatives, or non-White British ancestry were all excluded from the 
analysis. The largest possible subset (vertices) of individuals without relatedness were 
identified using an algorithm implemented in the R package “i-graph (v1.0.1)” developed by 
Bycroft et al (421). The detailed procedures for QC and the selection of target population are 
described in the Supplementary Methods. As a result, a subset of 339,256 unrelated 
individuals of White British ancestry were finally included in analysis.  
6.3.3 Weighted genetic risk score  
To generate a genetic proxy for SUA level, genetic risk loci associated with SUA level were 
searched across the GWAS catalogue and literature. Thirty genetic variants that were 
identified in previous GWASs and associated with SUA at p<5×10-8 among European 
population were used in the GRS (150, 151). In comparison to the genetic instruments used 
in the MR analysis performed by White et al (323), one additional SNP, rs164009 located in 
the PRPSAP1 gene (p=7.06×10-7), was included on the basis of its functional role in urate 
metabolism (encoding a protein involved in the regulation of purine synthesis). Therefore, a 
total of 31 independent SNPs were selected as components of the genetic proxy for SUA 
level. The overall proportion of variance (adjusted R2) of SUA level explained by the 31 
genetic variants was estimated to be 7% (151). The SNP effect on SUA level (effect size and 
standard error [SE]) was taken from the largest meta-analysis of GWAS in the European 
population performed by the Global Urate Genetics Consortium (GUGC) consortium (151).  
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Genotypes of the 31 selected SNPs were extracted from the UK Biobank genetic datasets for 
the target population (n=339,256). A weighted genetic risk score (GRS) was constructed by 
incorporating effect estimates of the 31 SUA genetic risk loci. Specifically, the polygenic 
risk score was created by adding up the number of SUA-increasing alleles for each SNP 
weighted based on the SNP effect size (regression beta coefficients) (151) and then adding 
this weighted score for all 31 SNPs. For instance, if an individual 𝑖 carries 𝑔𝑖𝑘 copies of the 
SUA-increasing allele for each variant 𝑘 = 1, … ,31, the weight for variant 𝑘 is 𝑤𝑘  then their 
weighted polygenic score is  𝑍𝑖 = ∑ 𝑤𝑘𝑔𝑖𝑘
31
𝑘=1 . The weighted polygenic risk score was 
calculated by using plink 2.0.  
6.3.4 Phenome framework 
We analysed the three phenotypic datasets (in-patient hospital records, cancer registry data, 
and death registry data) available in the UK Biobank database. As we were interested in 
disease phenotypes, the framework of the phenome was defined based on the ICD codes in 
the electronic medical records. We pooled the hospital episode data, cancer registry data and 
death registry data together and included both the primary and secondary ICD codes. The 
breadth of ICD-10/9 codes used in the UK Biobank well described the range of disease of 
participants, however, individual ICD codes could not be directly used to define the 
phenome, as they were designed to represent increasingly specific sub-phenotypes instead of 
independent phenotypes. To account for the correlations between ICD codes, we applied two 
strategies: (i) the PheCODE schema that has been recently updated and successfully adopted 
in our previous MR-PheWAS (461); and (ii) a novel Bayesian analysis framework 
(TreeWAS) that was developed by the researchers from the Wellcome Trust Centre for 
Human Genetics (460).  
PheCODE schema - The PheCODE system was developed to combine one or more related 
ICD codes into distinct disease groups (433). To develop a phenotyping method applicable 
to the ICD-10 coding system in UK Biobank, we created a map to match ICD-10 codes to 
phecodes (461), The latest version of the PheCODE system includes 1,866 hierarchical 
phenotype codes that could be directly matched to the ICD-9/10 codes and provides a 
scheme to automatically exclude the patients that have similar or potentially overlapping 
disease states from the corresponding control group (e.g., excluding type 1 diabetes from 
being in control group when analysing the phenotype of type 2 diabetes). More details about 
the updated PheCODE system are described in the previous publication (461).  
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Tree-structured phenotypic model - A novel Bayesian analysis framework has recently been 
developed to interrogate the increasingly specific sub-phenotypes defined by ICD-10 coding 
system with increased statistical power to detect genotype-phenotype associations (460). In 
principle, this phenotyping method models the genetic coefficients across all phenotypes as a 
set of random variables. To model the correlations of the hierarchical tree-like structure of 
ICD-10 codes (termed as tree-structured phenotypic model]), a Markov process was applied 
to allow the genetic coefficients to evolve down the tree trunk and branches. The tree 
structure was determined based on the classification hierarchy of ICD-10 coding system, 
where each node in the tree represents a clinical term in the classification. More details about 
the tree-structured phenotyping process are described elsewhere (460).  
6.3.5 Statistical analysis  
To take advantage of both phenotyping models, we explored the association between the 
weighted GRS of urate and the phenome framework defined by both the PheCODE schema 
(described as PheWAS analysis) and the tree-structured phenotypic model (described as 
TreeWAS analysis), respectively. The correlation with weighted GRS was examined for a 
number of potential confounding factors including sex, age, BMI, assessment center and the 
first 5 PCs (Supplementary Table 6-1). In the PheWAS analysis, the associations between 
weighted GRS and phecodes (with no less than 20 cases) were examined by logistic 
regression. Given that many phecodes were not independent, we applied the false discovery 
rate (FDR) method to correct the significance threshold (corresponding to a FDR of q<0.05) 
to account for the multiple testing (473). In the TreeWAS analysis, associations between the 
weighted GRS and the phenome variables were tested by the Bayesian network analysis at 
both terminal and internal nodes of the tree structure. The marginal posterior probability (PP) 
for each node in the tree (where its genetic coefficient was non-zero) and the corresponding 
maximum posteriori effect estimate with 95% credible interval were determined by using the 
maximum a posteriori (MAP) estimator. Any association with any node of the tree at the PP
≥0.95 was highlighted for further investigation. Details about the TreeWAS analysis have 
been described before (460). All the statistical analyses were implemented by R 3.3.2.  
6.3.6 Replication in MR-base database 
To validate findings, PheWAS associations were further examined in the MR-base database 
for replication in different populations. MR-base is a database and analytical platform for 
MR methods developed by the Medical Research Council, Integrative Epidemiology Unit at 
the University of Bristol (524). We applied this platform to replicate the findings by two-
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sample MR analyses (i.e., inverse variance weighted MR [IVW MR] and Egger-MR) using 
summary data from the largest available GWASs for the disease outcomes of interest.  
6.3.7 Sensitivity analysis 
We then performed sensitivity analyses to explore any causal effect and pleiotropic 
association. To identify genetic variants with pleiotropy, we examined their association with 
a set of metabolic traits (i.e., body mass index [BMI], waist to hip ratio [WHR], total 
cholesterol [TC], low-density lipoprotein cholesterol [LDL-c], high-density lipoprotein 
cholesterol [HDL-c], apolipoprotein-A/B, fasting glucose, 2hr glucose, glycoproteins, 
systolic blood pressure [SBP], and diastolic blood pressure [DBP]) through the publicly 
available resources from various GWAS consortia: GIANT (Genetic Investigation of 
ANthropometric Traits) (525), GLGC (Global Lipids Genetic Consortium) (526), MAGIC 
(Meta-Analyses of Glucose and Insulin-related traits Consortium) (527), and ICBP 
(International Consortium for Blood Pressure) (528). Pleiotropy was declared when these 
GWAS summary data reported genetic association between serum urate risk loci and these 
metabolic traits at p<1.61×10-3 (0.05/31) (Supplementary Table 6-2, 6-3, 6-4, 6-5, 6-6): (i) 
urate-specific loci: including 14 SNPs with no pleiotropic effect on the examined metabolic 
traits (Supplementary Table 6-2); (ii) urate-obesity pleiotropic loci: including 10 SNPs with 
pleiotropic effects on BMI or WHR (Supplementary Table 6-3); (iii) urate-BP pleiotropic 
loci: including 10 SNPs with pleiotropic effects on blood pressures (i.e., DBP and SBP) 
(Supplementary Table 6-4); (iv) urate-lipid pleiotropic loci: including 6 SNPs with 
pleiotropic effects on lipids (i.e., TC, LDL-c, HDL-c, apolipoprotein-A/B) (Supplementary 
Table 6-5); (v) urate-glucose pleiotropic loci: including 6 SNPs with pleiotropic effects on 
blood glucose (fasting glucose, 2hr glucose, glycoproteins) (Supplementary Table 6-6). A 
set of GRSs were created accordingly to re-calculate the effect estimates in PheWAS 
analysis.  
6.4 Results 
We included 339,256 unrelated White British individuals from the full UK Biobank cohort, 
consisting of 157,146 men and 182,110 women. The mean age of study population was 
56.87 (standard deviation [SD]: 7.99) and the mean BMI was 27.40 (SD: 4.76) kg/m2 at the 
time of recruitment. Other sociodemographic characteristics of the study population are 
summarised in Supplementary Table 6-1. The mean value of weighted GRS among the 
study population was 0.44 (SD: 0.31), which is equivalent to 0.44 mg/dL of serum urate 
level. The correlations between the weighted GRS and potential confounding factors (i.e., 
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age, sex, BMI, assessment centre and the PCs) are examined in Supplementary Table 6-1. 
Of these, two variables (i.e., assessment centre and the PCs) were statistically significantly 
correlated with the weighted GRS and therefore were adjusted as covariates.  
6.4.1 PheWAS and TreeWAS associations 
Within the study population, we identified 10,750 unique ICD-10 codes and 3,113 ICD-9 
codes in total. After mapping the diagnostic ICD-10/9 codes in UK Biobank to phecodes, the 
phenome defined by PheCODE schema consisted of 1807 distinct phecodes among the study 
population. After filtering the phecodes with no less than 20 cases, PheWAS analysis was 
performed for 1,431 phecodes (median number of cases: 345 [range: 20-107,298]) which 
could be classified into 17 broadly related disease categories (Table 6-1). Associations with 
the weighted GRS of urate were examined for 1,431 case-control groups, leading to an 
adjusted significance threshold of p<3.35×10-4 (corresponding to a FDR of q<0.05) to 
account for multiple testing. Of these, 13 phecodes were identified to be associated with 
genetically determined high serum urate level at p<3.35×10-4 (Table 6-2). These phecodes 
represent 4 disease groups: inflammatory polyarthropathies (OR=1.28; 95%CI: 1.21 to 1.35; 
p=4.97×10-19), hypertensive disease (OR=1.08; 95%CI: 1.05-1.11; p=6.02×10-7), circulatory 
disease (OR=1.05; 95%CI: 1.02 to 1.07; p=3.29×10-4) and metabolic disorders (OR=1.07; 
95%CI: 1.03 to 1.11; p= 3.33×10-4), and 9 disease outcomes: gout (OR=5.37; 95%CI: 4.67 to 
6.18; p= 4.27×10-123), gouty arthropathy (OR=5.11; 95%CI: 2.45 to 10.66; p=1.39×10-5), 
pyogenic arthritis (OR=2.10; 95%CI: 1.41 to 3.14; p=2.87×10-4), essential hypertension 
(OR=1.08; 95%CI: 1.05 to 1.11; p=6.62×10-7), coronary atherosclerosis (OR=1.10; 95%CI: 
1.05 to 1.15; p=1.17×10-5), ischaemic heart disease (OR=1.10, 95%CI: 1.05 to 1.15; 
p=1.73×10-5), chronic ischaemic heart disease (OR=1.10, 95%CI: 1.05 to 1.15; p=1.52×10-5), 
myocardial infarction (OR=1.15, 95%CI:1.07 to 1.23, p=5.23×10-5), and 
hypercholesterolaemia (OR=1.08, 95%CI: 1.04 to 1.13, p=3.34×10-4). 
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Table 6 - 1: The number of phenotypes and cases in each disease category.  
 
 
Disease categories Number of phenotypes 
Number of cases 
Median Mean Maxium 
Circulatory system 140 434 3,581 107,298 
Congenital anomalies  45 102 230 1,480 
Dermatological diseases 74 283 2,544 89,976 
Diseases in sense organs 104 253 1,228 31,845 
Digestive diseases  143 551 3,123 62,862 
Neoplasms 129 493 2,558 84,098 
Infectious diseases 48 190 958 8,600 
Endocrine and metabolic diseases 103 154 1,590 35,954 
Haematopoietic diseases 40 228 1,200 10,095 
Neurological diseases 69 224 1,180 32,194 
Respiratory diseases  71 674 2,448 49,782 
Mental disorders  64 260 1,493 23,226 
Genitourinary diseases 140 655 2,536 82,964 
Pregnancy complications 28 237 914 7,518 
Musculoskeletal diseases 109 347 2,847 59,852 
Clinical symptoms 27 711 3,741 33,553 
Injuries and poisonings  97 388 1,079 13,303 
Chapter 6  PWMR analysis 
258 
 
Table 6 - 2: Phenotypes associated with the weighted GRS of SUA level in PheWAS analysis (p<3.35×10-4). 
Phecode Description Group n_cases n_controls beta se OR (95%CI) P-value 
274.1 Gout endocrine/metabolic 2,532 335,108 1.682 0.071 5.37 (4.67, 6.18) 4.27E-123 
714 Inflammatory polyarthropathies musculoskeletal 15,408 320,862 0.244 0.027 1.27 (1.21, 1.34) 4.97E-19 
401 Hypertension circulatory system 63,694 274,477 0.076 0.015 1.07 (1.05, 1.11) 6.02E-07 
401.1 Essential hypertension circulatory system 63,442 274,477 0.077 0.015 1.08 (1.05, 1.11) 6.26E-07 
411.4 Coronary atherosclerosis circulatory system 25,795 311,554 0.096 0.022 1.10 (1.05, 1.14) 1.17E-05 
274.11 Gouty arthropathy endocrine/metabolic 88 335,108 1.631 0.375 5.10 (2.45, 10.66) 1.39E-05 
411.8 Chronic ischaemic heart disease, unspecified circulatory system 25,567 311,554 0.095 0.022 1.09 (1.05, 1.14) 1.52E-05 
411 Ischaemic Heart Disease circulatory system 25,617 311,554 0.094 0.022 1.09 (1.05, 1.14) 1.73E-05 
411.2 Myocardial infarction circulatory system 9,829 311,554 0.138 0.034 1.14 (1.07, 1.22) 5.23E-05 
711.1 Pyogenic arthritis musculoskeletal 270 277,590 0.742 0.205 2.10 (1.41, 3.13) 2.87E-04 
459.9 Circulatory disease  circulatory system 107,298 230,622 0.046 0.013 1.04 (1.02, 1.07) 3.29E-04 
277 Disorders of metabolism endocrine/metabolic 35,954 302,209 0.067 0.019 1.07 (1.03, 1.11) 3.33E-04 
272.11 Hypercholesterolaemia endocrine/metabolic 27,040 308,948 0.077 0.021 1.08 (1.04, 1.12) 3.34E-04 
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In the Bayesian analysis framework, containing 10,750 diagnostic terms, a total of 27 
parent/child nodes of ICD-10 terms were identified with PP≥0.95. They were clustered 
mainly in five branches of the hierarchical tree structure (Supplementary Table 6-7): (i) 
block M10 (gout, OR=5.16, 95%CI 4.55 to 5.84; PP=1.00) and its sub-phenotypes M10.0 
(idiopathic gout) and M10.9 (gout, unspecified); (ii) block I10-I15 (hypertensive disease, 
OR=1.07, 95%CI 1.06 to 1.08; PP>0.99) and its sub-phenotype I10 (essential hypertension); 
(iii) block I20-I25 (ischaemic heart diseases, OR=1.07, 95%CI 1.06 to 1.08; PP>0.99) and its 
sub-phenotypes I20 (angina pectoris), I21 (acute myocardial infarction), I25 (chronic 
ischaemic heart disease), I25.1 (atherosclerotic heart disease), I25.2 (old myocardial 
infarction); (iv) block I30-I52 (other forms of heart disease, OR=1.07, 95%CI 1.06 to 1.08; 
PP>0.99) and its sub-phenotype I50 (heart failure) and I50.1 (left ventricular failure); (v) 
block I60-I69 (cerebrovascular diseases, OR=1.07, 95%CI 1.06 to 1.08; PP>0.99) and its 
sub-phenotype I10 (cerebral infarction).  
Findings from PheWAS and TreeWAS were generally consistent in their associations with 
gout, hypertensive disease, and heart diseases, while more sub-phenotypes were identified by 
TreeWAS. Association with the disease group of inflammatory polyarthropathies was 
statistically significant in PheWAS (OR=1.28, 95%CI: 1.21 to 1.35, p=4.97×10-19) but had a 
moderate PP in TreeWAS (OR=1.07, 95%CI: 1.06 to 1.08, PP=0.76). We examined the 
specific diseases included in this disease group (M05-M06: rheumatoid arthritis [RA], M07: 
psoriatic and enteropathic arthropathies, M08-09: juvenile arthritis, M10: gout, and M11-14: 
arthropathies and other arthritis), and only gout had a statistically significant association with 
the genetically determined serum urate levels. Association with cerebrovascular diseases had 
a high PP in TreeWAS (OR=1.07, 95%CI: 1.06 to 1.08, PP>0.99) but did not reach 
significance threshold of PheWAS (OR=1.08, 95%CI: 0.99 to 1.16, p=0.07), although their 
estimates were of the same direction. We re-calculated the PheWAS estimates by adding up 
self-reported stroke cases to increase statistical power (n=4,541), but the corresponding 
estimates were still not statistically significant (OR=1.05, 95%CI: 0.99 to 1.13, p=0.13, 
n=9,528). 
6.4.2 Replication in MR-base database 
To validate the findings, we performed two-sample MR analyses on associated diseases (i.e., 
gout, RA, CHD, myocardial infarction, ischaemic stroke) or on their corresponding 
intermediate traits or surrogate outcomes (i.e., SBP, DBP, total cholesterol, LDL-c, HDL-c) 
(Table 6-3). Results from IVW MR suggested that genetically determined high serum urate 
level was associated with increased risk of gout (OR=4.53, 95%CI: 3.64 to 5.64, p= 9.66×10-
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42), CHD (OR=4.53, 95%CI: 3.64 to 5.64, P=9.66×10-42), myocardial infarction (OR=4.53, 
95%CI: 3.64 to 5.64, P=9.66×10-42) and decreased level of HDL-c (OR=4.53, 95%CI: 3.64 
to 5.64, p=9.66×10-42), but had no effect on RA (OR=0.92, 95%CI: 0.84 to 1.01, p=0.085) 
and ischaemic stroke (OR=1.03, 95%CI: 0.93 to 1.14, p=0.582). Egger MR indicated 
pleiotropic effects on the causal estimates of DBP (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.014), SBP (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.003), 
CHD (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.008), myocardial infarction (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 = 0.014) and HDL-c (𝑃𝑝𝑙𝑒𝑖𝑜𝑡𝑟𝑜𝑝𝑦 =
0.014). When balancing out the potential pleiotropic effects in Egger MR, causal effect can 
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Table 6 - 3: Replication of MR effect estimates in MR-base database.  
Outcome beta se OR (95% CI) P effect P pleiotropy n_cases n_total Data source 
Replication of significant PheWAS findings 
     
Gout 
        
PheWAS 1.682 0.071 5.37 (4.67, 6.18) 4.27E-123 -- 2,532 337,640 UKBB 
IVW MR 1.511 0.112 4.53 (3.64, 5.64) 9.66E-42 -- 
2,115 67,259 GUGC 
Egger MR 1.427 0.163 4.17 (3.03, 5.74) 1.27E-09 0.485 
Hypertension 
       
PheWAS 0.076 0.015 1.07 (1.05, 1.11) 6.02E-07 -- 63,694 338,171 UKBB 
DBP 
    
 
   
IVW MR 0.427 0.272 1.53 (0.90, 2.61) 0.116 -- -- 
69,395 ICBP 
Egger MR -0.219 0.351 0.80 (0.40, 1.60) 0.538 0.014 -- 
SBP 
    
 
   
IVW MR 0.409 0.402 1.51 (0.68, 3.31) 0.308 -- -- 
69,395 ICBP 
Egger MR -0.713 0.496 0.49 (0.19, 1.29) 0.161 0.003 -- 
Coronary heart disease 
        
PheWAS 0.094 0.022 1.09 (1.05, 1.14) 1.73E-05 -- 25,617 337,171 UKBB 
IVW MR 0.098 0.038 1.10 (1.02, 1.19) 0.009 -- 
60,801 123,504 CARDIoGRAMplusC4D 
Egger MR 0.001 0.048 1.00 (0.91, 1.10) 0.977 0.008 
Myocardial infarction 
       
PheWAS 0.138 0.034 1.14 (1.07, 1.22) 5.23E-05 -- 9,829 321,383 UKBB 
IVW MR 0.105 0.041 1.00 (0.90, 1.11) 0.983 -- 
43,676 128,199 CARDIoGRAMplusC4D 
Egger MR -0.001 0.053 1.11 (1.02, 1.20) 0.011 0.008 




       
PheWAS 0.077 0.021 1.08 (1.04, 1.12) 3.34E-04 -- 27,040 335,988 UKBB 
Total cholesterol 
       
IVW MR 0.028 0.036 1.03 (0.96, 1.10) 0.433 -- -- 
94,595 GLGC 
Egger MR 0.048 0.052 1.05 (0.95, 1.16) 0.368 0.602 -- 
HDL-c 
        
IVW MR -0.075 0.026 0.93 (0.88, 0.98) 4.00E-03 -- -- 
94,311 GLGC 
Egger MR -0.010 0.035 0.99 (0.92, 1.06) 0.767 0.016 -- 
LDL-c 
        
IVW MR 0.011 0.023 1.05 (0.95, 1.16) 0.623 -- -- 
89,888 GLGC 
Egger MR 0.045 0.033 1.05 (0.98, 1.12) 0.188 0.175 -- 
Replication of non-significant PWMR findings 
     
RA 
        
PheWAS 0.095 0.055 1.10 (0.99, 1.22) 0.683 -- 3,522 324,384 UKBB 
IVW MR -0.081 0.047 0.92 (0.84, 1.01) 0.085 -- 
19,234 61,565 MR-base 
Egger MR -0.103 0.066 0.90 (0.79, 1.03) 0.132 0.645 
Ischaemic stroke 
       
PheWAS 0.071 0.04 1.08 (0.99-1.16) 0.070 -- 9,528 338,172 UKBB 
IVW MR 0.029 0.052 1.03 (0.93, 1.14) 0.582 -- 
10,307 19,326 ISGC 
Egger MR -0.028 0.074 0.97 (0.84, 1.12) 0.707 0.290 
UKBB, UK Biobank; GUGC, Global Urate Genetics Consortium; ICBP, International Consortium of Blood Pressure; CARDIoGRAMplusC4D,  
Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics) consortium;  
GLGC, Global Lipids Genetics Consortium; ISGC, International Stroke Genetics Consortium. 
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6.4.3 Sensitivity analysis 
To further investigate the influence of pleiotropy, we re-calculated the PheWAS estimates by 
using a number of GRSs created based on their association with a set of metabolic traits 
(Figure 6-1). The GRS of urate-specific loci was only associated with gout and its 
encompassing disease group of inflammatory polyarthropathies, but not with any 
cardiovascular/metabolic diseases. In contrast, the GRSs of loci pleiotropic influence on 
obesity, BP, lipids and glucose showed significant association with both gout and the 
cardiovascular/metabolic diseases. Specifically, the GRS of pleiotropic loci on lipids was 
significantly associated with all cardiovascular/metabolic diseases, including hypertensive 
diseases (i.e., essential hypertension), heart diseases (i.e., ischaemic heart diseases), and 
metabolic disorders (i.e., hypercholesterolaemia). Additionally, the GRS of pleiotropic loci 
on glucose was significantly associated with diabetes mellitus (i.e., type 2 diabetes). When 
removing any group of pleiotropic loci from the creation of GRS, their association with 
hypertensive diseases, heart diseases, and metabolic disorders were not statistically 
significant (Table 6-4). The effects of pleiotropic loci (mapped with genes) on SUA levels 
against their effects on four representative disease outcomes were plotted in Figure 6-2, in 
which the two urate transporter genes (SLC2A9 and ABCG2) are recognised as the leading 
loci driving the association with gout, the GCKR gene is the leading locus driving the 
association with hypercholesterolaemia, and the PTPN11/ATXN2 gene is the leading locus 
driving the association with hypertension and ischaemic heart diseases.  




Figure 6 - 1: A network plot for sensitivity analysis of PheWAS using different sets of 
weighted GRSs.  
(M05-M14: Inflammatory polyarthropathies; I10-I15: Hypertensive diseases; I20-I25: Ischaemic heart 
diseases; E70-E90: Metabolic disorders) 
 




Figure 6 - 2: A scatter plot for the effects of pleiotropic loci (mapped with genes) on SUA 
levels against their effects on four representative disease outcomes. 
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Table 6 - 4: Sensitivity analysis by removing the pleiotropic loci on metabolic traits. 
Disease 
outcomes 
GRS of all-urate loci (n=31) 
GRS of loci without pleiotropy on 
obesity (n=21) 
GRS of loci without pleiotropy on 
BP (n=21) 
GRS of loci without pleiotropy on 
lipids (n=25) 
GRS of loci without pleiotropy on 
glucose (n=28) 



















































































































































































































































































































The present study demonstrated that genetically determined high serum urate level was 
consistently associated with increased risk of several disease groups, including inflammatory 
polyarthropathies (e.g., gout and gouty arthropathy), hypertensive diseases (e.g., essential 
hypertension), heart diseases (e.g., coronary atherosclerosis, myocardial infarction, angina 
pectoris,  ischaemic heart disease and heart failure) and metabolic disorders (e.g., 
hypercholesterolaemia). This study using data from the full UK Biobank cohort (n=339,256) 
replicated the associations discovered in the previous MR-PheWAS study based on the 
interim release of UK Biobank genetic data (n=120,091) (461), and identified a number of 
new sub-phenotypes of diseases (e.g., gouty arthropathy, angina pectoris, and heart failure). 
Association between urate and the risk of gout, CHD, myocardial infarction and decreased 
level of HDL-c were also successfully replicated in different populations by analysing 
various GWAS consortium data documented in the MR-base database (524),  but a causal 
relationship was only supported for gout. The role of urate in the development of 
cerebrovascular diseases is debatable, as their association was only identified in TreeWAS 
but cannot be replicated in PheWAS or MR analysis. Overall, findings from the current 
study supported the epidemiological observations that high serum urate level is correlated 
with high risk of hypertensive diseases, heart diseases, and metabolic disorders, and 
indicated that their associations were likely due to genetic pleiotropy instead of causality.  
6.5.1 Main findings and possible explanations 
Our finding that genetically predicted serum urate level is causally associated with increased 
risk of gout and its sub-phenotypes is not surprising, as it is well known that the causal factor 
of gout is represented by the monosodium urate crystals (MSU), which leads to acute local 
inflammation in joints (529). Moreover, this study also detected an association between urate 
and the disease group of inflammatory polyarthropathies. To investigate if there was any 
other type of inflammatory polyarthropathies associated with urate, we examined the 
association of urate with all specific diseases included in this group, but none of them are 
statistically significant. When removing gout cases from analysis, the disease group of 
inflammatory polyarthropathies was no longer associated with urate, indicating the observed 
association was driven by gout. As emerging evidence supports the notion that urate has pro-
inflammatory effects and may contribute to a growing family of auto-inflammatory disease 
(e.g., RA) through the production of a panel of inflammatory cytokines including IL-1β, IL-8, 
TNF-α, and IL-6 (529) (530). It is hypothesised that these findings are of relevance to RA, as 
IL-6 is a key pro-inflammatory cytokine that is originally described as a T-cell-derived B-
Chapter 6  PWMR analysis 
268 
 
cell differentiation factor and may stimulate the production of autoantibodies such as 
rheumatoid factor (531, 532). In this study, we additionally examined the association 
between the GRS of urate and RA in both UK biobank population (3,522 cases) and a larger 
European population (19,234 cases) (533), but neither of them detected any significant 
association. Our study did not provide any supportive evidence on the aetiological relevance 
between urate and RA as suggested by prior studies.  
Numerous epidemiological studies have reported that elevated serum urate level is related to 
increased risk of hypertension and their relationship has been consistent, showing a dose-
response relationship and of similar magnitude (486). Findings from this study supported 
their association, but the magnitude of estimated effect size (OR=1.07; 95%CI: 1.05 to 1.11) 
is relatively smaller than that of traditional epidemiological studies, in which a recent meta-
analysis synthesised data from 97,824 individuals and reported a pooled OR of 1.15 (95%CI: 
1.06 to 1.26) for incident hypertension for a 1 mg/dL increase of serum urate level (534). 
Similarly, the association between urate and a multitude of cardiac events of varying severity, 
including coronary atherosclerosis, angina pectoris, ischaemic heart diseases, acute/old 
myocardial infarction and heart failure, were also well explored in this study. The PheWAS, 
TreeWAS, and IVW MR replication analysis consistently supported a moderate association 
between urate and different types of heart diseases. However, the Egger-MR analysis 
reported here provided no evidence for causality, but suggested the presence of pleiotropy in 
their associations.  
Large epidemiological studies have established an association between high serum urate 
level and the increased risk of metabolic disorders (535). The NHANES III survey study 
suggested that high serum urate level was associated with increased level of serum LDL-c, 
triglycerides, total cholesterol, apolipoprotein-B, and decreased level of HDL-c (536). Our 
study further strengthened this epidemiological evidence and highlighted an association 
between urate and hypercholesterolaemia. Our IVW MR analysis replicated the 
corresponding association with its surrogate outcome (i.e., HDL-c), but the Egger-MR 
analysis suggested the presence of pleiotropy instead of causality. Additionally, 
epidemiological studies have also indicated that high serum urate level is associated with 
increased risk of diabetes (537). However, this association was not detected in the main 
PheWAS or TreeWAS analysis, while sensitivity analysis using the GRS of urate-glucose 
pleiotropic loci (i.e., GCKR, IGF1R, and SLC16A9) identified significant association with 
type 2 diabetes. 
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To explore how genetic pleiotropy influences the association with cardiovascular/metabolic 
diseases, we analysed all 31 urate loci across a set of metabolic traits and identified 14 SNPs 
(urate-specific loci) that were exclusively associated with urate and 17 SNPs (pleiotropic loci) 
that were associated with metabolic traits. When examining the urate-specific loci, their GRS 
was only associated with gout and its encompassing disease group of inflammatory 
polyarthropathies, but not with any cardiovascular or metabolic diseases. In contrast, when 
categorising the pleiotropic loci into different groups (e.g., GRS of urate-obesity loci, GRS 
of urate-BP loci, GRS of urate-lipids loci and GRS of urate-glucose loci), the GRSs of 
pleiotropic loci showed consistent associations with both gout and the 
cardiovascular/metabolic diseases. When removing any group of pleiotropic loci from the 
creation of GRS (e.g., GRS of urate without pleiotropic loci on BP, or GRS of urate without 
pleiotropic loci on lipids), their association with heart diseases and metabolic disorders was 
not statistically significant. Based on these findings, our study suggests that the association 
between urate and cardiovascular/metabolic diseases is probably due to the pleiotropic 
effects of genetic variants on urate and metabolic traits.  
Examining the associations between individual urate genetic risk loci and the related disease 
outcomes highlighted two loci, GCKR and PTPN11/ATXN2 that drive their association with 
hypercholesterolaemia, hypertension and ischaemic heart disease. Pathway network analysis 
of the leading pleiotropic genes provides some clues on how genetic pleiotropy contributes 
to the association between urate and cardiovascular/metabolic disease. Genetic variation in 
GCKR is shown to be associated with concentrations of urate, triglyceride and glucose (538). 
The most plausible explanation for this observation is that GCKR affects both serum urate, 
triglyceride and glucose levels by a common unconfirmed mediator which is proposed to be 
glucose-6-phosphate (539). GCKR controls the hepatic production of glucose-6-phosphate, 
which is catabolised for triglyceride synthesis via glycolysis, into pyruvate, and acetyl 
coenzyme A, while glucose-6-phosphate is also a precursor of purine (uric acid) metabolism 
(539). Additionally, gene functional annotation of PTPN11/ATXN2 highlights another 
subnetwork around haemostasis pathways, including platelet activation, aggregation, and 
sensitisation (activated by LDL-c) (540), and these may be relevant to the observed 
association with hypertension and heart diseases, but how this gene influences serum urate 
levels has not yet been clearly demonstrated. 
6.5.2 Clinical implications and future research 
The detection of a multitude of cross-phenotype associations in this study adds our 
understanding of the extent of shared genetic/biological components between urate and 
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metabolic traits. Further characterising the associations between urate and disease outcomes 
as causal or pleiotropic contributes to our knowledge of how the role of urate should be 
interpreted and used in clinical practice in the management of related disease conditions. 
Given that the associations between urate and cardiovascular/metabolic diseases are more 
likely due to pleiotropy rather than causality, our study supports the notion that urate could 
be a predictor but not be a target for the development of compounds that could reduce 
cardiovascular/metabolic disease risk. The linked biological pathways between urate and 
metabolic traits indicated that the frequent co-existence of gout with hypertension, 
cardiovascular diseases and hyperlipidaemia is a range of inter-related disease outcomes due 
to linked pathogenic components, rather than isolated events. This supports the European 
League against Rheumatism (EULAR) recommendation of systematic screening and 
assessment of cardiovascular/metabolic comorbidities in gout patients (541). The finding of 
genetic pleiotropy indicates the existence of common upstream pathological elements 
influencing both urate and metabolic traits, and this may suggest new opportunities and 
challenges for developing drugs targeting a more distal mediator that would be beneficial for 
both the treatment of gout and the prevention of cardiovascular/metabolic comorbidities. 
This study has focused on the detection of cross-phenotype associations and highlighted the 
importance of pleiotropy in the links of these complex diseases. We have made efforts to try 
to understand the cross-phenotype association in the context of a pleiotropy model, but 
functionally characterising the underlying biological mechanisms remains a challenge in this 
field and is worthy of further investigation. 
6.5.3 Strengths and weaknesses of the study 
The strengths of this study include its potential to examine a broad spectrum of disease 
outcomes related to urate and to reflect the shared biological relevance among associated 
phenotypes. Compared to the previous MR-PheWAS (461), the present study extends the 
prior findings by combining genetic risk loci of urate into a weighted GRS, exploring genetic 
pleiotropy on a set of metabolic traits systematically, investigating more disease outcomes, 
assessing their associations with >3-fold more cases, examining consistency of findings 
across two different phenotyping models to reduce the probability of false positive/negative 
findings due to factors related to the model, and replicating the findings by performing two-
sample MR in different populations. Our study demonstrated the performance of two 
phenotyping models by accounting for the differences in the specificity and granularity of 
different phenome definitions and by characterising the phenotypic correlations among 
different levels of ICD hierarchy. TreeWAS is shown to increase statistical power by up to 
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20%, and can detect new associations missed by conventional PheWAS. One of the major 
accomplishments of this study together with the previous MR-PheWAS have been the 
establishment of a framework or workflow for PheWAS (461). We believe this study would 
be an excellent starting point for researchers who plan to use the UK Biobank resource to 
comprehensively interrogate the clinical significance of biomarkers. The updated version of 
the PheCODE schema used in this study is available for researchers who are interested in 
performing PheWAS in UK Biobank when requested.  
This study also has limitations. The causal inference in our study is limited by the common 
difficulty of pleiotropy caused by the use of multiple genetic instruments. Although we have 
performed sensitivity analyses by grouping the pleiotropic loci based on metabolic traits and 
exploring their association separately, there is still a probability of undetected pleiotropy or 
the possibility that the relatively weak causal effects of urate on diseases were concealed by 
the strong pleiotropic effects of the genetic variants on metabolic traits. Moreover, as most 
patients (cases) were identified from the in-patient hospital records, this may have impaired 
the coverage of case ascertainment, especially for the diseases that do not usually cause 
events for hospitalisation. The incorporation of self-reported data would improve this 
limitation but is likely to mistakenly include cases who do not have a true diagnosis and 
introduce information biases. As UK Biobank is currently conducting biomarker assays and 
processing linkage to general practice records and out-patient data, it would be beneficial to 
confirm the potential association based on a widely-covered and accurately-defined criteria 
for case ascertainment in the future.  
6.6 Conclusion  
Overall, when taken together the findings from PheWAS/TreeWAS, MR replication and 
sensitivity analysis, we conclude a robust association between urate and a group of diseases, 
including gout, hypertensive diseases, heart diseases and metabolic disorders of lipids, but 
the causal role of urate is only supported in gout. Our study indicates that the association 
between urate and cardiovascular/metabolic diseases is probably due to the pleiotropic 
effects of genetic variants on urate and metabolic traits. These findings suggest that urate 
could be a good predictor for the cardiovascular/metabolic disease risk. Further investigation 
on therapies targeting on the shared biological pathways between urate and metabolic traits 
would be beneficial for the treatment of gout and the primary prevention of 
cardiovascular/metabolic comorbidities.  
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6.7 Supplementary information 
Supplementary Table 6 - 1: Association between the GRS of urate and potential 
confounding factors. 
Continuous variable Mean (SD) Beta (SE) P-value 
Age 56.87 (7.99) 0.010 (0.044) 0.830 
BMI 27.40 (4.76) -0.023 (0.027) 0.381 
PC1 score -12.35 (1.61) 0.007 (0.009) 0.408 
PC2 score 3.78 (1.50) -0.023 (0.008) 0.007* 
PC3 score -1.59 (1.58) -0.003 (0.009) 0.753 
PC4 score 1.29 (2.94) 0.104 (0.016) 1.74e-10* 
PC5 score -0.81 (6.61) 0.344 (0.037) 2.20e-16* 
Categorical variable Levels F-value P-value 
Sex male/female 0.476 0.490 
Assessment centre 22 centres 3.451 1.41e-07* 
BMI, body mass index; PC, genetic principal component.  
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Supplementary Table 6 - 2: A summary of 31 urate SNPs identified in previous GWAS.  
SNP Chr Closest/GRAIL gene Effect allele Allele freq beta se P Pleiotropy 
rs10821905 10 A1CF/ASAH2 A 0.824 0.053 0.007 3.45E-12 No 
rs1165151 6 SLC17A1/SLC17A3 T 0.549 -0.092 0.005 4.52E-60 No 
rs12498742 4 SLC2A9/SLC2A9 A 0.232 0.380 0.006 0.00E+00 No 
rs1394125 15 UBE2Q2/NRG4 A 0.638 0.043 0.006 9.78E-11 No 
rs1471633 1 PDZK1/PDZK1 A 0.538 0.061 0.005 1.40E-26 No 
rs164009 17 QRICH2/PRPSAP1 A 0.387 0.029 0.006 7.06E-07 No 
rs17632159 5 TMEM171/TMEM171 C 0.697 -0.038 0.006 2.00E-09 No 
rs17786744 8 STC1/STC1 A 0.410 -0.031 0.005 8.82E-08 No 
rs2078267 11 SLC22A11/SLC22A11 T 0.452 -0.078 0.006 8.73E-36 No 
rs675209 6 RREB1/RREB1 T 0.731 0.063 0.006 1.38E-21 No 
rs6770152 3 SFMBT1/MUSTN1 T 0.424 -0.048 0.006 2.66E-16 No 
rs7188445 16 MAF/MAF A 0.672 -0.032 0.006 1.15E-07 No 
rs7224610 17 HLF/HLF A 0.396 -0.038 0.006 4.74E-11 No 
rs742132 6 LRRC16A/LRRC16A A 0.294 0.035 0.006 1.90E-08 No 
rs10480300 7 PRKAG2/PRKAG2 T 0.727 0.032 0.006 9.37E-07 Yes 
rs11264341 1 TRIM46/PKLR T 0.571 -0.048 0.006 1.04E-14 Yes 
rs1171614 10 SLC16A9/SLC16A9 T 0.769 -0.074 0.007 6.48E-23 Yes 
rs1178977 7 BAZ1B/MLXIPL A 0.198 0.050 0.007 6.68E-12 Yes 
rs1260326 2 GCKR/GCKR T 0.607 0.077 0.006 1.31E-40 Yes 
rs17050272 2 INHBB/INHBB A 0.589 0.037 0.006 9.36E-09 Yes 
rs2079742 17 BCAS3/C17orf82 T 0.136 0.051 0.008 6.24E-09 Yes 
rs2231142 4 ABCG2/ABCG2 T 0.887 0.220 0.009 4.43E-116 Yes 
rs2307394 2 ORC4L/ACVR2A T 0.303 -0.035 0.006 7.26E-09 Yes 
rs2941484 8 HNF4G/HNF4G T 0.553 0.049 0.006 3.91E-17 Yes 
rs3741414 12 INHBC/INHBE T 0.755 -0.071 0.007 9.79E-22 Yes 
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SNP Chr Closest/GRAIL gene Effect allele Allele freq beta se p-val Pleiotropy 
rs478607 11 NRXN2/SLC22A12 A 0.153 -0.048 0.007 5.31E-10 Yes 
rs642803 11 OVOL1/LTBP3 T 0.536 -0.043 0.005 4.51E-14 Yes 
rs653178 12 ATXN2/PTPN11 T 0.483 -0.036 0.005 2.45E-10 Yes 
rs6598541 15 IGF1R/IGF1R A 0.645 0.044 0.006 5.20E-13 Yes 
rs7193778 16 NFAT5/NFAT5 T 0.150 -0.047 0.008 2.36E-08 Yes 
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Supplementary Table 6 - 3: A summary of the pleiotropic effect of urate SNPs on obesity.   
SNP Chr Closest/GRAIL gene effect_allele 
BMI (n=336,107) WHR (n=141,537) 
Pleiotropy 
beta se p beta se P 
rs2231142 4 ABCG2/ABCG2 T -0.081 0.017 2.16E-06 0.029 0.025 0.261 Yes 
rs7193778 16 NFAT5/NFAT5 T 0.339 0.072 2.17E-06 0.468 0.130 3.10E-04 Yes 
rs2941484 8 HNF4G/HNF4G T 0.207 0.050 3.07E-05 -0.204 0.088 0.020 Yes 
rs1260326 2 GCKR/GCKR T -0.131 0.032 4.22E-05 0.130 0.045 0.004 Yes 
rs478607 11 NRXN2/SLC22A12 A -0.281 0.069 5.08E-05 0.152 0.119 0.200 Yes 
rs11264341 1 TRIM46/PKLR T 0.192 0.050 1.40E-04 -0.152 0.092 0.097 Yes 
rs642803 11 OVOL1/LTBP3 T 0.198 0.056 4.22E-04 0.133 0.077 0.084 Yes 
rs653178 12 ATXN2/PTPN11 T -0.233 0.067 4.93E-04 0.072 0.097 0.458 Yes 
rs6598541 15 IGF1R/IGF1R A 0.194 0.057 6.89E-04 0.089 0.077 0.251 Yes 
rs1178977 7 BAZ1B/MLXIPL A -0.179 0.060 0.003 0.360 0.086 2.84E-05 Yes 
rs1471633 1 PDZK1/PDZK1 A 0.091 0.039 0.021 -0.069 0.072 0.340 No 
rs2079742 17 BCAS3/C17orf82 T -0.158 0.069 0.022 -0.039 0.129 0.762 No 
rs3741414 12 INHBC/INHBE T -0.060 0.039 0.128 0.008 0.056 0.881 No 
rs7224610 17 HLF/HLF A -0.099 0.065 0.128 -0.082 0.113 0.471 No 
rs17050272 2 INHBB/INHBB A 0.099 0.066 0.133 -0.016 0.124 0.896 No 
rs729761 6 VEGFA/VEGFA T -0.087 0.058 0.136 0.261 0.104 0.012 No 
rs1171614 10 SLC16A9/SLC16A9 T 0.057 0.039 0.138 0.080 0.078 0.309 No 
rs2307394 2 ORC4L/ACVR2A T 0.106 0.075 0.159 -0.031 0.129 0.807 No 
rs1394125 15 UBE2Q2/NRG4 A -0.076 0.058 0.193 -0.067 0.114 0.554 No 
rs12498742 4 SLC2A9/SLC2A9 A 0.010 0.007 0.203 -0.001 0.013 0.952 No 
rs17786744 8 STC1/STC1 A 0.098 0.079 0.217 0.155 0.139 0.264 No 
rs10480300 7 PRKAG2/PRKAG2 T -0.103 0.084 0.222 -0.172 0.150 0.252 No 
rs675209 6 RREB1/RREB1 T -0.046 0.043 0.280 -0.206 0.079 0.009 No 
rs742132 6 LRRC16A/LRRC16A A 0.075 0.075 0.320 0.174 0.131 0.185 No 
rs1165151 6 SLC17A1/SLC17A3 T -0.025 0.026 0.345 0.050 0.046 0.273 No 
rs6770152 3 SFMBT1/MUSTN1 T 0.039 0.051 0.448 0.044 0.090 0.625 No 
rs2078267 11 SLC22A11/SLC22A11 T -0.023 0.031 0.453 -0.104 0.055 0.060 No 
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SNP Chr Closest/GRAIL gene 
Effect 
allele 
BMI (n=336,107) WHR (n=141,537) 
Pleiotropy 
beta se p beta se P 
rs10821905 10 A1CF/ASAH2 A -0.031 0.060 0.600 0.053 0.106 0.617 No 
rs17632159 5 TMEM171/TMEM171 C 0.027 0.069 0.694 -0.016 0.126 0.901 No 
rs7188445 16 MAF/MAF A 0.011 0.080 0.893 -0.203 0.141 0.149 No 
rs164009 17 QRICH2/PRPSAP1 A -0.007 0.085 0.936 -0.100 0.152 0.510 No 
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Supplementary Table 6 - 4: A summary of the pleiotropic effect of urate SNPs on blood pressure.   
SNP Chr Closest/GRAIL gene 
Effect 
allele 
DBP (n=317,754) SBP (n=317,756) 
Pleiotropy 
beta se P beta se P 
rs653178 12 ATXN2/PTPN11 T 1.057 0.068 6.66E-54 0.585 0.068 1.16E-17 Yes 
rs642803 11 OVOL1/LTBP3 T 0.377 0.057 4.83E-11 0.269 0.057 2.85E-06 Yes 
rs2307394 2 ORC4L/ACVR2A T 0.396 0.077 2.47E-07 0.091 0.077 0.235 Yes 
rs10480300 7 PRKAG2/PRKAG2 T 0.364 0.086 2.38E-05 0.453 0.086 1.45E-07 Yes 
rs729761 6 VEGFA/VEGFA T 0.236 0.060 7.38E-05 -0.040 0.060 0.506 Yes 
rs2941484 8 HNF4G/HNF4G T 0.194 0.051 1.30E-04 0.155 0.051 0.002 Yes 
rs1178977 7 BAZ1B/MLXIPL A 0.230 0.062 1.93E-04 0.026 0.062 0.676 Yes 
rs7193778 16 TRIM46/PKLR T -0.081 0.073 0.268 0.347 0.073 2.19E-06 Yes 
rs11264341 1 BCAS3/C17orf82 T 0.146 0.052 0.005 0.173 0.052 8.20E-04 Yes 
rs2079742 17 NFAT5/NFAT5 T 0.136 0.070 0.054 0.257 0.070 2.52E-04 Yes 
rs6770152 3 SFMBT1/MUSTN1 T 0.154 0.052 0.003 0.119 0.052 0.022 No 
rs7188445 16 MAF/MAF A -0.214 0.082 0.009 -0.037 0.082 0.655 No 
rs7224610 17 HLF/HLF A 0.174 0.067 0.009 0.202 0.067 0.002 No 
rs12498742 4 SLC2A9/SLC2A9 A 0.017 0.008 0.023 0.009 0.008 0.219 No 
rs1471633 1 PDZK1/PDZK1 A 0.080 0.040 0.048 0.041 0.040 0.313 No 
rs17786744 8 STC1/STC1 A 0.140 0.081 0.083 -0.114 0.081 0.159 No 
rs17050272 2 INHBB/INHBB A 0.111 0.068 0.099 0.063 0.068 0.354 No 
rs3741414 12 INHBC/INHBE T 0.062 0.040 0.126 0.125 0.040 0.002 No 
rs1165151 6 SLC17A1/SLC17A3 T 0.041 0.027 0.129 0.069 0.027 0.010 No 
rs1171614 10 SLC16A9/SLC16A9 T 0.048 0.039 0.224 0.103 0.039 0.009 No 
rs17632159 5 TMEM171/TMEM171 C -0.063 0.071 0.368 -0.066 0.070 0.349 No 
rs10821905 10 A1CF/ASAH2 A 0.046 0.061 0.447 0.174 0.061 0.004 No 
rs478607 11 NRXN2/SLC22A12 A 0.049 0.071 0.490 0.106 0.071 0.136 No 
rs2231142 4 ABCG2/ABCG2 T -0.012 0.018 0.497 -0.050 0.018 0.005 No 
rs2078267 11 SLC22A11/SLC22A11 T 0.020 0.032 0.523 0.000 0.032 0.999 No 
rs164009 17 QRICH2/PRPSAP1 A 0.050 0.087 0.570 -0.025 0.087 0.770 No 
rs1394125 15 UBE2Q2/NRG4 A 0.026 0.060 0.658 0.042 0.060 0.477 No 
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SNP Chr Closest/GRAIL gene 
Effect 
allele 
DBP (n=317,754) SBP (n=317,756) 
Pleiotropy 
beta se P beta se P 
rs6598541 15 IGF1R/IGF1R A 0.023 0.059 0.698 -0.029 0.059 0.618 No 
rs1260326 2 GCKR/GCKR T -0.012 0.033 0.714 0.066 0.033 0.044 No 
rs675209 6 RREB1/RREB1 T 0.012 0.044 0.792 -0.024 0.044 0.593 No 
rs742132 6 LRRC16A/LRRC16A A 0.005 0.077 0.950 0.003 0.077 0.966 No 
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TC (n=94,595) LDL-c (n=89,888) HDL-c (n=94,311) ApoA (n=18,403) ApoB (n=20,689) 
Pleiotropy 
beta se p beta se p beta se p beta se p beta se p 
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Supplementary Table 6 - 6: A summary of the pleiotropic effect of urate SNPs on glucose.   
SNP Chr Closest/GRAIL gene 
Effect 
allele 
Fasting glucose (n=15,234) 2hr glucose (n=58,074) Glycoproteins (n=18,732) 
Pleiotropy 
beta se p beta se p beta se p 
rs1260326 2 GCKR/GCKR T 1.182 0.247 1.67E-06 -0.416 0.040 5.57E-25 -0.078 0.151 0.603 Yes 
rs6598541 15 IGF1R/IGF1R A -0.682 0.455 0.134 0.273 0.075 2.77E-04 0.297 0.251 0.236 Yes 
rs1171614 10 SLC16A9/SLC16A9 T -0.297 0.392 0.448 -0.085 0.057 0.134 0.747 0.192 1.01E-04 Yes 
rs1394125 15 UBE2Q2/NRG4 A -1.302 0.512 0.011 0.009 0.084 0.912 -0.302 0.295 0.306 No 
rs17050272 2 INHBB/INHBB A 1.568 0.622 0.012 0.135 0.097 0.165 0.179 0.298 0.549 No 
rs7224610 17 HLF/HLF A 1.158 0.500 0.021 0.018 0.084 0.827 0.532 0.298 0.074 No 
rs478607 11 NRXN2/SLC22A12 A -1.083 0.521 0.038 0.025 0.088 0.775 0.189 0.276 0.493 No 
rs653178 12 ATXN2/PTPN11 T 0.833 0.528 0.114 -0.053 0.089 0.553 -0.044 0.302 0.883 No 
rs3741414 12 INHBC/INHBE T -0.479 0.324 0.139 0.014 0.054 0.792 0.083 0.177 0.638 No 
rs6770152 3 SFMBT1/MUSTN1 T 0.563 0.396 0.155 0.044 0.065 0.498 0.490 0.226 0.030 No 
rs7188445 16 MAF/MAF A -0.813 0.625 0.194 -0.191 0.103 0.065 -0.601 0.355 0.091 No 
rs10480300 7 PRKAG2/PRKAG2 T -0.719 0.656 0.273 -0.313 0.109 0.004 0.495 0.409 0.226 No 
rs2231142 4 ABCG2/ABCG2 T -0.150 0.145 0.302 0.031 0.024 0.199 0.104 0.093 0.264 No 
rs1165151 6 SLC17A1/SLC17A3 T 0.207 0.207 0.317 0.068 0.034 0.042 0.112 0.116 0.335 No 
rs164009 17 QRICH2/PRPSAP1 A 0.655 0.655 0.317 0.086 0.110 0.435 -0.040 0.380 0.915 No 
rs7193778 16 NFAT5/NFAT5 T 0.447 0.574 0.437 0.136 0.096 0.155 0.050 0.324 0.878 No 
rs1178977 7 BAZ1B/MLXIPL A -0.340 0.480 0.479 -0.122 0.080 0.127 -0.268 0.279 0.338 No 
rs2307394 2 ORC4L/ACVR2A T -0.400 0.571 0.484 -0.191 0.094 0.042 -0.252 0.339 0.457 No 
rs11264341 1 TRIM46/PKLR T -0.292 0.417 0.484 -0.075 0.069 0.275 -0.355 0.222 0.109 No 
rs2078267 11 SLC22A11/SLC22A11 T -0.154 0.244 0.528 -0.067 0.041 0.104 -0.027 0.137 0.843 No 
rs1471633 1 PDZK1/PDZK1 A -0.197 0.311 0.528 0.036 0.051 0.478 -0.035 0.173 0.839 No 
rs742132 6 LRRC16A/LRRC16A A -0.371 0.600 0.536 0.089 0.097 0.362 -0.219 0.341 0.521 No 
rs2941484 8 HNF4G/HNF4G T 0.180 0.388 0.643 0.067 0.063 0.287 -0.021 0.219 0.924 No 
rs675209 6 RREB1/RREB1 T -0.156 0.349 0.656 0.130 0.057 0.023 0.215 0.183 0.240 No 
rs2079742 17 BCAS3/C17orf82 T 0.235 0.529 0.657 -0.059 0.090 0.514 -0.622 0.274 0.023 No 
rs17786744 8 STC1/STC1 A 0.255 0.613 0.678 0.132 0.100 0.186 -0.187 0.344 0.588 No 
rs729761 6 VEGFA/VEGFA T -0.150 0.478 0.754 -0.202 0.078 0.010 -0.347 0.257 0.177 No 
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SNP Chr Closest/GRAIL gene 
Effect 
allele 
Fasting glucose (n=15,234) 2hr glucose (n=58,074) Glycoproteins (n=18,732) 
Pleiotropy 
beta se p beta se p beta se p 
rs17632159 5 TMEM171/TMEM171 C -0.161 0.579 0.782 -0.050 0.092 0.587 -0.093 0.317 0.769 No 
rs10821905 10 A1CF/ASAH2 A 0.045 0.453 0.920 0.079 0.075 0.294 -0.413 0.241 0.087 No 
rs642803 11 OVOL1/LTBP3 T -0.014 0.442 0.975 0.014 0.072 0.847 0.068 0.249 0.785 No 
rs12498742 4 SLC2A9/SLC2A9 A -0.001 0.058 0.985 0.000 0.009 0.978 0.029 0.033 0.376 No 
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Supplementary Table 6 - 7: Phenotypes associated with the weighted GRS of urate in TreeWAS analysis (PP>0.95). 
ICD-10 coding Disease description max_b† b_ci_lhs† b_ci_rhs† OR (95%CI) PP* 
M10 M10 Gout 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M100 M10.0 Idiopathic gout 1.640 1.515 1.765 5.16 (4.55, 5.84) 0.993 
M1007 M10.07 Idiopathic gout (Ankle and foot) 1.640 1.515 1.765 5.16 (4.55, 5.84) 0.993 
M1099 M10.99 Gout, unspecified (Site unspecified) 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M109 M10.9 Gout, unspecified 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M1097 M10.97 Gout, unspecified (Ankle and foot) 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M1096 M10.96 Gout, unspecified (Lower leg) 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M1094 M10.94 Gout, unspecified (Hand) 1.640 1.515 1.765 5.16 (4.55, 5.84) 0.993 
M1090 M10.90 Gout, unspecified (Multiple sites) 1.640 1.515 1.765 5.16 (4.55, 5.84) 0.985 
M109_int M10.9 Gout, unspecified_int 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
M100_int M10.01 Idiopathic gout_int 1.640 1.515 1.765 5.16 (4.55, 5.84) 1.000 
Chapter IX Chapter IX Diseases of the circulatory system 0.070 0.055 0.085 1.07 (1.06, 1.09) 1.000 
Block I10-I15 I10-I15 Hypertensive diseases 0.070 0.055 0.085 1.07 (1.06, 1.09) 1.000 
I10 I10 Essential (primary) hypertension 0.070 0.055 0.085 1.07 (1.06, 1.09) 1.000 
Block I20-I25 I20-I25 Ischaemic heart diseases 0.070 0.055 0.085 1.07 (1.06, 1.09) 1.000 
I20 I20 Angina pectoris 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.994 
I209 I20.9 Angina pectoris, unspecified 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.972 
I21 I21 Acute myocardial infarction 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.994 
I219 I21.9 Acute myocardial infarction, unspecified 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.966 
I25 I25 Chronic ischaemic heart disease 0.070 0.055 0.085 1.07 (1.06, 1.09) 1.000 
I251 I25.1 Atherosclerotic heart disease 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.999 
I252 I25.2 Old myocardial infarction 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.987 
Block I30-I52 I30-I52 Other forms of heart disease 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.999 
I50 I50 Heart failure 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.994 
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ICD-10 coding Disease description max_b† b_ci_lhs† b_ci_rhs† OR (95%CI) PP* 
I501 I50.1 Left ventricular failure 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.966 
Block I60-I69 I60-I69 Cerebrovascular diseases 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.991 
I63 I63 Cerebral infarction 0.070 0.055 0.085 1.07 (1.06, 1.09) 0.951 
* PP, posterior probability for the beta (β) estimate in the tree analysis not being zero. 
† max_b: maximum a posteriori effect estimate (beta) and the 95% credible interval (max_b_lhs, max_b_rhs). 
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Supplementary Table 6 - 8: Sensitivity analysis by using pleiotropic loci on metabolic traits.  
Disease 
outcomes 
GRS of all-urate loci (n=31) 
GRS of urate-specific loci 
(n=14) 
GRS of urate-obesity 
pleiotropic loci (n=10) 
GRS of urate-BP 
pleiotropic loci (n=10) 
GRS of urate-lipid 
pleiotropic loci (GRS=6) 
GRS of urate-glucose 








































































































































































































































































































































































































































GRS, genetic risk score; FDR, false discovery rate; OR, odds ratio.   
  




7.1 Introduction  
In this thesis, background information regarding uric acid metabolism, hyperuricaemia, and 
the genetic determinants of SUA level have been presented in Chapter 1; the aims and 
objectives of this thesis have been outlined in Chapter 2; a systematic literature review on 
the range of health outcomes related to SUA level has been summarised in Chapter 3; the 
characteristics of UK biobank cohort and the manipulation process of UK Biobank data have 
been described in Chapter 4; Chapter 5 presents a MR-PheWAS analysis using the interim 
release of UK Biobank data and describes the methods and results, and interprets the 
findings; similarly, Chapter 6 presents an enlarged PWMR analysis using the full UK 
Biobank cohort and describes the methods and results, and interprets the findings.  
In this chapter, I will firstly discuss the methodological issues that have not been fully 
elaborated in the earlier chapters. I will also present and discuss the comments that have 
been proposed by the co-authors of the publications or the peer reviewers of the journals that 
this work has been submitted to. I will finally draw conclusions based on the findings of this 
thesis and provide suggestions on future research focus.  
7.2 Methodological and analytical issues  
The first part of this chapter discusses the main issues of the applied methodologies. These 
include (i) umbrella review; (ii) PheWAS approach: the PheCODE schema; (iii) MR 
methods: Two-stage MR, Wald Ratio MR, MR IVW and MR Egger; (iv) TreeWAS: the 
Bayesian analysis framework. Then, the common analytical issues of these methods are 
presented and the corresponding strategies for dealing with these issues are explained and 
discussed. These include (i) study population: why selecting the unrelated white British 
population for analysis instead of a broader target population of European descent; (ii) 
genetic instruments: why using the multiple genetic instruments rather than the single variant 
within the gene of which the function is well understood; (iii) covariates: why adjusting the 
PheWAS analysis only for the PCs and BMI but not for other potential confounding factors 
(e.g., sex, age, renal function); (iv) case ascertainment: how to define the individual as being 
a case or a control. 
7.2.1 Umbrella review 
To provide the research community with a comprehensive overview of the entirety of the 
published literature in relation to serum urate levels, I performed an umbrella review to 
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comprehensively assess the evidence available on the association between serum urate across 
all reported outcomes based on systematic reviews/meta-analyses of observational studies 
and RCTs as well as Mendelian randomisation (MR) studies. The main methodological 
issues have been fully discussed in Chapter 3, Section 3.5 “Discussion”, hereby, I only 
discuss a few remaining issues.   
7.2.1.1 Selection of eligible studies 
The methodology of umbrella review generally builds on the systematic analysis of meta-
analyses. The selection of studies for inclusion in this umbrella review is relatively 
asymmetrical with the inclusion of systematic reviews and meta-analyses of observational 
studies, meta-analyses of RCTs, and finally, individual MR studies. The reason I sought to 
collect information from systematic reviews (not only meta-analyses) of observational 
studies was to map the breadth of outcomes investigated in relation to serum urate levels. 
Even though the systematic reviews were included in the umbrella review, they were not 
taken forward for quantitative analysis. For MR studies, only one meta-analysis was 
available, thus I decided to include individual studies instead. I sought to collect information 
from only systematic meta-analyses instead of all meta-analyses, this was because I aimed to 
keep the umbrella review to be systematic, objective and transparent. For meta-analyses 
which are not strictly systematic, there is always an unavoidable layer of subjectivity in 
making decisions about which papers should be included, and how the results should be 
interpreted and/or discussed. Nevertheless, there are concerns that some non-systematic 
meta-analyses cover questions that have not been addressed by systematic ones; if not 
including them, the breadth of health outcomes is limited. This has been discussed in 
Chapter 3, Section “3.5 Discussion” as a limitation of this umbrella review. 
Additionally, another issue about the selection of the largest/latest meta-analysis when 
multiple (overlapping) meta-analyses exist for the same population/outcome has been 
questioned. This approach doesn’t assume that the larger the meta-analyses, the better the 
quality, although there is some empirical evidence that this assumption is adequate within 
RCTs. Due to the large number of meta-analyses identified, it would be challenging to 
perform formal quantitative appraisal for all included meta-analyses and their component 
studies. Instead, I chose to present the main results of all identified meta-analyses and 
compare the findings for outcomes with more than one meta-analysis, and select one meta-
analysis for each outcome to do the credibility assessment. The reason I selected the 
largest/latest meta-analysis for overlapping outcomes was because I expected that individual 
studies included in multiple meta-analyses should be considerably overlapped (if they 
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addressed the same question in the same population) and any difference should be due to 
new component studies being published and then being included in the most recent meta-
analysis. However, there were some exceptions when the latest MA was not the largest and 
this was when the latest meta-analyses only included prospective studies whereas the largest 
meta-analyses included both prospective and retrospective studies. In this case I always 
selected the meta-analyses including the largest number of prospective studies. I then 
compared the consistency of the findings among these overlapping meta-analyses, aiming to 
see if the significance and/or direction of the association changed when new individual 
studies are added. 
7.2.1.2 Criteria for credibility assessment 
There were some criticisms that the criteria used for credibility assessment was largely based 
on statistical concepts (p-values, 95%PI, heterogeneity, etc.), highly dependent on sample 
size and the number of included studies. I realised that the credibility assessment based on 
statistical concepts is not sufficient to capture all features of the quality of meta-analyses, but 
these quantitative metrics are valid in identifying major biases. Considering that this 
umbrella review included 175 meta-analyses and each meta-analysis included multiple 
individual studies, it would be challenging to additionally perform a formal quality appraisal 
for all included meta-analyses and their component studies. It has been acknowledged that 
the assessment of the quality of the individual studies was beyond the scope of this umbrella 
review and it should be the aim of the original meta-analyses. Therefore, I examined the 
grading quality reported in the original meta-analyses (if any), but found quite a few meta-
analyses using the GRADE (or other equivalent system) to assess the quality of their 
individual studies. The lack of the quality assessment of the component studies was 
highlighted as a common issue for the published meta-analyses. To improve this 
methodological limitation, I therefore applied a two-step assessment: I firstly performed 
quantitative assessment for all meta-analyses, and the statistical metrics filtered out meta-
analyses with obvious/serious biases (Class III and IV); I then re-assessed the remaining 
meta-analyses (with high level evidence - Class I and II) on the basis of study design (case-
control, retrospective, or prospective) and also by assessing the eligibility/quality of 
individual studies; and then conducted further evaluation on meta-analyses with high ranking 
evidence (Class I and II) to capture other quality issues that could have been missed in the 
quantitative assessment. In principle, although there are limitations, the methodologies I 
applied for credibility assessment can identify major biases and capture the essential features 
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of the quality of the included meta-analyses. Further evaluation for the meta-analyses which 
already have obvious/serious biases, would not add much value to the assessment. 
7.2.1.3 Interpreting different types of evidence  
In this umbrella review, different types of evidence (i.e., observational studies, RCTs and 
Mendelian randomisation studies) were incorporated. Although none of these study types are 
infallible, all are able to provide useful information about causal inference and can 
complement each other to achieve increasing certainty about causality. Observational studies 
examined the association between the exposure and the outcome and tested whether the 
association is caused by chance, bias, or confounding, but they are typically affected by 
residual confounding, undetected bias, or reverse causality, which may generate associations 
that are not reliable indicators of causality. RCT aimed to obtain evidence of a causal effect 
of a treatment or intervention on a disease process by eliminating many of possible biases 
and confounding factors, but they are limited by the issues of non-adherence to the assigned 
intervention, limited external validity, short term intervention effects, and non-retention, 
which can all render the results invalid or questionable. MR studies provided a cost-effective 
analogy to a RCT by using genetic variants as proxies to test the causality of an association 
between exposure and outcome; they are generally not influenced by the common 
confounding factors and not seriously affected by reverse causality, but do rely on several 
assumptions (the genetic instruments should be associated with the exposure of interest, they 
should not be associated with known confounders, and they should affect the outcome solely 
through the exposure) that can be hard to identify and control, and lack power when the 
proportion of trait variance explained by the genetic instruments is small. It is recognised 
that different types of epidemiological studies have specific strengths and weaknesses that 
can be seen as complementary, this study would therefore benefit from clarification as to the 
type of questions that each type of study is likely to address in terms of potential bias, 
generalisability and power limitation. Given the differences between different designs, I thus 
assessed each type of evidence separately and made specific conclusions for each study 
design type (the overall conclusion was a simple summary of specific conclusions).  Specific 
conclusions were drawn for each of the three study types. In particular: 1) no association 
from meta-analyses of observational studies was classified as convincing; 2) only one 
outcome from meta-analyses of RCTs (decreased risk of nephrolithiasis recurrence with 
SUA-lowering treatment) had p<10-3, 95% prediction interval excluding the null and no 
large heterogeneity or bias and was classified as convincing; 3) only one outcome from MR 
studies (increased risk of gout with high SUA levels) had p<0.01 with adequate power; the 
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overall conclusion of the chapter was a summary of specific conclusions: convincing 
evidence exists for only gout and nephrolithiasis. The comparison of the concordance across 
different study types aimed to see if evidence from RCTs and MR can strengthen the 
observed associations. 
7.2.1.4 Strengths and limitations of umbrella review 
The strengths and limitations of umbrella review have been fully discussed in Chapter 3, 
Section “3.5 Discussion”. In summary, strengths mainly includes:  
(i) Providing an overview of the entirety of the published literature in relation to serum 
urate levels (reporting an impressive number [136 in total] of outcomes), and 
presented all published findings in a comprehensive way. 
(ii) Collecting and evaluating evidence from multiple resources systematically, with 
recognising that different types of epidemiological studies were designed to address 
different questions but could be seen as complementary evidence for the same 
research topic.  
(iii) Employing evidence classification criteria to identify biases and to capture the 
essential features of the quality of the published meta-analyses, to assess the 
credibility of the reported evidence.  
(iv) Helping investigators to judge the relative priority of health outcomes related to serum 
urate levels and direct research or therapeutic efforts away from less important health 
outcomes in the future research and clinical management of diseases.  
Limitations includes:  
(i) Some meta-analyses were excluded from heterogeneity and bias tests because they did 
not provide adequate data to do the respective analyses.  
(ii) Both asymmetry and excess statistical significance tests offer suggestions of bias, and 
not definitive proof thereof.  
(iii) Effect inflation might affect even the results of the largest studies because often these 
studies were not necessarily very large or might have had inherent biases themselves. 
Thus, our estimates of the extent of excess statistical significance are probably 
conservative.  
(iv) The quality of the individual component primary studies were not appraised because 
this was beyond the scope of this umbrella review. This was the aim of the original 
systematic reviews and meta-analyses, which should include an assessment of study 
quality and whether the study should be included in the quantitative calculations. 
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7.2.2 PheWAS approach 
To complement GWAS, the concept of PheWAS has been developed. In essence, PheWAS 
is a reverse approach of GWAS, which provides a systematic method to explore the range of 
diseases and traits that are associated with a number of given SNPs or biomarkers (542). The 
concept of PheWAS is to perform a series of case-control tests on varying phenotypes to 
discover significant associations with pre-defined genetic variants or biomarkers of interest. 
Identifying the correlations among comprehensively collected phenotypes is believed to 
provide important information on the networks underlying human disease and health. 
PheWAS could be performed in a variety of datasets derived from electronic medical records 
(EMRs) or large population-based epidemiological studies (542). In particular, since the 
emergence of large biobanks (e.g., UK Biobank), in which a large volume of genotypic data 
is linked to extensive EMRs, it provides a unique opportunity to perform powerful PheWAS, 
even though there are some challenges to be overcome. The purpose of this section is to 
discuss the main technical issues of the PheWAS methodology and report the progress of 
PheWAS method that has been made based on the work of this thesis.  
7.2.2.1 Phenotyping: ICD codes  
The focus on a wider spectrum of phenotypes is an important aspect of the PheWAS design. 
Therefore, defining the individuals’ phenotypes, termed as phenotyping, is the most critical 
step. Phenotyping has been defined as the precise and comprehensive analysis of phenotypic 
characteristics of an individual (543). The term of “phenome” has been used as a systematic 
and comprehensive set of phenotypes, including the clinical, biochemical and imaging traits. 
Unlike the genome, in which genotyping could be performed by reliable biological 
techniques, the measurement of phenome relies highly on the availability of health data. The 
most commonly used data fields for phenotyping are from the electronic medical records 
(EMRs) and the epidemiological survey data, which could be measured as either outcome 
phenotypes (binary disease status) or intermediate phenotypes (quantitative clinical variables) 
(542).  
 EMRs based phenotyping  
For EMRs based phenotyping, the most effective and straightforward way is to use the ICD 
codes. The ICD coding system is a medical classification list developed by the World Health 
Organisation (544). This system is designed to map health conditions to corresponding 
generic categories together with specific variations. The major categories are designed to 
include a set of similar diseases. The ICD has been applied as a health care classification 
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system, which provides a system of diagnostic codes for classifying diseases and a wide 
variety of signs, symptoms, abnormal findings, complaints, social circumstances, and 
external causes of injury or disease (544).  
The ICD is revised periodically and is currently in its 10th version (ICD-10) (545). 
Establishment of ICD-10 began in 1983 and completed in 1992. The ICD-10 was first 
mandated for use in the UK in 1995 (before 1995, the adopted version was ICD-9). In 2010, 
the UK Government made a commitment to update the UK version of ICD-10 every three 
years (546). From April 1st 2016, the ICD-10 5th Edition was applied as the mandated 
diagnostic classification within the UK (546). The current version of ICD-10 includes more 
than 14,400 different codes (permitting the tracking of many new diagnoses compared 
to ICD-9) and through the use of optional sub-classifications, the number of codes can be 
expanded to over 16,000 (544). The unchanged international version of ICD-10 is used in 
more than 110 countries, with a few exceptions. For example, the United States, Australia 
and Canada, have developed their own adaptations of ICD, which include more procedure 
codes for classification of operative or diagnostic procedures. The United States expanded 
the code set to a modified version, named ICD-10 Clinical Modification (ICD-10-CM), 
which has 70,000 different codes (547). Adoption of ICD-10-CM was slow in the United 
States and it has been used since October 1, 2015. The ICD-10-CM was provided by the 
National Centre for Health Statistics (NCHS) and the Centres for Medicare and Medicaid 
Services (CMS) and the use of ICD-10-CM codes are now mandated for all inpatient 
medical reporting requirements in the United States (547).  
As known, the ICD-codes are organised in a hierarchical structure that the sibling ICD codes 
representing different subgroups belong to a similar set of disease group coded by their 
parent ICD code (544). Based on this hierarchical structure, a holistic phenotyping method 
was proposed for PheWAS, in which individual ICD codes at varying levels of phenotypic 
granularity are adopted to define cases and controls. For example, M10.1 and M10.2 are 
firstly classified into two different case groups, but then are combined into the same M10 
case group. The advantage of this method is that the phenotyping is performed without 
making any assumptions about the similarity of outcomes and the ICD codes are treated as 
representing independent disease outcomes. However, given the fact that the majority of ICD 
codes are designed to include a set of similar diseases, this phenotyping method would 
greatly reduce the study power and increase the burden of multiple test.  
To address these issues, the curated phenotyping method has been adopted to aggregate the 
ICD codes into an appropriate version for phenotyping. The curated phenotyping is built on 
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the backbone of the first three digital ICD codes and further refined based on clinical and 
biological knowledge (548). In principle, the fourth and fifth digital ICD codes, or 
sometimes even the third, representing diseases sharing the common aetiology are combined 
into one phenotype group. On the other hand, for some diseases with distinctly different 
aetiologies, like type 1 and type 2 diabetes, even if they are under the same three digit ICD 
code, their individual codes are retained and allocated into different phenotype groups. In 
addition, ICD codes, using the terms of “others” or “not elsewhere classified” are removed. 
Through the curated phenotyping, the number of cases for each phenotype is increased and 
the number of phenotypes examined in PheWAS is reduced, therefore, the multiple test 
burden is lower and the power to detect associations is higher due to increased number of 
cases. This phenotyping method also has its disadvantages, in which biases may be 
introduced by assuming that some diseases share the same aetiology. Despite this, curated 
phenotyping is still one of the most widely adopted methods in the published PheWAS. 
Based on the principles of curated phenotyping, a PheCODE schema has been developed for 
the researchers who are interested in the EMRs based phenotyping (details are discussed in 
the Section 7.2.2.2 “PheCODE schema”).  
 Epidemiological survey-based phenotyping  
Another important source of phenotypic data is the epidemiological surveys, in which a large 
number of phenotypes are collected. Compared with ICD codes, phenotyping in 
epidemiological data is even more challenging. Considering the relatively small sample size 
and the limited coverage of human diseases investigated in a single epidemiological survey, 
combination of phenotypic data from multiple studies is always required (548). Additionally, 
since the diseases investigated in epidemiological studies are not as well-structured and 
standardised as ICD codes, it is difficult to harmonise all phenotypes, and thus phenotypes 
are always manually binned into phenotype classifications (441). Although this method can 
reuse the epidemiological data to perform PheWAS, it is not the best option to harmonise the 
phenotypes of individuals.  
7.2.2.2 Phenome framework: PheCODE schema 
As discussed above, the ICD codes remain the most common data source of phenotyping. To 
address the need for an aggregation method, the electronic Medical Records and Genomics 
(eMERGE) developed a schema called “PheCODE” to represent disease phenotypes 
documented in the EMR (433). The PheCODE schema was first introduced in 2010, 
containing 733 distinct phenotype codes (459). This schema was developed based on the 
ICD-9-CM codes by combining one or more related ICD-9-CM codes into distinct diseases 
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or traits (459). The eMERGE group are continuously refining the PheCODE schema with 
additional clinical experts helping with revisions of different domains, such as cardiology 
and oncology. The latest version of the PheCODE system involved 1,866 hierarchical 
phenotype codes (433).  
Although the PheCODE schema is effective at replicating genotype-phenotype associations, 
as explained above, the phenotyping algorithm developed by the US eMERGE group was 
based on the ICD-9-CM and it meant that the phenotyping algorithm could not be used 
directly for the UK Biobank data, in which the EMRs are largely encoded by the ICD-10 
version. In order to adopt the PheCODE schema to define the phenome, the US eMERGE 
group in Vanderbilt University Medical Center (VUMC) helped to create the mapping of 
ICD-10 codes to the current PheCODE system and evaluated the coverage performance of 
PheCODE for EMRs documented in the UK Biobank. Although multiple ways were applied 
to create the mapping to phecodes, about 26.8% ICD-10 codes used in the UK Biobank 
could not be mapped to any phecode. An examination on these codes showed that the 
majority were encounter/procedural codes or supplementary codes that are not descriptions 
of specific phenotypes or diseases. Of the ICD-10 codes that were successfully mapped to 
phecodes, about 8,947 ICD-10 codes were mapped to at least one phecode, and 256 (2.9%) 
codes were mapped to more than one phecodes. For example, the ICD-10 code B21.1 was 
mapped to two phecodes: 071.1 [HIV infection, symptomatic] and 202.2 [Non-Hodgkins 
lymphoma]. In addition, ICD-10 codes involving in personal or family history were also 
largely unmapped, and this revealed a potential shortcoming of the current PheCODE system 
(i.e., the missing element of family history) and demonstrated an area of which the system 
should be expanded and improved.  
7.2.2.3 Other phenotyping resources 
Apart from the eMERGE network, there are several other notable efforts focused on 
developing a more unambiguous definition of phenome, including the work from the Human 
Disease Ontology (DO) resource (549) and the Human Phenotype Ontology (HPO) project 
(550).  
The Human DO is a standards-based ontology that focuses on representing common and rare 
disease concepts captured from biomedical resources and organised by disease aetiology 
(549). The latest revision includes 8803 classes (terms) (6419 non-obsolete, 2384 obsolete) 
and provides textual definitions for 32% of DO classes (terms) (549). Human DO is a 
disease-focused database by design and thus it includes only concepts of disease. More 
specifically, it integrates disease concepts from ICD-9, the National Cancer Institute (NCI) 
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Thesaurus (551), SNOMED-CT (552) and MeSH 
(https://www.nlm.nih.gov/mesh/MBrowser.html) extracted from the UMLS (553) based on 
the UMLS CUI for each disease term; it also includes disease terms extracted directly from 
Online Mendelian Inheritance in Man (OMIM) (554), and the Experimental Factor Ontology 
(EFO, http://www.ebi.ac.uk/efo/). However, the Human DO does not include progression 
(early, late, metastasis, stages) or manifestations (transient, acute, chronic) of disease as part 
of the disease definition; and it does not include compound disease terms (those describing 
the combination of two disease terms) such as glaucoma associated with pupillary block 
either. Instead, these diseases are represented by two distinct disease terms. Details about the 
Human DO resource are available at http://www.disease-ontology.org. 
The Human Phenotype Ontology (HPO) project includes a wide range of phenotypic 
abnormalities described in human diseases (550). At the time of writing this thesis, The HPO 
provided a structured, comprehensive and well-defined set of 10,088 classes/terms 
describing human phenotypic abnormalities. About 65% (6,603) of the classes are described 
by a detailed textual definition created by clinical experts. In addition, a logical definition is 
developed for 46% of all HPO classes using terms from ontologies for anatomy, cell types, 
function, embryology, pathology and other domains. The HPO is organised as three 
independent sub-ontologies covering different categories: the mode of inheritance, the onset 
and clinical course and the largest category of phenotypic abnormalities. Details about the 
HPO database are available at http://www.human-phenotype-ontology.org.  
Compared to the other phenotyping resource (e.g., the HPO and Human DO), the PheCODE 
schema remains the most direct way to use the diagnosis codes and enables the performance 
of PheWAS by leveraging EMRs for high-throughput analysis. Additionally, machine-
learning approaches like trained logistic regression models or support vector machines are 
also proposed to be used in phenotyping (548). Principle component analysis is another 
possible method to transform a number of phenotypic variables into a smaller number of 
phenotypic groups (555). Efforts are also made to evaluate the accuracy of combining 
various structured and unstructured data sources (549, 550). Hopefully, in the near future, 
more advanced phenotyping methods will be developed with collaboration from multiple 
organisations to discover disease subclasses and provide the means to better capture, store, 
exchange, and analyse phenotypic data.   
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7.2.3 TreeWAS method 
A limitation of the conventional PheWAS using PheCODE schema is testing a tree-
structured phenotype spectrum with a general linear model by assuming independence, 
although they are actually correlated. This would result in over correction of p value when 
adjusting for multiple testing. This issue was addressed by the alternative Bayesian analysis 
of a tree-structured phenotypic model (TreeWAS).  
In TreeWAS analysis, phenotypes are organised into a tree structure following the 
hierarchical structure of ICD10 codes to better capture the underlying biological process 
affecting the origin and progression of disease. The associations between weighted GRS and 
phenotypes were tested by the Bayesian network analysis at both terminal and internal nodes 
of the tree structure. The expected degree of correlation between genetic coefficients across 
each node in the tree was determined by the prior probabilities. The coefficient at a parent 
node can either be inherited by a child node with a probability, or can transition to a new 
uncorrelated value with a probability. The transition probabilities controlled the Markov 
process and the likelihoods over the genetic coefficients were calculated across all clinical 
phenotypes using a dynamic programming model and the forward and backward algorithms. 
The value of TreeWAS lies in enhancing power to identify groups of endpoints affected by 
exploiting the encoding of medical ontologies. With taking into account the correlations 
among clinical phenotypes, this new approach is shown to increase statistical power by up to 
20%.    
Additionally, TreeWAS using a Bayesian network analysis has an advantage in detection of 
non-linear associations that could be missed by conventional PheWAS. PheWAS analysis 
tested the association by running a logistic regression under a hypothesis of a linear model, 
thus any association that is non-linear would be less likely to be detected. The association 
between serum urate level and the risk of cerebrovascular diseases (e.g., stroke) is probably a 
case of non-linear association, which was only observed in TreeWAS but not in PheWAS. 
Previous studies assessing the association between serum urate level and cerebrovascular 
diseases (e.g., stroke) reported conflicting results, where some studies found a positive 
association whereas other studies reported a negative association. Some studies suggested 
that high SUA level was neuroprotective and associated with better outcomes after acute 
ischaemic stroke, while other studies reported that high SUA level was injurious and had a 
statistically significant association with the high risk of stroke incidence and mortality (556-
558).  Given the contradictory role of urate as both an antioxidant and a pro-oxidant, a 
compromise hypothesis of U-shaped relationship has been proposed that suggests low serum 
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urate level may increase the risk of cerebrovascular disease as a result of inadequate anti-
oxidative level and high serum urate level may function more as a pro-oxidant to increase the 
risk of stroke and other cerebrovascular diseases (558). If the presence of U-shaped 
relationship is true, the PheWAS analysis, in which association was tested under a 
hypothesis of a linear model, would be thereby unable to detect this association, however 
TreeWAS, testing the association without assumption of any linear model, reported a 
significant association.  
7.2.4 MR methods 
To interpret the observed PheWAS associations, I applied MR to determine whether there is 
any causal effect of SUA level on the identified diseases. MR is a method that uses genetic 
variants as instrumental variables (IVs) to examine the causal effect of an exposure on a 
disease (559). MR relies on the natural, random assortment of genetic variants during 
meiosis, which yields a random distribution of genetic variants in a population. Specially, 
individuals are naturally assigned at birth to inherit or not inherit the genetic variants that 
affect an intermediate phenotype (e.g., genetic variants raising SUA level); individuals who 
carry the risk genetic variants and those who do not are then followed up for the 
development of an outcome of interest. Ideally, as genetic variants are typically not 
associated with the common confounders and the transmission of genetic information is 
usually unidirectional, differences in the disease outcome between those who carry the 
variant and those who do not, can be attributed to the difference in the risk factor. This 
section will focus on the methodological issues that are prominent in the MR method.  
For the MR analyses of SUA levels conducted in this thesis, a list of crucial issues with 
regards to the MR approaches are carefully and sufficiently assessed and discussed, in 
particular the assumptions that underpin the MR design, the use of multiple instrumental 
variables, the choice of statistical methods for robust effect estimation, the statistical power 
to detect a moderate/small causal effect, and the interpretation of associations due to 
pleiotropy or genetic linkage disequilibrium.   
7.2.4.1 MR assumptions 
There are three main assumptions that underpin the MR method (as briefly mentioned in 
Chapter 4). These are:  
(i) The genotype is associated with the exposure. This assumption can be verified by 
statistical analysis. Reporting guidelines for MR analysis recommend the use of the 
partial F-statistic as a measure of the strength of the association between the IV and the 




The F statistic is defined as the ratio of the mean square of the model (the first-stage 
regression of exposure on the IV) to the mean square of the error. In the MR reporting 
guidelines, a threshold of F <10 is typically used to define a ‘weak IV’. This criterion is 
based on the observation that the F value greater than 11 ensures the relative bias to be <10% 
regardless of the number of IVs used in MR analysis (560). However, in the MR analyses of 
SUA level there are no biomarker data available for the SUA levels of the UK Biobank 
participants. Therefore, I calculated the statistical power to report the strength of IVs, given 
that the F statistic encompasses information on the first-stage R2 (the proportion of variance 
in SUA level that is explained by IVs), the sample size and the number of IVs, which are 
also indicators of the statistical power of MR analysis (257). Power >80% was regarded as 
sufficient to detect the corresponding causal effect, otherwise, a statement on inadequate 
power was made to acknowledge the lack of strength to detect the causal effect. Details 
about the power estimation are further discussed in the Section “7.2.4.3 Statistical power of 
MR”).   
(ii) The genotype is associated with the outcome through the exposure of interest only. 
This assumption is likely be violated when the genotype has multiple (pleiotropic) 
effects, or when a nearby genetic variant in linkage disequilibrium with the IV 
affects the outcome in other ways than through the exposure of interest.  
One of the primary concerns on evaluating this assumption is whether the genetic variants 
used as IVs are likely to be pleiotropic. Pleiotropy can affect the interpretation of MR studies 
in multiple ways: (i) a reverse pleiotropic effect can counteract the effect of the biomarker on 
the disease, which will give a null finding even when there is a true causal effect between the 
biomarker and the disease; or alternately (ii) a positive pleiotropic effect can result in a 
positive association between the genetic variant and the disease that is likely to be 
mistakenly interpreted as a causal effect. To validate this assumption, I examined the 
presence of pleiotropy and balanced out pleiotropic effects by using a more advanced 
statistical technique, the MR Egger analysis that has recently been proposed to account for 
unbalanced pleiotropy. Details about MR Egger method are discussed in the Section “7.2.4.2 
MR methods”. 
Another concern about this assumption is genetic linkage disequilibrium, given the fact that 
SNPs located closely on a chromosome are usually inherited together. The closer the 
distance on a chromosome, the higher the extent of linkage disequilibrium. For example, a 
genetic variant that affects the exposure level of A (e.g., SUA) may be in linkage 
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disequilibrium with a SNP affecting the exposure level of B (e.g., LDL). If the exposure B is 
causally related to a disease outcome, the MR findings using the genetic variant in linkage 
disequilibrium with the genetic variant affecting exposure B would be mistakenly interpreted 
as that the exposure A being responsible for the corresponding disease outcome. To avoid 
any potential misinterpretation, the ideal IVs should be SNPs that localise in genomic 
regions without proximity to the loci that might affect the association of the SNP and the 
disease. However this is not always possible given the complexity of human genetic 
architecture. To validate this assumption, I applied the HEIDI test to examine if any of the 
observed associations are due to linkage disequilibrium instead of causality. Details on the 
HEIDI test have been elaborated in Chapter 5, Section “5.3 Method”, “5.5 Discussion” and 
“5.6 Supplementary information”) 
(iii) The genotype is independent of other factors, which affect the outcome (independence 
assumption). This assumption would be violated if subgroups in the study population 
have both different genotype frequencies and different distributions of the outcome 
(population stratification), or if there is an association between the genetic instruments 
and confounders.  
Population stratification refers to the confounding of genotypic associations by factors due to 
differences in subgroup populations. If the study population is not homogenous, any disease 
outcome that is at higher prevalence in one of the subpopulations may be associated with all 
SNPs that are more frequent in this group. To address this issue, I performed the SUA MR 
analyses in a very homogenous population (white British subset) and adjusted using the 
genetic principle components as covariates. For assessing the second common issue related 
to this assumption, I tested whether the genetic instruments of SUA level were associated 
with other common confounders such as BMI, smoking, assessment centre and any related 
confounders were adjusted as covariates in the analysis (Details about adjustment for 
covariates are discussed in the Section “7.2.5.3 Adjustment for covariates”).  
7.2.4.2 MR methods  
A number of statistical methods have been proposed for MR to obtain robust causal 
estimates and/or to examine the instrumental variable assumptions (561). These include the 
standard MR methods (i.e., two-stage method, Wald Ratio method) that are most frequently 
used when the individual-level data (i.e., data on exposure, outcome and IVs) are available 
from a single population (one-sample MR), and the more complicated methods (i.e., inverse-
variance weighted [IVW] MR, Egger MR) that are developed to integrate data from multiple 
samples (two-sample MR) and multiple IVs. In this section, I mainly discuss the mostly 
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common used methods as mentioned above, but it should be noted that this is not an 
exhaustive list of methods that are available for MR. 
 Two-stage method 
One of the most frequently used statistical methods for MR is two-stage analysis. This 
involves two stages of regression. The first stage is a linear regression with the instrument 
(genotype) as the independent variable and the exposure as the dependent variable, which is 
then used to obtain the exposure levels predicted by the instruments. The second stage is a 
regression with the outcome as the dependent variable and the genetically determined 
exposure level as the independent variable. With continuous outcomes under a linear model, 
the two-stage method is also known as two-stage least squares (2SLS). With binary 
outcomes, the second-stage (exposure–outcome) regression is a logistic regression model. 
The causal estimate is the second-stage regression coefficient that is explained as the change 
in the outcome caused by a unit change in the exposure and the estimator is expressed as a 
causal relative risk or odds ratio. However, there is a debate on the concern that estimates for 
binary outcomes from this method is inflated, as the uncertainty in the first-stage regression 
is not accounted for and the non-linear model does not guarantee that the residuals from the 
second-stage regression are uncorrelated with the instruments (561, 562). Despite this, the 
two-stage estimator with a logistic regression second-stage model still provides a valid test 
for the null hypothesis.  
 Wald Ratio method 
The Wald Ratio method, also known as the ratio of coefficients method, is the simplest way 
to estimate the causal effect of the exposure (X) on the outcome (Y). The ratio method 
typically uses a single IV (Z). If the coefficient of the regression of the exposure on the IV is 
denoted as 𝑏𝑧𝑥 and the coefficient of the regression of the outcome on the IV is denoted as 
𝑏𝑧𝑦, then the causal estimate could be calculated by the formula: ratio method estimate= 
𝑏𝑧y/𝑏𝑧𝑥 (563). Intuitively, this estimate could be explained as follows. The change in the 
outcome for a unit increase in the exposure is equal to the change in the exposure for a unit 
increase in the IV that is scaled to the change in the exposure for a unit increase in the IV. 
With a single IV, the causal estimate from the ratio method is the same as that of the 2SLS 
method (561). With multiple IVs, the 2SLS estimate could be viewed as a weighted mean of 
the ratio estimates calculated by using one instrument at a time, where the weights are 
determined by the corresponding coefficients obtained from the first-stage regression (561).  
The MR methods discussed above, particularly the two-stage method, require individual-
level data on genetic instruments, exposure and outcome from a single population. However, 
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in the case of SUA MR analysis performed in this thesis ,where the SUA levels were not yet 
available in UK Biobank, I therefore performed the alternative two-sample MR (2SMR) by 
using data from two independent populations, where the coefficient of the regression of SUA 
level on the genetic variant was taken from the summary-level GWAS data of European 
decent that were provided by the GUGC consortium (151) and the coefficient of the 
regression of outcome on the genetic variant was estimated by using the individual-level data 
from UK Biobank.  
 Inverse-variance weighted method  
The standard statistical method for performing two-sample MR is the inverse variance 
weighted (IVW) approach which is developed by combining the concepts of the ratio method 
and meta-analysis (474). For a single IV, the causal estimate for each IV could be calculated 
by the ratio method. With multiple IVs, the ratio estimates from each genetic variant can be 
averaged using an inverse-variance weighted formula that is taken from meta-analysis, 
where the IV-specific causal estimates are equivalent to the study-specific estimates, and the 
weights are the inverse-variance weights (474). The causal effect of the exposure on the 
outcome is estimated using a weighted linear regression where the residual standard error is 
set to one and the intercept is set to zero (474). This weighted regression model is equivalent 
to performing a fixed-effect meta-analysis (564). When using a fixed-effect model for 
combining the IV-specific causal estimates, no heterogeneity between the causal estimates of 
the individual genetic variants is expected (564). When substantial heterogeneity is present, 
the MR IVW analysis using a fixed-effect model is not recommended. Additionally, the MR 
IVW method also relies highly on the three fundamental assumptions listed above. As 
emphasised, if the three assumptions (i)–(iii) hold, then the causal estimate from IVW MR is 
robust and unbiased. However, assumptions (ii)–(iii) are likely to be violated in the MR 
study using multiple genetic instruments. To validate these assumptions, I thus applied the 
MR Egger method to assess whether the genetic variants have any pleiotropic effect 
(directional pleiotropy) and to provide an unbiased causal estimate under weaker 
assumptions — the InSIDE (Instrument Strength Independent of Direct Effect) assumption 
(469). 
 MR Egger method  
The MR Egger method is developed to provide robustness against misspecification of the 
MR assumptions (469). MR Egger is performed by a simple modification to the weighted 
linear regression described above. Instead of setting the intercept term to be zero, the 
intercept is estimated as part of the regression. If the genetic instruments are not pleiotropic, 
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then the intercept term should tend to be zero and the MR Egger estimate should be equal to 
the IVW estimate. Otherwise, if the genetic instruments are pleiotropic but the direct effects 
of the genetic variants on the outcome are independent of the associations of the genetic 
variants with the exposure (known as the InSIDE assumption), then the MR Egger regression 
will return a null estimate for the intercept (469). Under the InSIDE assumption, the 
intercept can be interpreted as an estimate of the average direct effects of the genetic variants 
on the outcome (469). If the average direct effect (intercept) is zero (referred as ‘balanced 
pleiotropy’), and the InSIDE assumption is satisfied, then the estimates of MR Egger should 
be robust. If the intercept term differs from zero (the average direct effect is not zero), then 
the InSIDE assumption is violated (referred as ‘directional pleiotropy’), and the MR estimate 
is biased. Hence, testing the intercept from the MR Egger analysis provides an assessment of 
the validity of the IV assumptions. Although the MR Egger is more robust in dealing with 
pleiotropy, this method is not infallible, and a number of methodological issues (i.e. the 
precision of the estimate, the influence of outlying variants, and the violation of the InSIDE 
assumption) have been proposed as limitations and these should be noted when interpreting 
the results (481).  
The precision of the MR Egger estimate not only depends on the proportion of variance in 
the exposure explained by the genetic variants (measured as R2 statistic), but also depends on 
the variability of the strength of individual genetic instruments (481). A precise MR Egger 
estimate requires the consistency of the causal estimates across the genetic variants. The use 
of pleiotropic variants, where heterogeneity between the causal estimates is observed, would 
result in over-dispersion in the MR Egger regression, in which a random-effects model is 
preferred. Therefore, the standard error of the causal estimate from the MR Egger method 
(random-effects model) is typically larger than that from the MR IVW method (fixed-effect 
model) and accordingly the 95%CI of the causal estimate from the MR Egger method is also 
wider than that from the MR IVW, which would result in an imprecise estimate.  
Besides, the MR Egger estimate is easily influenced by any outlying variant (481). If one 
genetic variant has a much stronger association with the exposure than others, then this 
variant would have a larger influence on the coefficients in the MR Egger regression. As 
illustrated by the example of hypertension mentioned in Chapter 5 Section “5.5 Discussion”, 
it is found that the outlying variant (rs12498742 in SLC2A9/SLC2A9 gene) that had the 
strongest association with SUA level showed a negative effect on hypertension and reversed 
the sign of the overall putative causal effect. In such a case, it implies that the InSIDE 
assumption is likely to be violated. The test for directional pleiotropy indicates that the 
genetic variants are not all valid instruments, thus the negative MR Egger estimate is highly 
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dubious, as the causal estimates from each variant are all positive.  
Given the respective limitations and strengths of the MR IVW and MR Egger methods 
discussed above, the next important issue is the interpretation of the discordant results from 
MR Egger and MR IVW. As discussed above, if the intercept parameter is close to zero, then 
the MR Egger estimate should be close to the IVW estimate, but the 95%CI of the causal 
effect estimated from MR Egger method is wider than that estimated from the IVW method 
due to the imprecision of MR Egger regression (481). In this case, the MR Egger analysis 
does not contradict evidence for a causal effect estimated from MR IVW analysis. On the 
contrary, if the intercept parameter is not zero, it implies the MR assumptions are violated 
and the pleiotropic effects from multiple instruments cannot even be balanced, thus neither 
the MR IVW estimate nor the MR Egger estimate are robust.  
In conclusion, it should be emphasised that the main point of the MR analysis is the 
assessment of the IV assumptions or the use of valid instruments. If the IV assumptions do 
not hold, then inferences from any analysis method will be unreliable. Although there are 
some situations where a particular method is more suitable than others (e.g., MR Egger 
method is more robust for the use of multiple instruments with balanced pleiotropy), there is 
no single MR method that is universally best. Instead, it makes sense for using different IV 
methods (e.g., MR Egger analysis) as sensitivity analyses to assess if the estimate given by a 
particular choice of MR method (e.g., MR IVW analysis) is credible or not.  
7.2.4.3 MR statistical power  
Statistical power is the probability that the null hypothesis (H0: no association) can be 
rejected if a specific alternative hypothesis (H1: a true association of the biomarker with 
disease risk) is true. The statistical power ranges from 0 to 1, and as statistical power 
increases, the probability of a type 2 error (false negative) decreases. In the published MR 
studies, investigators typically evaluate the F-statistic and the R2 from the first-stage 
regression (exposure-genetic variant) to directly reflect the power of MR analysis. Recently, 
Brion et al develops a non-centrality parameter (NCP)-based approach for calculating power 
of an MR study (254). The F-statistic and the R2 are strong determinants of the statistical 
power to detect a causal effect. Other determinants of statistical power include the sample 
size, the prevalence of the outcome in the study population and the true effect size of the 
exposure on the outcome. A formula for power estimation has been provided as an online 
web tool for researchers to perform calculation (http://glimmer.rstudio.com/kn3in/ mRnd/).  
As genetic variants typically explain a small/moderate proportion of the variance in 
biomarkers, the statistical power to detect an association between the variant and outcome in 
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MR can be relatively low and usually a large sample size is required to achieve adequate 
statistical power. Estimating statistical power is important as it can inform whether a null 
finding is representative of a true null causal association, or simply a lack of power to detect 
an effect size of clinical interest. Statistical power can be improved by the use of multiple 
genetic instruments to increase the proportion of variance of explained by the biomarker, or 
by increasing the sample size.  
Ideally, a power calculation is typically used in estimating sufficient sample size to achieve 
adequate power, thus it is usually performed before the study is carried out. However, in this 
thesis using data from UK Biobank cohort, where the sample size (and the number of cases 
for specific disease) is fixed, statistical power was calculated by using the NCP-based 
approach to investigate the minimum effect size that is likely to be detected. As the MR 
analysis is incorporated within the PheWAS analysis to investigate a wide range of 
phenotypes, the numbers of cases for different diseases can be considerably different 
depending on their prevalence. Therefore, the power of MR analyses for different diseases 
varies significantly from 1.0 to 0.01. The statistical power of MR studies to detect the 
specific causal effects have been noted and discussed in Chapter 5, Section “5.3 Method”, 
“5.5 Discussion”.   
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7.2.5 Analytical issues 
This section mainly discusses the analytical issues proposed by the peer reviewers and/or the 
co-authors of the publications derived from this thesis.  
7.2.5.1 Study of white British population 
When submitting the MR-PheWAS paper to the journal of Annals of the Rheumatic Diseases, 
one of reviewers proposed that “the use of the self-reported British (confirmed by PCA) is 
totally fine but a broader study population of European descent could add around 20K 
participants to increase the power and the use of interim release data sets a further limitation 
on the power of this study.”  
I agree with the reviewer that the use of interim release of data for MR-PheWAS analysis 
limited the power of this study and have acknowledged the proposed point as a limitation in 
the paper. The use of self-reported British (confirmed by PCA) was to minimise the 
influence of population stratification. I agree with the reviewer that the use of British 
population reduced the sample size when compared with the use of European descent, 
however, given the fact that the genetic determines of SUA level are diverse in different 
ethnicities and that the excluded samples consist of more controls than cases, I decided to 
use a homogenous British population after weighing the gains (minimise the influence of 
population stratification) and losses (lose study samples). Additionally, it should be noted 
that even the British people are not definitely homogenous, further adjustments for principal 
components of ancestry should be considered to minimise the influence of the population 
stratification.     
7.2.5.2 Use of multiple instrumental variables 
Another reviewer commented that “Clearly, pleiotropy is an issue, with some of the serum-
associated PheWAS variants used (e.g. GCKR) associated with multiple other phenotypes. 
Therefore I wonder why a simpler approach, using genetic variation within the well 
understood SLC2A9 gene, with no evidence for pleiotropy, is not used in studies.” 
I agree that the SLC2A9 gene suggested by the reviewer is a good candidate instrument, as it 
has the strongest association with SUA level and its biological function is well characterised 
as a urate transporter. So far as I know, there is no other disease (except gout) that has been 
reported to be associated with this locus (without observed evidence for pleiotropy), 
although it should be noted that the SLC2A9 gene is also a glucose/fructose transporter, 
which may leave the possibility for unobserved pleiotropy. However, the main reason for 
using multiple genetic variants in MR was to increase the strength of genetic instrument, as 
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the 31 SNPs all together can explain about 7% of SUA variance, while the SLC2A9 gene 
only accounted for less than 2% (151). An MR analysis using a weak instrument would 
easily suffer from bias and would tend to underestimate the true uncertainty, leading to 
inflated type 1 error rate (561).  
Furthermore, the use of multiple genetic instruments would strengthen the causal inference 
by noting the disease outcomes associated with at multiple SUA risk loci. This could be 
analogous to the RCTs using different SUA-lowering drugs, which work through different 
mechanisms and have different potential side-effects but lower SUA to the same degree. If 
the different SUA-lowering drugs produce the same reduction in the disease risk, then it is 
less likely that this effect is through agent-specific effect of the drugs, instead it points to 
SUA lowering as being the key. For example, gout is associated with multiple independent 
SUA risk loci, pointing to the same underlying SUA-outcome (gout) association; intuitively 
it is less likely that the association is caused by the reintroduced confounding (e.g. pleiotropy 
or LD), unless the reintroduced confounding acts in a way influencing two unlinked genetic 
variants. 
In addition to causality, I was also interested in pleiotropy, which may reflect common 
aetiology or biological pathways shared by the affected diseases. Using multiple genetic 
instruments allowed me to investigate pleiotropic associations of interest. As acknowledged, 
the use of multiple genetic instruments increases the risk to break the MR assumptions due to 
pleiotropy. To address this problem without vitiating the statistical power or losing the 
chance to investigate pleiotropic association, I therefore applied the advanced MR Egger 
analysis to correct for the observed and unobserved pleiotropy that was potentially caused by 
using multiple genetic instruments.  
7.2.5.3 Adjustment for covariates 
Additionally, one of the reviewers suggested not adjusting for BMI in the PheWAS analysis, 
given that BMI is known to be causally linked to urate levels. If adjusting for BMI, why not 
adjust for renal function?  
It is acknowledged that using genetic variants as proxy of exposure has the advantage of not 
be influenced by most confounding factors, since genetic variants are fixed at conception and 
typically do not change due to environment factors. Adjusting with covariates may lead to 
bias in the causal estimate when a covariate is on the causal pathway of the exposure to the 
outcome or is a collider or causally downstream of a collider (565). Briefly, a collider is 
variable that could be influenced both by the exposure and by the outcome. This was the 
reason why we did not adjust for renal function, since it is possible that renal function could 
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be influenced by both the SUA level and multiple disease conditions (e.g., chronic kidney 
disease, or hypertensive nephropathy).  
However, in some cases, adjustment for covariates is necessary to ensure validity of the IVs. 
One example is population stratification, in which the sample population consists of ethnic 
subgroups that have different distributions of the IVs and the outcome. An association 
between the IVs and outcome may be solely due to differences in ethnicity instead of any 
biological effect of the exposure. This can be addressed at least partially by adjusting for 
genetic PCs in the analysis. When I was performing the analysis, adjusting 5-6 principal 
components of ancestry was standard practice (in the past), thus I followed the old fashion 
and only adjusted for the first 5 principal components. However, recent results suggest that 
40 PCs are more appropriate for large cohorts. This may present as a limitation of this study. 
Besides, if the measured covariates can explain variation in the exposure or the outcome, 
then including such covariates in the analysis can generally improve the statistical power and 
increase the precision of the causal estimate. The rationale here is that accounting for a true 
risk factor decreases the residual variance of the outcome/phenotype and therefore increases 
the ratio of the true effect size of a predictor of interest (i.e. SUA) over the total phenotypic 
variance, which leads to increased statistical power and better precision in the causal 
estimate. Under these situations, adjusting for covariates is supportive. 
In relation to BMI, it is unlikely that it is a collider, as BMI is known to be upstream of the 
SUA metabolism pathway, as well as a known causal factor for disease development. 
Besides, given that BMI is a common risk factor for a large number of diseases, it is likely 
that adjusting for BMI contributes to stronger statistical power of PheWAS by reducing the 
residual variance. With the purpose of being more rigorous, I re-performed the PheWAS 
without adjusting for BMI as a sensitivity analysis. The unadjusted results have been 
provided as supplementary material, in which all identified genetic associations retained 
their statistical significance with slight changes in their regression coefficients. 
7.2.5.4 Case ascertainment  
For the causal effect of SUA level on gout, one reviewer questioned that “regarding use of 
ICD codes for gout, they are likely to be un-representative of gout given that hospitalised 
gout is complicated by co-morbidities (566) - this should be explicitly investigated and 
acknowledged as a limitation. It would be interesting for the authors to use the classification 
criteria of Cadzow et al (480) to calculate a causal effect size for serum urate in gout.” 
Chapter 7  Discussion 
309 
 
Considering the possibility of introducing information bias in this study, we did not 
incorporate the self-reported data into the PheWAS analysis and I agree with the reviewer 
that this is a limitation of this study, as acknowledged in Chapter 5, Section “5.5 
Discussion”. Alternatively, we used a group of ICD diagnosis codes (ICD-10 code “M10” 
and its sub-codes; ICD-9 code “274” and its sub-codes) to represent gout. Gout cases were 
accordingly ascertained based on the primary or secondary hospital discharge coding. Gout 
cases derived from hospitalisation, as noted by the reviewer, are likely to be un-
representative of gout given that hospitalised gout is complicated by co-morbidities (566). 
We are also interested whether using the classification criteria proposed by Cadzow et al 
(480) would make any change to the causal effect size of SUA on gout ascertained from 
different resources. By following the reviewer’s suggestion, I conducted a sensitivity 
analysis to compare the MR estimates for hospital-diagnosed gout, self-reported gout and 
hospital-diagnosed/self-reported gout. The MR IVW/Egger estimates are consistently 
statistically significant in any of the cases, but the effect size are different and the self-
reported gout has the largest relative risk. 
7.3 Interpretation of the main findings  
Respective findings and conclusions derived from the umbrella review, the MR-PheWAS of 
the interim release of UK Biobank data and the PWMR of the full UK Biobank data have 
been discussed in the corresponding chapters (i.e., Chapter 3, Chapter 5, and Chapter 6). In 
this section, I will provide an overall discussion and conclusion by incorporating findings 
from these three chapters.  
7.3.1 Causality supported by convincing evidence 
7.3.1.1 Gout 
The causal relationship between uric acid and gout is robustly verified in this thesis with 
consistent evidence from the umbrella review, the MR-PheWAS of the interim release of UK 
Biobank data and the PWMR of the full UK Biobank data. Regarding the causal effect size 
on gout risk, estimates from these three sources of evidence are generally consistent. The 
umbrella review identified a MR analysis investigating the causal effect with 3,151 gout 
cases and 68,350 controls and reported that 1 SD increase in genetically determined SUA 
levels was associated with an increased risk of gout with an OR of 5.84 (95%CI: 4.56 to 7.49) 
(327). The causal effect size of SUA level on gout estimated form the MR-PheWAS 
including 1,003 gout cases and 119,555 controls presented a similar estimate with wider 
confidence interval (OR=4.58; 95%CI: 2.72 to 7.72) after correction of pleiotropy in MR 
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Egger regression (461). The causal effect estimated from the PWMR including 2,532 gout 
cases and 335,108 controls in UK Biobank reported a very similar magnitude of effect size 
on gout (OR=5.37; 95%CI: 4.67 to 6.18; p= 4.27×10-123). Overall, the causal effect of SUA 
level on gout is consistently supported in both direction and magnitude of effect size by the 
three lines of evidence incorporated in this thesis.  
7.3.2 Association supported by suggestive evidence 
7.3.2.1 Hypertension 
Apart from gout, the association between SUA and hypertension was classified as highly 
suggestive. In the umbrella review, a meta-analysis of observational studies provided highly 
suggestive evidence to support this association. The selected (largest) meta-analysis of RCTs 
on corresponding intermediate traits or surrogate outcomes (e.g., SBP, DBP) showed 
concordant evidence to support the causal effect. Evidence from published MR studies 
reported discordant evidence, in which the causal relationship was not verified (232). The 
MR-PheWAS and PWMR analysis performed in this thesis using data from UK Biobank 
demonstrated that SUA level shared genetic risk with hypertension at multiple loci, however, 
due to the presence of unbalanced pleiotropy detected by the MR Egger analysis, the causal 
association was not robustly inferred (461). Overall, when considering our emerging findings 
together with the previous evidence from umbrella review, it is reasonable to conclude an 
independent association between SUA level and hypertension, although there is not enough 
evidence at present to robustly conclude that this is causal.  
7.3.2.2 Heart diseases 
In the umbrella review, a wide range of heart diseases (including coronary heart disease, 
heart failure, and atrial fibrillation) has been identified to be associated with SUA level from 
observational studies, but there was a lack of concordance with clinically relevant endpoints 
from RCTs or surrogate endpoints from MR studies. Therefore, the evidence from the 
umbrella review is insufficient to support any casual effect of SUA level on these outcomes 
(232). In the MR-PheWAS and PWMR analysis, a wide range of cardiac diseases of varying 
severity, including coronary atherosclerosis, angina pectoris, ischaemic heart diseases, 
acute/old myocardial infarction and heart failure, were identified to be associated with the 
genetically determined SUA level (461). The association between SUA and cardiac diseases 
is favoured in both the previous studies and multiple analyses conducted in this thesis, 
however, given the same caveat in the causal inference with hypertension, a conclusion of 
causality on cardiac diseases is not robust enough.  
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7.3.2.3 Metabolic disorders 
Epidemiological evidence from the umbrella review indicated that high SUA level was 
associated with some of the components of metabolic syndrome (537), such as blood glucose 
levels or type 2 diabetes. However, the MR-PheWAS and PWMR analysis in this thesis did 
not identify any significant association between SUA and specific metabolic other than 
hypercholesterolaemia. When taken together the line of evidence from experimental studies, 
which indicated that high SUA level promoted the oxidation of low-density lipoprotein and 
disrupted the process of reverse cholesterol transport, it is likely that there is an underlying 
biological link between hyperuricaemia and hypercholesterolaemia.  
7.3.3 Association supported by weak evidence 
7.3.3.1 Cerebrovascular diseases 
The role of SUA level in the development of cerebrovascular diseases is debatable. The 
findings from this thesis are not completely consistent. Previous studies assessed in the 
umbrella review reported conflicting results for the association between SUA level and 
cerebrovascular diseases (e.g. stroke), where some studies suggested that high SUA level 
was neuroprotective whereas some studies reported that high SUA level was injurious. The 
TreeWAS analysis identified a positive association between the weighted GRS of SUA and 
cerebrovascular diseases, but this association was not replicated in the PheWAS analysis. In 
conclusion, findings in this thesis do not support the hypothesis that high SUA levels are 
neuroprotective as an anti-oxidant in the setting of cerebrovascular diseases. 
7.3.3.2 Respiratory diseases 
In addition to the findings discussed above, a few other disease outcomes were identified to 
be associated with SUA level with weak evidence. The sex-stratified MR-PheWAS analysis 
identified that a group of respiratory diseases were potentially linked with the genetically 
determined SUA level in women. The umbrella review did not provide any evidence 
regarding the respiratory diseases, but findings from experimental studies demonstrated that 
human airway epithelial cells and lung tissue expressed a functional UA production/secretion 
system and UA was crucial in mediating the development of allergic airway diseases and 
regulating the antigen-specific T-cell proliferation (494-497). Overall, the evidence in 
relation to the association between SUA level and respiratory diseases has not been well 
explored (499, 500). Our study contributes knowledge to the clinical relevance of SUA level 
in lung health and respiratory diseases. 




Another possible association identified from the PheWAS analysis was that of SUA level 
with cataract. Although the MR analyses did not indicate any putative causal links (with 
limited power = 0.37), a review of the literature demonstrated that various presentations of 
ocular abnormalities have been described in relation to SUA level. These include the 
depositions of MSU crystals in different locations in the eye (e.g. cornea, conjunctivae, and 
iris), and the abnormalities of dry eye syndrome and intraocular hypertension frequently 
observed in hyperuricaemia patients (567). In addition, an association between gout and 
nuclear, posterior subscapular and cortical cataracts have also been reported, in which gout 
was suggested as a risk factor for cataract development (568). The exact biological role of 
SUA level in ocular disease development has not been fully understood. Our observation 
adds to the current evidence indicating a potential relationship between SUA level and ocular 
diseases. We believe that this accumulating evidence should lead to further investigation of 
ocular diseases in patients with hyperuricaemia and gout if this is of clinical relevance.
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8 CONCLUSION  
This thesis presents a comprehensive investigation on the health outcomes in relation to SUA 
levels. In conclusion, I firstly performed an umbrella review to provide a comprehensive 
overview of reported associations between serum uric acid (SUA) levels and a wide range of 
health outcomes by incorporating evidence from systematic reviews and meta-analyses of 
observational studies, meta-analyses of randomised controlled trials, and Mendelian 
randomisation studies. This remarkable assembly of evidence explored 136 unique health 
outcomes and concluded convincing evidence of a causal clear role of SUA level in gout. I 
then investigated the associations of the 31 individual SNPs related to SUA level with a very 
wide range of disease outcomes by using MR-PheWAS design (phenome-wide association 
study incorporated with Mendelian randomisation [MR]) with the interim release data of UK 
Biobank (n=120,091); this MR-PheWAS analysis demonstrated that SUA level shared 
genetic risk loci with multiple disease outcomes, particularly cardiovascular/metabolic 
diseases and autoimmune disorders. When balancing out the pleiotropy on MR Egger 
analysis, a robust conclusion on causality was made only for gout. When enlarging the 
sample size of PheWAS with 3-fold more cases by using the data from the full UK Biobank 
data (n=339,256), the analysis demonstrated that genetically determined SUA level is 
independently and consistently associated with several disease groups including 
inflammatory polyarthropathies (e.g., gout), hypertensive disease (e.g., essential 
hypertension), ischaemic heart diseases (e.g., coronary atherosclerosis, myocardial infarction, 
chronic ischaemic heart disease), metabolic disorders (e.g., hypercholesterolaemia) and 
suggest possible association with cerebrovascular diseases (e.g., cerebral infarction). These 
associations with gout, CHD, myocardial infarction and decreased level of HDL-c were 
successfully replicated in different populations by analysing data from various GWAS 
consortia. The analysis of causal inference detected the existence of unbalanced genetic 
pleiotropy in most of the associations. To further investigate the influence of pleiotropy, I re-
calculated the PheWAS estimates by using a number of GRSs created based on their 
association with a set of metabolic traits. The GRS of urate-specific loci was only associated 
with gout and its encompassing disease group of inflammatory polyarthropathies, but not 
with any cardiovascular/metabolic diseases. In contrast, the GRSs of pleiotropic loci on BMI, 
BP, lipids and glucose showed association with both gout and the cardiovascular/metabolic 
diseases. When removing any group of pleiotropic loci from the creation of GRS, their 
association with hypertensive diseases, heart diseases, and metabolic disorders were not 
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statistically significant. When balancing out the potential pleiotropic effects in Egger MR, a 
causal effect can only be verified for gout.     
The causal inference in this study is also limited by the common difficulty of pleiotropy 
caused by the use of multiple genetic instruments. Although we have performed a number of 
sensitivity analyses by excluding the key pleiotropic loci, there is still the probability of 
unmeasured pleiotropy. In particular, unbalanced pleiotropy was recognised as an issue for 
the causal inference on the association between SUA level and hypertension. The potential 
causal link of SUA level with respiratory diseases and ocular diseases is also worthy of 
further investigation. Overall, when taken together the findings from umbrella review, MR-
PheWAS, TreeWAS, MR replication and sensitivity analysis, I conclude that there are robust 
associations between urate and several disease  groups, including gout, hypertensive 
diseases, heart diseases and metabolic disorders of lipids, but the causal role of urate only 
exists in gout. The study in this thesis indicates that the pleiotropic effects of genetic variants 
on urate and metabolic traits may contribute to the observed associations between urate and 
cardiovascular/metabolic diseases. These findings suggest that urate could be a good 
predictor for the cardiovascular/metabolic disease risk, but may not a therapeutic target for 
reducing the risk of cardiovascular/metabolic diseases. Further investigation on therapies 
targeting on a more distal mediator (or biological pathway) shared between urate and 
metabolic traits would be beneficial for the treatment of gout and the primary prevention of 
cardiovascular/metabolic comorbidities. 
The research work presented in this thesis provides a comprehensive and thorough 
examination of urate-associated disease outcomes across the whole ICD spectrum and 
illustrates how serum urate level might influence the overall health. The detection of a 
multitude of cross-phenotype associations in this study adds to our understanding of the 
extent of shared genetic/biological components between urate and metabolic traits and 
increase our knowledge of how the role of urate should be interpreted and used in clinical 
practice in the management of related disease conditions. The overall analyses were limited 
by the lack of SUA biomarker data in UK Biobank. As UK Biobank is currently conducting 
biomarker assays, it would be beneficial to assess whether measured SUA level, rather than 
its genetic proxies, is also associated with the observed disease outcomes.  
With regard to the PheWAS methodology applied in this thesis, updating the PheCODE 
schema or applying a novel Bayesian analysis with a tree-structured phenotypic model 
progresses the establishment of a framework or workflow of PheWAS design for 
comprehensively interrogating the clinical influence of a biomarker. The ongoing challenge 
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for PheWAS is the possibility of misclassification, misdiagnosis and miscoding in routine 
healthcare data. It is expected that exploring the genetic basis of the healthcare phenome can 
expose disease areas where improvements are required to ameliorate disease perception or 
strengthen diagnostic practices. Digital phenotyping using genetic data together with 
longitudinal clinical records, physical measures, images and biomarkers may be helpful to 
rectify misclassification, misdiagnosis and miscoding present in healthcare data and to infer 
missing phenotypes. Processing linkage to general practice records and out-patient data 
would also be helpful to build up the individual’s phenome based on widely-covered and 
accurately-defined criteria in the future.
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